<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Plasma expanders for people with cirrhosis and large ascites treated with abdominal paracentesis - Simonetti, RG - 2019 | Cochrane Library</title> <meta content="Plasma expanders for people with cirrhosis and large ascites treated with abdominal paracentesis - Simonetti, RG - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004039.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Plasma expanders for people with cirrhosis and large ascites treated with abdominal paracentesis - Simonetti, RG - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004039.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD004039.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Plasma expanders for people with cirrhosis and large ascites treated with abdominal paracentesis" name="citation_title"/> <meta content="Rosa G Simonetti" name="citation_author"/> <meta content="Cochrane Hepato‐Biliary Group" name="citation_author_institution"/> <meta content="simonettimarino@gmail.com" name="citation_author_email"/> <meta content="Giovanni Perricone" name="citation_author"/> <meta content="Dimitrinka Nikolova" name="citation_author"/> <meta content="Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Goran Bjelakovic" name="citation_author"/> <meta content="Medical Faculty, University of Nis" name="citation_author_institution"/> <meta content="Christian Gluud" name="citation_author"/> <meta content="Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD004039.pub2" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/06/28" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004039.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004039.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004039.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Ascites [etiology, therapy]; *Liver Cirrhosis [complications]; *Paracentesis; *Plasma Substitutes [therapeutic use]; Quality of Life; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004039.pub2&amp;doi=10.1002/14651858.CD004039.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004039.pub2&amp;doi=10.1002/14651858.CD004039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004039.pub2&amp;doi=10.1002/14651858.CD004039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004039.pub2&amp;doi=10.1002/14651858.CD004039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004039.pub2&amp;doi=10.1002/14651858.CD004039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004039.pub2&amp;doi=10.1002/14651858.CD004039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004039.pub2&amp;doi=10.1002/14651858.CD004039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004039.pub2&amp;doi=10.1002/14651858.CD004039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004039.pub2&amp;doi=10.1002/14651858.CD004039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004039.pub2&amp;doi=10.1002/14651858.CD004039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004039.pub2&amp;doi=10.1002/14651858.CD004039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004039.pub2&amp;doi=10.1002/14651858.CD004039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004039.pub2&amp;doi=10.1002/14651858.CD004039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004039.pub2&amp;doi=10.1002/14651858.CD004039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004039.pub2&amp;doi=10.1002/14651858.CD004039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004039.pub2&amp;doi=10.1002/14651858.CD004039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004039.pub2&amp;doi=10.1002/14651858.CD004039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004039.pub2&amp;doi=10.1002/14651858.CD004039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004039.pub2&amp;doi=10.1002/14651858.CD004039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004039.pub2&amp;doi=10.1002/14651858.CD004039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004039.pub2&amp;doi=10.1002/14651858.CD004039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004039.pub2&amp;doi=10.1002/14651858.CD004039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004039.pub2&amp;doi=10.1002/14651858.CD004039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="Nio3SV1W";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD004039\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD004039\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004039\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004039\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ms","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD004039.pub2",title:"Plasma expanders for people with cirrhosis and large ascites treated with abdominal paracentesis",firstPublishedDate:"Jun 28, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Hepato‐Biliary Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Nio3SV1W&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004039.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004039.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD004039.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD004039.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004039.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD004039.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD004039.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD004039.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD004039.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD004039.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>13753 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD004039.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004039.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004039.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004039.pub2/full#CD004039-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004039.pub2/full#CD004039-sec-0199"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004039.pub2/full#CD004039-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004039.pub2/full#CD004039-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004039.pub2/full#CD004039-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004039.pub2/full#CD004039-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004039.pub2/full#CD004039-sec-0063"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004039.pub2/full#CD004039-sec-0193"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004039.pub2/appendices#CD004039-sec-0204"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/table_n/CD004039StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/table_n/CD004039StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004039.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004039.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004039.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004039.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004039.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD004039.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Plasma expanders for people with cirrhosis and large ascites treated with abdominal paracentesis </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004039.pub2/information#CD004039-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Rosa G Simonetti</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004039.pub2/information#CD004039-cr-0003">Giovanni Perricone</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004039.pub2/information#CD004039-cr-0004">Dimitrinka Nikolova</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004039.pub2/information#CD004039-cr-0005">Goran Bjelakovic</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004039.pub2/information#CD004039-cr-0006">Christian Gluud</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/information/en#CD004039-sec-0208">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 28 June 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD004039.pub2">https://doi.org/10.1002/14651858.CD004039.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD004039-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004039-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004039-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004039-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004039-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD004039-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD004039-abs-0001" lang="en"> <section id="CD004039-sec-0001"> <h3 class="title" id="CD004039-sec-0001">Background</h3> <p>Plasma volume expanders are used in connection to paracentesis in people with cirrhosis to prevent reduction of effective plasma volume, which may trigger deleterious effect on haemodynamic balance, and increase morbidity and mortality. Albumin is considered the standard product against which no plasma expansion or other plasma expanders, e.g. other colloids (polygeline , dextrans, hydroxyethyl starch solutions, fresh frozen plasma), intravenous infusion of ascitic fluid, crystalloids, or mannitol have been compared. However, the benefits and harms of these plasma expanders are not fully clear. </p> </section> <section id="CD004039-sec-0002"> <h3 class="title" id="CD004039-sec-0002">Objectives</h3> <p>To assess the benefits and harms of any plasma volume expanders such as albumin, other colloids (polygeline, dextrans, hydroxyethyl starch solutions, fresh frozen plasma), intravenous infusion of ascitic fluid, crystalloids, or mannitol versus no plasma volume expander or versus another plasma volume expander for paracentesis in people with cirrhosis and large ascites. </p> </section> <section id="CD004039-sec-0003"> <h3 class="title" id="CD004039-sec-0003">Search methods</h3> <p>We searched the Cochrane Hepato‐Biliary Group Controlled Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, LILACS, CNKI, VIP, Wanfang, Science Citation Index Expanded, and Conference Proceedings Citation Index until January 2019. Furthermore, we searched FDA, EMA, WHO (last search January 2019), <a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov/</a>, and <a href="http://www.controlled-trials.com/" target="_blank">www.controlled‐trials.com/</a> for ongoing trials. </p> </section> <section id="CD004039-sec-0004"> <h3 class="title" id="CD004039-sec-0004">Selection criteria</h3> <p>Randomised clinical trials, no matter their design or year of publication, publication status, and language, assessing the use of any type of plasma expander versus placebo, no intervention, or a different plasma expander in connection with paracentesis for ascites in people with cirrhosis. We considered quasi‐randomised, retrieved with the searches for randomised clinical trials only, for reports on harms. </p> </section> <section id="CD004039-sec-0005"> <h3 class="title" id="CD004039-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane. We calculated the risk ratio (RR) or mean difference (MD) using the fixed‐effect model and the random‐effects model meta‐analyses, based on the intention‐to‐treat principle, whenever possible. If the fixed‐effect and random‐effects models showed different results, then we made our conclusions based on the analysis with the highest P value (the more conservative result). We assessed risks of bias of the individual trials using predefined bias risk domains. We assessed the certainty of the evidence at an outcome level, using GRADE, and constructed 'Summary of Findings' tables for seven of our review outcomes. </p> </section> <section id="CD004039-sec-0006"> <h3 class="title" id="CD004039-sec-0006">Main results</h3> <p>We identified 27 randomised clinical trials for inclusion in this review (24 published as full‐text articles and 3 as abstracts). Five of the trials, with 271 participants, assessed plasma expanders (albumin in four trials and ascitic fluid in one trial) versus no plasma expander. The remaining 22 trials, with 1321 participants, assessed one type of plasma expander, i.e. dextran, hydroxyethyl starch, polygeline, intravenous infusion of ascitic fluid, crystalloids, or mannitol versus another type of plasma expander, i.e. albumin in 20 of these trials and polygeline in one trial. Twenty‐five trials provided data for quantitative meta‐analysis. According to the Child‐Pugh classification, most participants were at an intermediate to advanced stage of liver disease in the absence of hepatocellular carcinoma, recent gastrointestinal bleeding, infections, and hepatic encephalopathy. All trials were assessed as at overall high risk of bias. Ten trials seemed not to have been funded by industry; twelve trials were considered unclear about funding; and five trials were considered funded by industry or a for‐profit institution. </p> <p>We found no evidence of a difference in effect between plasma expansion versus no plasma expansion on mortality (RR 0.52, 95% CI 0.06 to 4.83; 248 participants; 4 trials; very low certainty); renal impairment (RR 0.32, 95% CI 0.02 to 5.88; 181 participants; 4 trials; very low certainty); other liver‐related complications (RR 1.61, 95% CI 0.79 to 3.27; 248 participants; 4 trials; very low certainty); and non‐serious adverse events (RR 1.04, 95% CI 0.32 to 3.40; 158 participants; 3 trials; very low certainty). Two of the trials stated that no serious adverse events occurred while the remaining trials did not report on this outcome. No trial reported data on health‐related quality of life. </p> <p>We found no evidence of a difference in effect between experimental plasma expanders versus albumin on mortality (RR 1.03, 95% CI 0.82 to 1.30; 1014 participants; 14 trials; very low certainty); serious adverse events (RR 0.89, 95% CI 0.10 to 8.30; 118 participants; 2 trials; very low certainty); renal impairment (RR 1.17, 95% CI 0.71 to 1.91; 1107 participants; 17 trials; very low certainty); other liver‐related complications (RR 1.10, 95% CI 0.82 to 1.48; 1083 participants; 16 trials; very low certainty); and non‐serious adverse events (RR 1.37, 95% CI 0.66 to 2.85; 977 participants; 14 trials; very low certainty). We found no data on heath‐related quality of life and refractory ascites. </p> </section> <section id="CD004039-sec-0007"> <h3 class="title" id="CD004039-sec-0007">Authors' conclusions</h3> <p>Our systematic review and meta‐analysis did not find any benefits or harms of plasma expanders versus no plasma expander or of one plasma expander such as polygeline, dextrans, hydroxyethyl starch, intravenous infusion of ascitic fluid, crystalloids, or mannitol versus albumin on primary or secondary outcomes. The data originated from few, small, mostly short‐term trials at high risks of systematic errors (bias) and high risks of random errors (play of chance). GRADE assessments concluded that the evidence was of very low certainty. Therefore, we can neither demonstrate or discard any benefit of plasma expansion versus no plasma expansion, and differences between one plasma expander versus another plasma expander. </p> <p>Larger trials at low risks of bias are needed to assess the role of plasma expanders in connection with paracentesis. Such trials should be conducted according to the SPIRIT guidelines and reported according to the CONSORT guidelines. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD004039-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004039-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004039-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004039-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004039-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD004039-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD004039-abs-0006">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD004039-abs-0007">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD004039-abs-0005" lang="en"> <h3>Plasma expanders for people with cirrhosis and large ascites treated with abdominal paracentesis </h3> <p><b>Background</b> </p> <p>People with cirrhosis (scarring of the liver tissue) can accumulate fluid (ascites) in their abdomen which may be hard or impossible to treat with diuretics (drugs that increase urinary excretion of water and salt). Abdominal paracentesis, evacuation of fluid from the abdomen through a needle, can be done. Paracentesis can alter the equilibrium between circulation and the abdomen fluid and lead to renal dysfunction and alteration of the fluid balance. We studied if infusion of special fluids, so called plasma expanders, could stop these alterations and reduce complications and mortality. </p> <p><b>Objective</b> </p> <p>To assess the benefits and harms of any intravenous fluid infusion (acting as plasma expansion) in people with cirrhosis and ascites treated by paracentesis. </p> <p><b>Review methods and criteria</b> </p> <p>The evidence is current up to 22 January 2019.</p> <p>This systematic review assessed the role of plasma expanders evaluated in 27 trials including 1592 participants. Four trials compared albumin and one trial compared intravenous ascitic fluid infusion versus no plasma expander. Twenty‐one trials compared one plasma expander such as dextran, polygeline, hydroxyethyl starch, fresh frozen plasma, intravenous infusion of ascitic fluid, crystalloids, or mannitol versus albumin. One trial compared intravenous ascitic fluid infusion versus polygeline. Primary outcomes were mortality due to any cause; serious adverse events; and health‐related quality of life. Secondary outcomes were refractory ascites (ascites that could not be treated medically); renal impairment; other complications due to liver cirrhosis such as gastrointestinal bleeding, hepatic encephalopathy (decline in brain function due to liver disease) or infections; and non‐serious adverse events. </p> <p><b>Trial funding sources</b> </p> <p>Ten trials seemed not to have been funded by industry; twelve trials were considered unclear about funding; and five trials were considered funded by industry or a for‐profit institution. </p> <p><b>Key results</b> </p> <p>Our systematic review could not show any benefit or harm of plasma expansion versus no plasma expansion or of one plasma expander like dextran, polygeline, hydroxyethyl starch, intravenous infusion of ascitic fluid, crystalloids, or mannitol versus albumin on primary or secondary outcomes. </p> <p><b>Certainty of the evidence</b> </p> <p>The data came from only few, small, mostly short‐term trials, at high risks of systematic errors (bias) and high risks of random errors (play of chance). Accordingly, we concluded that the certainty of evidence for each of our prespecified review outcomes was very low. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD004039-sec-0199" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004039-sec-0199">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004039-sec-0256">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD004039-sec-0199"></div> <h3 class="title" id="CD004039-sec-0200">Implications for practice</h3> <section id="CD004039-sec-0200"> <p>Based on the results of key clinical outcomes in this systematic review, we can neither demonstrate nor disprove any benefit of plasma expansion versus no plasma expansion, and differences between one plasma expander versus another plasma expander to be used after therapeutic paracentesis for large ascites in people with cirrhosis. So, the decision to use a plasma expander after large volume paracentesis, and the choice of the type could be based on the physician's and patient's values and preferences. </p> <p>The increased risk of hyponatraemia and post‐paracentesis circulatory dysfunction with other plasma expanders compared to albumin, even considering the limits of their prognostic meaning and the very low level of evidence, could suggest caution in the choice of the plasma expanders in clinical practice. </p> <p>Regulatory agencies introduced risk reduction minimisation measures, for hydroxyethyl starch. Its use is contraindicated in patients with sepsis, who are critically ill, with renal impairment or undergoing renal replacement therapy, with severe coagulopathy, or with impaired hepatic function and other severe conditions (<a href="./references#CD004039-bbs2-0072" title="Food , DrugAdministration . FDA safety communication: boxed warning on increased mortality and severe renal injury, and additional warning on risk of bleeding, for use of hydroxyethylstarch solutions in some settings. fffenterprises.com/assets/downloads/Article‐FDASafetyCommunicationBoxedWarning6‐13.pdf (accessed prior to 16 June 2019). ">FDA 2013</a>, <a href="./references#CD004039-bbs2-0071" title="European Medicines Agency. Hydroxyethyl starch solutions: CMDh introduces new measures to protect patients. www.ema.europa.eu/documents/referral/hydroxyethyl‐starch‐article‐107i‐referral‐hydroxyethyl‐starch‐solutions‐cmdh‐introduces‐new‐measures_en.pdf (accessed prior to 16 June 2019). ">EMA 2018</a>; <a href="./references#CD004039-bbs2-0036" title="Agenzia Italiana delFarmaco . Nota informativa importante sulla restrizione d’uso di HES. www.agenziafarmaco.gov.it/sites/default/files/IT_DHPC_HES_common.pdf (accessed prior to 16 June 2019). ">AIFA 2018</a>). According to some regulatory authorities, its use should be limited to managing hypovolaemia due to acute blood loss only when crystalloids are not considered sufficient (<a href="./references#CD004039-bbs2-0036" title="Agenzia Italiana delFarmaco . Nota informativa importante sulla restrizione d’uso di HES. www.agenziafarmaco.gov.it/sites/default/files/IT_DHPC_HES_common.pdf (accessed prior to 16 June 2019). ">AIFA 2018</a>; <a href="./references#CD004039-bbs2-0071" title="European Medicines Agency. Hydroxyethyl starch solutions: CMDh introduces new measures to protect patients. www.ema.europa.eu/documents/referral/hydroxyethyl‐starch‐article‐107i‐referral‐hydroxyethyl‐starch‐solutions‐cmdh‐introduces‐new‐measures_en.pdf (accessed prior to 16 June 2019). ">EMA 2018</a>). </p> <p>Albumin is considerably more expensive than the other intravenous fluids.</p> <p>Intravenous infusion of ascitic fluid requires specialised staff and technical devices for filtration and concentration which can reduce its use. </p> <p>The uncertainty of the results should suggest taking into account alternative treatments that improve the natural history of patients with decompensated cirrhosis, such as transjugular intrahepatic portosystemic shunt (TIPS) or orthotopic liver transplantation (OLT) when other criteria are satisfied (<a href="./references#CD004039-bbs2-0035" title="RunyonBA , AASLD . AASLD Practice Guideline. Management of adult patients with ascites due to cirrhosis: update 2012. Hepatology2013;57(4):1651‐3. [PUBMED: 23463403] ">AASLD 2012</a>; <a href="./references#CD004039-bbs2-0068" title="European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Liver transplantation. Journal of Hepatology2016;64(2):433‐85. [PUBMED: 26597456] ">EASL 2016</a>; <a href="./references#CD004039-bbs2-0069" title="European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. Journal of Hepatology2018;69(2):406‐60. [PUBMED: 29653741] ">EASL 2018</a>). </p> </section> <h3 class="title" id="CD004039-sec-0201">Implications for research</h3> <section id="CD004039-sec-0201"> <p>More large, high‐quality randomised clinical trials are necessary to assess the role of plasma expanders in connection with paracentesis in the treatment of ascites in cirrhotic participants. Such randomised clinical trials should be designed according to the SPIRIT guidelines (Standard Protocol Items: Recommendations for Interventional Trials; www.spirit‐statement.org) and reported according to the CONSORT guidelines (www.consort‐statement.org). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD004039-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD004039-sec-0029"></div> <div class="table" id="CD004039-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Plasma expanders versus no plasma expanders for people with cirrhosis and large ascites treated with abdominal paracentesis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Plasma expanders versus no plasma expanders for people with cirrhosis and large ascites treated with abdominal paracentesis: primary and secondary outcomes</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> cirrhotic participants with large ascites treated by paracentesis </p> <p><b>Settings:</b> specialised units in an intensive or semi‐intensive setting </p> <p><b>Intervention:</b> plasma expander </p> <p><b>Comparison:</b> no plasma expander </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No plasma expander</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Plasma expander</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality</b> </p> <p>mean follow‐up 64 days (1‐222)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR</b> 0.52 (0.06 to 4.83) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>248<br/> (4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> very low<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>180 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>94 per 1000</b><br/> (11 to 869) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>mean follow‐up 15 days (1‐30)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>See comment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>See comment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>See comment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108<br/> (2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> very low<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two trials reported that no serious adverse events occurred</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data provided in any of the six trials</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Refractory ascites</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data provided in any of the six trials</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Other liver‐related complications</b> </p> <p>mean follow‐up 64 days (1‐222)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.61</b> </p> <p>(0.79 to 3.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>248<br/> (4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> very low<sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>90 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>145 per 1000</b><br/> (71 to 294) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Non‐serious adverse events</b> </p> <p>mean follow‐up 91 days (1‐222)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.04</b> </p> <p>(0.32 to 3.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>158<br/> (3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> very low<sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>62 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>64 per 1000</b><br/> (20 to 210) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>* <b>Assumed risk</b> is the risk in comparison group. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded 4 levels because of within study risk of bias: all trials were at high risk of bias (‐2 levels); heterogeneity: high heterogeneity (76%) (‐1 level); imprecision: the required information size as calculated by GRADE was not reached (‐1 level)<br/> <sup>2</sup> Downgraded 4 levels because of within study risk of bias: all trials were at high risk of bias (‐2 levels); imprecision: there were no events (‐2 levels)<br/> <sup>3</sup> Downgraded 5 levels because of within study risk of bias: all trials were at high risk of bias (‐2 levels); high heterogeneity (67%) (‐1 level); imprecision: there were few events and the CI included appreciable benefit and harm (‐2 levels)<br/> <sup>4</sup> Downgraded 3 levels because of within study risk of bias: all trials were at high risk of bias (‐2 levels); imprecision: the required information size as calculated by GRADE was not met (‐1 level)<br/> <sup>5</sup> Downgraded 4 levels because of within study risk of bias: all trials were at high risk of bias (‐2 levels); imprecision: there were few events and the CI included appreciable benefit and harm (‐2 levels) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004039-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Other plasma expanders versus albumin for people with cirrhosis and large ascites treated with abdominal paracentesis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Other plasma expanders versus albumin for people with cirrhosis and large ascites treated with abdominal paracentesis: primary and secondary outcomes</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> cirrhotic participants with large ascites treated by paracentesis </p> <p><b>Settings:</b> specialised units in an intensive or semi‐intensive setting </p> <p><b>Intervention:</b> all plasma expanders except albumin </p> <p><b>Comparison:</b> albumin </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Albumin</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Experimental plasma expanders</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality</b> </p> <p>mean follow‐up 208 days</p> <p>(3‐638)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.03</p> <p>(0.82 to 1.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1014<br/> (14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝</p> <p>very low <sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>183 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>188 per 1000</b><br/> (150 to 238) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events</b> </p> <p>mean follow‐up 93 days</p> <p>(6‐180)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.89 (0.10 to 8.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>118<br/> (2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝</p> <p>very low <sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>16 per 1000</b><br/> (1.8 to 149) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data provided in any of the 20 trials</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Refractory ascites</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data provided in any of the 20 trials</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Renal impairment</b> </p> <p>mean follow‐up 174 days</p> <p>(3‐628)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.17</p> <p>(0.71 to 1.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1107<br/> (17) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> very low <sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>49 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>57 per 1000</b><br/> (35 to 94) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Other liver‐related complications</b> </p> <p>mean follow‐up 147 days</p> <p>(3‐638)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.10</p> <p>(0.82 to 1.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1083<br/> (16) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> very low <sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>185 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>203 per 1000</b><br/> (152 to 274) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Non‐serious adverse events</b> </p> <p>mean follow‐up 194 days</p> <p>(3‐638)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.37</p> <p>(0.66 to 2.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>977</p> <p>(14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> very low <sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b><br/> (16 to 71) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>* <b>Assumed risk</b> is the risk in comparison group. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded 4 levels because of within study risk of bias: all trials were at high risk of bias (‐2 levels); imprecision: the required information size as calculated by GRADE was not reached (‐1 level); publication bias (‐1 level)<br/> <sup>2</sup> Downgraded 4 levels because of within study risk of bias: all trials were at high risk of bias (‐2 levels); imprecision: there were few events and the CI included appreciable benefit and harm (‐2 levels)<br/> <sup>3</sup> Downgraded 4 levels because of within study risk of bias: all trials were at high risk of bias (‐2 levels); imprecision: the required information size as calculated by GRADE was not reached (‐1 level); publication bias (‐ 1 level)<br/> <sup>4</sup> Downgraded 4 levels because of within study risk of bias: all trials were at high risk of bias (‐2 levels); imprecision: the required information size as calculated by GRADE was not reached (‐1 level); publication bias (‐ 1 level)<br/> <sup>5</sup> Downgraded 3 levels because of within study risk of bias: all trials were at high risk of bias (‐2 levels); imprecision: the required information size as calculated by GRADE was not reached (‐1 level). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD004039-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004039-sec-0030">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004039-sec-0217">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD004039-sec-0030"></div> <section id="CD004039-sec-0031"> <h3 class="title" id="CD004039-sec-0031">Description of the condition</h3> <p>Ascites is associated with increased mortality in people with cirrhosis (<a href="./references#CD004039-bbs2-0065" title="D'AmicoG , MorabitoA , PagliaroL , MarubiniE . Survival and prognostic indicators in compensated and decompensated cirrhosis. Digestive Diseases and Sciences1986;31(5):468‐75. [PUBMED: 3009109] ">D'Amico 1986</a>; <a href="./references#CD004039-bbs2-0023" title="SalernoF , BadalamentiS , LorenzanoE , MoserP , IncertiP . Randomized comparative study of hemaccel vs albumin infusion after total paracentesis in cirrhotic patients with refractory ascites. Hepatology1991;13(4):707‐13. [PUBMED: 1826281] ">Salerno 1991</a>; <a href="./references#CD004039-bbs2-0066" title="D’AmicoG , Garcia‐TsaoG , PagliaroL . Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. Journal of Hepatology2006;44(1):217‐31. [PUBMED: 16298014] ">D'Amico 2006</a>). Ascites is graded as mild, moderate, and large (<a href="./references#CD004039-bbs2-0034" title="RunyonBA , AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology2009;49(6):2087‐107. [PUBMED: 19475696] ">AASLD 2009</a>; <a href="./references#CD004039-bbs2-0035" title="RunyonBA , AASLD . AASLD Practice Guideline. Management of adult patients with ascites due to cirrhosis: update 2012. Hepatology2013;57(4):1651‐3. [PUBMED: 23463403] ">AASLD 2012</a>; <a href="./references#CD004039-bbs2-0069" title="European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. Journal of Hepatology2018;69(2):406‐60. [PUBMED: 29653741] ">EASL 2018</a>). It has been shown that people with mild or moderate ascites respond positively to dietary sodium restriction and diuretics (<a href="./references#CD004039-bbs2-0149" title="RunyonBA . Management of adult patients with ascites caused by cirrhosis. Hepatology1998;27(1):264‐72. [PUBMED: 9425946] ">Runyon 1998</a>; <a href="./references#CD004039-bbs2-0034" title="RunyonBA , AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology2009;49(6):2087‐107. [PUBMED: 19475696] ">AASLD 2009</a>; <a href="./references#CD004039-bbs2-0035" title="RunyonBA , AASLD . AASLD Practice Guideline. Management of adult patients with ascites due to cirrhosis: update 2012. Hepatology2013;57(4):1651‐3. [PUBMED: 23463403] ">AASLD 2012</a>; <a href="./references#CD004039-bbs2-0069" title="European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. Journal of Hepatology2018;69(2):406‐60. [PUBMED: 29653741] ">EASL 2018</a>). However, people with large ascites may have respiratory problems, in which case paracentesis is usually used to provide relief (<a href="./references#CD004039-bbs2-0079" title="GinésP , ArroyoV , QuinteroE , PlanasR , BoryF , CabreraJ , et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. Gastroenterology1987;93(2):234‐41. [PUBMED: 3297907] ">Ginés 1987</a>). Paracentesis can be partial, defined as repeated sessions of paracentesis, or total, when performed in one session (<a href="./references#CD004039-bbs2-0168" title="TitóL , GinèsP , ArroyoV , PlanasR , PlanésJ , RimolaA , et al. Total paracentesis associated with intravenous albumin management of patients with cirrhosis and ascites. Gastroenterology1990;98(1):146‐51. [PUBMED: 2293573] ">Titó 1990</a>). Abdominal paracentesis seems to be associated with lower incidence of adverse events and quicker resolution compared with diuretic treatment (<a href="./references#CD004039-bbs2-0079" title="GinésP , ArroyoV , QuinteroE , PlanasR , BoryF , CabreraJ , et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. Gastroenterology1987;93(2):234‐41. [PUBMED: 3297907] ">Ginés 1987</a>). Moreover, repeated paracentesis is used in people with large ascites who are unresponsive to intensive diuretic treatment and dietary sodium restriction, or in those who experience adverse effects from these treatments (e.g. hypotension, hyponatraemia, hyperkalaemia, renal impairment, or hepatic encephalopathy). This type of ascites is defined as refractory (<a href="./references#CD004039-bbs2-0044" title="ArroyoV , GinèsP , GerbesAL , DudleyFJ , GentiliniP , LaffiG , et al. International Ascites Club. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology1996;23(1):164‐76. [PUBMED: 8550036] ">Arroyo 1996</a>; <a href="./references#CD004039-bbs2-0149" title="RunyonBA . Management of adult patients with ascites caused by cirrhosis. Hepatology1998;27(1):264‐72. [PUBMED: 9425946] ">Runyon 1998</a>; <a href="./references#CD004039-bbs2-0130" title="MooreKP , WongF , GinesP , BernardiM , OchsA , SalernoF , et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology2003;38(1):258‐66. [PUBMED: 12830009] ">Moore 2003</a>; <a href="./references#CD004039-bbs2-0034" title="RunyonBA , AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology2009;49(6):2087‐107. [PUBMED: 19475696] ">AASLD 2009</a>; <a href="./references#CD004039-bbs2-0035" title="RunyonBA , AASLD . AASLD Practice Guideline. Management of adult patients with ascites due to cirrhosis: update 2012. Hepatology2013;57(4):1651‐3. [PUBMED: 23463403] ">AASLD 2012</a>; <a href="./references#CD004039-bbs2-0069" title="European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. Journal of Hepatology2018;69(2):406‐60. [PUBMED: 29653741] ">EASL 2018</a>). </p> <p>Paracentesis may induce hypovolaemia and haemodynamic changes with circulatory dysfunction which is expressed by a marked increase of the plasma renin activity in about 27% to 40% of the people undergoing paracentesis, as reported by <a href="./references#CD004039-bbs2-0148" title="Ruiz‐del–ArbolL , MonescilloA , JimenénW , Garcia‐PlazaA , ArroyoV , RodésJ . Paracentesis‐induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology1997;113(2):579‐86. [PUBMED: 9247479] ">Ruiz‐del‐Arbol 1997</a> and <a href="./references#CD004039-bbs2-0170" title="VilaMC , SolàR , MolinaL , AndreuM , CollS , GanaJ , et al. Hemodynamic changes in patients developing effective hypovolemia after total paracentesis. Journal of Hepatology1998;28(4):639‐45. [PUBMED: 9566833] ">Vila 1998</a>. This syndrome, referred to as post‐paracentesis circulatory dysfunction (or paracentesis‐induced circulatory dysfunction), may be associated with shorter time to readmission, and shorter survival (<a href="./references#CD004039-bbs2-0013" title="GinèsA , Fernández‐EsparrachG , MonescilloA , VilaC , DomènechE , AbecasisR , et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology1996;111(4):1002‐10. [PUBMED: 8831595] International Group for the Study of Ascites in Cirrhosis. Comparison of albumin, dextran‐70 and hemaccel in the prevention of effective hypovolemia in cirrhotic patients with ascites treated with total paracentesis. A randomized multicenter study. Hepatology1995;22(4 Suppl):220A. ">Ginès 1996</a>), but it is not clear if its prevention would reduce morbidity and mortality. </p> </section> <section id="CD004039-sec-0032"> <h3 class="title" id="CD004039-sec-0032">Description of the intervention</h3> <p>The intravenous infusion of fluids, acting as a plasma expander, could counterbalance the deleterious effects of paracentesis. </p> <p>The results of haemodynamic (<a href="./references#CD004039-bbs2-0010" title="García‐CompeánD , VillarealJZ , CuevasHB , CantúDAG , EstrellaM , TamezEG , et al. Total therapeutic paracentesis (TTP) with and without intravenous albumin in the treatment of cirrhotic tense ascites: a randomized controlled trial. Liver1993;13(5):233‐8. [PUBMED: 8259034] ">García‐Compeán 1993</a>; <a href="./references#CD004039-bbs2-0018" title="LucaA , García‐PagánJ , BoschJ , FeuF , JiménezW , GinésA , et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology1995;22(3):753‐8. [PUBMED: 7657279] ">Luca 1995</a>) and clinical studies (<a href="./references#CD004039-bbs2-0012" title="GinèsP , TitóL , ArroyoV , PlanasR , PanésJ , ViverJ , et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology1988;94(6):1493‐1502. [PUBMED: 3360270] ">Ginès 1988</a>; <a href="./references#CD004039-bbs2-0013" title="GinèsA , Fernández‐EsparrachG , MonescilloA , VilaC , DomènechE , AbecasisR , et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology1996;111(4):1002‐10. [PUBMED: 8831595] International Group for the Study of Ascites in Cirrhosis. Comparison of albumin, dextran‐70 and hemaccel in the prevention of effective hypovolemia in cirrhotic patients with ascites treated with total paracentesis. A randomized multicenter study. Hepatology1995;22(4 Suppl):220A. ">Ginès 1996</a>) suggest that the risk of hypovolaemia and circulatory dysfunction may be reduced by the intravenous infusion of albumin. As albumin is expensive, volume expansion is also carried out by administering cheaper colloids (polygeline, dextrans, hydroxyethyl starch solutions, fresh frozen plasma), crystalloids, mannitol or by intravenous infusion of the removed ascitic fluid. The effects of these interventions have been compared with that of albumin in randomised clinical trials, but the results have been heterogeneous (<a href="./references#CD004039-bbs2-0022" title="PlanasR , GinèsP , ArroyoV , LlachJ , PanésJ , VargasV , et al. Dextran‐70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study. Gastroenterology1990;99(6):1736‐44. [PUBMED: 1699835] PlanasR , LlachJ , GinèsP , PanésJ , VargasV , SalmeronJM , et al. Albumin versus dextran‐70 in cirrhotics with tense ascites treated with total paracentesis. Final results of a multicenter randomized comparative study. Journal of Hepatology1990;11(Suppl 2):S49. ">Planas 1990</a>; <a href="./references#CD004039-bbs2-0025" title="SmartHL , TrigerDR . A randomised prospective trial comparing daily paracentesis and intravenous albumin with recirculation in diuretic refractory ascites. Journal of Hepatology1990;10(2):191‐7. [PUBMED: 2185298] ">Smart 1990</a>; <a href="./references#CD004039-bbs2-0023" title="SalernoF , BadalamentiS , LorenzanoE , MoserP , IncertiP . Randomized comparative study of hemaccel vs albumin infusion after total paracentesis in cirrhotic patients with refractory ascites. Hepatology1991;13(4):707‐13. [PUBMED: 1826281] ">Salerno 1991</a>; <a href="./references#CD004039-bbs2-0006" title="BrunoS , BorzioM , RomagnoniM , BattezzatiPM , RossiS , ChiesaA , et al. Comparison of spontaneous ascites filtration and reinfusion with total paracentesis with intravenous albumin infusion in cirrhotic patients with tense ascites. BMJ1992;304:1655‐8. [PUBMED: 1633517] BrunoS , BorzioM , RomagnoniM , ChiesaA , RossiS , PavesiS , et al. Spontaneous ascites filtration and reinfusion (SAFR) vs total paracentesis (TP) with i.v. albumin infusion in cirrhotic patients with tense ascites. Hepatology1990;12:855. ">Bruno 1992</a>; <a href="./references#CD004039-bbs2-0009" title="FassioE , TergR , LandeiraG , AbecasisR , SalemneM , PodestaA , et al. Paracentesis with dextran 70 vs paracentesis with albumin in cirrhosis with tense ascites. Results of a randomized study. Journal of Hepatology1992;14(2‐3):310‐6. [PUBMED: 1380024] ">Fassio 1992</a>; <a href="./references#CD004039-bbs2-0013" title="GinèsA , Fernández‐EsparrachG , MonescilloA , VilaC , DomènechE , AbecasisR , et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology1996;111(4):1002‐10. [PUBMED: 8831595] International Group for the Study of Ascites in Cirrhosis. Comparison of albumin, dextran‐70 and hemaccel in the prevention of effective hypovolemia in cirrhotic patients with ascites treated with total paracentesis. A randomized multicenter study. Hepatology1995;22(4 Suppl):220A. ">Ginès 1996</a>; <a href="./references#CD004039-bbs2-0021" title="MoreauR , VallaD‐C , Durand‐ZaleskiI , BronowickiJ‐P , DurandF , ChaputJ‐C , et al. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trial. Liver International2006;26(1):46‐54. [PUBMED: 16420509] ">Moreau 2006</a>; <a href="./references#CD004039-bbs2-0002" title="Al SebaeyA , Abdel‐RazekW , BassuniA , RewishaEA , KhalilM , WakedI , et al. Alternatives to albumin for prevention of paracentesis induced circulatory dysfunction (PICD) in cirrhosis. Hepatology2012;56(S1):915A. ">Al Sebaey 2012</a>). </p> </section> <section id="CD004039-sec-0033"> <h3 class="title" id="CD004039-sec-0033">How the intervention might work</h3> <p>Paracentesis can increase arterial vasodilation in people with cirrhotic ascites, which may lead to reduced effective circulating plasma volume and may result in a reduction of arterial pressure and activation of the renin‐angiotensin‐aldosterone system (RAAS) as well as the sympathetic nervous system (SNS). This, in turn, may lead to increased sodium and water retention, and renal vasoconstriction (<a href="./references#CD004039-bbs2-0148" title="Ruiz‐del–ArbolL , MonescilloA , JimenénW , Garcia‐PlazaA , ArroyoV , RodésJ . Paracentesis‐induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology1997;113(2):579‐86. [PUBMED: 9247479] ">Ruiz‐del‐Arbol 1997</a>; <a href="./references#CD004039-bbs2-0152" title="SalóJ , GinèsA , GinèsP , PieraC , JiménezW , GuevaraM , et al. Effect of therapeutic paracentesis on plasma volume and transvascular escape rate of albumin in patients with cirrhosis. Journal of Hepatology1997;27(4):645‐53. [PUBMED: 9365040] ">Saló 1997</a>; <a href="./references#CD004039-bbs2-0170" title="VilaMC , SolàR , MolinaL , AndreuM , CollS , GanaJ , et al. Hemodynamic changes in patients developing effective hypovolemia after total paracentesis. Journal of Hepatology1998;28(4):639‐45. [PUBMED: 9566833] ">Vila 1998</a>). </p> <p>Plasma expansion could prevent or improve the haemodynamic derangement induced by the paracentesis, by filling up the vascular system, and balancing the decreased vascular resistance ‐ thus, preventing the subsequent activation of vasoconstrictive systems (<a href="./references#CD004039-bbs2-0012" title="GinèsP , TitóL , ArroyoV , PlanasR , PanésJ , ViverJ , et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology1988;94(6):1493‐1502. [PUBMED: 3360270] ">Ginès 1988</a>). The use of albumin is based on its effect on intravascular volume and also on its anti‐inflammatory and vasoconstrictive properties (<a href="./references#CD004039-bbs2-0075" title="Garcia‐MartinezR , CaraceniP , BernardiM , GinesP , ArroyoV , JalanR . Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology2013;58(5):1836‐46. [PUBMED: 23423799] ">Garcia‐Martinez 2013</a>; <a href="./references#CD004039-bbs2-0076" title="Garcia‐TsaoG . Long‐term albumin in cirrhosis: is it the ANSWER?. Lancet2018;391(10138):2391‐2. [PUBMED: 29861077] ">Garcia‐Tsao 2018</a>). </p> </section> <section id="CD004039-sec-0034"> <h3 class="title" id="CD004039-sec-0034">Why it is important to do this review</h3> <p>The benefits of albumin and other colloids have been questioned for a long time. Many randomised clinical trials have been conducted to assess the role of albumin or colloids in the intensive care setting, and several Cochrane systematic reviews have been published on this topic (<a href="./references#CD004039-bbs2-0063" title="Cochrane Injuries Group Albumin Reviewers. Human albumin administration in critically ill patients: systematic review of randomised controlled trials. BMJ1998;317(7153):235‐40. [PUBMED: 9677209] ">Cochrane Injuries Group Albumin Reviewers 1998</a>; <a href="./references#CD004039-bbs2-0155" title="SchierhoutG , RobertsI . Fluid resuscitation with colloid or crystalloid solutions in critically ill patients: a systematic review of randomised trials. BMJ1998;316(7136):961‐4. [PUBMED: 9550953] ">Schierhout 1998a</a>; <a href="./references#CD004039-bbs2-0039" title="AldersonP , BunnF , LefebvreC , Li Wan PoA , LiL , RobertsI , et al. the AlbuminReviewers . Human albumin solution for resuscitation and volume expansion in critically ill patients. Cochrane Database of Systematic Reviews2002, Issue 1. [DOI: 10.1002/14651858.CD001208; PUBMED: 11869596] ">Alderson 2002</a>; <a href="./references#CD004039-bbs2-0146" title="RobertsI , BlackhallK , AldersonP , BunnF , SchierhoutG . Human albumin solution for resuscitation and volume expansion in critically ill patients. Cochrane Database of Systematic Reviews2011, Issue 11. [DOI: 10.1002/14651858.CD001208.pub4; PUBMED: 22071799] ">Roberts 2011</a>; <a href="./references#CD004039-bbs2-0137" title="PerelP , RobertI , KerK . Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database of Systematic Reviews2013, Issue 2. [DOI: 10.1002/14651858.CD000567.pub6; PUBMED: 23450531] ">Perel 2013</a>; <a href="./references#CD004039-bbs2-0122" title="LewisSR , PritchardMW , EvansDJ , ButlerAR , AldersonP , SmithAF , et al. Colloids versus crystalloids for fluid resuscitation in critically ill people. Cochrane Database of Systematic Reviews2018, Issue 8. [DOI: 10.1002/14651858.CD000567.pub7; PUBMED: 30073665] ">Lewis 2018</a>). In the Cochrane review by Perel and colleagues, no benefit was found for colloids, including albumin, when compared with crystalloids for fluid resuscitation in critically ill people with trauma, burns, or following surgery. However, the review found evidence of increased mortality due to the use of hydroxyethyl starch (<a href="./references#CD004039-bbs2-0137" title="PerelP , RobertI , KerK . Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database of Systematic Reviews2013, Issue 2. [DOI: 10.1002/14651858.CD000567.pub6; PUBMED: 23450531] ">Perel 2013</a>). These results are not consistent with results of two other systematic reviews (<a href="./references#CD004039-bbs2-0104" title="HeB , XuB , XuX , LiL , RenR , ChenZ , et al. Hydroxyethyl starch versus other fluids for non‐septic patients in the intensive care unit: a meta‐analysis of randomized controlled trials. Critical Care2015;19:92. [PUBMED: 25886952] ">He 2015</a>; <a href="./references#CD004039-bbs2-0141" title="QureshiSH , RizviSI , PatelNN , MurphyGJ . Meta‐analysis of colloids versus crystalloids in critically ill, trauma and surgical patients. British Journal of Surgery2016;103(1):14‐26. [PUBMED: 26522616] ">Qureshi 2016</a>). More recently, Lewis and colleagues updated the <a href="./references#CD004039-bbs2-0137" title="PerelP , RobertI , KerK . Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database of Systematic Reviews2013, Issue 2. [DOI: 10.1002/14651858.CD000567.pub6; PUBMED: 23450531] ">Perel 2013</a> review, excluding the participants scheduled for elective surgery, and the review authors confirmed that colloids compared with crystalloids for fluid replacement probably made little or no difference in mortality of critically ill people. The review authors did not find increased mortality due to hydroxyethyl starch solutions either (<a href="./references#CD004039-bbs2-0122" title="LewisSR , PritchardMW , EvansDJ , ButlerAR , AldersonP , SmithAF , et al. Colloids versus crystalloids for fluid resuscitation in critically ill people. Cochrane Database of Systematic Reviews2018, Issue 8. [DOI: 10.1002/14651858.CD000567.pub7; PUBMED: 30073665] ">Lewis 2018</a>). hydroxyethyl starch seems to increase mortality in people with severe sepsis, following the studies by <a href="./references#CD004039-bbs2-0100" title="HaaseN , PernerA , HenningsLI , SiegemundM , LauridsenB , WetterslevM , et al. Hydroxyethyl starch 130/0.38‐0.45 versus crystalloid or albumin in patients with sepsis: systematic review with meta‐analysis and trial sequential analysis. BMJ2013;346:f839. [PUBMED: 23418281] ">Haase 2013</a>, <a href="./references#CD004039-bbs2-0101" title="HaaseNR . Hydroxyethyl starch in sepsis. Danish Medical Journal2014;61(1):B4764. [PUBMED: 24393593] ">Haase 2014</a>, and <a href="./references#CD004039-bbs2-0138" title="PernerA , HaaseN , WinkelP , GuttormsenAB , TenhunenJ , KlemenzsonG , et al. Long‐term outcomes in patients with severe sepsis randomised to resuscitation with hydroxyethyl starch 130/0.42 or Ringer's acetate. Intensive Care Medicine2014;40(7):927‐34. [PUBMED: 24807084] ">Perner 2014</a>. These results continue to raise a debate, above all, on the use of albumin and other plasma expanders in intensive care patients (<a href="./references#CD004039-bbs2-0048" title="BapatPP , RaineGJ . Fluid resuscitation with colloid or crystalloid solutions. Use of dextran‐70 for fluid resuscitation has been dying out. BMJ1998;317(7153):278. [PUBMED: 9729073] ">Bapat 1998</a>; <a href="./references#CD004039-bbs2-0049" title="BealeRJ , WyncollDL , McLuckieA . Human albumin administration in critically ill patients. Analysis is superficial and conclusions exaggerated. BMJ1998;317(7162):884. [PUBMED: 9786698] ">Beale 1998</a>; <a href="./references#CD004039-bbs2-0061" title="ChalmersI . Human albumin administration in critically ill patients. I would not want an albumin transfusion. BMJ1998;317(7162):885. [PUBMED: 9786701] ">Chalmers 1998</a>; <a href="./references#CD004039-bbs2-0064" title="CorderAP . Fluid resuscitation with colloid or crystalloid solutions. Virtually identical article had appeared in Cochrane Library. BMJ1998;317(7153):279. [PUBMED: 9729075] ">Corder 1998</a>; <a href="./references#CD004039-bbs2-0074" title="FrameJD , MoiememN . Human albumin administration in critically ill patients. Statisticians not trained in burns care should not evaluate data. BMJ1998;317(7162):884‐5. [PUBMED: 9786700] ">Frame 1998</a>; <a href="./references#CD004039-bbs2-0083" title="GoodmanNW . Human albumin administration in critically ill patients. Paper failed to mention earlier review. BMJ1998;317(7162):884. [PUBMED: 9786699] ">Goodman 1998</a>; <a href="./references#CD004039-bbs2-0084" title="GoslingP . Fluid resuscitation with colloid or crystalloid solutions. Newer synthetic colloids should not be abandoned. BMJ1998;317(7153):277. [PUBMED: 9729070] ">Gosling 1998</a>; <a href="./references#CD004039-bbs2-0115" title="KaagM , ZoetmulderFA . Human albumin administration in critically ill patients. More research into proper use of albumin is needed. BMJ1998;317(7162):883. [PUBMED: 9786696] ">Kaag 1998</a>; <a href="./references#CD004039-bbs2-0121" title="LawlerPG , MorganGA . Human albumin administration in critically ill patients. Modified editorial might have restrained media response. BMJ1998;317(7162):885. [PUBMED: 9786702] ">Lawler 1998</a>; <a href="./references#CD004039-bbs2-0124" title="MakinA , PlenderleithL . Fluid resuscitation with colloid or crystalloid solutions. One conclusion could be that hypertonic saline is better than colloids in trauma. BMJ.1998;317(7153):277‐8. [PUBMED: 9729071] ">Makin 1998</a>; <a href="./references#CD004039-bbs2-0126" title="McAnultyGR , GroundsRM . Fluid resuscitation with colloid or crystalloid solutions. Eight studies should have been excluded. BMJ1998;317(7153):278. [PUBMED: 9729072] ">McAnulty 1998</a>; <a href="./references#CD004039-bbs2-0132" title="NadelS , MarriageS , DeMunterC , BrittoJ , HabibiP , LevinM . Human albumin administration in critically ill patients. Review did not provide recommendations for alternative treatment. BMJ1998;317(7162):882‐3. [PUBMED: 9786694] ">Nadel 1998</a>; <a href="./references#CD004039-bbs2-0133" title="NelR . Human albumin administration in critically ill patients. Critical analysis of original studies has to take place. BMJ1998;317(7162):882. [PUBMED: 9786693] ">Nel 1998</a>; <a href="./references#CD004039-bbs2-0135" title="OffringaM . Excess mortality after human albumin administration in critically ill patients. Clinical and pathophysiological evidence suggests albumin is harmful. BMJ1998;317(7153):223‐4. [PUBMED: 9677204] ">Offringa 1998</a>; <a href="./references#CD004039-bbs2-0139" title="PetrosA , SchindlerM , PierceC , JacobeS , MokQ . Human albumin administration in critically ill patients. Evidence needs to be shown in paediatrics. BMJ1998; Vol. 317, issue 7162:882. [PUBMED: 9748194] ">Petros 1998</a>; <a href="./references#CD004039-bbs2-0143" title="RiordanFA , WilliamsA , ThomsonAP . Human albumin administration in critically ill patients. Albumin has been used in meningococcal disease. BMJ 317;7162:883. [PUBMED: 9786695] ">Riordan 1998</a>; <a href="./references#CD004039-bbs2-0144" title="RobertsI . Human albumin administration in critically ill patients. Authors’ response. BMJ1998;317(7162):886. ">Roberts 1998</a>; <a href="./references#CD004039-bbs2-0156" title="SchierhoutGH , RobertsI . Authors’ reply. BMJ1998;317(7153):279. ">Schierhout 1998b</a>; <a href="./references#CD004039-bbs2-0158" title="ShweKH , BhavnaniM . Human albumin administration in critically ill patients. Some patients may benefit. BMJ1998;317(7162):885‐6. [PUBMED: 9786703] ">Shwe 1998</a>; <a href="./references#CD004039-bbs2-0161" title="SoniN . Human albumin administration in critically ill patients. Validity of review methods must be assessed. BMJ1998;317(7162):883‐4. [PUBMED: 9786697] ">Soni 1998</a>; <a href="./references#CD004039-bbs2-0172" title="WattsJ . Fluid resuscitation with colloid or crystalloid solutions. Comparing different studies is difficult. BMJ1998; Vol. 317, issue 7153:277. [PUBMED: 9677228] ">Watts 1998</a>; <a href="./references#CD004039-bbs2-0179" title="WyncollDL , BealeRJ , McLuckieA . Fluid resuscitation with colloid or crystalloid solutions. Conditions and patient groups were too heterogeneous to allow meaningful comparisons. BMJ1998;317(7153):278‐9. [PUBMED: 9729074] ">Wyncoll 1998</a>; <a href="./references#CD004039-bbs2-0145" title="RobertsI , EdwardsP , McLellandB . More on albumin. Use of human albumin in UK fell substantially when systematic review was published. BMJ1999;318(7192):1214‐5. [PUBMED: 10221965] ">Roberts 1999</a>; <a href="./references#CD004039-bbs2-0103" title="HartogCS , NatansonC , SunJ , KleinHG , ReinhartK . Concerns over use of hydroxyethyl starch solutions. BMJ2014;349:g5981. [PUBMED: 25385352] ">Hartog 2014</a>; <a href="./references#CD004039-bbs2-0101" title="HaaseNR . Hydroxyethyl starch in sepsis. Danish Medical Journal2014;61(1):B4764. [PUBMED: 24393593] ">Haase 2014</a>). </p> <p>In patients with cirrhosis, albumin has been used with different results in connection with paracentesis (<a href="./references#CD004039-bbs2-0079" title="GinésP , ArroyoV , QuinteroE , PlanasR , BoryF , CabreraJ , et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. Gastroenterology1987;93(2):234‐41. [PUBMED: 3297907] ">Ginés 1987</a>; <a href="./references#CD004039-bbs2-0012" title="GinèsP , TitóL , ArroyoV , PlanasR , PanésJ , ViverJ , et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology1988;94(6):1493‐1502. [PUBMED: 3360270] ">Ginès 1988</a>; <a href="./references#CD004039-bbs2-0168" title="TitóL , GinèsP , ArroyoV , PlanasR , PlanésJ , RimolaA , et al. Total paracentesis associated with intravenous albumin management of patients with cirrhosis and ascites. Gastroenterology1990;98(1):146‐51. [PUBMED: 2293573] ">Titó 1990</a>), or in connection with diuretics (<a href="./references#CD004039-bbs2-0078" title="GentiliniP , Casini‐RaggiV , DiFioreG , RomanelliRG , BuzzelliG , PinzaniM , et al. Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. Journal of Hepatology1999;30(4):639‐45. [PUBMED: 10207805] ">Gentilini 1999</a>; <a href="./references#CD004039-bbs2-0147" title="RomanelliRG , LaVillaG , BarlettaG , VizzuttiF , LaniniF , ArenaU , et al. Long‐term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. World Journal of Gastroenterology2006;12(9):1403‐7. [PUBMED: 16552809] ">Romanelli 2006</a>), or in people having spontaneous bacterial peritonitis, or other bacterial infections (<a href="./references#CD004039-bbs2-0162" title="SortP , NavasaM , ArroyoV , AldeguerX , PlanasR , Ruiz‐del‐ArbolL , et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. New England Journal of Medicine1999;341(6):403‐9. [PUBMED: 10432325] ">Sort 1999</a>; <a href="./references#CD004039-bbs2-0087" title="GuevaraM , TerraC , NazarA , SolàE , FernándezJ , PavesiM . Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study. Journal of Hepatology2012;57(4):759‐65. [PUBMED: 22732511] ">Guevara 2012</a>; <a href="./references#CD004039-bbs2-0118" title="KwokCS , KrupaL , MahtaniA , KayeD , RushbrookSM , PhillipsMG , et al. Albumin reduces paracentesis‐induced circulatory dysfunction and reduces death and renal impairment among patients with cirrhosis and infection: a systematic review and meta‐analysis. Biomed Research International2013;2013:1‐8. [DOI: 10.1155/2013/295153; PUBMED: 24222902] ">Kwok 2013</a>; <a href="./references#CD004039-bbs2-0151" title="SalernoF , NavickisRJ , WilkesMM . Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis: a meta‐analysis of randomized trials. Clinical Gastroenterology and Hepatology2013;11(2):123‐30.e1. [PUBMED: 23178229] ">Salerno 2013</a>; <a href="./references#CD004039-bbs2-0167" title="ThévenotT , Bureau C, ObertiF , AntyR , LouvetA , PlessierA , et al. Effect of albumin in cirrhotic patients with infection other than spontaneous bacterial peritonitis. A randomized trial. Journal of Hepatology2015;62(4):822‐30. [PUBMED: 25463545] ">Thévenot 2015</a>), or in patients with hepatorenal syndrome with or without the use of vasoconstrictors (<a href="./references#CD004039-bbs2-0125" title="Martín‐LlahíM , PépinMN , GuevaraM , DíazF , TorreA , MonescilloA , et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology2008;134(5):1352‐9. [PUBMED: 18471512] ">Martín‐Llahí 2008</a>; <a href="./references#CD004039-bbs2-0056" title="BoyerTD , SanyalAJ , WongF , FrederickRT , LakeJR , O'LearyJG , et al. Terlipressin plus albumin Is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology2016;150(7):1579‐89.e2. [PUBMED: 26896734] ">Boyer 2016</a>), or in patients with hyponatraemia (<a href="./references#CD004039-bbs2-0127" title="McCormickPA , MistryP , KayeG , BurroughsAK , McIntyreN . Intravenous albumin infusion is an effective therapy for hyponatraemia in cirrhotic patients with ascites. Gut1990;31(2):204‐7. [PUBMED: 2311979] ">McCormick 1990</a>; <a href="./references#CD004039-bbs2-0114" title="JalanR , MookerjeeRP , CheshireLM , WilliamsR , DaviesNA . Albumin infusion for severe hyponatremia in patients with refractory ascites: a randomized clinical trial. Journal of Hepatology2007;46(1 Suppl):S95. [PUBMED: 17571340] ">Jalan 2007</a>; <a href="./references#CD004039-bbs2-0046" title="BajajJS , TandonP , O'LearyJG , BigginsSW , WongF , KamathPS , et al. The impact of albumin use on resolution of hyponatremia in hospitalized patients with cirrhosis. American Journal of Gastroenterology2018;113(9):1339. [PUBMED: 29880972] ">Bajaj 2018</a>). Recently, an increased survival with long‐term albumin administration was observed in a large open‐label randomised trial including participants with decompensated cirrhosis and uncomplicated ascites treated by diuretics (<a href="./references#CD004039-bbs2-0059" title="CaraceniP , RiggioO , AngeliP , AlessandriaC , NeriS , FoschiFG , et al. Long‐term albumin administration in decompensated cirrhosis (ANSWER): an open‐label randomised trial. Lancet2018;391(10138):2417‐29. [PUBMED: 29861076] ">Caraceni 2018</a>) and in a non randomised study including cirrhotic participants with refractory ascites (<a href="./references#CD004039-bbs2-0067" title="DiPascoliM , FasolatoS , PianoS , BolognesiM , AngeliP . Long‐term administration of human albumin improves survival in patients with cirrhosis and refractory ascites. Liver International2019;39(1):98‐105. [PUBMED: 30230204] ">Di Pascoli 2019</a>). On the contrary, in participants with cirrhosis awaiting liver transplantation, treatment with albumin and midodrine neither prevented complications of cirrhosis nor improved survival (<a href="./references#CD004039-bbs2-0136" title="O’BrienA , KamathPS , TrotterJ . MACHT – Outpatient albumin infusions do not prevent complications of cirrhosis in patients on the liver transplant waiting list. Journal of Hepatology2018;69(6):1217‐8. [DOI: 10.1016/j.jhep.2018.09.025; PUBMED: 30314843] ">O’Brien 2018</a>; <a href="./references#CD004039-bbs2-0160" title="SolàE , SoléC , Simón‐TaleroM , Martín‐LlahíM , CastelloteJ , Garcia‐MartínezR , et al. Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo‐controlled trial. Journal of Hepatology2018;69(6):1250‐9. [PUBMED: 30138685] ">Solà 2018</a>). Conflicting opinions have been recently published on the use of albumin in this peculiar setting of patients (<a href="./references#CD004039-bbs2-0054" title="BernardiM , ZaccheriniG , CaraceniP . Pro: the role of albumin in pre‐liver transplant management. Liver Transplantation2019;25(1):128‐34. [PUBMED: 30346096] ">Bernardi 2019</a>; <a href="./references#CD004039-bbs2-0134" title="O'BrienA . Con: the unclear benefit of albumin. Liver Transplantation2019;25(1):135‐9. [PUBMED: 30447173] ">O'Brien 2019</a>). </p> <p>A meta‐analysis of randomised clinical trials of albumin for a series of indications including treatment of people with cirrhosis and tense ascites (probably comparable to large ascites) showed no effect on mortality (<a href="./references#CD004039-bbs2-0176" title="WilkesM , NavickisRJ . Patient survival after human albumin administration. A meta‐analysis of randomized, controlled trials. Annals of Internal Medicine2001;135(3):149‐64. [PUBMED: 11487482] ">Wilkes 2001</a>). Several other meta‐analyses have followed, including only people with cirrhosis and large ascites (<a href="./references#CD004039-bbs2-0177" title="WongCL , Holroyd‐LeducJ , ThorpeKE , StrausSE . Does this patient have bacterial peritonitis or portal hypertension? How do I perform a paracentesis and analyze the results?. JAMA2008;299(10):1166‐78. [PUBMED: 18334692] ">Wong 2008</a>; <a href="./references#CD004039-bbs2-0051" title="BernardiM , CaraceniP , NavickisRJ , WilkesMM . Albumin infusion in patients undergoing large‐volume paracentesis: a meta‐analysis of randomized trials. Hepatology2012;55(4):1172‐81. [PUBMED: 22095893] ">Bernardi 2012</a>; <a href="./references#CD004039-bbs2-0171" title="WangY‐C , FengM‐l . A meta‐analysis of albumin infusion in patients undergoing large‐volume paracentesis [大量放腹水后输注人体白蛋白疗效的 Meta分析]. Chinese Hepatology2015;20(5):381‐5. [DOI: 10.14000/j.cnki.issn.1008‐1704.2015.05.010] ">Wang 2015</a>). In the meta‐analyses of Bernardi and colleagues in paracentesis‐treated people, albumin versus no treatment reduced post‐paracentesis circulatory dysfunction and hyponatraemia, and albumin versus alternative treatments (other plasma‐expanders and vasoconstrictors) reduced post‐paracentesis circulatory dysfunction, hyponatraemia, and mortality. There was no reduction of other complications (<a href="./references#CD004039-bbs2-0051" title="BernardiM , CaraceniP , NavickisRJ , WilkesMM . Albumin infusion in patients undergoing large‐volume paracentesis: a meta‐analysis of randomized trials. Hepatology2012;55(4):1172‐81. [PUBMED: 22095893] ">Bernardi 2012</a>). Similar results were obtained in the meta‐analysis by Wang and colleagues, in which albumin was compared with other plasma expanders and with vasoconstrictors (<a href="./references#CD004039-bbs2-0171" title="WangY‐C , FengM‐l . A meta‐analysis of albumin infusion in patients undergoing large‐volume paracentesis [大量放腹水后输注人体白蛋白疗效的 Meta分析]. Chinese Hepatology2015;20(5):381‐5. [DOI: 10.14000/j.cnki.issn.1008‐1704.2015.05.010] ">Wang 2015</a>). Wong and colleagues reported data on paracentesis performed with or without albumin, or another plasma expander, and they observed no consistent effect on morbidity or mortality between the interventions (<a href="./references#CD004039-bbs2-0177" title="WongCL , Holroyd‐LeducJ , ThorpeKE , StrausSE . Does this patient have bacterial peritonitis or portal hypertension? How do I perform a paracentesis and analyze the results?. JAMA2008;299(10):1166‐78. [PUBMED: 18334692] ">Wong 2008</a>). The latest meta‐analysis, published by Kütting and colleagues, concluded that there was insufficient evidence of benefit on mortality due to albumin substitution in hepatocellular cancer‐free cirrhotic participants undergoing large volume paracentesis (<a href="./references#CD004039-bbs2-0119" title="KüttingF , SchubertJ , FranklinJ , BoweA , HoffmannV , DemirM , et al. Insufficient evidence of benefit regarding mortality due to albumin substitution in HCC‐free cirrhotic patients undergoing large volume paracentesis. Journal of Gastroenterology and Hepatology2017;32(2):327–38. [PUBMED: 27149296] ">Kütting 2017</a>). </p> <p>Despite the conflicting conclusions of these systematic reviews, plasma expansion with albumin after large volume paracentesis is recommended in several guidelines (<a href="./references#CD004039-bbs2-0035" title="RunyonBA , AASLD . AASLD Practice Guideline. Management of adult patients with ascites due to cirrhosis: update 2012. Hepatology2013;57(4):1651‐3. [PUBMED: 23463403] ">AASLD 2012</a>; <a href="./references#CD004039-bbs2-0037" title="Italian Association for the Study of the Liver (AISF), Italian Society of Transfusion Medicine and Immunohaematology (SIMTI). AISF‐SIMTI position paper: the appropriate use of albumin in patients with liver cirrhosis. Digestive and Liver Disease2016;48(1):4‐15. [PUBMED: 26802734] ">AISF 2016</a>; <a href="./references#CD004039-bbs2-0069" title="European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. Journal of Hepatology2018;69(2):406‐60. [PUBMED: 29653741] ">EASL 2018</a>) with a high grade of recommendations, referring to the <a href="./references#CD004039-bbs2-0051" title="BernardiM , CaraceniP , NavickisRJ , WilkesMM . Albumin infusion in patients undergoing large‐volume paracentesis: a meta‐analysis of randomized trials. Hepatology2012;55(4):1172‐81. [PUBMED: 22095893] ">Bernardi 2012</a> meta‐analysis. </p> <p>The current systematic review will not assess the benefits and harms of plasma expanders in cirrhotic patients for long‐term administration or in people with spontaneous bacterial peritonitis or hepatorenal syndrome, or when used after paracentesis compared with diuretics, or transjugular intrahepatic portosystemic shunt (TIPS). Our objectives are described below. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD004039-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004039-sec-0035">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004039-sec-0222">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD004039-sec-0035"></div> <p>To assess the benefits and harms of any plasma volume expanders such as albumin, other colloids, intravenous infusion of ascitic fluid, crystalloids, or mannitol versus no plasma volume expander or versus another plasma volume expander for paracentesis in people with cirrhosis and large ascites. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD004039-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004039-sec-0036">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004039-sec-0223">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD004039-sec-0036"></div> <section id="CD004039-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD004039-sec-0038"> <h4 class="title">Types of studies</h4> <p>Randomised clinical trials examining plasma volume expanders administered in connection with abdominal paracentesis procedure in people with cirrhosis and large ascites. Trials could have been unpublished or published as full papers, abstracts, or poster presentations. We included trials irrespective of blinding, language, and date of publication. We considered quasi‐randomised studies that were retrieved with the searches for randomised clinical trials for report on harms only, as uncommon adverse events are rarely captured in randomised clinical trials (<a href="./references#CD004039-bbs2-0163" title="StorebøOJ , PedersenN , RamstadE , KielsholmML , NielsenSS , KroghHB , et al. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents – assessment of adverse events in non‐randomised studies. Cochrane Database of Systematic Reviews2018, Issue 5. [DOI: 10.1002/14651858.CD012069.pub2] ">Storebø 2018</a>). We are aware that by using these selection methods we are putting more focus on benefits than on harms of these interventions. </p> </section> <section id="CD004039-sec-0039"> <h4 class="title">Types of participants</h4> <p>Adults with liver cirrhosis and large ascites, either diuretic‐responsive or refractory ascites. The diagnosis of cirrhosis could have been established by clinical and laboratory data, or liver histology. We excluded trials including people with cirrhosis having spontaneous bacterial peritonitis, acute‐on‐chronic liver failure (ACLF), or hepatocellular carcinoma, or people with prior surgical and para‐surgical therapy (surgical large‐caval anastomosis, liver transplantation, and transjugular intrahepatic portosystemic shunt (TIPS)). </p> <p>Ascites is defined as refractory if it could not be mobilised, or the early recurrence of which could not be prevented because of a lack of response to sodium restriction and diuretic treatment (diuretic‐resistant ascites), or because of development of diuretic‐induced complications (e.g. hypotension, hepatic encephalopathy, functional renal impairment, hyponatraemia, etc.) that precluded the use of an effective diuretic dosage (diuretic‐intractable ascites) (<a href="./references#CD004039-bbs2-0044" title="ArroyoV , GinèsP , GerbesAL , DudleyFJ , GentiliniP , LaffiG , et al. International Ascites Club. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology1996;23(1):164‐76. [PUBMED: 8550036] ">Arroyo 1996</a>; <a href="./references#CD004039-bbs2-0130" title="MooreKP , WongF , GinesP , BernardiM , OchsA , SalernoF , et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology2003;38(1):258‐66. [PUBMED: 12830009] ">Moore 2003</a>). We recorded the definition of refractory ascites used in the trials if it deferred from the provided definition above (<a href="./references#CD004039-bbs2-0044" title="ArroyoV , GinèsP , GerbesAL , DudleyFJ , GentiliniP , LaffiG , et al. International Ascites Club. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology1996;23(1):164‐76. [PUBMED: 8550036] ">Arroyo 1996</a>; <a href="./references#CD004039-bbs2-0130" title="MooreKP , WongF , GinesP , BernardiM , OchsA , SalernoF , et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology2003;38(1):258‐66. [PUBMED: 12830009] ">Moore 2003</a>). We labelled 'trials without refractory ascites' those in which participants with refractory ascites were excluded or, if not clearly stated, those trials in which diuretic treatment had been reported until hospital admission, and the mean levels of blood urea, blood creatinine, and blood natrium were normal, because we expected that the proportion of refractory ascites, if present, was low. </p> </section> <section id="CD004039-sec-0040"> <h4 class="title">Types of interventions</h4> <p> <ul id="CD004039-list-0001"> <li> <p>Plasma volume expansion using albumin, other colloids, intravenous infusion of ascitic fluid, crystalloids, or mannitol versus no plasma volume expander (i.e. placebo or no intervention), administered in connection with paracentesis. </p> </li> <li> <p>Plasma volume expansion using one plasma volume expander versus another plasma volume expander, administered in connection with paracentesis. </p> </li> </ul> </p> <p>We included randomised clinical trials with collateral interventions if used in the same way in the trial comparison groups. </p> </section> <section id="CD004039-sec-0041"> <h4 class="title">Types of outcome measures</h4> <section id="CD004039-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD004039-list-0002"> <li> <p>All‐cause mortality at the end of the maximal follow‐up.</p> </li> <li> <p>Serious adverse events at the end of the maximal follow‐up, excluding those for which definition of other liver‐related complications could be applied (see below). We considered an event as a serious adverse event if it fulfilled the definition of serious adverse events of the International Conference on Harmonization (ICH) Guidelines (<a href="./references#CD004039-bbs2-0109" title="International Conference on Harmonisation Expert Working Group. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice CFR &amp; ICH Guidelines. Vol. 1, Philadelphia (PA) 19063‐2043, USA: Barnett International/PAREXEL, 1997. ">ICH 1997</a>), that is, any event that leads to death, is life‐threatening, requires inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability, congenital birth or anomaly, and any important medical event which may have jeopardised the patient or requires intervention to prevent it. We considered all other adverse events as non‐serious. </p> </li> <li> <p>Health‐related quality of life as measured by the trials.</p> </li> </ol> </p> </section> <section id="CD004039-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD004039-list-0003"> <li> <p>Refractory ascites (see the definition above).</p> </li> <li> <p>Renal impairment.</p> </li> <li> <p>Other complications due to liver cirrhosis such as gastrointestinal bleeding, hepatic encephalopathy, or infections (which we defined as 'other liver‐related complications'). This outcome did not include the outcomes listed under exploratory outcomes. </p> </li> <li> <p>Non‐serious adverse events.</p> </li> </ol> </p> <section id="CD004039-sec-0044"> <h6 class="title">Exploratory outcomes</h6> <p> <ol id="CD004039-list-0004"> <li> <p>Recurrence of ascites, defined as ascites that requires repeated paracentesis or hospitalisation, or both. </p> </li> <li> <p>Hypotension as defined by the trial authors.</p> </li> <li> <p>Hyponatraemia as defined by the trial authors.</p> </li> <li> <p>Post‐paracentesis circulatory dysfunction, defined as an increase in the plasma renin activity of more than 50 per cent of the pretreatment value to a level of more than 4 ng/mL/h on the sixth day after paracentesis (<a href="./references#CD004039-bbs2-0013" title="GinèsA , Fernández‐EsparrachG , MonescilloA , VilaC , DomènechE , AbecasisR , et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology1996;111(4):1002‐10. [PUBMED: 8831595] International Group for the Study of Ascites in Cirrhosis. Comparison of albumin, dextran‐70 and hemaccel in the prevention of effective hypovolemia in cirrhotic patients with ascites treated with total paracentesis. A randomized multicenter study. Hepatology1995;22(4 Suppl):220A. ">Ginès 1996</a>). </p> </li> </ol> </p> </section> </section> </section> </section> <section id="CD004039-sec-0045"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD004039-sec-0046"> <h4 class="title">Electronic searches</h4> <p>We identified relevant studies by searching the Cochrane Hepato‐Biliary Group Controlled Trials Register (January 2019), the Cochrane Central Register of Controlled Trials (CENTRAL in the Cochrane Library, Issue 1, 2019), MEDLINE (1946 to January 2019), Embase (1974 to January 2019), LILACS (1982 to January 2019), three Chinese database including CNKI, VIP, and Wanfang (to August 2015), Science Citation Index Expanded (1900 to January 2019), and Conference Proceedings Citation Index (1990 to January 2019). </p> <p>We also searched databases of ongoing trials (<a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov/</a> and <a href="http://www.controlled-trials.com/" target="_blank">www.controlled‐trials.com/</a>) (with links to several databases). In addition, we searched the European Medicines Agency (EMA, www.ema.europe.eu), US Food and Drug Administration (FDA, www.fda.gov), and the World Health Organization International Clinical Trials Registry Platform (<a href="./references#CD004039-bbs2-0110" title="World Health Organization. International Clinical Trials Registry Platform (ICTRP). www.who.int/ictrp/en/ (accessed prior to 16 June 2016). ">ICTRP 2011</a>) until January 2019. For detailed search strategies, see <a href="./appendices#CD004039-sec-0205">Appendix 1</a>. We did not apply any language or document type restrictions. We contacted authors of the included trials to request missing information. </p> </section> <section id="CD004039-sec-0047"> <h4 class="title">Searching other resources</h4> <p>We checked references of included trials, meta‐analyses, and other publications that were retrieved with the searches for randomised clinical trials in order to identify further trials of relevance to our review. </p> </section> </section> <section id="CD004039-sec-0048"> <h3 class="title" id="CD004039-sec-0048">Data collection and analysis</h3> <p>We performed the systematic review and meta‐analyses following recommendations of Cochrane (<a href="./references#CD004039-bbs2-0107" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. available from handbook.cochrane.org. ">Higgins 2011</a>), and the Cochrane Hepato‐Biliary Group (<a href="./references#CD004039-bbs2-0082" title="GluudC , NikolovaD , KlingenbergSL , Cochrane Hepato‐Biliary Group. About Cochrane (Cochrane Review Groups (CRGs)). CHBG Module. hbg.cochrane.org (accessed prior to 16 June 2019). ">Gluud 2015</a>). In the case of cross‐over trials, we included data only from the first period (<a href="./references#CD004039-bbs2-0107" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. available from handbook.cochrane.org. ">Higgins 2011</a>). We performed the analyses using Review Manager 5.3 (<a href="./references#CD004039-bbs2-0142" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>) and Trial Sequential Analysis version 0.9 (<a href="./references#CD004039-bbs2-0173" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [PUBMED: 18083463] ">Wetterslev 2008</a>; <a href="./references#CD004039-bbs2-0166" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for Trial Sequential Analysis (TSA). www.ctu.dk/tsa/files/TSA_manual.pdf (accessed prior to 16 June 2019). ">Thorlund 2011</a>; <a href="./references#CD004039-bbs2-0169" title="Copenhagen Trial Unit, Center for Clinical Intervention Research, Rigshospitalet. TSA ‐ Trial Sequential Analysis. Version 0.9.5.10 Beta. Copenhagen, Denmark: Copenhagen Trial Unit, Center for Clinical Intervention Research, Rigshospitalet, 2011. ">TSA 2011</a>). We assessed the evidence according to recommendations from Jakobsen and colleagues (<a href="./references#CD004039-bbs2-0111" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14:120. [PUBMED: 25416419] ">Jakobsen 2014</a>). </p> <section id="CD004039-sec-0049"> <h4 class="title">Selection of studies</h4> <p>Two of the authors, RGS and GP, independently of each other, identified the trials for inclusion in accordance with the inclusion criteria of the updated review protocol and listed the excluded studies with the reasons for their exclusion. RGS and GP resolved disagreements through discussions. </p> </section> <section id="CD004039-sec-0050"> <h4 class="title">Data extraction and management</h4> <p>Two authors, RGS and GP, independently extracted data. We resolved disagreements by discussion. Data extraction encompassed:<br/> ‐ trial inclusion and exclusion criteria;<br/> ‐ the comparability between the groups randomised to alternative treatments regarding baseline prognostic variables: aetiology of cirrhosis; mean age; proportion of males/females; participants with Child‐Pugh stages A, B, or C (<a href="./references#CD004039-bbs2-0140" title="PughRN , Murray‐LyonIM , DawsonJL , PietroniMC , WilliamsR . Transection of the oesophagus for bleeding oesophageal varices. British Journal of Surgery1973;60(8):646‐9. [PUBMED: 4541913] ">Pugh 1973</a>); proportion of participants with hepatic encephalopathy, with previous gastrointestinal bleeding episodes, with type of ascites (that is, large ascites: either diuretic‐responsive, or refractory ascites), or with arterial hypotension; mean arterial pressure; renal impairment; hyponatraemia. Furthermore, we recorded plasma renin activity, plasma aldosterone levels, urinary sodium excretion, and information on liver biochemistry (serum bilirubin, albumin, and prothrombin time or international normalised ratio);<br/> ‐ treatments during the trial: type and dose of plasma expander, and timing of administration of plasma expander in connection to paracentesis; for intravenous infusion of ascitic fluid, whether or not the ascitic fluid was filtered and concentrated; type of paracentesis (partial or total paracentesis); total amount of ascitic fluid removed; length of the procedure; sodium restriction and diuretics (type and dose) before and after paracentesis; timing for clinical and laboratory assessment;<br/> ‐ sample size calculation performed and reported;<br/> ‐ completeness and length of follow‐up of treatment groups and reasons for withdrawals;<br/> ‐ presence of, absence of or unknown for‐profit support. </p> </section> <section id="CD004039-sec-0051"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Due to the risk of overestimation of beneficial intervention effects and underestimation of harmful intervention effects in randomised clinical trials at unclear risk of bias or at high risk of bias (<a href="./references#CD004039-bbs2-0157" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408‐12. [PUBMED: 7823387] ">Schulz 1995</a>; <a href="./references#CD004039-bbs2-0129" title="MoherD , PhamB , JonesA , CookDJ , JadadAR , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet1998;352(9128):609‐13. [PUBMED: 9746022] ">Moher 1998</a>; <a href="./references#CD004039-bbs2-0117" title="KjaergardLL , VillumsenJ , GluudC . Reported methodological quality and dicrepancies between small and large randomized trials in meta‐analysis. Annals of Internal Medicine2001;135(11):982‐9. [PUBMED: 11730399] ">Kjaergard 2001</a>; <a href="./references#CD004039-bbs2-0178" title="WoodL , EggerM , GluudLL , SchulzKF , JüniP , AltmanGD , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ2008;336(7644):601‐5. [PUBMED: 18316340] ">Wood 2008</a>; <a href="./references#CD004039-bbs2-0153" title="SavovićJ , JonesHE , AltmanD , HarrisR , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials: combined analysis of meta‐epidemiological studies. Health Technology Assessment2012;16(35):1‐82. [PUBMED: 22989478] ">Savović 2012a</a>; <a href="./references#CD004039-bbs2-0154" title="SavovićJ , JonesHE , AltmanDG , HarrisRJ , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157(6):429‐38. [PUBMED: 22945832] ">Savović 2012b</a>), we assessed the influence of the risk of bias on our results. We used the domains with definitions provided below to assess the risk of bias in the included trials (<a href="./references#CD004039-bbs2-0107" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. available from handbook.cochrane.org. ">Higgins 2011</a>; <a href="./references#CD004039-bbs2-0082" title="GluudC , NikolovaD , KlingenbergSL , Cochrane Hepato‐Biliary Group. About Cochrane (Cochrane Review Groups (CRGs)). CHBG Module. hbg.cochrane.org (accessed prior to 16 June 2019). ">Gluud 2015</a>). </p> <p><b>Allocation sequence generation</b> </p> <p> <ul id="CD004039-list-0005"> <li> <p>Low risk of bias: sequence generation was achieved using computer random number generation or a random number table. Drawing lots, tossing a coin, shuffling cards, and throwing dice are adequate if performed by an independent research assistant not otherwise involved in the trial. </p> </li> <li> <p>Unclear risk of bias: the method of sequence generation was not specified.</p> </li> <li> <p>High risk of bias: the sequence generation method was not random.</p> </li> </ul> </p> <p><b>Allocation concealment</b> </p> <p> <ul id="CD004039-list-0006"> <li> <p>Low risk of bias: the participant allocations could not have been foreseen in advance of, or during enrolment. Allocation was controlled by a central and independent randomisation unit. The allocation sequence was unknown to the investigators (for example, if the allocation sequence was hidden in sequentially numbered, opaque, and sealed envelopes). </p> </li> <li> <p>Unclear risk of bias: the method used to conceal the allocation was not described so that intervention allocations may have been foreseen in advance of, or during enrolment. </p> </li> <li> <p>High risk of bias: the allocation sequence was likely to be known to the investigators who assigned the participants. </p> </li> </ul> </p> <section id="CD004039-sec-0052"> <h5 class="title">Blinding of participants and personnel</h5> <p> <ul id="CD004039-list-0007"> <li> <p>Low risk of bias: any of the following: no blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding; or blinding of participants and key study personnel ensured, and it is unlikely that the blinding could have been broken. </p> </li> <li> <p>Unclear risk of bias: any of the following: insufficient information to permit judgement of ‘low risk’ or ‘high risk’; or the trial did not address this outcome. </p> </li> <li> <p>High risk of bias: any of the following: no blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding; or blinding of key study participants and personnel attempted, but likely that the blinding could have been broken, and the outcome is likely to be influenced by lack of blinding. </p> </li> </ul> </p> </section> <section id="CD004039-sec-0053"> <h5 class="title">Blinding of outcome assessment</h5> <p> <ul id="CD004039-list-0008"> <li> <p>Low risk of bias: any of the following: no blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding; or blinding of outcome assessment ensured, and unlikely that the blinding could have been broken. </p> </li> <li> <p>Unclear risk of bias: any of the following: insufficient information to permit judgement of ‘low risk’ or ‘high risk’; or the trial did not address this outcome. </p> </li> <li> <p>High risk of bias: any of the following: no blinding of outcome assessment, and the outcome measurement is likely to be influenced by lack of blinding; or blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blinding. </p> </li> </ul> </p> <p><b>Incomplete outcome data</b> </p> <p> <ul id="CD004039-list-0009"> <li> <p>Low risk of bias: missing data were unlikely to make treatment effects depart from plausible values. The study used sufficient methods, such as multiple imputation, to handle missing data. </p> </li> <li> <p>Unclear risk of bias: there was insufficient information to assess whether missing data in combination with the method used to handle missing data were likely to induce bias on the results. </p> </li> <li> <p>High risk of bias: the results were likely to be biased due to missing data.</p> </li> </ul> </p> <p><b>Selective outcome reporting</b> </p> <p> <ul id="CD004039-list-0010"> <li> <p>Low risk of bias: the trial reported the following predefined outcomes: all‐cause mortality, serious adverse events, refractory ascites, renal impairment, other complications due to liver cirrhosis such as gastrointestinal bleeding, hepatic encephalopathy, or infections, and non‐serious adverse events. If the original protocol was available, the outcomes should be those called for in that protocol. If the trial protocol was obtained from a trial registry (e.g. <a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>), the outcomes sought should have been those enumerated in the original protocol if the trial protocol was registered before or at the time when the trial was begun. If the trial protocol was registered after the trial was begun, those outcomes were not considered to be reliable. </p> </li> <li> <p>Unclear risk of bias: the study authors did not report all predefined outcomes fully, or it was not clear whether data on this outcomes were recorded or not. </p> </li> <li> <p>High risk of bias: the study authors did not report all‐cause mortality or more secondary predefined outcomes. </p> </li> </ul> </p> <p><b>Other bias</b> </p> <p> <ul id="CD004039-list-0011"> <li> <p>Low risk of bias: the trial appeared to be free of other bias domains that could put it at risk of bias. </p> </li> <li> <p>Unclear risk of bias: the trial might or might not have been free of other domains that could have put it at risk of bias. </p> </li> <li> <p>High risk of bias: there are other factors in the trial that could put it at risk of bias. </p> </li> </ul> </p> <p>RGS and GP judged a trial to be at an overall low risk of bias when the trial was assessed as having a low risk of bias in all the above domains. RGS and GP judged a trial to be at an overall high risk of bias when the trial was assessed as having an unclear risk of bias or a high a risk of bias in one or more of the above domains. </p> <p>RGS and GP resolved disagreements by discussion.</p> </section> </section> <section id="CD004039-sec-0054"> <h4 class="title">Measures of treatment effect</h4> <p><b>Dichotomous outcomes</b><br/> We used the risk ratio (RR) with 95% CI. We used both fixed‐effect and random‐effects meta‐analysis models. </p> <p><b>Continuous outcomes</b><br/> We planned to use the mean difference (MD) with 95% CI or the standard mean difference (SMD) with 95% CI, depending on whether the scales used in the trials were the same or different. </p> </section> <section id="CD004039-sec-0055"> <h4 class="title">Unit of analysis issues</h4> <p>The participants as randomised to the intervention groups of the clinical trials. In trials with a two parallel group design, we compared the experimental intervention group versus the control group. In the trials with a parallel group design with more than two intervention groups, we compared separately each of the experimental groups with the control group divided proportionately according to number of experimental groups. </p> <p>In cross‐over trials, we only included the data from the first trial period in order avoid residual effects from the treatment (<a href="./references#CD004039-bbs2-0107" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. available from handbook.cochrane.org. ">Higgins 2011</a>). In order to avoid repeated observations on trial participants, we used participant trial data at the longest follow‐up (<a href="./references#CD004039-bbs2-0107" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. available from handbook.cochrane.org. ">Higgins 2011</a>). </p> </section> <section id="CD004039-sec-0056"> <h4 class="title">Dealing with missing data</h4> <p>We tried to obtain missing data from authors of the included trials. We investigated attrition bias (i.e. dropouts, losses to follow‐up, and withdrawals). We performed our analyses based on the intention‐to‐treat principle, whenever possible. </p> <p>Regarding the primary outcomes, we included participants with incomplete or missing data in sensitivity analyses by imputing them according to the following two extreme case scenarios (<a href="./references#CD004039-bbs2-0108" title="HollisS , CampbellF . What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ1999;319(7211):670‐4. [PUBMED: 10480822] ">Hollis 1999</a>): </p> <p>‐ Extreme case analysis favouring the experimental intervention ('best‐worst' case scenario): none of the dropouts/participants lost from the experimental arm, but all of the dropouts/participants lost from the control arm experienced the outcome, including all randomised participants in the denominator.<br/> ‐ Extreme case analysis favouring the control ('worst‐best' case scenario): all dropouts/participants lost from the experimental arm, but none from the control arm experienced the outcome, including all randomised participants in the denominator. </p> </section> <section id="CD004039-sec-0057"> <h4 class="title">Assessment of heterogeneity</h4> <p>We checked for heterogeneity through visual inspection of the forest plots by using a standard Chi<sup>2</sup> test and a significance level of α = 0.1. In view of the low power of such tests, we also examined heterogeneity by using the I<sup>2</sup> statistic (<a href="./references#CD004039-bbs2-0105" title="HigginsJP , ThompsonSG . Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine2002;21(11):1539‐58. [PUBMED: 12111919] ">Higgins 2002</a>); I<sup>2</sup> values of 50% or more indicate a substantial level of heterogeneity (<a href="./references#CD004039-bbs2-0106" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. [PUBMED: 12958120] ">Higgins 2003</a>). When heterogeneity was found, we attempted to determine potential reasons for it by examining individual trial characteristics and subgroups. For heterogeneity adjustment of the required information size, we used diversity, the D<sup>2</sup> statistic (<a href="./references#CD004039-bbs2-0174" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in a random‐effects meta‐analysis. BMC Medical Research Methodology2009;9:86. [PUBMED: 20042080] ">Wetterslev 2009</a>). </p> </section> <section id="CD004039-sec-0058"> <h4 class="title">Assessment of reporting biases</h4> <p>Whenever we had 10 or more trials, we drew funnel plots to assess reporting biases from the individual trials by plotting the risk ratio (RR) on a logarithmic scale against its standard error (<a href="./references#CD004039-bbs2-0070" title="EggerM , SmithGD , PhillipsAN . Meta‐analysis: principles and procedure. BMJ1997;315(7121):1533‐7. [PUBMED: 9432252] ">Egger 1997</a>; <a href="./references#CD004039-bbs2-0107" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. available from handbook.cochrane.org. ">Higgins 2011</a>). </p> <p>For dichotomous outcomes, we tested asymmetry using the Harbord test in case tau<sup>2</sup> was less than 0.1 (<a href="./references#CD004039-bbs2-0102" title="HarbordRM , EggerM , SterneJA . A modified test for small‐study effects in meta‐analyses of controlled trials with binary endpoints. Statistics in Medicine2006;25(20):3443‐57. [PUBMED: 16345038] ">Harbord 2006</a>), and we used <a href="./references#CD004039-bbs2-0150" title="RückerG , SchwarzerG , CarpenterJ . Arcsine test for publication bias in meta‐analyses with binary outcomes. Statistics in Medicine2008;27(5):746‐63. [PUBMED: 17592831] ">Rücker 2008</a> in case tau<sup>2</sup> was more than 0.1. We planned to use the regression asymmetry test (<a href="./references#CD004039-bbs2-0070" title="EggerM , SmithGD , PhillipsAN . Meta‐analysis: principles and procedure. BMJ1997;315(7121):1533‐7. [PUBMED: 9432252] ">Egger 1997</a>) and the adjusted rank correlation coefficient (<a href="./references#CD004039-bbs2-0050" title="BeggCB , MazumdarM . Operating characteristics of a rank correlation test for publication bias. Biometrics1994;50(4):1088‐101. [PUBMED: 7786990] ">Begg 1994</a>) for our continuous outcome, health‐related quality of life. </p> </section> <section id="CD004039-sec-0059"> <h4 class="title">Data synthesis</h4> <p><b>Meta‐analysis</b> </p> <p>For the statistical analyses, we used Review Manager 5 (<a href="./references#CD004039-bbs2-0142" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). For dichotomous outcomes, we calculated the Mantel‐Haenszel risk ratios (RRs). We planned to use the mean difference (MD) for the continuous outcome, health‐related quality of life. </p> <p>We performed the analyses using the intention‐to‐treat (ITT) principle, including all randomly assigned participants, irrespective of completeness of data. </p> <p>Review Manager 5 does not include trials with zero events in both intervention groups when calculating RR (<a href="./references#CD004039-bbs2-0142" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). To account for trials with zero events, we used Trial Sequential Analysis with a continuity correction (<a href="./references#CD004039-bbs2-0166" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for Trial Sequential Analysis (TSA). www.ctu.dk/tsa/files/TSA_manual.pdf (accessed prior to 16 June 2019). ">Thorlund 2011</a>; <a href="./references#CD004039-bbs2-0169" title="Copenhagen Trial Unit, Center for Clinical Intervention Research, Rigshospitalet. TSA ‐ Trial Sequential Analysis. Version 0.9.5.10 Beta. Copenhagen, Denmark: Copenhagen Trial Unit, Center for Clinical Intervention Research, Rigshospitalet, 2011. ">TSA 2011</a>). </p> <p>We compared the intervention effects in subgroups of trials using <a href="./references#CD004039-bbs2-0142" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>. </p> <p>We intended to calculate the number‐needed‐to‐treat for an additional beneficial outcome (NNTB). </p> <p><b>Trial Sequential Analysis</b> </p> <p>As a sensitivity analysis for our GRADE assessment of imprecision (see below), we used Trial Sequential Analysis which considers choice of statistical model (fixed or random) and diversity (<a href="./references#CD004039-bbs2-0166" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for Trial Sequential Analysis (TSA). www.ctu.dk/tsa/files/TSA_manual.pdf (accessed prior to 16 June 2019). ">Thorlund 2011</a>; <a href="./references#CD004039-bbs2-0169" title="Copenhagen Trial Unit, Center for Clinical Intervention Research, Rigshospitalet. TSA ‐ Trial Sequential Analysis. Version 0.9.5.10 Beta. Copenhagen, Denmark: Copenhagen Trial Unit, Center for Clinical Intervention Research, Rigshospitalet, 2011. ">TSA 2011</a>). We calculated the diversity‐adjusted required information size (DARIS, i.e. the number of participants needed in a meta‐analysis to detect or reject a certain intervention effect) (<a href="./references#CD004039-bbs2-0057" title="BrokJ , ThorlundK , GluudC , WetterslevJ . Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta‐analyses. Journal of Clinical Epidemiology2008;61(8):763‐9. [PUBMED: 18411040] ">Brok 2008</a>; <a href="./references#CD004039-bbs2-0173" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [PUBMED: 18083463] ">Wetterslev 2008</a>; <a href="./references#CD004039-bbs2-0058" title="BrokJ , ThorlundK , WetterslevJ , GluudC . Apparently conclusive meta‐analyses may be inconclusive ‐ trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta‐analyses. International Journal of Epidemiology2009;38(1):287‐98. [PUBMED: 18824466] ">Brok 2009</a>; <a href="./references#CD004039-bbs2-0174" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in a random‐effects meta‐analysis. BMC Medical Research Methodology2009;9:86. [PUBMED: 20042080] ">Wetterslev 2009</a>; <a href="./references#CD004039-bbs2-0165" title="ThorlundK , AnemaA , MillsE . Interpreting meta‐analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV‐infected individuals. Clinical Epidemiology2010;2:57‐66. [PUBMED: 20865104] ">Thorlund 2010</a>; <a href="./references#CD004039-bbs2-0175" title="WetterslevJ , JakobsenJC , GluudC . Trial Sequential Analysis in systematic reviews with meta‐analysis. BMC Medical Research Methodology2017;17(1):39. [PUBMED: 28264661] ">Wetterslev 2017</a>). </p> <p>The underlying assumption of Trial Sequential Analysis is that testing for statistical significance may be performed each time a new trial is added to the meta‐analysis. We added the trials according to the year of publication, and, if more than one trial was published in a year, we added the trials alphabetically according to the last name of the first author. On the basis of the DARIS, we constructed the trial sequential monitoring boundaries for benefit, harm, and futility (<a href="./references#CD004039-bbs2-0173" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [PUBMED: 18083463] ">Wetterslev 2008</a>; <a href="./references#CD004039-bbs2-0174" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in a random‐effects meta‐analysis. BMC Medical Research Methodology2009;9:86. [PUBMED: 20042080] ">Wetterslev 2009</a>; <a href="./references#CD004039-bbs2-0166" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for Trial Sequential Analysis (TSA). www.ctu.dk/tsa/files/TSA_manual.pdf (accessed prior to 16 June 2019). ">Thorlund 2011</a>; <a href="./references#CD004039-bbs2-0175" title="WetterslevJ , JakobsenJC , GluudC . Trial Sequential Analysis in systematic reviews with meta‐analysis. BMC Medical Research Methodology2017;17(1):39. [PUBMED: 28264661] ">Wetterslev 2017</a>). These boundaries determine the statistical inference one may draw regarding the cumulative meta‐analysis that has not reached the DARIS; if the trial sequential monitoring boundary for benefit or harm is crossed before the DARIS is reached, firm evidence may be established and further trials may be superfluous. However, if the boundaries for benefit or harm are not crossed, it is most probably necessary to continue doing trials in order to detect or reject a certain intervention effect. However, if the cumulative Z‐curve crosses the trial sequential monitoring boundaries for futility, no more trials may be needed. </p> <p>In our Trial Sequential Analysis of the two primary dichotomous outcomes, we based the DARIS on the event proportion in the control group; assuming a plausible relative risk reduction for mortality of 10% and a relative risk reduction for serious adverse events of 5%; a risk of type I error of 2.5% due to the three primary outcomes (<a href="./references#CD004039-bbs2-0111" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14:120. [PUBMED: 25416419] ">Jakobsen 2014</a>); a risk of type II error of 20%; and the diversity of the included trials in the meta‐analysis. For the continuous outcome, health‐related quality of life, we planned to estimate the DARIS using a minimal relevant difference of 10% of the mean response observed in the control group; the standard deviation of the meta‐analysis; alpha of 2.5% due to the three primary outcomes (<a href="./references#CD004039-bbs2-0111" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14:120. [PUBMED: 25416419] ">Jakobsen 2014</a>); beta of 20%; and the diversity as estimated from the trials in the meta‐analysis (<a href="./references#CD004039-bbs2-0174" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in a random‐effects meta‐analysis. BMC Medical Research Methodology2009;9:86. [PUBMED: 20042080] ">Wetterslev 2009</a>). We also calculated the Trial Sequential Analysis‐adjusted confidence intervals (CI) (<a href="./references#CD004039-bbs2-0166" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for Trial Sequential Analysis (TSA). www.ctu.dk/tsa/files/TSA_manual.pdf (accessed prior to 16 June 2019). ">Thorlund 2011</a>; <a href="./references#CD004039-bbs2-0175" title="WetterslevJ , JakobsenJC , GluudC . Trial Sequential Analysis in systematic reviews with meta‐analysis. BMC Medical Research Methodology2017;17(1):39. [PUBMED: 28264661] ">Wetterslev 2017</a>). </p> <p>In our Trial Sequential Analysis of secondary outcomes, we based the DARIS for dichotomous outcomes on the event proportion in the control group; we made an assumption of a relative risk reduction of 10% for refractory ascites, renal impairment, other liver‐related complications, and non‐severe adverse events; a type I error risk of 2.0% due to the four secondary outcomes (<a href="./references#CD004039-bbs2-0111" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14:120. [PUBMED: 25416419] ">Jakobsen 2014</a>); a risk of type II error of 20%; and the diversity of the included trials in the meta‐analysis. </p> <p>A more detailed description of Trial Sequential Analysis and software program can be found at <a href="http://www.ctu.dk/tsa/" target="_blank">www.ctu.dk/tsa/</a> (<a href="./references#CD004039-bbs2-0166" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for Trial Sequential Analysis (TSA). www.ctu.dk/tsa/files/TSA_manual.pdf (accessed prior to 16 June 2019). ">Thorlund 2011</a>). </p> <p><b>Assessment of significance based on the standard meta‐analysis method and Trials Sequential Analysis method</b> </p> <p>We conducted both fixed‐effect and random‐effects model meta‐analyses. If the fixed‐effect and random‐effects models showed different results, then the most conservative result (the analysis with the highest P value, i.e. closest to the null hypothesis) was chosen as the main result of the two analyses (<a href="./references#CD004039-bbs2-0111" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14:120. [PUBMED: 25416419] ">Jakobsen 2014</a>). </p> <p>We considered a P value of 0.025 or less, two‐tailed, as statistically significant if the DARIS was reached due to our three primary outcomes (<a href="./references#CD004039-bbs2-0111" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14:120. [PUBMED: 25416419] ">Jakobsen 2014</a>). We considered a P value of 0.02 or less, two‐tailed, as statistically significant if the required information size was reached due to our four secondary outcomes. We used the eight‐step procedure to assess if the thresholds for significance were crossed (<a href="./references#CD004039-bbs2-0111" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14:120. [PUBMED: 25416419] ">Jakobsen 2014</a>). We presented heterogeneity using the I<sup>2</sup> statistic (<a href="./references#CD004039-bbs2-0105" title="HigginsJP , ThompsonSG . Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine2002;21(11):1539‐58. [PUBMED: 12111919] ">Higgins 2002</a>). We presented the results of the individual trials and meta‐analyses in the form of forest plots. </p> <p>Where data were only available from one trial, we used Fisher's exact test for dichotomous data (<a href="./references#CD004039-bbs2-0073" title="FisherRA . On the interpretation of X2 from contingency tables, and the calculation of P. Journal of the Royal Statistical Society1922;85(1):87‐94. ">Fisher 1922</a>). We planned to use Student's t‐test for continuous data such as 'health‐related quality of life' (<a href="./references#CD004039-bbs2-0164" title="Student . The probable error of a mean. Biometrika1908;6(1):1‐25. ">Student 1908</a>). </p> </section> <section id="CD004039-sec-0060"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to perform the following subgroup analyses:</p> <p> <ul id="CD004039-list-0012"> <li> <p>risk of bias, analysing separately randomised clinical trials at low risk of bias and trials at high risk of bias; </p> </li> <li> <p>type of plasma expanders, analysing separately randomised clinical trials according to the plasma expander used; </p> </li> <li> <p>refractory ascites, analysing separately randomised clinical trials including participants with refractory ascites and trials including participants without refractory ascites; </p> </li> <li> <p>modality of paracentesis, analysing separately randomised clinical trials in which partial paracentesis repeated until disappearance of ascites were used, and randomised clinical trials in which total, one‐session paracentesis were used; </p> </li> <li> <p>length of follow‐up, analysing separately randomised clinical trials with up to one month follow‐up (short follow‐up trials) and trials with a follow‐up longer than one month (long follow‐up trials); </p> </li> <li> <p>trials without for‐profit support compared to trials with or unknown for‐profit support (see <a href="./appendices#CD004039-sec-0206">Appendix 2</a> for definition) (<a href="./references#CD004039-bbs2-0123" title="LundhA , LexchinJ , MintzesB , SchrollJB , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.MR000033.pub3; PUBMED: 28207928] ">Lundh 2017</a>). </p> </li> </ul> </p> <p>To determine whether a statistically significant subgroup difference was detected, we considered the P value from the test for subgroup differences. We used the test to assess the difference between the pooled effect estimates for each subgroup. A P value of less than 0.1 showed a significant subgroup effect. </p> </section> <section id="CD004039-sec-0061"> <h4 class="title">Sensitivity analysis</h4> <p>For sensitivity analyses, see <a href="https://archie.cochrane.org/sections/documents/view?version=z1502271417501886861534682026219%26format=REVMAN#MISSING_DATA" target="_blank">Dealing with missing data</a> and 'Summary of findings' tables paragraphs. </p> <section id="CD004039-sec-0062"> <h5 class="title">'Summary of findings' tables</h5> <p>We assessed the certainty of the evidence using the GRADE system to present review results in 'Summary of findings' (SoF) tables, using GRADEPro 3.6 (<a href="http://ims.cochrane.org/revman/gradepro" target="_blank">http://ims.cochrane.org/revman/gradepro</a>). In SoF tables, we included three <a href="#CD004039-sec-0042">Primary outcomes</a> as well as four <a href="#CD004039-sec-0043">Secondary outcomes</a>. We designed two Sof tables as we have two comparisons (<a href="./full#CD004039-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD004039-tbl-0002">summary of findings Table 2</a>). A SoF table consists of three parts: information about the review, a summary of the statistical results, and the grade of the certainty of evidence. The assessment of certainty of the available evidence is comprised of the number of studies, the types of studies (randomised or observational), and five factors including within study risk of bias, inconsistency of results (heterogeneity), indirectness of evidence (population, intervention, control, outcomes), imprecision of results, and publication bias that affect the certainty of the evidence (<a href="./references#CD004039-bbs2-0088" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. [PUBMED: 18436948] ">Guyatt 2008</a>; <a href="./references#CD004039-bbs2-0047" title="BalshemH , HelfandM , SchünemannHJ , OxmanAD , KunzR , BrozekJ , et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology2011;64(4):401‐6. [PUBMED: 21208779] ">Balshem 2011</a>; <a href="./references#CD004039-bbs2-0089" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction ‐ GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383‐94. [PUBMED: 21195583] ">Guyatt 2011a</a>; <a href="./references#CD004039-bbs2-0090" title="GuyattGH , OxmanAD , KunzR , AtkinsD , BrozekJ , VistG , et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. Journal of Clinical Epidemiology2011;64(4):395‐400. [PUBMED: 21194891] ">Guyatt 2011b</a>; <a href="./references#CD004039-bbs2-0091" title="GuyattGH , OxmanAD , VistG , KunzR , BrozekJ , Alonso‐CoelloP , et al. GRADE guidelines: 4. Rating the quality of evidence ‐ study limitations (risk of bias). Journal of Clinical Epidemiology2011;64(4):407‐15. [PUBMED: 21247734] ">Guyatt 2011c</a>; <a href="./references#CD004039-bbs2-0092" title="GuyattGH , OxmanAD , MontoriV , VistG , KunzR , BrozekJ , et al. GRADE guidelines: 5. Rating the quality of evidence ‐ publication bias. Journal of Clinical Epidemiology2011;64(12):1277‐82. [PUBMED: 21802904] ">Guyatt 2011d</a>; <a href="./references#CD004039-bbs2-0093" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso‐CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence ‐ imprecision. Journal of Clinical Epidemiology2011;64(12):1283‐93. [PUBMED: 21839614] ">Guyatt 2011e</a>; <a href="./references#CD004039-bbs2-0094" title="GuyattGH , OxmanAD , KunzR , WoodcockJ , BrozekJ , HelfandM , et al. GRADE guidelines: 7. Rating the quality of evidence ‐ inconsistency. Journal of Clinical Epidemiology2011;64(12):1294‐302. [PUBMED: 21803546] ">Guyatt 2011f</a>; <a href="./references#CD004039-bbs2-0095" title="GuyattGH , OxmanAD , KunzR , WoodcockJ , BrozekJ , HelfandM , et al. GRADE guidelines: 8. Rating the quality of evidence ‐ indirectness. Journal of Clinical Epidemiology2011;64(12):1303‐10. [PUBMED: 21802903] ">Guyatt 2011g</a>; <a href="./references#CD004039-bbs2-0096" title="GuyattGH , OxmanAD , SultanS , GlasziouP , AklEA , Alonso‐CoelloP , et al. GRADE guidelines: 9. Rating up the quality of evidence. Journal of Clinical Epidemiology2011;64(12):1311‐6. [PUBMED: 21802902] ">Guyatt 2011h</a>; <a href="./references#CD004039-bbs2-0097" title="GuyattG , OxmanAD , SultanS , BrozekJ , GlasziouP , Alonso‐CoelloP , et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. Journal of Clinical Epidemiology2013;66(2):151‐7. [PUBMED: 22542023] ">Guyatt 2013a</a>; <a href="./references#CD004039-bbs2-0098" title="GuyattGH , OxmanAD , SantessoN , HelfandM , VistG , KunzR , et al. GRADE guidelines: 12. Preparing summary of findings tables ‐ binary outcomes. Journal of Clinical Epidemiology2013;66(2):158‐72. [PUBMED: 22609141] ">Guyatt 2013b</a>; <a href="./references#CD004039-bbs2-0099" title="GuyattGH , ThorlundK , OxmanAD , WalterSD , PatrickD , FurukawaTA , et al. GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles ‐ continuous outcomes. Journal of Clinical Epidemiology2013;66(2):173‐83. [PUBMED: 23116689] ">Guyatt 2013c</a>; <a href="./references#CD004039-bbs2-0131" title="MustafaRA , SantessoN , BrozekJ , AklEA , WalterSD , NormanG , et al. The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence syntheses. Journal of Clinical Epidemiology2013;66(7):736‐42. [PUBMED: 23623694] ">Mustafa 2013</a>). The five factors are used to judge whether the certainty of the collected evidence should be downgraded or upgraded. </p> <p>As sensitivity analysis, we compared imprecision evaluation with GRADE based on the GRADE Handbook, with GRADE based on authors' choice of plausible relative risk reduction (RRR) and multiplicity correction, and according to our Trial Sequential Analysis (TSA) with a similar choice of plausible RRR and multiplicity correction, in addition to considering the choice of meta‐analytic model and diversity (<a href="./references#CD004039-bbs2-0111" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14:120. [PUBMED: 25416419] ">Jakobsen 2014</a>; <a href="./references#CD004039-bbs2-0060" title="CastelliniG , BruschettiniM , GianolaS , GluudC , MojaL . Assessing imprecision in Cochrane systematic reviews: a comparison of GRADE and Trial Sequential Analysis. Systematic Reviews2018;7(1):110. [PUBMED: 30055658] ">Castellini 2018</a>; <a href="./references#CD004039-bbs2-0077" title="GartlehnerG , Nussbaumer‐StreitB , WagnerG , PatelS , Swinson‐EvansT , DobrescuA , et al. Increased risks for random errors are common in outcomes graded as high certainty of evidence. Journal of Clinical Epidemiology2018;106:50‐9. [DOI: 10.1016/j.jclinepi.2018.10.009; PUBMED: 30342970] ">Gartlehner 2018</a>). </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD004039-sec-0063" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD004039-sec-0063"></div> <section id="CD004039-sec-0064"> <h3 class="title">Description of studies</h3> <p> See: <a href="http://archie.cochrane.org/sections/documents/view?version=z1404160933424465425983408581570%26format=REVMAN#CHARACTERISTICS_OF_INCLUDED_STUDIES" target="_blank">Characteristics of included studies</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1404160933424465425983408581570%26format=REVMAN#CHARACTERISTICS_OF_EXCLUDED_STUDIES" target="_blank">Characteristics of excluded studies</a>. </p> <section id="CD004039-sec-0065"> <h4 class="title">Results of the search</h4> <p>The reference flow is summarised in the study flow diagram (<a href="#CD004039-fig-0001">Figure 1</a>). For detailed search strategies, see <a href="./appendices#CD004039-sec-0205">Appendix 1</a>. </p> <div class="figure" id="CD004039-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD004039-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>We identified 1079 references through electronic searches of the Cochrane Hepato‐Biliary Group Controlled Trials Register (n = 86), Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library (n = 146), MEDLINE (n = 98), Embase (n = 234), LILACS (n = 21), Science Citation Index EXPANDED and Conference Proceedings Citation Index – Science (Web of Science) (n = 212<b>),</b> and three Chinese database including CNKI (China National Knowledge Infrastructure) (n = 154), VIP (n = 88), and Wanfang (n = 40). We also searched databases of ongoing trials (<a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov/</a> and <a href="http://www.controlled-trials.com/" target="_blank">www.controlled‐trials.com/</a>) (with links to several databases). One not yet recruiting trial was retrieved (<a href="./references#CD004039-bbs2-0033" title="NCT03202524 . Fresh frozen plasma as a substitute for albumin in patients receiving a large volume paracentesis. clinicaltrials.gov/ct2/show/study/NCT03202524 (first received 28 June 2017). ">NCT03202524</a>). In addition, we searched European Medicines Agency (<a href="http://www.ema.europe.eu" target="_blank">EMA</a>), US Food and Drug Adminitration (<a href="http://www.fda.gov" target="_blank">FDA</a>), and the World Health Organization International Clinical Trials Registry Platform (<a href="./references#CD004039-bbs2-0110" title="World Health Organization. International Clinical Trials Registry Platform (ICTRP). www.who.int/ictrp/en/ (accessed prior to 16 June 2016). ">ICTRP 2011</a>) until January 2019. One ongoing trial without interim data was retrieved (<a href="./references#CD004039-bbs2-0032" title="2010‐019783‐37/CZ . Two doses of albumin after large paracentesis in cirrhotics with refractory ascites: a randomized study. clinicaltrialsregister.eu/ctr‐search/trial/2010‐019783‐37/CZ (first received 15 June 2010). ">EudraCT 2010‐019783‐37</a>). We did not apply any language or document type restrictions. </p> <p>After the removal of 338 duplicates, we obtained 743 references. We then excluded 705 clearly irrelevant references through screening titles and reading abstracts. We retrieved 38 full‐text articles for further assessment. No references were identified through scanning reference lists of the identified randomised trials. Thirty‐four references were reports of 27 trials which fulfilled the inclusion criteria of our review. </p> <p>Two trials were used only in a qualitative synthesis (<a href="./references#CD004039-bbs2-0011" title="García‐CompeánD , BlancP , LarreyD , DauresJ‐P , HirtzJ , MendozaE , et al. Treatment of cirrhotic tense ascites with dextran‐40 versus albumin associated with large volume paracentesis. A randomized controlled trial. Annals of Hepatology2002;1(1):29‐35. [PUBMED: 15114293] ">García‐Compeán 2002</a>; <a href="./references#CD004039-bbs2-0007" title="DegoricijaV , Zjacic‐RotkvicV , MaroutJ , SeferS , TroskotB . Clinical and neurohumoral response to posture, physical exercise, and ascites treatment in Child‐Pugh C liver cirrhosis: randomized prospective trial. Croatian Medical Journal2003;44(2):178‐86. [PUBMED: 12698509] DegoricijaV , Zjacic‐RotkvicV , TroskotB , ŠeferS . Postparacentesis neurohumoral changes and impairment of renal water excretion in Child‐Pugh C cirrhosis with and without volume replacement. Journal of Hepatology2001;34:51. ">Degoricija 2003</a>). <a href="./references#CD004039-bbs2-0011" title="García‐CompeánD , BlancP , LarreyD , DauresJ‐P , HirtzJ , MendozaE , et al. Treatment of cirrhotic tense ascites with dextran‐40 versus albumin associated with large volume paracentesis. A randomized controlled trial. Annals of Hepatology2002;1(1):29‐35. [PUBMED: 15114293] ">García‐Compeán 2002</a> did not report the number of randomised participants for each group. Furthermore, they re‐randomised participants if readmitted for paracentesis during the follow‐up. <a href="./references#CD004039-bbs2-0007" title="DegoricijaV , Zjacic‐RotkvicV , MaroutJ , SeferS , TroskotB . Clinical and neurohumoral response to posture, physical exercise, and ascites treatment in Child‐Pugh C liver cirrhosis: randomized prospective trial. Croatian Medical Journal2003;44(2):178‐86. [PUBMED: 12698509] DegoricijaV , Zjacic‐RotkvicV , TroskotB , ŠeferS . Postparacentesis neurohumoral changes and impairment of renal water excretion in Child‐Pugh C cirrhosis with and without volume replacement. Journal of Hepatology2001;34:51. ">Degoricija 2003</a> did not report the number of events per intervention group. </p> </section> <section id="CD004039-sec-0066"> <h4 class="title">Included studies</h4> <section id="CD004039-sec-0067"> <h5 class="title">Trial characteristics</h5> <p>We included 27 randomised clinical trials. Twenty‐four trials were published as full‐text articles and three trials as abstracts. </p> <p>Two trial publications were in Korean (<a href="./references#CD004039-bbs2-0016" title="KangKE , KimBH , DongSH , KimHJ , ChangYW , LeeJII , et al. The efficacy of hydroxyethyl starch as plasma expander in cirrhotic patients with tense ascites treated with large volume paracentesis. Korean Journal of Gastroenterology1998;31:651‐60. ">Kang 1998</a>; <a href="./references#CD004039-bbs2-0004" title="BaikSK , KimHS , LeeDK , KimIH , KwonSO . Hemodynamic changes after single large volume paracentesis (SLVP) in cirrhosis with tense ascites ‐ focusing on the effect of albumin as plasma expander. Korean Journal of Medicine2000;58:276‐82. ">Baik 2000</a>) and two trials in Spanish (<a href="./references#CD004039-bbs2-0005" title="BertránX , Fernández‐BañaresF , PlanasF , CabréE , MorillasR , DeLeónR , et al. Effect on the nutritional status of total paracentesis plus albumin or dextran‐70 i.v. infusion for the treatment of tense ascites in liver cirrhosis [Repercusión sobre el estado nutricional energético‐proteico de la paracentesis total asociada a la infusión de albúmina o dextano‐70 en el tratamiento de la ascitis a tensión en la cirrhosis hepática]. Revista Espanola de Enfermedades Digestivas1991;79(5):320‐4. ">Bertrán 1991</a>; <a href="./references#CD004039-bbs2-0015" title="Hernández PérezRE , Aguilar RamírezJR , Hernández LopezJM , Gómez Maganday Silva T . Total paracentesis and infusion of dextran 70 vs albumin in cirrhotic patients with tense ascites [Paracentesis masiva con reposición de dextran 70 vs albúmina en pacientes cirróticos con ascitis a tensión]. Revista de Gastroenterologia de Mexico1995;60(1):22‐6. [PUBMED: 7543691] ">Hernández Pérez 1995</a>) languages. The remaining 23 trials were published in English. </p> <p>The trials were conducted in Canada, China, Croatia, France, Germany, India, Italy, Korea, Pakistan, Russia, Spain, and the United States. All trials were performed in specialised units in intensive care or semi‐intensive care settings. </p> <p>All trials had a parallel group design except one which used a cross‐over trial design (<a href="./references#CD004039-bbs2-0026" title="Sola‐VeraJ , MinanaJ , SorianoG , GonzalezB , PlanellaM , Lopez‐BalaguerJM , et al. Expansion with saline vs albumin in cirrhotic patients with tense ascites treated with total paracentesis. Result of a prospective randomized study. Gastroenterologia y Hepatologia2001;24(2):90 A6. Sola‐VeraJ , MiñanaJ , RicartE , PlanellaM , GonzálezB , TorrasX , et al. Randomized trial comparing albumin and saline in the prevention of paracentesis‐induced circultory dysfunction in cirrhotic patients with ascites. Hepatology2003;37(5):1147‐53. [PUBMED: 12717396] ">Sola‐Vera 2003</a>). From the 26 trials with a parallel group design, one trial had three intervention groups (<a href="./references#CD004039-bbs2-0013" title="GinèsA , Fernández‐EsparrachG , MonescilloA , VilaC , DomènechE , AbecasisR , et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology1996;111(4):1002‐10. [PUBMED: 8831595] International Group for the Study of Ascites in Cirrhosis. Comparison of albumin, dextran‐70 and hemaccel in the prevention of effective hypovolemia in cirrhotic patients with ascites treated with total paracentesis. A randomized multicenter study. Hepatology1995;22(4 Suppl):220A. ">Ginès 1996</a>), one had six intervention groups (<a href="./references#CD004039-bbs2-0008" title="DescosL , GauthierA , LevyVG , MichelH , QuintonA , RueffB , et al. Comparison of six treatments of ascites in patients with liver cirrhosis. A clinical trial. Hepato‐gastroenterology1983;30:15‐20. [PUBMED: 6339343] ">Descos 1983</a>), and two trials had five intervention groups (<a href="./references#CD004039-bbs2-0007" title="DegoricijaV , Zjacic‐RotkvicV , MaroutJ , SeferS , TroskotB . Clinical and neurohumoral response to posture, physical exercise, and ascites treatment in Child‐Pugh C liver cirrhosis: randomized prospective trial. Croatian Medical Journal2003;44(2):178‐86. [PUBMED: 12698509] DegoricijaV , Zjacic‐RotkvicV , TroskotB , ŠeferS . Postparacentesis neurohumoral changes and impairment of renal water excretion in Child‐Pugh C cirrhosis with and without volume replacement. Journal of Hepatology2001;34:51. ">Degoricija 2003</a>; <a href="./references#CD004039-bbs2-0002" title="Al SebaeyA , Abdel‐RazekW , BassuniA , RewishaEA , KhalilM , WakedI , et al. Alternatives to albumin for prevention of paracentesis induced circulatory dysfunction (PICD) in cirrhosis. Hepatology2012;56(S1):915A. ">Al Sebaey 2012</a>). The remaining 22 trials had two intervention groups. </p> <p>Ten trials seemed not to have been funded by industry (<a href="./references#CD004039-bbs2-0008" title="DescosL , GauthierA , LevyVG , MichelH , QuintonA , RueffB , et al. Comparison of six treatments of ascites in patients with liver cirrhosis. A clinical trial. Hepato‐gastroenterology1983;30:15‐20. [PUBMED: 6339343] ">Descos 1983</a>; <a href="./references#CD004039-bbs2-0012" title="GinèsP , TitóL , ArroyoV , PlanasR , PanésJ , ViverJ , et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology1988;94(6):1493‐1502. [PUBMED: 3360270] ">Ginès 1988</a>; <a href="./references#CD004039-bbs2-0022" title="PlanasR , GinèsP , ArroyoV , LlachJ , PanésJ , VargasV , et al. Dextran‐70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study. Gastroenterology1990;99(6):1736‐44. [PUBMED: 1699835] PlanasR , LlachJ , GinèsP , PanésJ , VargasV , SalmeronJM , et al. Albumin versus dextran‐70 in cirrhotics with tense ascites treated with total paracentesis. Final results of a multicenter randomized comparative study. Journal of Hepatology1990;11(Suppl 2):S49. ">Planas 1990</a>; <a href="./references#CD004039-bbs2-0024" title="RinaldiF , SimonettiRG , MaisanoS , DinoO , MilazzoG , LucaA , et al. Refractory ascites in cirrhosis: treatment with total paracentesis and reinfusion of filtrated and concentrated ascitic fluid. Italian Journal of Gastroenterology1990;22(4):261. SimonettiRG , RinaldiF , MilazzoG , DinoO , MaisanoS , LucaA , et al. Treatment of refractory ascites: a randomized prospective trial of total paracentesis with concentrated ascitic fluid reinfusion vs repeated paracentesis and albumin infusion. Italian Journal of Gastroenterology1991;23(7):473. ">Simonetti 1991</a>; <a href="./references#CD004039-bbs2-0009" title="FassioE , TergR , LandeiraG , AbecasisR , SalemneM , PodestaA , et al. Paracentesis with dextran 70 vs paracentesis with albumin in cirrhosis with tense ascites. Results of a randomized study. Journal of Hepatology1992;14(2‐3):310‐6. [PUBMED: 1380024] ">Fassio 1992</a>; <a href="./references#CD004039-bbs2-0018" title="LucaA , García‐PagánJ , BoschJ , FeuF , JiménezW , GinésA , et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology1995;22(3):753‐8. [PUBMED: 7657279] ">Luca 1995</a>; <a href="./references#CD004039-bbs2-0026" title="Sola‐VeraJ , MinanaJ , SorianoG , GonzalezB , PlanellaM , Lopez‐BalaguerJM , et al. Expansion with saline vs albumin in cirrhotic patients with tense ascites treated with total paracentesis. Result of a prospective randomized study. Gastroenterologia y Hepatologia2001;24(2):90 A6. Sola‐VeraJ , MiñanaJ , RicartE , PlanellaM , GonzálezB , TorrasX , et al. Randomized trial comparing albumin and saline in the prevention of paracentesis‐induced circultory dysfunction in cirrhotic patients with ascites. Hepatology2003;37(5):1147‐53. [PUBMED: 12717396] ">Sola‐Vera 2003</a>; <a href="./references#CD004039-bbs2-0021" title="MoreauR , VallaD‐C , Durand‐ZaleskiI , BronowickiJ‐P , DurandF , ChaputJ‐C , et al. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trial. Liver International2006;26(1):46‐54. [PUBMED: 16420509] ">Moreau 2006</a>; <a href="./references#CD004039-bbs2-0002" title="Al SebaeyA , Abdel‐RazekW , BassuniA , RewishaEA , KhalilM , WakedI , et al. Alternatives to albumin for prevention of paracentesis induced circulatory dysfunction (PICD) in cirrhosis. Hepatology2012;56(S1):915A. ">Al Sebaey 2012</a>; <a href="./references#CD004039-bbs2-0017" title="KhanMU , RahimIU , LatifM . Hemaccel as a cheaper alternative to human albumin for plasma expansion during paracentesis in cirrhotic patients. Pakistan Journal of Medical and Health Sciences2015;9(3):948‐51. ">Khan 2015</a>). Twelve trials were considered unclear about funding (<a href="./references#CD004039-bbs2-0005" title="BertránX , Fernández‐BañaresF , PlanasF , CabréE , MorillasR , DeLeónR , et al. Effect on the nutritional status of total paracentesis plus albumin or dextran‐70 i.v. infusion for the treatment of tense ascites in liver cirrhosis [Repercusión sobre el estado nutricional energético‐proteico de la paracentesis total asociada a la infusión de albúmina o dextano‐70 en el tratamiento de la ascitis a tensión en la cirrhosis hepática]. Revista Espanola de Enfermedades Digestivas1991;79(5):320‐4. ">Bertrán 1991</a>; <a href="./references#CD004039-bbs2-0006" title="BrunoS , BorzioM , RomagnoniM , BattezzatiPM , RossiS , ChiesaA , et al. Comparison of spontaneous ascites filtration and reinfusion with total paracentesis with intravenous albumin infusion in cirrhotic patients with tense ascites. BMJ1992;304:1655‐8. [PUBMED: 1633517] BrunoS , BorzioM , RomagnoniM , ChiesaA , RossiS , PavesiS , et al. Spontaneous ascites filtration and reinfusion (SAFR) vs total paracentesis (TP) with i.v. albumin infusion in cirrhotic patients with tense ascites. Hepatology1990;12:855. ">Bruno 1992</a>; <a href="./references#CD004039-bbs2-0020" title="MéndezC , SorianoG , GuarnerC , TomásA , MoyanoD , ToroH , et al. Total paracentesis in cirrhotics with refractory ascites: albumin vs HES as plasmatic expanders. Journal of Hepatology1991;13(Suppl 2):S145. ">Méndez 1991</a>; <a href="./references#CD004039-bbs2-0010" title="García‐CompeánD , VillarealJZ , CuevasHB , CantúDAG , EstrellaM , TamezEG , et al. Total therapeutic paracentesis (TTP) with and without intravenous albumin in the treatment of cirrhotic tense ascites: a randomized controlled trial. Liver1993;13(5):233‐8. [PUBMED: 8259034] ">García‐Compeán 1993</a>; <a href="./references#CD004039-bbs2-0015" title="Hernández PérezRE , Aguilar RamírezJR , Hernández LopezJM , Gómez Maganday Silva T . Total paracentesis and infusion of dextran 70 vs albumin in cirrhotic patients with tense ascites [Paracentesis masiva con reposición de dextran 70 vs albúmina en pacientes cirróticos con ascitis a tensión]. Revista de Gastroenterologia de Mexico1995;60(1):22‐6. [PUBMED: 7543691] ">Hernández Pérez 1995</a>; <a href="./references#CD004039-bbs2-0016" title="KangKE , KimBH , DongSH , KimHJ , ChangYW , LeeJII , et al. The efficacy of hydroxyethyl starch as plasma expander in cirrhotic patients with tense ascites treated with large volume paracentesis. Korean Journal of Gastroenterology1998;31:651‐60. ">Kang 1998</a>; <a href="./references#CD004039-bbs2-0019" title="MehtaNN , AbrahamP , AsharVJ , ShikareSS , SavantSS , KarnadDR , et al. Ascitic fluid filtration and intravenous infusion versus total‐volume paracentesis with infusion of plasma expander in cirrhosis with tense or intractable ascites. Indian Journal of Gastroenterology1998;17(3):93‐6. ">Mehta 1998</a>; <a href="./references#CD004039-bbs2-0004" title="BaikSK , KimHS , LeeDK , KimIH , KwonSO . Hemodynamic changes after single large volume paracentesis (SLVP) in cirrhosis with tense ascites ‐ focusing on the effect of albumin as plasma expander. Korean Journal of Medicine2000;58:276‐82. ">Baik 2000</a>; <a href="./references#CD004039-bbs2-0027" title="ZhaoJ , YuanC , WangD , LIX . Mannitolum infusion on cirrhotic patients with tense ascites treated by paracentesis. Chinese Medical Journal2000;113(1):27‐30. [PUBMED: 11775204] ">Zhao 2000</a>; <a href="./references#CD004039-bbs2-0011" title="García‐CompeánD , BlancP , LarreyD , DauresJ‐P , HirtzJ , MendozaE , et al. Treatment of cirrhotic tense ascites with dextran‐40 versus albumin associated with large volume paracentesis. A randomized controlled trial. Annals of Hepatology2002;1(1):29‐35. [PUBMED: 15114293] ">García‐Compeán 2002</a>; <a href="./references#CD004039-bbs2-0007" title="DegoricijaV , Zjacic‐RotkvicV , MaroutJ , SeferS , TroskotB . Clinical and neurohumoral response to posture, physical exercise, and ascites treatment in Child‐Pugh C liver cirrhosis: randomized prospective trial. Croatian Medical Journal2003;44(2):178‐86. [PUBMED: 12698509] DegoricijaV , Zjacic‐RotkvicV , TroskotB , ŠeferS . Postparacentesis neurohumoral changes and impairment of renal water excretion in Child‐Pugh C cirrhosis with and without volume replacement. Journal of Hepatology2001;34:51. ">Degoricija 2003</a>; <a href="./references#CD004039-bbs2-0001" title="Abdel‐KhalekEE , ArifS . Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients With liver cirrhosis and tense ascites after large‐volume paracentesis. Journal of Hepatology2010;52:S327. Abdel‐KhalekEE , ArifSE . Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients with liver cirrhosis and tense ascites following large volume paracentesis. Arab Journal of Gastroenterology2010;11:24‐9. ">Abdel‐Khalek 2010</a>). Five trials were considered funded by industry or a for‐profit institution (<a href="./references#CD004039-bbs2-0025" title="SmartHL , TrigerDR . A randomised prospective trial comparing daily paracentesis and intravenous albumin with recirculation in diuretic refractory ascites. Journal of Hepatology1990;10(2):191‐7. [PUBMED: 2185298] ">Smart 1990</a>; <a href="./references#CD004039-bbs2-0023" title="SalernoF , BadalamentiS , LorenzanoE , MoserP , IncertiP . Randomized comparative study of hemaccel vs albumin infusion after total paracentesis in cirrhotic patients with refractory ascites. Hepatology1991;13(4):707‐13. [PUBMED: 1826281] ">Salerno 1991</a>; <a href="./references#CD004039-bbs2-0013" title="GinèsA , Fernández‐EsparrachG , MonescilloA , VilaC , DomènechE , AbecasisR , et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology1996;111(4):1002‐10. [PUBMED: 8831595] International Group for the Study of Ascites in Cirrhosis. Comparison of albumin, dextran‐70 and hemaccel in the prevention of effective hypovolemia in cirrhotic patients with ascites treated with total paracentesis. A randomized multicenter study. Hepatology1995;22(4 Suppl):220A. ">Ginès 1996</a>; <a href="./references#CD004039-bbs2-0014" title="GraziottoA , RossaroL , InturriP , SalvagniniM . Reinfusion of concentrated ascitic fluid versus total paracentesis. A randomized prospective trial. Digestive Diseases and Sciences1997;42(8):1708‐14. [PUBMED: 9286238] ">Graziotto 1997</a>; <a href="./references#CD004039-bbs2-0003" title="AltmanC , BernardB , RoulotD , VitteR‐L , InkO . Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis. European Journal of Gastroenterology &amp; Hepatology1998;10:5‐10. [PUBMED: 9512946] ">Altman 1998</a>). </p> </section> <section id="CD004039-sec-0068"> <h5 class="title">Participant characteristics</h5> <p>The trials included 1592 randomised participants with a mean sample size of 59 participants (range 12 to 289 participants). The mean age of the participants was 56.4 years with a mean range of 42.0 to 61.3 years. The mean proportion of males in the trial groups was 67.7%. The reported aetiology of cirrhosis was alcoholic in 60.9% of the participants (range 13% to 94%; 20 trials) and viral in 27.8% of the participants (range 2% to 70.6%; 17 trials). According to the Child‐Pugh classification, most participants had an intermediate to advanced stage of cirrhosis. Nine trials reported a mean Child‐Pugh score of 10.4 points (range 9.6 to 12), and seven trials reported that between 33% and 60% of the participants were in class B Child‐Pugh, and between 37% to 58% of the participants were in class C Child‐Pugh. One trial reported that 65% of the participants were in class C and for the remaining 35%, the class was not reported. In three trials, the proportion of participants in class A Child‐Pugh ranged between 2.9% and 8.3% (<a href="./references#CD004039-bbs2-0005" title="BertránX , Fernández‐BañaresF , PlanasF , CabréE , MorillasR , DeLeónR , et al. Effect on the nutritional status of total paracentesis plus albumin or dextran‐70 i.v. infusion for the treatment of tense ascites in liver cirrhosis [Repercusión sobre el estado nutricional energético‐proteico de la paracentesis total asociada a la infusión de albúmina o dextano‐70 en el tratamiento de la ascitis a tensión en la cirrhosis hepática]. Revista Espanola de Enfermedades Digestivas1991;79(5):320‐4. ">Bertrán 1991</a>; <a href="./references#CD004039-bbs2-0006" title="BrunoS , BorzioM , RomagnoniM , BattezzatiPM , RossiS , ChiesaA , et al. Comparison of spontaneous ascites filtration and reinfusion with total paracentesis with intravenous albumin infusion in cirrhotic patients with tense ascites. BMJ1992;304:1655‐8. [PUBMED: 1633517] BrunoS , BorzioM , RomagnoniM , ChiesaA , RossiS , PavesiS , et al. Spontaneous ascites filtration and reinfusion (SAFR) vs total paracentesis (TP) with i.v. albumin infusion in cirrhotic patients with tense ascites. Hepatology1990;12:855. ">Bruno 1992</a>; <a href="./references#CD004039-bbs2-0026" title="Sola‐VeraJ , MinanaJ , SorianoG , GonzalezB , PlanellaM , Lopez‐BalaguerJM , et al. Expansion with saline vs albumin in cirrhotic patients with tense ascites treated with total paracentesis. Result of a prospective randomized study. Gastroenterologia y Hepatologia2001;24(2):90 A6. Sola‐VeraJ , MiñanaJ , RicartE , PlanellaM , GonzálezB , TorrasX , et al. Randomized trial comparing albumin and saline in the prevention of paracentesis‐induced circultory dysfunction in cirrhotic patients with ascites. Hepatology2003;37(5):1147‐53. [PUBMED: 12717396] ">Sola‐Vera 2003</a>). In the remaining eleven trials, this information was not provided. Almost all trials excluded participants with hepatocellular carcinoma as well as recent gastrointestinal bleeding, infections, or hepatic encephalopathy. In <a href="./references#CD004039-bbs2-0023" title="SalernoF , BadalamentiS , LorenzanoE , MoserP , IncertiP . Randomized comparative study of hemaccel vs albumin infusion after total paracentesis in cirrhotic patients with refractory ascites. Hepatology1991;13(4):707‐13. [PUBMED: 1826281] ">Salerno 1991</a>, 30% of participants had hepatocellular carcinoma. Seven trials assessed the effects of treatments in people with refractory ascites according to authors' diagnostic definitions (<a href="./references#CD004039-bbs2-0025" title="SmartHL , TrigerDR . A randomised prospective trial comparing daily paracentesis and intravenous albumin with recirculation in diuretic refractory ascites. Journal of Hepatology1990;10(2):191‐7. [PUBMED: 2185298] ">Smart 1990</a>; <a href="./references#CD004039-bbs2-0020" title="MéndezC , SorianoG , GuarnerC , TomásA , MoyanoD , ToroH , et al. Total paracentesis in cirrhotics with refractory ascites: albumin vs HES as plasmatic expanders. Journal of Hepatology1991;13(Suppl 2):S145. ">Méndez 1991</a>; <a href="./references#CD004039-bbs2-0023" title="SalernoF , BadalamentiS , LorenzanoE , MoserP , IncertiP . Randomized comparative study of hemaccel vs albumin infusion after total paracentesis in cirrhotic patients with refractory ascites. Hepatology1991;13(4):707‐13. [PUBMED: 1826281] ">Salerno 1991</a>; <a href="./references#CD004039-bbs2-0024" title="RinaldiF , SimonettiRG , MaisanoS , DinoO , MilazzoG , LucaA , et al. Refractory ascites in cirrhosis: treatment with total paracentesis and reinfusion of filtrated and concentrated ascitic fluid. Italian Journal of Gastroenterology1990;22(4):261. SimonettiRG , RinaldiF , MilazzoG , DinoO , MaisanoS , LucaA , et al. Treatment of refractory ascites: a randomized prospective trial of total paracentesis with concentrated ascitic fluid reinfusion vs repeated paracentesis and albumin infusion. Italian Journal of Gastroenterology1991;23(7):473. ">Simonetti 1991</a>; <a href="./references#CD004039-bbs2-0014" title="GraziottoA , RossaroL , InturriP , SalvagniniM . Reinfusion of concentrated ascitic fluid versus total paracentesis. A randomized prospective trial. Digestive Diseases and Sciences1997;42(8):1708‐14. [PUBMED: 9286238] ">Graziotto 1997</a>; <a href="./references#CD004039-bbs2-0019" title="MehtaNN , AbrahamP , AsharVJ , ShikareSS , SavantSS , KarnadDR , et al. Ascitic fluid filtration and intravenous infusion versus total‐volume paracentesis with infusion of plasma expander in cirrhosis with tense or intractable ascites. Indian Journal of Gastroenterology1998;17(3):93‐6. ">Mehta 1998</a>; <a href="./references#CD004039-bbs2-0001" title="Abdel‐KhalekEE , ArifS . Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients With liver cirrhosis and tense ascites after large‐volume paracentesis. Journal of Hepatology2010;52:S327. Abdel‐KhalekEE , ArifSE . Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients with liver cirrhosis and tense ascites following large volume paracentesis. Arab Journal of Gastroenterology2010;11:24‐9. ">Abdel‐Khalek 2010</a>) (<a href="./references#CD004039-sec-0214" title="">Characteristics of included studies</a>). The remaining 20 trials included participants without refractory ascites because the mean value of blood urea was 21.86 + SD 8.58 mg/dL and the mean value of serum creatinine was 0.96 + SD 0.12 mg/dL (<a href="./references#CD004039-sec-0214" title="">Characteristics of included studies</a>). The proportion of people with renal impairment was reported in 10 trials (<a href="./references#CD004039-bbs2-0012" title="GinèsP , TitóL , ArroyoV , PlanasR , PanésJ , ViverJ , et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology1988;94(6):1493‐1502. [PUBMED: 3360270] ">Ginès 1988</a>; <a href="./references#CD004039-bbs2-0022" title="PlanasR , GinèsP , ArroyoV , LlachJ , PanésJ , VargasV , et al. Dextran‐70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study. Gastroenterology1990;99(6):1736‐44. [PUBMED: 1699835] PlanasR , LlachJ , GinèsP , PanésJ , VargasV , SalmeronJM , et al. Albumin versus dextran‐70 in cirrhotics with tense ascites treated with total paracentesis. Final results of a multicenter randomized comparative study. Journal of Hepatology1990;11(Suppl 2):S49. ">Planas 1990</a>; <a href="./references#CD004039-bbs2-0009" title="FassioE , TergR , LandeiraG , AbecasisR , SalemneM , PodestaA , et al. Paracentesis with dextran 70 vs paracentesis with albumin in cirrhosis with tense ascites. Results of a randomized study. Journal of Hepatology1992;14(2‐3):310‐6. [PUBMED: 1380024] ">Fassio 1992</a>; <a href="./references#CD004039-bbs2-0015" title="Hernández PérezRE , Aguilar RamírezJR , Hernández LopezJM , Gómez Maganday Silva T . Total paracentesis and infusion of dextran 70 vs albumin in cirrhotic patients with tense ascites [Paracentesis masiva con reposición de dextran 70 vs albúmina en pacientes cirróticos con ascitis a tensión]. Revista de Gastroenterologia de Mexico1995;60(1):22‐6. [PUBMED: 7543691] ">Hernández Pérez 1995</a>; <a href="./references#CD004039-bbs2-0013" title="GinèsA , Fernández‐EsparrachG , MonescilloA , VilaC , DomènechE , AbecasisR , et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology1996;111(4):1002‐10. [PUBMED: 8831595] International Group for the Study of Ascites in Cirrhosis. Comparison of albumin, dextran‐70 and hemaccel in the prevention of effective hypovolemia in cirrhotic patients with ascites treated with total paracentesis. A randomized multicenter study. Hepatology1995;22(4 Suppl):220A. ">Ginès 1996</a>; <a href="./references#CD004039-bbs2-0003" title="AltmanC , BernardB , RoulotD , VitteR‐L , InkO . Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis. European Journal of Gastroenterology &amp; Hepatology1998;10:5‐10. [PUBMED: 9512946] ">Altman 1998</a>; <a href="./references#CD004039-bbs2-0027" title="ZhaoJ , YuanC , WangD , LIX . Mannitolum infusion on cirrhotic patients with tense ascites treated by paracentesis. Chinese Medical Journal2000;113(1):27‐30. [PUBMED: 11775204] ">Zhao 2000</a>; <a href="./references#CD004039-bbs2-0011" title="García‐CompeánD , BlancP , LarreyD , DauresJ‐P , HirtzJ , MendozaE , et al. Treatment of cirrhotic tense ascites with dextran‐40 versus albumin associated with large volume paracentesis. A randomized controlled trial. Annals of Hepatology2002;1(1):29‐35. [PUBMED: 15114293] ">García‐Compeán 2002</a>; <a href="./references#CD004039-bbs2-0026" title="Sola‐VeraJ , MinanaJ , SorianoG , GonzalezB , PlanellaM , Lopez‐BalaguerJM , et al. Expansion with saline vs albumin in cirrhotic patients with tense ascites treated with total paracentesis. Result of a prospective randomized study. Gastroenterologia y Hepatologia2001;24(2):90 A6. Sola‐VeraJ , MiñanaJ , RicartE , PlanellaM , GonzálezB , TorrasX , et al. Randomized trial comparing albumin and saline in the prevention of paracentesis‐induced circultory dysfunction in cirrhotic patients with ascites. Hepatology2003;37(5):1147‐53. [PUBMED: 12717396] ">Sola‐Vera 2003</a>; <a href="./references#CD004039-bbs2-0021" title="MoreauR , VallaD‐C , Durand‐ZaleskiI , BronowickiJ‐P , DurandF , ChaputJ‐C , et al. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trial. Liver International2006;26(1):46‐54. [PUBMED: 16420509] ">Moreau 2006</a>); it ranged from 0% in <a href="./references#CD004039-bbs2-0003" title="AltmanC , BernardB , RoulotD , VitteR‐L , InkO . Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis. European Journal of Gastroenterology &amp; Hepatology1998;10:5‐10. [PUBMED: 9512946] ">Altman 1998</a> and <a href="./references#CD004039-bbs2-0009" title="FassioE , TergR , LandeiraG , AbecasisR , SalemneM , PodestaA , et al. Paracentesis with dextran 70 vs paracentesis with albumin in cirrhosis with tense ascites. Results of a randomized study. Journal of Hepatology1992;14(2‐3):310‐6. [PUBMED: 1380024] ">Fassio 1992</a> to 28% in <a href="./references#CD004039-bbs2-0011" title="García‐CompeánD , BlancP , LarreyD , DauresJ‐P , HirtzJ , MendozaE , et al. Treatment of cirrhotic tense ascites with dextran‐40 versus albumin associated with large volume paracentesis. A randomized controlled trial. Annals of Hepatology2002;1(1):29‐35. [PUBMED: 15114293] ">García‐Compeán 2002</a>, with a mean of 12%. Seventeen trials reported mean arterial pressure of 88 (SD 5.6) mmHg, and 15 trials reported the mean renin activity of 10.42 (SD 5.73) ng/mL/hour. </p> </section> <section id="CD004039-sec-0069"> <h5 class="title">Paracentesis characteristics</h5> <p>All trial participants were treated with paracentesis. Total paracentesis completed in a single session was used in the experimental and control groups of 20 trials (<a href="./references#CD004039-bbs2-0008" title="DescosL , GauthierA , LevyVG , MichelH , QuintonA , RueffB , et al. Comparison of six treatments of ascites in patients with liver cirrhosis. A clinical trial. Hepato‐gastroenterology1983;30:15‐20. [PUBMED: 6339343] ">Descos 1983</a>; <a href="./references#CD004039-bbs2-0022" title="PlanasR , GinèsP , ArroyoV , LlachJ , PanésJ , VargasV , et al. Dextran‐70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study. Gastroenterology1990;99(6):1736‐44. [PUBMED: 1699835] PlanasR , LlachJ , GinèsP , PanésJ , VargasV , SalmeronJM , et al. Albumin versus dextran‐70 in cirrhotics with tense ascites treated with total paracentesis. Final results of a multicenter randomized comparative study. Journal of Hepatology1990;11(Suppl 2):S49. ">Planas 1990</a>; <a href="./references#CD004039-bbs2-0005" title="BertránX , Fernández‐BañaresF , PlanasF , CabréE , MorillasR , DeLeónR , et al. Effect on the nutritional status of total paracentesis plus albumin or dextran‐70 i.v. infusion for the treatment of tense ascites in liver cirrhosis [Repercusión sobre el estado nutricional energético‐proteico de la paracentesis total asociada a la infusión de albúmina o dextano‐70 en el tratamiento de la ascitis a tensión en la cirrhosis hepática]. Revista Espanola de Enfermedades Digestivas1991;79(5):320‐4. ">Bertrán 1991</a>; <a href="./references#CD004039-bbs2-0020" title="MéndezC , SorianoG , GuarnerC , TomásA , MoyanoD , ToroH , et al. Total paracentesis in cirrhotics with refractory ascites: albumin vs HES as plasmatic expanders. Journal of Hepatology1991;13(Suppl 2):S145. ">Méndez 1991</a>; <a href="./references#CD004039-bbs2-0023" title="SalernoF , BadalamentiS , LorenzanoE , MoserP , IncertiP . Randomized comparative study of hemaccel vs albumin infusion after total paracentesis in cirrhotic patients with refractory ascites. Hepatology1991;13(4):707‐13. [PUBMED: 1826281] ">Salerno 1991</a>; <a href="./references#CD004039-bbs2-0006" title="BrunoS , BorzioM , RomagnoniM , BattezzatiPM , RossiS , ChiesaA , et al. Comparison of spontaneous ascites filtration and reinfusion with total paracentesis with intravenous albumin infusion in cirrhotic patients with tense ascites. BMJ1992;304:1655‐8. [PUBMED: 1633517] BrunoS , BorzioM , RomagnoniM , ChiesaA , RossiS , PavesiS , et al. Spontaneous ascites filtration and reinfusion (SAFR) vs total paracentesis (TP) with i.v. albumin infusion in cirrhotic patients with tense ascites. Hepatology1990;12:855. ">Bruno 1992</a>; <a href="./references#CD004039-bbs2-0010" title="García‐CompeánD , VillarealJZ , CuevasHB , CantúDAG , EstrellaM , TamezEG , et al. Total therapeutic paracentesis (TTP) with and without intravenous albumin in the treatment of cirrhotic tense ascites: a randomized controlled trial. Liver1993;13(5):233‐8. [PUBMED: 8259034] ">García‐Compeán 1993</a>; <a href="./references#CD004039-bbs2-0015" title="Hernández PérezRE , Aguilar RamírezJR , Hernández LopezJM , Gómez Maganday Silva T . Total paracentesis and infusion of dextran 70 vs albumin in cirrhotic patients with tense ascites [Paracentesis masiva con reposición de dextran 70 vs albúmina en pacientes cirróticos con ascitis a tensión]. Revista de Gastroenterologia de Mexico1995;60(1):22‐6. [PUBMED: 7543691] ">Hernández Pérez 1995</a>; <a href="./references#CD004039-bbs2-0018" title="LucaA , García‐PagánJ , BoschJ , FeuF , JiménezW , GinésA , et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology1995;22(3):753‐8. [PUBMED: 7657279] ">Luca 1995</a>; <a href="./references#CD004039-bbs2-0013" title="GinèsA , Fernández‐EsparrachG , MonescilloA , VilaC , DomènechE , AbecasisR , et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology1996;111(4):1002‐10. [PUBMED: 8831595] International Group for the Study of Ascites in Cirrhosis. Comparison of albumin, dextran‐70 and hemaccel in the prevention of effective hypovolemia in cirrhotic patients with ascites treated with total paracentesis. A randomized multicenter study. Hepatology1995;22(4 Suppl):220A. ">Ginès 1996</a>; <a href="./references#CD004039-bbs2-0014" title="GraziottoA , RossaroL , InturriP , SalvagniniM . Reinfusion of concentrated ascitic fluid versus total paracentesis. A randomized prospective trial. Digestive Diseases and Sciences1997;42(8):1708‐14. [PUBMED: 9286238] ">Graziotto 1997</a>; <a href="./references#CD004039-bbs2-0016" title="KangKE , KimBH , DongSH , KimHJ , ChangYW , LeeJII , et al. The efficacy of hydroxyethyl starch as plasma expander in cirrhotic patients with tense ascites treated with large volume paracentesis. Korean Journal of Gastroenterology1998;31:651‐60. ">Kang 1998</a>; <a href="./references#CD004039-bbs2-0019" title="MehtaNN , AbrahamP , AsharVJ , ShikareSS , SavantSS , KarnadDR , et al. Ascitic fluid filtration and intravenous infusion versus total‐volume paracentesis with infusion of plasma expander in cirrhosis with tense or intractable ascites. Indian Journal of Gastroenterology1998;17(3):93‐6. ">Mehta 1998</a>; <a href="./references#CD004039-bbs2-0004" title="BaikSK , KimHS , LeeDK , KimIH , KwonSO . Hemodynamic changes after single large volume paracentesis (SLVP) in cirrhosis with tense ascites ‐ focusing on the effect of albumin as plasma expander. Korean Journal of Medicine2000;58:276‐82. ">Baik 2000</a>; <a href="./references#CD004039-bbs2-0011" title="García‐CompeánD , BlancP , LarreyD , DauresJ‐P , HirtzJ , MendozaE , et al. Treatment of cirrhotic tense ascites with dextran‐40 versus albumin associated with large volume paracentesis. A randomized controlled trial. Annals of Hepatology2002;1(1):29‐35. [PUBMED: 15114293] ">García‐Compeán 2002</a>; <a href="./references#CD004039-bbs2-0026" title="Sola‐VeraJ , MinanaJ , SorianoG , GonzalezB , PlanellaM , Lopez‐BalaguerJM , et al. Expansion with saline vs albumin in cirrhotic patients with tense ascites treated with total paracentesis. Result of a prospective randomized study. Gastroenterologia y Hepatologia2001;24(2):90 A6. Sola‐VeraJ , MiñanaJ , RicartE , PlanellaM , GonzálezB , TorrasX , et al. Randomized trial comparing albumin and saline in the prevention of paracentesis‐induced circultory dysfunction in cirrhotic patients with ascites. Hepatology2003;37(5):1147‐53. [PUBMED: 12717396] ">Sola‐Vera 2003</a>; <a href="./references#CD004039-bbs2-0021" title="MoreauR , VallaD‐C , Durand‐ZaleskiI , BronowickiJ‐P , DurandF , ChaputJ‐C , et al. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trial. Liver International2006;26(1):46‐54. [PUBMED: 16420509] ">Moreau 2006</a>; <a href="./references#CD004039-bbs2-0001" title="Abdel‐KhalekEE , ArifS . Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients With liver cirrhosis and tense ascites after large‐volume paracentesis. Journal of Hepatology2010;52:S327. Abdel‐KhalekEE , ArifSE . Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients with liver cirrhosis and tense ascites following large volume paracentesis. Arab Journal of Gastroenterology2010;11:24‐9. ">Abdel‐Khalek 2010</a>; <a href="./references#CD004039-bbs2-0002" title="Al SebaeyA , Abdel‐RazekW , BassuniA , RewishaEA , KhalilM , WakedI , et al. Alternatives to albumin for prevention of paracentesis induced circulatory dysfunction (PICD) in cirrhosis. Hepatology2012;56(S1):915A. ">Al Sebaey 2012</a>; <a href="./references#CD004039-bbs2-0017" title="KhanMU , RahimIU , LatifM . Hemaccel as a cheaper alternative to human albumin for plasma expansion during paracentesis in cirrhotic patients. Pakistan Journal of Medical and Health Sciences2015;9(3):948‐51. ">Khan 2015</a>). Partial paracentesis, repeated until disappearance of ascites, was used in both intervention groups of four trials (<a href="./references#CD004039-bbs2-0012" title="GinèsP , TitóL , ArroyoV , PlanasR , PanésJ , ViverJ , et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology1988;94(6):1493‐1502. [PUBMED: 3360270] ">Ginès 1988</a>; <a href="./references#CD004039-bbs2-0009" title="FassioE , TergR , LandeiraG , AbecasisR , SalemneM , PodestaA , et al. Paracentesis with dextran 70 vs paracentesis with albumin in cirrhosis with tense ascites. Results of a randomized study. Journal of Hepatology1992;14(2‐3):310‐6. [PUBMED: 1380024] ">Fassio 1992</a>; <a href="./references#CD004039-bbs2-0003" title="AltmanC , BernardB , RoulotD , VitteR‐L , InkO . Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis. European Journal of Gastroenterology &amp; Hepatology1998;10:5‐10. [PUBMED: 9512946] ">Altman 1998</a>; <a href="./references#CD004039-bbs2-0027" title="ZhaoJ , YuanC , WangD , LIX . Mannitolum infusion on cirrhotic patients with tense ascites treated by paracentesis. Chinese Medical Journal2000;113(1):27‐30. [PUBMED: 11775204] ">Zhao 2000</a>). Single‐session paracentesis was used in the experimental group and partial paracentesis in the control group of two trials (<a href="./references#CD004039-bbs2-0025" title="SmartHL , TrigerDR . A randomised prospective trial comparing daily paracentesis and intravenous albumin with recirculation in diuretic refractory ascites. Journal of Hepatology1990;10(2):191‐7. [PUBMED: 2185298] ">Smart 1990</a>; <a href="./references#CD004039-bbs2-0024" title="RinaldiF , SimonettiRG , MaisanoS , DinoO , MilazzoG , LucaA , et al. Refractory ascites in cirrhosis: treatment with total paracentesis and reinfusion of filtrated and concentrated ascitic fluid. Italian Journal of Gastroenterology1990;22(4):261. SimonettiRG , RinaldiF , MilazzoG , DinoO , MaisanoS , LucaA , et al. Treatment of refractory ascites: a randomized prospective trial of total paracentesis with concentrated ascitic fluid reinfusion vs repeated paracentesis and albumin infusion. Italian Journal of Gastroenterology1991;23(7):473. ">Simonetti 1991</a>); the paracentesis was repeated until disappearance of ascites on alternate days in <a href="./references#CD004039-bbs2-0024" title="RinaldiF , SimonettiRG , MaisanoS , DinoO , MilazzoG , LucaA , et al. Refractory ascites in cirrhosis: treatment with total paracentesis and reinfusion of filtrated and concentrated ascitic fluid. Italian Journal of Gastroenterology1990;22(4):261. SimonettiRG , RinaldiF , MilazzoG , DinoO , MaisanoS , LucaA , et al. Treatment of refractory ascites: a randomized prospective trial of total paracentesis with concentrated ascitic fluid reinfusion vs repeated paracentesis and albumin infusion. Italian Journal of Gastroenterology1991;23(7):473. ">Simonetti 1991</a> and every day in <a href="./references#CD004039-bbs2-0025" title="SmartHL , TrigerDR . A randomised prospective trial comparing daily paracentesis and intravenous albumin with recirculation in diuretic refractory ascites. Journal of Hepatology1990;10(2):191‐7. [PUBMED: 2185298] ">Smart 1990</a>. A single paracentesis of 6 L was performed in <a href="./references#CD004039-bbs2-0007" title="DegoricijaV , Zjacic‐RotkvicV , MaroutJ , SeferS , TroskotB . Clinical and neurohumoral response to posture, physical exercise, and ascites treatment in Child‐Pugh C liver cirrhosis: randomized prospective trial. Croatian Medical Journal2003;44(2):178‐86. [PUBMED: 12698509] DegoricijaV , Zjacic‐RotkvicV , TroskotB , ŠeferS . Postparacentesis neurohumoral changes and impairment of renal water excretion in Child‐Pugh C cirrhosis with and without volume replacement. Journal of Hepatology2001;34:51. ">Degoricija 2003</a>. </p> </section> <section id="CD004039-sec-0070"> <h5 class="title">Intervention characteristics</h5> <p>Out of the 27 trials, five trials, including 271 participants, assessed plasma volume expansion versus no plasma volume expansion (<a href="./references#CD004039-bbs2-0008" title="DescosL , GauthierA , LevyVG , MichelH , QuintonA , RueffB , et al. Comparison of six treatments of ascites in patients with liver cirrhosis. A clinical trial. Hepato‐gastroenterology1983;30:15‐20. [PUBMED: 6339343] ">Descos 1983</a>; <a href="./references#CD004039-bbs2-0012" title="GinèsP , TitóL , ArroyoV , PlanasR , PanésJ , ViverJ , et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology1988;94(6):1493‐1502. [PUBMED: 3360270] ">Ginès 1988</a>; <a href="./references#CD004039-bbs2-0010" title="García‐CompeánD , VillarealJZ , CuevasHB , CantúDAG , EstrellaM , TamezEG , et al. Total therapeutic paracentesis (TTP) with and without intravenous albumin in the treatment of cirrhotic tense ascites: a randomized controlled trial. Liver1993;13(5):233‐8. [PUBMED: 8259034] ">García‐Compeán 1993</a>; <a href="./references#CD004039-bbs2-0018" title="LucaA , García‐PagánJ , BoschJ , FeuF , JiménezW , GinésA , et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology1995;22(3):753‐8. [PUBMED: 7657279] ">Luca 1995</a>; <a href="./references#CD004039-bbs2-0004" title="BaikSK , KimHS , LeeDK , KimIH , KwonSO . Hemodynamic changes after single large volume paracentesis (SLVP) in cirrhosis with tense ascites ‐ focusing on the effect of albumin as plasma expander. Korean Journal of Medicine2000;58:276‐82. ">Baik 2000</a>). Four of these trials used albumin as a plasma expander (<a href="./references#CD004039-bbs2-0012" title="GinèsP , TitóL , ArroyoV , PlanasR , PanésJ , ViverJ , et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology1988;94(6):1493‐1502. [PUBMED: 3360270] ">Ginès 1988</a>; <a href="./references#CD004039-bbs2-0010" title="García‐CompeánD , VillarealJZ , CuevasHB , CantúDAG , EstrellaM , TamezEG , et al. Total therapeutic paracentesis (TTP) with and without intravenous albumin in the treatment of cirrhotic tense ascites: a randomized controlled trial. Liver1993;13(5):233‐8. [PUBMED: 8259034] ">García‐Compeán 1993</a>; <a href="./references#CD004039-bbs2-0018" title="LucaA , García‐PagánJ , BoschJ , FeuF , JiménezW , GinésA , et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology1995;22(3):753‐8. [PUBMED: 7657279] ">Luca 1995</a>; <a href="./references#CD004039-bbs2-0004" title="BaikSK , KimHS , LeeDK , KimIH , KwonSO . Hemodynamic changes after single large volume paracentesis (SLVP) in cirrhosis with tense ascites ‐ focusing on the effect of albumin as plasma expander. Korean Journal of Medicine2000;58:276‐82. ">Baik 2000</a>) and the remaining trial with six trial groups assessed plasma volume expansion with intravenous infusion of filtrated ascitic fluid versus intravenous infusion of unmodified ascitic fluid versus no plasma expansion, or versus several different diuretic treatments (<a href="./references#CD004039-bbs2-0008" title="DescosL , GauthierA , LevyVG , MichelH , QuintonA , RueffB , et al. Comparison of six treatments of ascites in patients with liver cirrhosis. A clinical trial. Hepato‐gastroenterology1983;30:15‐20. [PUBMED: 6339343] ">Descos 1983</a>). For the purpose of our review, we put together, in the experimental group, the data from people treated with intravenous infusion of filtrated or unmodified ascitic fluid. </p> <p>Twenty‐two trials, including 1321 participants, assessed the effect of a plasma volume expander versus another plasma volume expander. Overall, the experimental treatments were Dextran 70 in five trials (<a href="./references#CD004039-bbs2-0022" title="PlanasR , GinèsP , ArroyoV , LlachJ , PanésJ , VargasV , et al. Dextran‐70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study. Gastroenterology1990;99(6):1736‐44. [PUBMED: 1699835] PlanasR , LlachJ , GinèsP , PanésJ , VargasV , SalmeronJM , et al. Albumin versus dextran‐70 in cirrhotics with tense ascites treated with total paracentesis. Final results of a multicenter randomized comparative study. Journal of Hepatology1990;11(Suppl 2):S49. ">Planas 1990</a>; <a href="./references#CD004039-bbs2-0005" title="BertránX , Fernández‐BañaresF , PlanasF , CabréE , MorillasR , DeLeónR , et al. Effect on the nutritional status of total paracentesis plus albumin or dextran‐70 i.v. infusion for the treatment of tense ascites in liver cirrhosis [Repercusión sobre el estado nutricional energético‐proteico de la paracentesis total asociada a la infusión de albúmina o dextano‐70 en el tratamiento de la ascitis a tensión en la cirrhosis hepática]. Revista Espanola de Enfermedades Digestivas1991;79(5):320‐4. ">Bertrán 1991</a>; <a href="./references#CD004039-bbs2-0009" title="FassioE , TergR , LandeiraG , AbecasisR , SalemneM , PodestaA , et al. Paracentesis with dextran 70 vs paracentesis with albumin in cirrhosis with tense ascites. Results of a randomized study. Journal of Hepatology1992;14(2‐3):310‐6. [PUBMED: 1380024] ">Fassio 1992</a>; <a href="./references#CD004039-bbs2-0015" title="Hernández PérezRE , Aguilar RamírezJR , Hernández LopezJM , Gómez Maganday Silva T . Total paracentesis and infusion of dextran 70 vs albumin in cirrhotic patients with tense ascites [Paracentesis masiva con reposición de dextran 70 vs albúmina en pacientes cirróticos con ascitis a tensión]. Revista de Gastroenterologia de Mexico1995;60(1):22‐6. [PUBMED: 7543691] ">Hernández Pérez 1995</a>; <a href="./references#CD004039-bbs2-0013" title="GinèsA , Fernández‐EsparrachG , MonescilloA , VilaC , DomènechE , AbecasisR , et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology1996;111(4):1002‐10. [PUBMED: 8831595] International Group for the Study of Ascites in Cirrhosis. Comparison of albumin, dextran‐70 and hemaccel in the prevention of effective hypovolemia in cirrhotic patients with ascites treated with total paracentesis. A randomized multicenter study. Hepatology1995;22(4 Suppl):220A. ">Ginès 1996</a>) and Dextran 40 in one trial (<a href="./references#CD004039-bbs2-0011" title="García‐CompeánD , BlancP , LarreyD , DauresJ‐P , HirtzJ , MendozaE , et al. Treatment of cirrhotic tense ascites with dextran‐40 versus albumin associated with large volume paracentesis. A randomized controlled trial. Annals of Hepatology2002;1(1):29‐35. [PUBMED: 15114293] ">García‐Compeán 2002</a>); polygeline in five trials (<a href="./references#CD004039-bbs2-0023" title="SalernoF , BadalamentiS , LorenzanoE , MoserP , IncertiP . Randomized comparative study of hemaccel vs albumin infusion after total paracentesis in cirrhotic patients with refractory ascites. Hepatology1991;13(4):707‐13. [PUBMED: 1826281] ">Salerno 1991</a>; <a href="./references#CD004039-bbs2-0013" title="GinèsA , Fernández‐EsparrachG , MonescilloA , VilaC , DomènechE , AbecasisR , et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology1996;111(4):1002‐10. [PUBMED: 8831595] International Group for the Study of Ascites in Cirrhosis. Comparison of albumin, dextran‐70 and hemaccel in the prevention of effective hypovolemia in cirrhotic patients with ascites treated with total paracentesis. A randomized multicenter study. Hepatology1995;22(4 Suppl):220A. ">Ginès 1996</a>; <a href="./references#CD004039-bbs2-0007" title="DegoricijaV , Zjacic‐RotkvicV , MaroutJ , SeferS , TroskotB . Clinical and neurohumoral response to posture, physical exercise, and ascites treatment in Child‐Pugh C liver cirrhosis: randomized prospective trial. Croatian Medical Journal2003;44(2):178‐86. [PUBMED: 12698509] DegoricijaV , Zjacic‐RotkvicV , TroskotB , ŠeferS . Postparacentesis neurohumoral changes and impairment of renal water excretion in Child‐Pugh C cirrhosis with and without volume replacement. Journal of Hepatology2001;34:51. ">Degoricija 2003</a>; <a href="./references#CD004039-bbs2-0021" title="MoreauR , VallaD‐C , Durand‐ZaleskiI , BronowickiJ‐P , DurandF , ChaputJ‐C , et al. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trial. Liver International2006;26(1):46‐54. [PUBMED: 16420509] ">Moreau 2006</a>; <a href="./references#CD004039-bbs2-0017" title="KhanMU , RahimIU , LatifM . Hemaccel as a cheaper alternative to human albumin for plasma expansion during paracentesis in cirrhotic patients. Pakistan Journal of Medical and Health Sciences2015;9(3):948‐51. ">Khan 2015</a>); hydroxyethyl starch in five trials (<a href="./references#CD004039-bbs2-0020" title="MéndezC , SorianoG , GuarnerC , TomásA , MoyanoD , ToroH , et al. Total paracentesis in cirrhotics with refractory ascites: albumin vs HES as plasmatic expanders. Journal of Hepatology1991;13(Suppl 2):S145. ">Méndez 1991</a>; <a href="./references#CD004039-bbs2-0003" title="AltmanC , BernardB , RoulotD , VitteR‐L , InkO . Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis. European Journal of Gastroenterology &amp; Hepatology1998;10:5‐10. [PUBMED: 9512946] ">Altman 1998</a>; <a href="./references#CD004039-bbs2-0016" title="KangKE , KimBH , DongSH , KimHJ , ChangYW , LeeJII , et al. The efficacy of hydroxyethyl starch as plasma expander in cirrhotic patients with tense ascites treated with large volume paracentesis. Korean Journal of Gastroenterology1998;31:651‐60. ">Kang 1998</a>; <a href="./references#CD004039-bbs2-0001" title="Abdel‐KhalekEE , ArifS . Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients With liver cirrhosis and tense ascites after large‐volume paracentesis. Journal of Hepatology2010;52:S327. Abdel‐KhalekEE , ArifSE . Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients with liver cirrhosis and tense ascites following large volume paracentesis. Arab Journal of Gastroenterology2010;11:24‐9. ">Abdel‐Khalek 2010</a>; <a href="./references#CD004039-bbs2-0002" title="Al SebaeyA , Abdel‐RazekW , BassuniA , RewishaEA , KhalilM , WakedI , et al. Alternatives to albumin for prevention of paracentesis induced circulatory dysfunction (PICD) in cirrhosis. Hepatology2012;56(S1):915A. ">Al Sebaey 2012</a>); fresh frozen plasma in one trial (<a href="./references#CD004039-bbs2-0007" title="DegoricijaV , Zjacic‐RotkvicV , MaroutJ , SeferS , TroskotB . Clinical and neurohumoral response to posture, physical exercise, and ascites treatment in Child‐Pugh C liver cirrhosis: randomized prospective trial. Croatian Medical Journal2003;44(2):178‐86. [PUBMED: 12698509] DegoricijaV , Zjacic‐RotkvicV , TroskotB , ŠeferS . Postparacentesis neurohumoral changes and impairment of renal water excretion in Child‐Pugh C cirrhosis with and without volume replacement. Journal of Hepatology2001;34:51. ">Degoricija 2003</a>); intravenous infusion of ascitic fluid in four trials (<a href="./references#CD004039-bbs2-0025" title="SmartHL , TrigerDR . A randomised prospective trial comparing daily paracentesis and intravenous albumin with recirculation in diuretic refractory ascites. Journal of Hepatology1990;10(2):191‐7. [PUBMED: 2185298] ">Smart 1990</a>; <a href="./references#CD004039-bbs2-0024" title="RinaldiF , SimonettiRG , MaisanoS , DinoO , MilazzoG , LucaA , et al. Refractory ascites in cirrhosis: treatment with total paracentesis and reinfusion of filtrated and concentrated ascitic fluid. Italian Journal of Gastroenterology1990;22(4):261. SimonettiRG , RinaldiF , MilazzoG , DinoO , MaisanoS , LucaA , et al. Treatment of refractory ascites: a randomized prospective trial of total paracentesis with concentrated ascitic fluid reinfusion vs repeated paracentesis and albumin infusion. Italian Journal of Gastroenterology1991;23(7):473. ">Simonetti 1991</a>; <a href="./references#CD004039-bbs2-0006" title="BrunoS , BorzioM , RomagnoniM , BattezzatiPM , RossiS , ChiesaA , et al. Comparison of spontaneous ascites filtration and reinfusion with total paracentesis with intravenous albumin infusion in cirrhotic patients with tense ascites. BMJ1992;304:1655‐8. [PUBMED: 1633517] BrunoS , BorzioM , RomagnoniM , ChiesaA , RossiS , PavesiS , et al. Spontaneous ascites filtration and reinfusion (SAFR) vs total paracentesis (TP) with i.v. albumin infusion in cirrhotic patients with tense ascites. Hepatology1990;12:855. ">Bruno 1992</a>; <a href="./references#CD004039-bbs2-0014" title="GraziottoA , RossaroL , InturriP , SalvagniniM . Reinfusion of concentrated ascitic fluid versus total paracentesis. A randomized prospective trial. Digestive Diseases and Sciences1997;42(8):1708‐14. [PUBMED: 9286238] ">Graziotto 1997</a>); saline solution in one trial (<a href="./references#CD004039-bbs2-0026" title="Sola‐VeraJ , MinanaJ , SorianoG , GonzalezB , PlanellaM , Lopez‐BalaguerJM , et al. Expansion with saline vs albumin in cirrhotic patients with tense ascites treated with total paracentesis. Result of a prospective randomized study. Gastroenterologia y Hepatologia2001;24(2):90 A6. Sola‐VeraJ , MiñanaJ , RicartE , PlanellaM , GonzálezB , TorrasX , et al. Randomized trial comparing albumin and saline in the prevention of paracentesis‐induced circultory dysfunction in cirrhotic patients with ascites. Hepatology2003;37(5):1147‐53. [PUBMED: 12717396] ">Sola‐Vera 2003</a>); and mannitol(um) in one trial (<a href="./references#CD004039-bbs2-0027" title="ZhaoJ , YuanC , WangD , LIX . Mannitolum infusion on cirrhotic patients with tense ascites treated by paracentesis. Chinese Medical Journal2000;113(1):27‐30. [PUBMED: 11775204] ">Zhao 2000</a>). In 21 trials, albumin was used as the control intervention. Dextran 70 and polygeline were assessed in a three‐armed trial compared with albumin (<a href="./references#CD004039-bbs2-0013" title="GinèsA , Fernández‐EsparrachG , MonescilloA , VilaC , DomènechE , AbecasisR , et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology1996;111(4):1002‐10. [PUBMED: 8831595] International Group for the Study of Ascites in Cirrhosis. Comparison of albumin, dextran‐70 and hemaccel in the prevention of effective hypovolemia in cirrhotic patients with ascites treated with total paracentesis. A randomized multicenter study. Hepatology1995;22(4 Suppl):220A. ">Ginès 1996</a>). Albumin, fresh frozen plasma and polygeline plus bed rest, no plasma expanders without bed rest and diuretic treatment without paracentesis and bed rest were compared in a 5‐armed trial. For the purpose of this review, we used the data from the first three intervention groups (<a href="./references#CD004039-bbs2-0007" title="DegoricijaV , Zjacic‐RotkvicV , MaroutJ , SeferS , TroskotB . Clinical and neurohumoral response to posture, physical exercise, and ascites treatment in Child‐Pugh C liver cirrhosis: randomized prospective trial. Croatian Medical Journal2003;44(2):178‐86. [PUBMED: 12698509] DegoricijaV , Zjacic‐RotkvicV , TroskotB , ŠeferS . Postparacentesis neurohumoral changes and impairment of renal water excretion in Child‐Pugh C cirrhosis with and without volume replacement. Journal of Hepatology2001;34:51. ">Degoricija 2003</a>). Hydroxyethyl starch, terlipressin, midodrine, and albumin in two different doses (6 g/L of ascitic fluid in one group and 3 g/L in another group) were compared in a five‐armed trial (<a href="./references#CD004039-bbs2-0002" title="Al SebaeyA , Abdel‐RazekW , BassuniA , RewishaEA , KhalilM , WakedI , et al. Alternatives to albumin for prevention of paracentesis induced circulatory dysfunction (PICD) in cirrhosis. Hepatology2012;56(S1):915A. ">Al Sebaey 2012</a>). For the purpose of this review, we compared the hydroxyethyl starch group with the two albumin groups, put together (<a href="./references#CD004039-bbs2-0002" title="Al SebaeyA , Abdel‐RazekW , BassuniA , RewishaEA , KhalilM , WakedI , et al. Alternatives to albumin for prevention of paracentesis induced circulatory dysfunction (PICD) in cirrhosis. Hepatology2012;56(S1):915A. ">Al Sebaey 2012</a>). We did not use the data from the other two intervention groups of this trial. Intravenous infusion of ascitic fluid was compared with polygeline in one trial (<a href="./references#CD004039-bbs2-0019" title="MehtaNN , AbrahamP , AsharVJ , ShikareSS , SavantSS , KarnadDR , et al. Ascitic fluid filtration and intravenous infusion versus total‐volume paracentesis with infusion of plasma expander in cirrhosis with tense or intractable ascites. Indian Journal of Gastroenterology1998;17(3):93‐6. ">Mehta 1998</a>). </p> <p>Overall, 175 participants were treated with Dextran 70, 209 with polygeline, 135 with hydroxyethyl starch, 77 with intravenous ascitic fluid infusion, 35 with 3.5% saline, and 32 with mannitol, and 10 participants with fresh frozen plasma versus 579 participants treated with albumin. The number of participants treated by Dextran 40 is unknown (see above, <a href="./references#CD004039-bbs2-0011" title="García‐CompeánD , BlancP , LarreyD , DauresJ‐P , HirtzJ , MendozaE , et al. Treatment of cirrhotic tense ascites with dextran‐40 versus albumin associated with large volume paracentesis. A randomized controlled trial. Annals of Hepatology2002;1(1):29‐35. [PUBMED: 15114293] ">García‐Compeán 2002</a>). </p> <p>The dose of the plasma expanders for each litre of removed ascitic fluid was as follows: for albumin 2 g to 10 g, for dextran 6 g to 8 g, for hydroxyethyl starch 7.7 g to 13 g, for polygeline 4 g to 8 g, for 3.5% saline 170 mL, for mannitol 8 g to 16 g, and for fresh frozen plasma 100 mL. </p> <p>The mean volume (± SD) of removed ascitic fluid reported in 24 trials was 8.1 L (SD 2.96) (range 4.0 L to 15.9 L). Diuretic treatment was used after paracentesis in 13 trials.      </p> <p>If recurrence of ascites occurred during the follow‐up period, the participants in seven trials were treated with the same schedule to which they were randomised originally (<a href="./references#CD004039-bbs2-0012" title="GinèsP , TitóL , ArroyoV , PlanasR , PanésJ , ViverJ , et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology1988;94(6):1493‐1502. [PUBMED: 3360270] ">Ginès 1988</a>; <a href="./references#CD004039-bbs2-0022" title="PlanasR , GinèsP , ArroyoV , LlachJ , PanésJ , VargasV , et al. Dextran‐70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study. Gastroenterology1990;99(6):1736‐44. [PUBMED: 1699835] PlanasR , LlachJ , GinèsP , PanésJ , VargasV , SalmeronJM , et al. Albumin versus dextran‐70 in cirrhotics with tense ascites treated with total paracentesis. Final results of a multicenter randomized comparative study. Journal of Hepatology1990;11(Suppl 2):S49. ">Planas 1990</a>; <a href="./references#CD004039-bbs2-0023" title="SalernoF , BadalamentiS , LorenzanoE , MoserP , IncertiP . Randomized comparative study of hemaccel vs albumin infusion after total paracentesis in cirrhotic patients with refractory ascites. Hepatology1991;13(4):707‐13. [PUBMED: 1826281] ">Salerno 1991</a>; <a href="./references#CD004039-bbs2-0024" title="RinaldiF , SimonettiRG , MaisanoS , DinoO , MilazzoG , LucaA , et al. Refractory ascites in cirrhosis: treatment with total paracentesis and reinfusion of filtrated and concentrated ascitic fluid. Italian Journal of Gastroenterology1990;22(4):261. SimonettiRG , RinaldiF , MilazzoG , DinoO , MaisanoS , LucaA , et al. Treatment of refractory ascites: a randomized prospective trial of total paracentesis with concentrated ascitic fluid reinfusion vs repeated paracentesis and albumin infusion. Italian Journal of Gastroenterology1991;23(7):473. ">Simonetti 1991</a>; <a href="./references#CD004039-bbs2-0009" title="FassioE , TergR , LandeiraG , AbecasisR , SalemneM , PodestaA , et al. Paracentesis with dextran 70 vs paracentesis with albumin in cirrhosis with tense ascites. Results of a randomized study. Journal of Hepatology1992;14(2‐3):310‐6. [PUBMED: 1380024] ">Fassio 1992</a>; <a href="./references#CD004039-bbs2-0013" title="GinèsA , Fernández‐EsparrachG , MonescilloA , VilaC , DomènechE , AbecasisR , et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology1996;111(4):1002‐10. [PUBMED: 8831595] International Group for the Study of Ascites in Cirrhosis. Comparison of albumin, dextran‐70 and hemaccel in the prevention of effective hypovolemia in cirrhotic patients with ascites treated with total paracentesis. A randomized multicenter study. Hepatology1995;22(4 Suppl):220A. ">Ginès 1996</a>; <a href="./references#CD004039-bbs2-0001" title="Abdel‐KhalekEE , ArifS . Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients With liver cirrhosis and tense ascites after large‐volume paracentesis. Journal of Hepatology2010;52:S327. Abdel‐KhalekEE , ArifSE . Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients with liver cirrhosis and tense ascites following large volume paracentesis. Arab Journal of Gastroenterology2010;11:24‐9. ">Abdel‐Khalek 2010</a>). Participants were treated with an alternative treatment in one trial (<a href="./references#CD004039-bbs2-0026" title="Sola‐VeraJ , MinanaJ , SorianoG , GonzalezB , PlanellaM , Lopez‐BalaguerJM , et al. Expansion with saline vs albumin in cirrhotic patients with tense ascites treated with total paracentesis. Result of a prospective randomized study. Gastroenterologia y Hepatologia2001;24(2):90 A6. Sola‐VeraJ , MiñanaJ , RicartE , PlanellaM , GonzálezB , TorrasX , et al. Randomized trial comparing albumin and saline in the prevention of paracentesis‐induced circultory dysfunction in cirrhotic patients with ascites. Hepatology2003;37(5):1147‐53. [PUBMED: 12717396] ">Sola‐Vera 2003</a>). As this trial was a cross‐over trial, we used the results from the first period of the trial on day 6 after paracentesis for all outcomes, except for the recurrence of ascites for which data were reported after discharge of trial participants. </p> </section> <section id="CD004039-sec-0071"> <h5 class="title">Follow‐up and withdrawals</h5> <p>Fifteen trials reported analyses of outcomes within one month: at 24 hours in <a href="./references#CD004039-bbs2-0018" title="LucaA , García‐PagánJ , BoschJ , FeuF , JiménezW , GinésA , et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology1995;22(3):753‐8. [PUBMED: 7657279] ">Luca 1995</a>, at two days in <a href="./references#CD004039-bbs2-0004" title="BaikSK , KimHS , LeeDK , KimIH , KwonSO . Hemodynamic changes after single large volume paracentesis (SLVP) in cirrhosis with tense ascites ‐ focusing on the effect of albumin as plasma expander. Korean Journal of Medicine2000;58:276‐82. ">Baik 2000</a>, at three days in <a href="./references#CD004039-bbs2-0016" title="KangKE , KimBH , DongSH , KimHJ , ChangYW , LeeJII , et al. The efficacy of hydroxyethyl starch as plasma expander in cirrhotic patients with tense ascites treated with large volume paracentesis. Korean Journal of Gastroenterology1998;31:651‐60. ">Kang 1998</a>, at five days in <a href="./references#CD004039-bbs2-0020" title="MéndezC , SorianoG , GuarnerC , TomásA , MoyanoD , ToroH , et al. Total paracentesis in cirrhotics with refractory ascites: albumin vs HES as plasmatic expanders. Journal of Hepatology1991;13(Suppl 2):S145. ">Méndez 1991</a> and <a href="./references#CD004039-bbs2-0010" title="García‐CompeánD , VillarealJZ , CuevasHB , CantúDAG , EstrellaM , TamezEG , et al. Total therapeutic paracentesis (TTP) with and without intravenous albumin in the treatment of cirrhotic tense ascites: a randomized controlled trial. Liver1993;13(5):233‐8. [PUBMED: 8259034] ">García‐Compeán 1993</a>, at six days in <a href="./references#CD004039-bbs2-0007" title="DegoricijaV , Zjacic‐RotkvicV , MaroutJ , SeferS , TroskotB . Clinical and neurohumoral response to posture, physical exercise, and ascites treatment in Child‐Pugh C liver cirrhosis: randomized prospective trial. Croatian Medical Journal2003;44(2):178‐86. [PUBMED: 12698509] DegoricijaV , Zjacic‐RotkvicV , TroskotB , ŠeferS . Postparacentesis neurohumoral changes and impairment of renal water excretion in Child‐Pugh C cirrhosis with and without volume replacement. Journal of Hepatology2001;34:51. ">Degoricija 2003</a>, <a href="./references#CD004039-bbs2-0026" title="Sola‐VeraJ , MinanaJ , SorianoG , GonzalezB , PlanellaM , Lopez‐BalaguerJM , et al. Expansion with saline vs albumin in cirrhotic patients with tense ascites treated with total paracentesis. Result of a prospective randomized study. Gastroenterologia y Hepatologia2001;24(2):90 A6. Sola‐VeraJ , MiñanaJ , RicartE , PlanellaM , GonzálezB , TorrasX , et al. Randomized trial comparing albumin and saline in the prevention of paracentesis‐induced circultory dysfunction in cirrhotic patients with ascites. Hepatology2003;37(5):1147‐53. [PUBMED: 12717396] ">Sola‐Vera 2003</a>, <a href="./references#CD004039-bbs2-0002" title="Al SebaeyA , Abdel‐RazekW , BassuniA , RewishaEA , KhalilM , WakedI , et al. Alternatives to albumin for prevention of paracentesis induced circulatory dysfunction (PICD) in cirrhosis. Hepatology2012;56(S1):915A. ">Al Sebaey 2012</a> and <a href="./references#CD004039-bbs2-0017" title="KhanMU , RahimIU , LatifM . Hemaccel as a cheaper alternative to human albumin for plasma expansion during paracentesis in cirrhotic patients. Pakistan Journal of Medical and Health Sciences2015;9(3):948‐51. ">Khan 2015</a>, at eight days in <a href="./references#CD004039-bbs2-0006" title="BrunoS , BorzioM , RomagnoniM , BattezzatiPM , RossiS , ChiesaA , et al. Comparison of spontaneous ascites filtration and reinfusion with total paracentesis with intravenous albumin infusion in cirrhotic patients with tense ascites. BMJ1992;304:1655‐8. [PUBMED: 1633517] BrunoS , BorzioM , RomagnoniM , ChiesaA , RossiS , PavesiS , et al. Spontaneous ascites filtration and reinfusion (SAFR) vs total paracentesis (TP) with i.v. albumin infusion in cirrhotic patients with tense ascites. Hepatology1990;12:855. ">Bruno 1992</a>, at 14 days in <a href="./references#CD004039-bbs2-0015" title="Hernández PérezRE , Aguilar RamírezJR , Hernández LopezJM , Gómez Maganday Silva T . Total paracentesis and infusion of dextran 70 vs albumin in cirrhotic patients with tense ascites [Paracentesis masiva con reposición de dextran 70 vs albúmina en pacientes cirróticos con ascitis a tensión]. Revista de Gastroenterologia de Mexico1995;60(1):22‐6. [PUBMED: 7543691] ">Hernández Pérez 1995</a>, at 15 days in <a href="./references#CD004039-bbs2-0003" title="AltmanC , BernardB , RoulotD , VitteR‐L , InkO . Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis. European Journal of Gastroenterology &amp; Hepatology1998;10:5‐10. [PUBMED: 9512946] ">Altman 1998</a>, and at one month in <a href="./references#CD004039-bbs2-0008" title="DescosL , GauthierA , LevyVG , MichelH , QuintonA , RueffB , et al. Comparison of six treatments of ascites in patients with liver cirrhosis. A clinical trial. Hepato‐gastroenterology1983;30:15‐20. [PUBMED: 6339343] ">Descos 1983</a> and <a href="./references#CD004039-bbs2-0005" title="BertránX , Fernández‐BañaresF , PlanasF , CabréE , MorillasR , DeLeónR , et al. Effect on the nutritional status of total paracentesis plus albumin or dextran‐70 i.v. infusion for the treatment of tense ascites in liver cirrhosis [Repercusión sobre el estado nutricional energético‐proteico de la paracentesis total asociada a la infusión de albúmina o dextano‐70 en el tratamiento de la ascitis a tensión en la cirrhosis hepática]. Revista Espanola de Enfermedades Digestivas1991;79(5):320‐4. ">Bertrán 1991</a>. In <a href="./references#CD004039-bbs2-0019" title="MehtaNN , AbrahamP , AsharVJ , ShikareSS , SavantSS , KarnadDR , et al. Ascitic fluid filtration and intravenous infusion versus total‐volume paracentesis with infusion of plasma expander in cirrhosis with tense or intractable ascites. Indian Journal of Gastroenterology1998;17(3):93‐6. ">Mehta 1998</a>, the median follow‐up was 17.5 days. </p> <p>The other 12 trials had a follow‐up longer than a month (<a href="./references#CD004039-bbs2-0012" title="GinèsP , TitóL , ArroyoV , PlanasR , PanésJ , ViverJ , et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology1988;94(6):1493‐1502. [PUBMED: 3360270] ">Ginès 1988</a>; <a href="./references#CD004039-bbs2-0022" title="PlanasR , GinèsP , ArroyoV , LlachJ , PanésJ , VargasV , et al. Dextran‐70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study. Gastroenterology1990;99(6):1736‐44. [PUBMED: 1699835] PlanasR , LlachJ , GinèsP , PanésJ , VargasV , SalmeronJM , et al. Albumin versus dextran‐70 in cirrhotics with tense ascites treated with total paracentesis. Final results of a multicenter randomized comparative study. Journal of Hepatology1990;11(Suppl 2):S49. ">Planas 1990</a>; <a href="./references#CD004039-bbs2-0025" title="SmartHL , TrigerDR . A randomised prospective trial comparing daily paracentesis and intravenous albumin with recirculation in diuretic refractory ascites. Journal of Hepatology1990;10(2):191‐7. [PUBMED: 2185298] ">Smart 1990</a>; <a href="./references#CD004039-bbs2-0023" title="SalernoF , BadalamentiS , LorenzanoE , MoserP , IncertiP . Randomized comparative study of hemaccel vs albumin infusion after total paracentesis in cirrhotic patients with refractory ascites. Hepatology1991;13(4):707‐13. [PUBMED: 1826281] ">Salerno 1991</a>; <a href="./references#CD004039-bbs2-0024" title="RinaldiF , SimonettiRG , MaisanoS , DinoO , MilazzoG , LucaA , et al. Refractory ascites in cirrhosis: treatment with total paracentesis and reinfusion of filtrated and concentrated ascitic fluid. Italian Journal of Gastroenterology1990;22(4):261. SimonettiRG , RinaldiF , MilazzoG , DinoO , MaisanoS , LucaA , et al. Treatment of refractory ascites: a randomized prospective trial of total paracentesis with concentrated ascitic fluid reinfusion vs repeated paracentesis and albumin infusion. Italian Journal of Gastroenterology1991;23(7):473. ">Simonetti 1991</a>; <a href="./references#CD004039-bbs2-0009" title="FassioE , TergR , LandeiraG , AbecasisR , SalemneM , PodestaA , et al. Paracentesis with dextran 70 vs paracentesis with albumin in cirrhosis with tense ascites. Results of a randomized study. Journal of Hepatology1992;14(2‐3):310‐6. [PUBMED: 1380024] ">Fassio 1992</a>; <a href="./references#CD004039-bbs2-0011" title="García‐CompeánD , BlancP , LarreyD , DauresJ‐P , HirtzJ , MendozaE , et al. Treatment of cirrhotic tense ascites with dextran‐40 versus albumin associated with large volume paracentesis. A randomized controlled trial. Annals of Hepatology2002;1(1):29‐35. [PUBMED: 15114293] ">García‐Compeán 2002</a>; <a href="./references#CD004039-bbs2-0013" title="GinèsA , Fernández‐EsparrachG , MonescilloA , VilaC , DomènechE , AbecasisR , et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology1996;111(4):1002‐10. [PUBMED: 8831595] International Group for the Study of Ascites in Cirrhosis. Comparison of albumin, dextran‐70 and hemaccel in the prevention of effective hypovolemia in cirrhotic patients with ascites treated with total paracentesis. A randomized multicenter study. Hepatology1995;22(4 Suppl):220A. ">Ginès 1996</a>; <a href="./references#CD004039-bbs2-0014" title="GraziottoA , RossaroL , InturriP , SalvagniniM . Reinfusion of concentrated ascitic fluid versus total paracentesis. A randomized prospective trial. Digestive Diseases and Sciences1997;42(8):1708‐14. [PUBMED: 9286238] ">Graziotto 1997</a>; <a href="./references#CD004039-bbs2-0027" title="ZhaoJ , YuanC , WangD , LIX . Mannitolum infusion on cirrhotic patients with tense ascites treated by paracentesis. Chinese Medical Journal2000;113(1):27‐30. [PUBMED: 11775204] ">Zhao 2000</a>; <a href="./references#CD004039-bbs2-0021" title="MoreauR , VallaD‐C , Durand‐ZaleskiI , BronowickiJ‐P , DurandF , ChaputJ‐C , et al. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trial. Liver International2006;26(1):46‐54. [PUBMED: 16420509] ">Moreau 2006</a>; <a href="./references#CD004039-bbs2-0001" title="Abdel‐KhalekEE , ArifS . Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients With liver cirrhosis and tense ascites after large‐volume paracentesis. Journal of Hepatology2010;52:S327. Abdel‐KhalekEE , ArifSE . Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients with liver cirrhosis and tense ascites following large volume paracentesis. Arab Journal of Gastroenterology2010;11:24‐9. ">Abdel‐Khalek 2010</a>). In <a href="./references#CD004039-bbs2-0026" title="Sola‐VeraJ , MinanaJ , SorianoG , GonzalezB , PlanellaM , Lopez‐BalaguerJM , et al. Expansion with saline vs albumin in cirrhotic patients with tense ascites treated with total paracentesis. Result of a prospective randomized study. Gastroenterologia y Hepatologia2001;24(2):90 A6. Sola‐VeraJ , MiñanaJ , RicartE , PlanellaM , GonzálezB , TorrasX , et al. Randomized trial comparing albumin and saline in the prevention of paracentesis‐induced circultory dysfunction in cirrhotic patients with ascites. Hepatology2003;37(5):1147‐53. [PUBMED: 12717396] ">Sola‐Vera 2003</a> (a cross‐over trial), the follow‐up was longer than one month only for recurrence of ascites, whereas the other outcomes were recorded on day six. </p> <p>Fifteen trials followed up the participants after their discharge from hospital (<a href="./references#CD004039-bbs2-0008" title="DescosL , GauthierA , LevyVG , MichelH , QuintonA , RueffB , et al. Comparison of six treatments of ascites in patients with liver cirrhosis. A clinical trial. Hepato‐gastroenterology1983;30:15‐20. [PUBMED: 6339343] ">Descos 1983</a>; <a href="./references#CD004039-bbs2-0012" title="GinèsP , TitóL , ArroyoV , PlanasR , PanésJ , ViverJ , et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology1988;94(6):1493‐1502. [PUBMED: 3360270] ">Ginès 1988</a>; <a href="./references#CD004039-bbs2-0022" title="PlanasR , GinèsP , ArroyoV , LlachJ , PanésJ , VargasV , et al. Dextran‐70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study. Gastroenterology1990;99(6):1736‐44. [PUBMED: 1699835] PlanasR , LlachJ , GinèsP , PanésJ , VargasV , SalmeronJM , et al. Albumin versus dextran‐70 in cirrhotics with tense ascites treated with total paracentesis. Final results of a multicenter randomized comparative study. Journal of Hepatology1990;11(Suppl 2):S49. ">Planas 1990</a>; <a href="./references#CD004039-bbs2-0025" title="SmartHL , TrigerDR . A randomised prospective trial comparing daily paracentesis and intravenous albumin with recirculation in diuretic refractory ascites. Journal of Hepatology1990;10(2):191‐7. [PUBMED: 2185298] ">Smart 1990</a>; <a href="./references#CD004039-bbs2-0023" title="SalernoF , BadalamentiS , LorenzanoE , MoserP , IncertiP . Randomized comparative study of hemaccel vs albumin infusion after total paracentesis in cirrhotic patients with refractory ascites. Hepatology1991;13(4):707‐13. [PUBMED: 1826281] ">Salerno 1991</a>; <a href="./references#CD004039-bbs2-0024" title="RinaldiF , SimonettiRG , MaisanoS , DinoO , MilazzoG , LucaA , et al. Refractory ascites in cirrhosis: treatment with total paracentesis and reinfusion of filtrated and concentrated ascitic fluid. Italian Journal of Gastroenterology1990;22(4):261. SimonettiRG , RinaldiF , MilazzoG , DinoO , MaisanoS , LucaA , et al. Treatment of refractory ascites: a randomized prospective trial of total paracentesis with concentrated ascitic fluid reinfusion vs repeated paracentesis and albumin infusion. Italian Journal of Gastroenterology1991;23(7):473. ">Simonetti 1991</a>; <a href="./references#CD004039-bbs2-0009" title="FassioE , TergR , LandeiraG , AbecasisR , SalemneM , PodestaA , et al. Paracentesis with dextran 70 vs paracentesis with albumin in cirrhosis with tense ascites. Results of a randomized study. Journal of Hepatology1992;14(2‐3):310‐6. [PUBMED: 1380024] ">Fassio 1992</a>; <a href="./references#CD004039-bbs2-0013" title="GinèsA , Fernández‐EsparrachG , MonescilloA , VilaC , DomènechE , AbecasisR , et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology1996;111(4):1002‐10. [PUBMED: 8831595] International Group for the Study of Ascites in Cirrhosis. Comparison of albumin, dextran‐70 and hemaccel in the prevention of effective hypovolemia in cirrhotic patients with ascites treated with total paracentesis. A randomized multicenter study. Hepatology1995;22(4 Suppl):220A. ">Ginès 1996</a>; <a href="./references#CD004039-bbs2-0014" title="GraziottoA , RossaroL , InturriP , SalvagniniM . Reinfusion of concentrated ascitic fluid versus total paracentesis. A randomized prospective trial. Digestive Diseases and Sciences1997;42(8):1708‐14. [PUBMED: 9286238] ">Graziotto 1997</a>; <a href="./references#CD004039-bbs2-0003" title="AltmanC , BernardB , RoulotD , VitteR‐L , InkO . Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis. European Journal of Gastroenterology &amp; Hepatology1998;10:5‐10. [PUBMED: 9512946] ">Altman 1998</a>; <a href="./references#CD004039-bbs2-0019" title="MehtaNN , AbrahamP , AsharVJ , ShikareSS , SavantSS , KarnadDR , et al. Ascitic fluid filtration and intravenous infusion versus total‐volume paracentesis with infusion of plasma expander in cirrhosis with tense or intractable ascites. Indian Journal of Gastroenterology1998;17(3):93‐6. ">Mehta 1998</a>; <a href="./references#CD004039-bbs2-0011" title="García‐CompeánD , BlancP , LarreyD , DauresJ‐P , HirtzJ , MendozaE , et al. Treatment of cirrhotic tense ascites with dextran‐40 versus albumin associated with large volume paracentesis. A randomized controlled trial. Annals of Hepatology2002;1(1):29‐35. [PUBMED: 15114293] ">García‐Compeán 2002</a>; <a href="./references#CD004039-bbs2-0026" title="Sola‐VeraJ , MinanaJ , SorianoG , GonzalezB , PlanellaM , Lopez‐BalaguerJM , et al. Expansion with saline vs albumin in cirrhotic patients with tense ascites treated with total paracentesis. Result of a prospective randomized study. Gastroenterologia y Hepatologia2001;24(2):90 A6. Sola‐VeraJ , MiñanaJ , RicartE , PlanellaM , GonzálezB , TorrasX , et al. Randomized trial comparing albumin and saline in the prevention of paracentesis‐induced circultory dysfunction in cirrhotic patients with ascites. Hepatology2003;37(5):1147‐53. [PUBMED: 12717396] ">Sola‐Vera 2003</a>; <a href="./references#CD004039-bbs2-0021" title="MoreauR , VallaD‐C , Durand‐ZaleskiI , BronowickiJ‐P , DurandF , ChaputJ‐C , et al. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trial. Liver International2006;26(1):46‐54. [PUBMED: 16420509] ">Moreau 2006</a>; <a href="./references#CD004039-bbs2-0001" title="Abdel‐KhalekEE , ArifS . Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients With liver cirrhosis and tense ascites after large‐volume paracentesis. Journal of Hepatology2010;52:S327. Abdel‐KhalekEE , ArifSE . Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients with liver cirrhosis and tense ascites following large volume paracentesis. Arab Journal of Gastroenterology2010;11:24‐9. ">Abdel‐Khalek 2010</a>). </p> <p>In <a href="./references#CD004039-bbs2-0013" title="GinèsA , Fernández‐EsparrachG , MonescilloA , VilaC , DomènechE , AbecasisR , et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology1996;111(4):1002‐10. [PUBMED: 8831595] International Group for the Study of Ascites in Cirrhosis. Comparison of albumin, dextran‐70 and hemaccel in the prevention of effective hypovolemia in cirrhotic patients with ascites treated with total paracentesis. A randomized multicenter study. Hepatology1995;22(4 Suppl):220A. ">Ginès 1996</a> and <a href="./references#CD004039-bbs2-0026" title="Sola‐VeraJ , MinanaJ , SorianoG , GonzalezB , PlanellaM , Lopez‐BalaguerJM , et al. Expansion with saline vs albumin in cirrhotic patients with tense ascites treated with total paracentesis. Result of a prospective randomized study. Gastroenterologia y Hepatologia2001;24(2):90 A6. Sola‐VeraJ , MiñanaJ , RicartE , PlanellaM , GonzálezB , TorrasX , et al. Randomized trial comparing albumin and saline in the prevention of paracentesis‐induced circultory dysfunction in cirrhotic patients with ascites. Hepatology2003;37(5):1147‐53. [PUBMED: 12717396] ">Sola‐Vera 2003</a> trials, participants were followed up after discharge, but the authors reported data on the outcomes of interest only for the first hospitalisation (<a href="./references#CD004039-bbs2-0013" title="GinèsA , Fernández‐EsparrachG , MonescilloA , VilaC , DomènechE , AbecasisR , et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology1996;111(4):1002‐10. [PUBMED: 8831595] International Group for the Study of Ascites in Cirrhosis. Comparison of albumin, dextran‐70 and hemaccel in the prevention of effective hypovolemia in cirrhotic patients with ascites treated with total paracentesis. A randomized multicenter study. Hepatology1995;22(4 Suppl):220A. ">Ginès 1996</a>), and on the sixth day after paracentesis (<a href="./references#CD004039-bbs2-0026" title="Sola‐VeraJ , MinanaJ , SorianoG , GonzalezB , PlanellaM , Lopez‐BalaguerJM , et al. Expansion with saline vs albumin in cirrhotic patients with tense ascites treated with total paracentesis. Result of a prospective randomized study. Gastroenterologia y Hepatologia2001;24(2):90 A6. Sola‐VeraJ , MiñanaJ , RicartE , PlanellaM , GonzálezB , TorrasX , et al. Randomized trial comparing albumin and saline in the prevention of paracentesis‐induced circultory dysfunction in cirrhotic patients with ascites. Hepatology2003;37(5):1147‐53. [PUBMED: 12717396] ">Sola‐Vera 2003</a>). Therefore, we included them in the analysis of trials with a short follow‐up. </p> <p>The mean follow‐up period was 136 days (range 1 to 638) in 25 trials (<a href="./references#CD004039-bbs2-0008" title="DescosL , GauthierA , LevyVG , MichelH , QuintonA , RueffB , et al. Comparison of six treatments of ascites in patients with liver cirrhosis. A clinical trial. Hepato‐gastroenterology1983;30:15‐20. [PUBMED: 6339343] ">Descos 1983</a>; <a href="./references#CD004039-bbs2-0012" title="GinèsP , TitóL , ArroyoV , PlanasR , PanésJ , ViverJ , et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology1988;94(6):1493‐1502. [PUBMED: 3360270] ">Ginès 1988</a>; <a href="./references#CD004039-bbs2-0022" title="PlanasR , GinèsP , ArroyoV , LlachJ , PanésJ , VargasV , et al. Dextran‐70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study. Gastroenterology1990;99(6):1736‐44. [PUBMED: 1699835] PlanasR , LlachJ , GinèsP , PanésJ , VargasV , SalmeronJM , et al. Albumin versus dextran‐70 in cirrhotics with tense ascites treated with total paracentesis. Final results of a multicenter randomized comparative study. Journal of Hepatology1990;11(Suppl 2):S49. ">Planas 1990</a>; <a href="./references#CD004039-bbs2-0005" title="BertránX , Fernández‐BañaresF , PlanasF , CabréE , MorillasR , DeLeónR , et al. Effect on the nutritional status of total paracentesis plus albumin or dextran‐70 i.v. infusion for the treatment of tense ascites in liver cirrhosis [Repercusión sobre el estado nutricional energético‐proteico de la paracentesis total asociada a la infusión de albúmina o dextano‐70 en el tratamiento de la ascitis a tensión en la cirrhosis hepática]. Revista Espanola de Enfermedades Digestivas1991;79(5):320‐4. ">Bertrán 1991</a>; <a href="./references#CD004039-bbs2-0020" title="MéndezC , SorianoG , GuarnerC , TomásA , MoyanoD , ToroH , et al. Total paracentesis in cirrhotics with refractory ascites: albumin vs HES as plasmatic expanders. Journal of Hepatology1991;13(Suppl 2):S145. ">Méndez 1991</a>; <a href="./references#CD004039-bbs2-0023" title="SalernoF , BadalamentiS , LorenzanoE , MoserP , IncertiP . Randomized comparative study of hemaccel vs albumin infusion after total paracentesis in cirrhotic patients with refractory ascites. Hepatology1991;13(4):707‐13. [PUBMED: 1826281] ">Salerno 1991</a>; <a href="./references#CD004039-bbs2-0024" title="RinaldiF , SimonettiRG , MaisanoS , DinoO , MilazzoG , LucaA , et al. Refractory ascites in cirrhosis: treatment with total paracentesis and reinfusion of filtrated and concentrated ascitic fluid. Italian Journal of Gastroenterology1990;22(4):261. SimonettiRG , RinaldiF , MilazzoG , DinoO , MaisanoS , LucaA , et al. Treatment of refractory ascites: a randomized prospective trial of total paracentesis with concentrated ascitic fluid reinfusion vs repeated paracentesis and albumin infusion. Italian Journal of Gastroenterology1991;23(7):473. ">Simonetti 1991</a>; <a href="./references#CD004039-bbs2-0006" title="BrunoS , BorzioM , RomagnoniM , BattezzatiPM , RossiS , ChiesaA , et al. Comparison of spontaneous ascites filtration and reinfusion with total paracentesis with intravenous albumin infusion in cirrhotic patients with tense ascites. BMJ1992;304:1655‐8. [PUBMED: 1633517] BrunoS , BorzioM , RomagnoniM , ChiesaA , RossiS , PavesiS , et al. Spontaneous ascites filtration and reinfusion (SAFR) vs total paracentesis (TP) with i.v. albumin infusion in cirrhotic patients with tense ascites. Hepatology1990;12:855. ">Bruno 1992</a>; <a href="./references#CD004039-bbs2-0009" title="FassioE , TergR , LandeiraG , AbecasisR , SalemneM , PodestaA , et al. Paracentesis with dextran 70 vs paracentesis with albumin in cirrhosis with tense ascites. Results of a randomized study. Journal of Hepatology1992;14(2‐3):310‐6. [PUBMED: 1380024] ">Fassio 1992</a>; <a href="./references#CD004039-bbs2-0010" title="García‐CompeánD , VillarealJZ , CuevasHB , CantúDAG , EstrellaM , TamezEG , et al. Total therapeutic paracentesis (TTP) with and without intravenous albumin in the treatment of cirrhotic tense ascites: a randomized controlled trial. Liver1993;13(5):233‐8. [PUBMED: 8259034] ">García‐Compeán 1993</a>; <a href="./references#CD004039-bbs2-0015" title="Hernández PérezRE , Aguilar RamírezJR , Hernández LopezJM , Gómez Maganday Silva T . Total paracentesis and infusion of dextran 70 vs albumin in cirrhotic patients with tense ascites [Paracentesis masiva con reposición de dextran 70 vs albúmina en pacientes cirróticos con ascitis a tensión]. Revista de Gastroenterologia de Mexico1995;60(1):22‐6. [PUBMED: 7543691] ">Hernández Pérez 1995</a>; <a href="./references#CD004039-bbs2-0018" title="LucaA , García‐PagánJ , BoschJ , FeuF , JiménezW , GinésA , et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology1995;22(3):753‐8. [PUBMED: 7657279] ">Luca 1995</a>; <a href="./references#CD004039-bbs2-0013" title="GinèsA , Fernández‐EsparrachG , MonescilloA , VilaC , DomènechE , AbecasisR , et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology1996;111(4):1002‐10. [PUBMED: 8831595] International Group for the Study of Ascites in Cirrhosis. Comparison of albumin, dextran‐70 and hemaccel in the prevention of effective hypovolemia in cirrhotic patients with ascites treated with total paracentesis. A randomized multicenter study. Hepatology1995;22(4 Suppl):220A. ">Ginès 1996</a>; <a href="./references#CD004039-bbs2-0014" title="GraziottoA , RossaroL , InturriP , SalvagniniM . Reinfusion of concentrated ascitic fluid versus total paracentesis. A randomized prospective trial. Digestive Diseases and Sciences1997;42(8):1708‐14. [PUBMED: 9286238] ">Graziotto 1997</a>; <a href="./references#CD004039-bbs2-0003" title="AltmanC , BernardB , RoulotD , VitteR‐L , InkO . Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis. European Journal of Gastroenterology &amp; Hepatology1998;10:5‐10. [PUBMED: 9512946] ">Altman 1998</a>; <a href="./references#CD004039-bbs2-0016" title="KangKE , KimBH , DongSH , KimHJ , ChangYW , LeeJII , et al. The efficacy of hydroxyethyl starch as plasma expander in cirrhotic patients with tense ascites treated with large volume paracentesis. Korean Journal of Gastroenterology1998;31:651‐60. ">Kang 1998</a>; <a href="./references#CD004039-bbs2-0004" title="BaikSK , KimHS , LeeDK , KimIH , KwonSO . Hemodynamic changes after single large volume paracentesis (SLVP) in cirrhosis with tense ascites ‐ focusing on the effect of albumin as plasma expander. Korean Journal of Medicine2000;58:276‐82. ">Baik 2000</a>; <a href="./references#CD004039-bbs2-0027" title="ZhaoJ , YuanC , WangD , LIX . Mannitolum infusion on cirrhotic patients with tense ascites treated by paracentesis. Chinese Medical Journal2000;113(1):27‐30. [PUBMED: 11775204] ">Zhao 2000</a>; <a href="./references#CD004039-bbs2-0011" title="García‐CompeánD , BlancP , LarreyD , DauresJ‐P , HirtzJ , MendozaE , et al. Treatment of cirrhotic tense ascites with dextran‐40 versus albumin associated with large volume paracentesis. A randomized controlled trial. Annals of Hepatology2002;1(1):29‐35. [PUBMED: 15114293] ">García‐Compeán 2002</a>; <a href="./references#CD004039-bbs2-0007" title="DegoricijaV , Zjacic‐RotkvicV , MaroutJ , SeferS , TroskotB . Clinical and neurohumoral response to posture, physical exercise, and ascites treatment in Child‐Pugh C liver cirrhosis: randomized prospective trial. Croatian Medical Journal2003;44(2):178‐86. [PUBMED: 12698509] DegoricijaV , Zjacic‐RotkvicV , TroskotB , ŠeferS . Postparacentesis neurohumoral changes and impairment of renal water excretion in Child‐Pugh C cirrhosis with and without volume replacement. Journal of Hepatology2001;34:51. ">Degoricija 2003</a>, <a href="./references#CD004039-bbs2-0026" title="Sola‐VeraJ , MinanaJ , SorianoG , GonzalezB , PlanellaM , Lopez‐BalaguerJM , et al. Expansion with saline vs albumin in cirrhotic patients with tense ascites treated with total paracentesis. Result of a prospective randomized study. Gastroenterologia y Hepatologia2001;24(2):90 A6. Sola‐VeraJ , MiñanaJ , RicartE , PlanellaM , GonzálezB , TorrasX , et al. Randomized trial comparing albumin and saline in the prevention of paracentesis‐induced circultory dysfunction in cirrhotic patients with ascites. Hepatology2003;37(5):1147‐53. [PUBMED: 12717396] ">Sola‐Vera 2003</a>; <a href="./references#CD004039-bbs2-0021" title="MoreauR , VallaD‐C , Durand‐ZaleskiI , BronowickiJ‐P , DurandF , ChaputJ‐C , et al. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trial. Liver International2006;26(1):46‐54. [PUBMED: 16420509] ">Moreau 2006</a>; <a href="./references#CD004039-bbs2-0001" title="Abdel‐KhalekEE , ArifS . Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients With liver cirrhosis and tense ascites after large‐volume paracentesis. Journal of Hepatology2010;52:S327. Abdel‐KhalekEE , ArifSE . Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients with liver cirrhosis and tense ascites following large volume paracentesis. Arab Journal of Gastroenterology2010;11:24‐9. ">Abdel‐Khalek 2010</a>; <a href="./references#CD004039-bbs2-0002" title="Al SebaeyA , Abdel‐RazekW , BassuniA , RewishaEA , KhalilM , WakedI , et al. Alternatives to albumin for prevention of paracentesis induced circulatory dysfunction (PICD) in cirrhosis. Hepatology2012;56(S1):915A. ">Al Sebaey 2012</a>; <a href="./references#CD004039-bbs2-0017" title="KhanMU , RahimIU , LatifM . Hemaccel as a cheaper alternative to human albumin for plasma expansion during paracentesis in cirrhotic patients. Pakistan Journal of Medical and Health Sciences2015;9(3):948‐51. ">Khan 2015</a>). The median follow‐up period was 231 days in <a href="./references#CD004039-bbs2-0025" title="SmartHL , TrigerDR . A randomised prospective trial comparing daily paracentesis and intravenous albumin with recirculation in diuretic refractory ascites. Journal of Hepatology1990;10(2):191‐7. [PUBMED: 2185298] ">Smart 1990</a> and 17.5 days in <a href="./references#CD004039-bbs2-0019" title="MehtaNN , AbrahamP , AsharVJ , ShikareSS , SavantSS , KarnadDR , et al. Ascitic fluid filtration and intravenous infusion versus total‐volume paracentesis with infusion of plasma expander in cirrhosis with tense or intractable ascites. Indian Journal of Gastroenterology1998;17(3):93‐6. ">Mehta 1998</a>. </p> <p>In the five trials comparing plasma expansion versus no plasma expansion, the percentage of dropouts and withdrawals was 1.21%. In the twenty‐one trials comparing plasma expanders versus albumin, the percentage of reported dropouts and withdrawals was 5.27%. </p> </section> </section> <section id="CD004039-sec-0072"> <h4 class="title">Excluded studies</h4> <p><a href="./references#CD004039-sec-0215" title="">Characteristics of excluded studies</a> table presents the excluded studies with the reason for their exclusion. </p> <p>Three studies were excluded. Two studies were comparative, and not randomised trials (<a href="./references#CD004039-bbs2-0031" title="ZaakD , PaquetKJ , KuhnR . Prospective study comparing human albumin vs reinfusion of ultrafiltated‐ascitic fluid after total paracentesis in cirrhotic patients with tense ascites. Zeitschrift fur Gastroenterologie2001;39(1):5‐10. [PUBMED: 11215366] ">Zaak 2001</a>; <a href="./references#CD004039-bbs2-0030" title="NasrG , HassanA , AhmedS , SerwahA . Predictors of large volume paracentesis induced circulatory dysfunction in patients with massive hepatic ascites. Journal of Cardiovascular Disease Research2010;1(3):136‐44. [PUBMED: 21187868] ">Nasr 2010</a>). One study, published as abstract for the first time in 1990 (<a href="./references#CD004039-bbs2-0028" title="AntillonMR , RunyonBA , SteindelH , MontanoAA . Is albumin infusion needed after large volume paracentesis in patients with refractory ascites?. Gastroenterology1990;98:A565. ">Antillon 1990</a>), was still ongoing in 1991 (<a href="./references#CD004039-bbs2-0029" title="AntillonMR , RunyonBA . Postparacentesis plasma expansion prevents asymptomatic laboratory abnormalities, but does it have any impact on morbidity or mortality?. Gastroenterology1991;101(5):1455‐7. [PUBMED: 1936822] ">Antillon 1991</a>). We could obtain no further information on the study. </p> </section> </section> <section id="CD004039-sec-0073"> <h3 class="title">Risk of bias in included studies</h3> <p>We based our assessment on published information and on that received from trial authors (<a href="#CD004039-fig-0002">Figure 2</a>; <a href="#CD004039-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD004039-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD004039-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD004039-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD004039-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD004039-sec-0074"> <h4 class="title">Allocation</h4> <section id="CD004039-sec-0075"> <h5 class="title">Allocation sequence generation</h5> <p>Sixteen trials were at low risk of bias regarding allocation sequence generation (<a href="./references#CD004039-bbs2-0012" title="GinèsP , TitóL , ArroyoV , PlanasR , PanésJ , ViverJ , et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology1988;94(6):1493‐1502. [PUBMED: 3360270] ">Ginès 1988</a>; <a href="./references#CD004039-bbs2-0022" title="PlanasR , GinèsP , ArroyoV , LlachJ , PanésJ , VargasV , et al. Dextran‐70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study. Gastroenterology1990;99(6):1736‐44. [PUBMED: 1699835] PlanasR , LlachJ , GinèsP , PanésJ , VargasV , SalmeronJM , et al. Albumin versus dextran‐70 in cirrhotics with tense ascites treated with total paracentesis. Final results of a multicenter randomized comparative study. Journal of Hepatology1990;11(Suppl 2):S49. ">Planas 1990</a>; <a href="./references#CD004039-bbs2-0023" title="SalernoF , BadalamentiS , LorenzanoE , MoserP , IncertiP . Randomized comparative study of hemaccel vs albumin infusion after total paracentesis in cirrhotic patients with refractory ascites. Hepatology1991;13(4):707‐13. [PUBMED: 1826281] ">Salerno 1991</a>; <a href="./references#CD004039-bbs2-0024" title="RinaldiF , SimonettiRG , MaisanoS , DinoO , MilazzoG , LucaA , et al. Refractory ascites in cirrhosis: treatment with total paracentesis and reinfusion of filtrated and concentrated ascitic fluid. Italian Journal of Gastroenterology1990;22(4):261. SimonettiRG , RinaldiF , MilazzoG , DinoO , MaisanoS , LucaA , et al. Treatment of refractory ascites: a randomized prospective trial of total paracentesis with concentrated ascitic fluid reinfusion vs repeated paracentesis and albumin infusion. Italian Journal of Gastroenterology1991;23(7):473. ">Simonetti 1991</a>; <a href="./references#CD004039-bbs2-0006" title="BrunoS , BorzioM , RomagnoniM , BattezzatiPM , RossiS , ChiesaA , et al. Comparison of spontaneous ascites filtration and reinfusion with total paracentesis with intravenous albumin infusion in cirrhotic patients with tense ascites. BMJ1992;304:1655‐8. [PUBMED: 1633517] BrunoS , BorzioM , RomagnoniM , ChiesaA , RossiS , PavesiS , et al. Spontaneous ascites filtration and reinfusion (SAFR) vs total paracentesis (TP) with i.v. albumin infusion in cirrhotic patients with tense ascites. Hepatology1990;12:855. ">Bruno 1992</a>; <a href="./references#CD004039-bbs2-0009" title="FassioE , TergR , LandeiraG , AbecasisR , SalemneM , PodestaA , et al. Paracentesis with dextran 70 vs paracentesis with albumin in cirrhosis with tense ascites. Results of a randomized study. Journal of Hepatology1992;14(2‐3):310‐6. [PUBMED: 1380024] ">Fassio 1992</a>; <a href="./references#CD004039-bbs2-0010" title="García‐CompeánD , VillarealJZ , CuevasHB , CantúDAG , EstrellaM , TamezEG , et al. Total therapeutic paracentesis (TTP) with and without intravenous albumin in the treatment of cirrhotic tense ascites: a randomized controlled trial. Liver1993;13(5):233‐8. [PUBMED: 8259034] ">García‐Compeán 1993</a>; <a href="./references#CD004039-bbs2-0018" title="LucaA , García‐PagánJ , BoschJ , FeuF , JiménezW , GinésA , et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology1995;22(3):753‐8. [PUBMED: 7657279] ">Luca 1995</a>; <a href="./references#CD004039-bbs2-0013" title="GinèsA , Fernández‐EsparrachG , MonescilloA , VilaC , DomènechE , AbecasisR , et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology1996;111(4):1002‐10. [PUBMED: 8831595] International Group for the Study of Ascites in Cirrhosis. Comparison of albumin, dextran‐70 and hemaccel in the prevention of effective hypovolemia in cirrhotic patients with ascites treated with total paracentesis. A randomized multicenter study. Hepatology1995;22(4 Suppl):220A. ">Ginès 1996</a>; <a href="./references#CD004039-bbs2-0003" title="AltmanC , BernardB , RoulotD , VitteR‐L , InkO . Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis. European Journal of Gastroenterology &amp; Hepatology1998;10:5‐10. [PUBMED: 9512946] ">Altman 1998</a>; <a href="./references#CD004039-bbs2-0011" title="García‐CompeánD , BlancP , LarreyD , DauresJ‐P , HirtzJ , MendozaE , et al. Treatment of cirrhotic tense ascites with dextran‐40 versus albumin associated with large volume paracentesis. A randomized controlled trial. Annals of Hepatology2002;1(1):29‐35. [PUBMED: 15114293] ">García‐Compeán 2002</a>; <a href="./references#CD004039-bbs2-0026" title="Sola‐VeraJ , MinanaJ , SorianoG , GonzalezB , PlanellaM , Lopez‐BalaguerJM , et al. Expansion with saline vs albumin in cirrhotic patients with tense ascites treated with total paracentesis. Result of a prospective randomized study. Gastroenterologia y Hepatologia2001;24(2):90 A6. Sola‐VeraJ , MiñanaJ , RicartE , PlanellaM , GonzálezB , TorrasX , et al. Randomized trial comparing albumin and saline in the prevention of paracentesis‐induced circultory dysfunction in cirrhotic patients with ascites. Hepatology2003;37(5):1147‐53. [PUBMED: 12717396] ">Sola‐Vera 2003</a>; <a href="./references#CD004039-bbs2-0007" title="DegoricijaV , Zjacic‐RotkvicV , MaroutJ , SeferS , TroskotB . Clinical and neurohumoral response to posture, physical exercise, and ascites treatment in Child‐Pugh C liver cirrhosis: randomized prospective trial. Croatian Medical Journal2003;44(2):178‐86. [PUBMED: 12698509] DegoricijaV , Zjacic‐RotkvicV , TroskotB , ŠeferS . Postparacentesis neurohumoral changes and impairment of renal water excretion in Child‐Pugh C cirrhosis with and without volume replacement. Journal of Hepatology2001;34:51. ">Degoricija 2003</a>, <a href="./references#CD004039-bbs2-0021" title="MoreauR , VallaD‐C , Durand‐ZaleskiI , BronowickiJ‐P , DurandF , ChaputJ‐C , et al. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trial. Liver International2006;26(1):46‐54. [PUBMED: 16420509] ">Moreau 2006</a>; <a href="./references#CD004039-bbs2-0001" title="Abdel‐KhalekEE , ArifS . Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients With liver cirrhosis and tense ascites after large‐volume paracentesis. Journal of Hepatology2010;52:S327. Abdel‐KhalekEE , ArifSE . Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients with liver cirrhosis and tense ascites following large volume paracentesis. Arab Journal of Gastroenterology2010;11:24‐9. ">Abdel‐Khalek 2010</a>; <a href="./references#CD004039-bbs2-0017" title="KhanMU , RahimIU , LatifM . Hemaccel as a cheaper alternative to human albumin for plasma expansion during paracentesis in cirrhotic patients. Pakistan Journal of Medical and Health Sciences2015;9(3):948‐51. ">Khan 2015</a>). The remaining 11 trials were at unclear risk of bias. </p> </section> <section id="CD004039-sec-0076"> <h5 class="title">Allocation concealment</h5> <p>Five trials were at low risk of bias regarding allocation concealment (<a href="./references#CD004039-bbs2-0025" title="SmartHL , TrigerDR . A randomised prospective trial comparing daily paracentesis and intravenous albumin with recirculation in diuretic refractory ascites. Journal of Hepatology1990;10(2):191‐7. [PUBMED: 2185298] ">Smart 1990</a>; <a href="./references#CD004039-bbs2-0023" title="SalernoF , BadalamentiS , LorenzanoE , MoserP , IncertiP . Randomized comparative study of hemaccel vs albumin infusion after total paracentesis in cirrhotic patients with refractory ascites. Hepatology1991;13(4):707‐13. [PUBMED: 1826281] ">Salerno 1991</a>; <a href="./references#CD004039-bbs2-0024" title="RinaldiF , SimonettiRG , MaisanoS , DinoO , MilazzoG , LucaA , et al. Refractory ascites in cirrhosis: treatment with total paracentesis and reinfusion of filtrated and concentrated ascitic fluid. Italian Journal of Gastroenterology1990;22(4):261. SimonettiRG , RinaldiF , MilazzoG , DinoO , MaisanoS , LucaA , et al. Treatment of refractory ascites: a randomized prospective trial of total paracentesis with concentrated ascitic fluid reinfusion vs repeated paracentesis and albumin infusion. Italian Journal of Gastroenterology1991;23(7):473. ">Simonetti 1991</a>; <a href="./references#CD004039-bbs2-0003" title="AltmanC , BernardB , RoulotD , VitteR‐L , InkO . Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis. European Journal of Gastroenterology &amp; Hepatology1998;10:5‐10. [PUBMED: 9512946] ">Altman 1998</a>; <a href="./references#CD004039-bbs2-0026" title="Sola‐VeraJ , MinanaJ , SorianoG , GonzalezB , PlanellaM , Lopez‐BalaguerJM , et al. Expansion with saline vs albumin in cirrhotic patients with tense ascites treated with total paracentesis. Result of a prospective randomized study. Gastroenterologia y Hepatologia2001;24(2):90 A6. Sola‐VeraJ , MiñanaJ , RicartE , PlanellaM , GonzálezB , TorrasX , et al. Randomized trial comparing albumin and saline in the prevention of paracentesis‐induced circultory dysfunction in cirrhotic patients with ascites. Hepatology2003;37(5):1147‐53. [PUBMED: 12717396] ">Sola‐Vera 2003</a>). The risk of bias in the remaining 22 trials was unclear. </p> </section> </section> <section id="CD004039-sec-0077"> <h4 class="title">Blinding</h4> <section id="CD004039-sec-0078"> <h5 class="title">Blinding of participants and personnel</h5> <p>All the 27 trials were at unclear risk of bias regarding blinding of participants and personnel. </p> </section> <section id="CD004039-sec-0079"> <h5 class="title">Blinding of outcome assessment</h5> <p>We judged only one trial at low risk of bias regarding blinding of outcome assessment (<a href="./references#CD004039-bbs2-0026" title="Sola‐VeraJ , MinanaJ , SorianoG , GonzalezB , PlanellaM , Lopez‐BalaguerJM , et al. Expansion with saline vs albumin in cirrhotic patients with tense ascites treated with total paracentesis. Result of a prospective randomized study. Gastroenterologia y Hepatologia2001;24(2):90 A6. Sola‐VeraJ , MiñanaJ , RicartE , PlanellaM , GonzálezB , TorrasX , et al. Randomized trial comparing albumin and saline in the prevention of paracentesis‐induced circultory dysfunction in cirrhotic patients with ascites. Hepatology2003;37(5):1147‐53. [PUBMED: 12717396] ">Sola‐Vera 2003</a>). The remaining 26 trials were at unclear risk of bias. </p> </section> </section> <section id="CD004039-sec-0080"> <h4 class="title">Incomplete outcome data</h4> <p>We judged twenty trials to be at low risk of bias regarding attrition bias. The remaining seven trials were at unclear risk of bias (<a href="./references#CD004039-bbs2-0005" title="BertránX , Fernández‐BañaresF , PlanasF , CabréE , MorillasR , DeLeónR , et al. Effect on the nutritional status of total paracentesis plus albumin or dextran‐70 i.v. infusion for the treatment of tense ascites in liver cirrhosis [Repercusión sobre el estado nutricional energético‐proteico de la paracentesis total asociada a la infusión de albúmina o dextano‐70 en el tratamiento de la ascitis a tensión en la cirrhosis hepática]. Revista Espanola de Enfermedades Digestivas1991;79(5):320‐4. ">Bertrán 1991</a>; <a href="./references#CD004039-bbs2-0020" title="MéndezC , SorianoG , GuarnerC , TomásA , MoyanoD , ToroH , et al. Total paracentesis in cirrhotics with refractory ascites: albumin vs HES as plasmatic expanders. Journal of Hepatology1991;13(Suppl 2):S145. ">Méndez 1991</a>; <a href="./references#CD004039-bbs2-0013" title="GinèsA , Fernández‐EsparrachG , MonescilloA , VilaC , DomènechE , AbecasisR , et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology1996;111(4):1002‐10. [PUBMED: 8831595] International Group for the Study of Ascites in Cirrhosis. Comparison of albumin, dextran‐70 and hemaccel in the prevention of effective hypovolemia in cirrhotic patients with ascites treated with total paracentesis. A randomized multicenter study. Hepatology1995;22(4 Suppl):220A. ">Ginès 1996</a>; <a href="./references#CD004039-bbs2-0016" title="KangKE , KimBH , DongSH , KimHJ , ChangYW , LeeJII , et al. The efficacy of hydroxyethyl starch as plasma expander in cirrhotic patients with tense ascites treated with large volume paracentesis. Korean Journal of Gastroenterology1998;31:651‐60. ">Kang 1998</a>; <a href="./references#CD004039-bbs2-0004" title="BaikSK , KimHS , LeeDK , KimIH , KwonSO . Hemodynamic changes after single large volume paracentesis (SLVP) in cirrhosis with tense ascites ‐ focusing on the effect of albumin as plasma expander. Korean Journal of Medicine2000;58:276‐82. ">Baik 2000</a>; <a href="./references#CD004039-bbs2-0007" title="DegoricijaV , Zjacic‐RotkvicV , MaroutJ , SeferS , TroskotB . Clinical and neurohumoral response to posture, physical exercise, and ascites treatment in Child‐Pugh C liver cirrhosis: randomized prospective trial. Croatian Medical Journal2003;44(2):178‐86. [PUBMED: 12698509] DegoricijaV , Zjacic‐RotkvicV , TroskotB , ŠeferS . Postparacentesis neurohumoral changes and impairment of renal water excretion in Child‐Pugh C cirrhosis with and without volume replacement. Journal of Hepatology2001;34:51. ">Degoricija 2003</a>; <a href="./references#CD004039-bbs2-0002" title="Al SebaeyA , Abdel‐RazekW , BassuniA , RewishaEA , KhalilM , WakedI , et al. Alternatives to albumin for prevention of paracentesis induced circulatory dysfunction (PICD) in cirrhosis. Hepatology2012;56(S1):915A. ">Al Sebaey 2012</a>). </p> </section> <section id="CD004039-sec-0081"> <h4 class="title">Selective reporting</h4> <p>Twelve trials aimed to assess haemodynamic or neurohumoral changes after a short follow‐up period after paracentesis (<a href="./references#CD004039-bbs2-0005" title="BertránX , Fernández‐BañaresF , PlanasF , CabréE , MorillasR , DeLeónR , et al. Effect on the nutritional status of total paracentesis plus albumin or dextran‐70 i.v. infusion for the treatment of tense ascites in liver cirrhosis [Repercusión sobre el estado nutricional energético‐proteico de la paracentesis total asociada a la infusión de albúmina o dextano‐70 en el tratamiento de la ascitis a tensión en la cirrhosis hepática]. Revista Espanola de Enfermedades Digestivas1991;79(5):320‐4. ">Bertrán 1991</a>; <a href="./references#CD004039-bbs2-0020" title="MéndezC , SorianoG , GuarnerC , TomásA , MoyanoD , ToroH , et al. Total paracentesis in cirrhotics with refractory ascites: albumin vs HES as plasmatic expanders. Journal of Hepatology1991;13(Suppl 2):S145. ">Méndez 1991</a>; <a href="./references#CD004039-bbs2-0006" title="BrunoS , BorzioM , RomagnoniM , BattezzatiPM , RossiS , ChiesaA , et al. Comparison of spontaneous ascites filtration and reinfusion with total paracentesis with intravenous albumin infusion in cirrhotic patients with tense ascites. BMJ1992;304:1655‐8. [PUBMED: 1633517] BrunoS , BorzioM , RomagnoniM , ChiesaA , RossiS , PavesiS , et al. Spontaneous ascites filtration and reinfusion (SAFR) vs total paracentesis (TP) with i.v. albumin infusion in cirrhotic patients with tense ascites. Hepatology1990;12:855. ">Bruno 1992</a>; <a href="./references#CD004039-bbs2-0010" title="García‐CompeánD , VillarealJZ , CuevasHB , CantúDAG , EstrellaM , TamezEG , et al. Total therapeutic paracentesis (TTP) with and without intravenous albumin in the treatment of cirrhotic tense ascites: a randomized controlled trial. Liver1993;13(5):233‐8. [PUBMED: 8259034] ">García‐Compeán 1993</a>; <a href="./references#CD004039-bbs2-0015" title="Hernández PérezRE , Aguilar RamírezJR , Hernández LopezJM , Gómez Maganday Silva T . Total paracentesis and infusion of dextran 70 vs albumin in cirrhotic patients with tense ascites [Paracentesis masiva con reposición de dextran 70 vs albúmina en pacientes cirróticos con ascitis a tensión]. Revista de Gastroenterologia de Mexico1995;60(1):22‐6. [PUBMED: 7543691] ">Hernández Pérez 1995</a>; <a href="./references#CD004039-bbs2-0018" title="LucaA , García‐PagánJ , BoschJ , FeuF , JiménezW , GinésA , et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology1995;22(3):753‐8. [PUBMED: 7657279] ">Luca 1995</a>; <a href="./references#CD004039-bbs2-0003" title="AltmanC , BernardB , RoulotD , VitteR‐L , InkO . Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis. European Journal of Gastroenterology &amp; Hepatology1998;10:5‐10. [PUBMED: 9512946] ">Altman 1998</a>; <a href="./references#CD004039-bbs2-0016" title="KangKE , KimBH , DongSH , KimHJ , ChangYW , LeeJII , et al. The efficacy of hydroxyethyl starch as plasma expander in cirrhotic patients with tense ascites treated with large volume paracentesis. Korean Journal of Gastroenterology1998;31:651‐60. ">Kang 1998</a>; <a href="./references#CD004039-bbs2-0004" title="BaikSK , KimHS , LeeDK , KimIH , KwonSO . Hemodynamic changes after single large volume paracentesis (SLVP) in cirrhosis with tense ascites ‐ focusing on the effect of albumin as plasma expander. Korean Journal of Medicine2000;58:276‐82. ">Baik 2000</a>; <a href="./references#CD004039-bbs2-0007" title="DegoricijaV , Zjacic‐RotkvicV , MaroutJ , SeferS , TroskotB . Clinical and neurohumoral response to posture, physical exercise, and ascites treatment in Child‐Pugh C liver cirrhosis: randomized prospective trial. Croatian Medical Journal2003;44(2):178‐86. [PUBMED: 12698509] DegoricijaV , Zjacic‐RotkvicV , TroskotB , ŠeferS . Postparacentesis neurohumoral changes and impairment of renal water excretion in Child‐Pugh C cirrhosis with and without volume replacement. Journal of Hepatology2001;34:51. ">Degoricija 2003</a>; <a href="./references#CD004039-bbs2-0002" title="Al SebaeyA , Abdel‐RazekW , BassuniA , RewishaEA , KhalilM , WakedI , et al. Alternatives to albumin for prevention of paracentesis induced circulatory dysfunction (PICD) in cirrhosis. Hepatology2012;56(S1):915A. ">Al Sebaey 2012</a>; <a href="./references#CD004039-bbs2-0017" title="KhanMU , RahimIU , LatifM . Hemaccel as a cheaper alternative to human albumin for plasma expansion during paracentesis in cirrhotic patients. Pakistan Journal of Medical and Health Sciences2015;9(3):948‐51. ">Khan 2015</a>). </p> <p>Only four trials reported serious adverse events (<a href="./references#CD004039-bbs2-0008" title="DescosL , GauthierA , LevyVG , MichelH , QuintonA , RueffB , et al. Comparison of six treatments of ascites in patients with liver cirrhosis. A clinical trial. Hepato‐gastroenterology1983;30:15‐20. [PUBMED: 6339343] ">Descos 1983</a>; <a href="./references#CD004039-bbs2-0018" title="LucaA , García‐PagánJ , BoschJ , FeuF , JiménezW , GinésA , et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology1995;22(3):753‐8. [PUBMED: 7657279] ">Luca 1995</a>; <a href="./references#CD004039-bbs2-0021" title="MoreauR , VallaD‐C , Durand‐ZaleskiI , BronowickiJ‐P , DurandF , ChaputJ‐C , et al. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trial. Liver International2006;26(1):46‐54. [PUBMED: 16420509] ">Moreau 2006</a>; <a href="./references#CD004039-bbs2-0017" title="KhanMU , RahimIU , LatifM . Hemaccel as a cheaper alternative to human albumin for plasma expansion during paracentesis in cirrhotic patients. Pakistan Journal of Medical and Health Sciences2015;9(3):948‐51. ">Khan 2015</a>). No trials reported data on refractory ascites. We followed the recommendation of the Cochrane Handbook, which stated that "review authors should look hard for the evidence of collection by study investigators of a small number of key outcomes that are routinely measured in the area in question”. In addition, most trials were published before a formal definition of serious adverse events and refractory ascites. So, the lack of the reporting of these two outcomes did not necessarily put the trials at high risk of bias. </p> <p>Overall, we judged ten trials to be at high risk of bias of selective outcome reporting because information on mortality or more than one secondary outcome was missing (<a href="./references#CD004039-bbs2-0005" title="BertránX , Fernández‐BañaresF , PlanasF , CabréE , MorillasR , DeLeónR , et al. Effect on the nutritional status of total paracentesis plus albumin or dextran‐70 i.v. infusion for the treatment of tense ascites in liver cirrhosis [Repercusión sobre el estado nutricional energético‐proteico de la paracentesis total asociada a la infusión de albúmina o dextano‐70 en el tratamiento de la ascitis a tensión en la cirrhosis hepática]. Revista Espanola de Enfermedades Digestivas1991;79(5):320‐4. ">Bertrán 1991</a>; <a href="./references#CD004039-bbs2-0020" title="MéndezC , SorianoG , GuarnerC , TomásA , MoyanoD , ToroH , et al. Total paracentesis in cirrhotics with refractory ascites: albumin vs HES as plasmatic expanders. Journal of Hepatology1991;13(Suppl 2):S145. ">Méndez 1991</a>; <a href="./references#CD004039-bbs2-0015" title="Hernández PérezRE , Aguilar RamírezJR , Hernández LopezJM , Gómez Maganday Silva T . Total paracentesis and infusion of dextran 70 vs albumin in cirrhotic patients with tense ascites [Paracentesis masiva con reposición de dextran 70 vs albúmina en pacientes cirróticos con ascitis a tensión]. Revista de Gastroenterologia de Mexico1995;60(1):22‐6. [PUBMED: 7543691] ">Hernández Pérez 1995</a>; <a href="./references#CD004039-bbs2-0013" title="GinèsA , Fernández‐EsparrachG , MonescilloA , VilaC , DomènechE , AbecasisR , et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology1996;111(4):1002‐10. [PUBMED: 8831595] International Group for the Study of Ascites in Cirrhosis. Comparison of albumin, dextran‐70 and hemaccel in the prevention of effective hypovolemia in cirrhotic patients with ascites treated with total paracentesis. A randomized multicenter study. Hepatology1995;22(4 Suppl):220A. ">Ginès 1996</a>; <a href="./references#CD004039-bbs2-0003" title="AltmanC , BernardB , RoulotD , VitteR‐L , InkO . Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis. European Journal of Gastroenterology &amp; Hepatology1998;10:5‐10. [PUBMED: 9512946] ">Altman 1998</a>; <a href="./references#CD004039-bbs2-0019" title="MehtaNN , AbrahamP , AsharVJ , ShikareSS , SavantSS , KarnadDR , et al. Ascitic fluid filtration and intravenous infusion versus total‐volume paracentesis with infusion of plasma expander in cirrhosis with tense or intractable ascites. Indian Journal of Gastroenterology1998;17(3):93‐6. ">Mehta 1998</a>; <a href="./references#CD004039-bbs2-0004" title="BaikSK , KimHS , LeeDK , KimIH , KwonSO . Hemodynamic changes after single large volume paracentesis (SLVP) in cirrhosis with tense ascites ‐ focusing on the effect of albumin as plasma expander. Korean Journal of Medicine2000;58:276‐82. ">Baik 2000</a>; <a href="./references#CD004039-bbs2-0011" title="García‐CompeánD , BlancP , LarreyD , DauresJ‐P , HirtzJ , MendozaE , et al. Treatment of cirrhotic tense ascites with dextran‐40 versus albumin associated with large volume paracentesis. A randomized controlled trial. Annals of Hepatology2002;1(1):29‐35. [PUBMED: 15114293] ">García‐Compeán 2002</a>; <a href="./references#CD004039-bbs2-0007" title="DegoricijaV , Zjacic‐RotkvicV , MaroutJ , SeferS , TroskotB . Clinical and neurohumoral response to posture, physical exercise, and ascites treatment in Child‐Pugh C liver cirrhosis: randomized prospective trial. Croatian Medical Journal2003;44(2):178‐86. [PUBMED: 12698509] DegoricijaV , Zjacic‐RotkvicV , TroskotB , ŠeferS . Postparacentesis neurohumoral changes and impairment of renal water excretion in Child‐Pugh C cirrhosis with and without volume replacement. Journal of Hepatology2001;34:51. ">Degoricija 2003</a>; <a href="./references#CD004039-bbs2-0002" title="Al SebaeyA , Abdel‐RazekW , BassuniA , RewishaEA , KhalilM , WakedI , et al. Alternatives to albumin for prevention of paracentesis induced circulatory dysfunction (PICD) in cirrhosis. Hepatology2012;56(S1):915A. ">Al Sebaey 2012</a>). One trial was at unclear risk of bias (<a href="./references#CD004039-bbs2-0017" title="KhanMU , RahimIU , LatifM . Hemaccel as a cheaper alternative to human albumin for plasma expansion during paracentesis in cirrhotic patients. Pakistan Journal of Medical and Health Sciences2015;9(3):948‐51. ">Khan 2015</a>). The remaining sixteen trials were judged to be at low risk of bias (<a href="./references#CD004039-bbs2-0008" title="DescosL , GauthierA , LevyVG , MichelH , QuintonA , RueffB , et al. Comparison of six treatments of ascites in patients with liver cirrhosis. A clinical trial. Hepato‐gastroenterology1983;30:15‐20. [PUBMED: 6339343] ">Descos 1983</a>; <a href="./references#CD004039-bbs2-0012" title="GinèsP , TitóL , ArroyoV , PlanasR , PanésJ , ViverJ , et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology1988;94(6):1493‐1502. [PUBMED: 3360270] ">Ginès 1988</a>; <a href="./references#CD004039-bbs2-0022" title="PlanasR , GinèsP , ArroyoV , LlachJ , PanésJ , VargasV , et al. Dextran‐70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study. Gastroenterology1990;99(6):1736‐44. [PUBMED: 1699835] PlanasR , LlachJ , GinèsP , PanésJ , VargasV , SalmeronJM , et al. Albumin versus dextran‐70 in cirrhotics with tense ascites treated with total paracentesis. Final results of a multicenter randomized comparative study. Journal of Hepatology1990;11(Suppl 2):S49. ">Planas 1990</a>; <a href="./references#CD004039-bbs2-0025" title="SmartHL , TrigerDR . A randomised prospective trial comparing daily paracentesis and intravenous albumin with recirculation in diuretic refractory ascites. Journal of Hepatology1990;10(2):191‐7. [PUBMED: 2185298] ">Smart 1990</a>; <a href="./references#CD004039-bbs2-0023" title="SalernoF , BadalamentiS , LorenzanoE , MoserP , IncertiP . Randomized comparative study of hemaccel vs albumin infusion after total paracentesis in cirrhotic patients with refractory ascites. Hepatology1991;13(4):707‐13. [PUBMED: 1826281] ">Salerno 1991</a>; <a href="./references#CD004039-bbs2-0024" title="RinaldiF , SimonettiRG , MaisanoS , DinoO , MilazzoG , LucaA , et al. Refractory ascites in cirrhosis: treatment with total paracentesis and reinfusion of filtrated and concentrated ascitic fluid. Italian Journal of Gastroenterology1990;22(4):261. SimonettiRG , RinaldiF , MilazzoG , DinoO , MaisanoS , LucaA , et al. Treatment of refractory ascites: a randomized prospective trial of total paracentesis with concentrated ascitic fluid reinfusion vs repeated paracentesis and albumin infusion. Italian Journal of Gastroenterology1991;23(7):473. ">Simonetti 1991</a>; <a href="./references#CD004039-bbs2-0006" title="BrunoS , BorzioM , RomagnoniM , BattezzatiPM , RossiS , ChiesaA , et al. Comparison of spontaneous ascites filtration and reinfusion with total paracentesis with intravenous albumin infusion in cirrhotic patients with tense ascites. BMJ1992;304:1655‐8. [PUBMED: 1633517] BrunoS , BorzioM , RomagnoniM , ChiesaA , RossiS , PavesiS , et al. Spontaneous ascites filtration and reinfusion (SAFR) vs total paracentesis (TP) with i.v. albumin infusion in cirrhotic patients with tense ascites. Hepatology1990;12:855. ">Bruno 1992</a>; <a href="./references#CD004039-bbs2-0009" title="FassioE , TergR , LandeiraG , AbecasisR , SalemneM , PodestaA , et al. Paracentesis with dextran 70 vs paracentesis with albumin in cirrhosis with tense ascites. Results of a randomized study. Journal of Hepatology1992;14(2‐3):310‐6. [PUBMED: 1380024] ">Fassio 1992</a>; <a href="./references#CD004039-bbs2-0010" title="García‐CompeánD , VillarealJZ , CuevasHB , CantúDAG , EstrellaM , TamezEG , et al. Total therapeutic paracentesis (TTP) with and without intravenous albumin in the treatment of cirrhotic tense ascites: a randomized controlled trial. Liver1993;13(5):233‐8. [PUBMED: 8259034] ">García‐Compeán 1993</a>; <a href="./references#CD004039-bbs2-0018" title="LucaA , García‐PagánJ , BoschJ , FeuF , JiménezW , GinésA , et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology1995;22(3):753‐8. [PUBMED: 7657279] ">Luca 1995</a>; <a href="./references#CD004039-bbs2-0014" title="GraziottoA , RossaroL , InturriP , SalvagniniM . Reinfusion of concentrated ascitic fluid versus total paracentesis. A randomized prospective trial. Digestive Diseases and Sciences1997;42(8):1708‐14. [PUBMED: 9286238] ">Graziotto 1997</a>; <a href="./references#CD004039-bbs2-0016" title="KangKE , KimBH , DongSH , KimHJ , ChangYW , LeeJII , et al. The efficacy of hydroxyethyl starch as plasma expander in cirrhotic patients with tense ascites treated with large volume paracentesis. Korean Journal of Gastroenterology1998;31:651‐60. ">Kang 1998</a>; <a href="./references#CD004039-bbs2-0027" title="ZhaoJ , YuanC , WangD , LIX . Mannitolum infusion on cirrhotic patients with tense ascites treated by paracentesis. Chinese Medical Journal2000;113(1):27‐30. [PUBMED: 11775204] ">Zhao 2000</a>; <a href="./references#CD004039-bbs2-0026" title="Sola‐VeraJ , MinanaJ , SorianoG , GonzalezB , PlanellaM , Lopez‐BalaguerJM , et al. Expansion with saline vs albumin in cirrhotic patients with tense ascites treated with total paracentesis. Result of a prospective randomized study. Gastroenterologia y Hepatologia2001;24(2):90 A6. Sola‐VeraJ , MiñanaJ , RicartE , PlanellaM , GonzálezB , TorrasX , et al. Randomized trial comparing albumin and saline in the prevention of paracentesis‐induced circultory dysfunction in cirrhotic patients with ascites. Hepatology2003;37(5):1147‐53. [PUBMED: 12717396] ">Sola‐Vera 2003</a>; <a href="./references#CD004039-bbs2-0021" title="MoreauR , VallaD‐C , Durand‐ZaleskiI , BronowickiJ‐P , DurandF , ChaputJ‐C , et al. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trial. Liver International2006;26(1):46‐54. [PUBMED: 16420509] ">Moreau 2006</a>; <a href="./references#CD004039-bbs2-0001" title="Abdel‐KhalekEE , ArifS . Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients With liver cirrhosis and tense ascites after large‐volume paracentesis. Journal of Hepatology2010;52:S327. Abdel‐KhalekEE , ArifSE . Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients with liver cirrhosis and tense ascites following large volume paracentesis. Arab Journal of Gastroenterology2010;11:24‐9. ">Abdel‐Khalek 2010</a>). </p> </section> <section id="CD004039-sec-0082"> <h4 class="title">Other potential sources of bias</h4> <p>We could suspect no other potential sources of bias in nineteen trials (<a href="./references#CD004039-bbs2-0008" title="DescosL , GauthierA , LevyVG , MichelH , QuintonA , RueffB , et al. Comparison of six treatments of ascites in patients with liver cirrhosis. A clinical trial. Hepato‐gastroenterology1983;30:15‐20. [PUBMED: 6339343] ">Descos 1983</a>; <a href="./references#CD004039-bbs2-0012" title="GinèsP , TitóL , ArroyoV , PlanasR , PanésJ , ViverJ , et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology1988;94(6):1493‐1502. [PUBMED: 3360270] ">Ginès 1988</a>; <a href="./references#CD004039-bbs2-0022" title="PlanasR , GinèsP , ArroyoV , LlachJ , PanésJ , VargasV , et al. Dextran‐70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study. Gastroenterology1990;99(6):1736‐44. [PUBMED: 1699835] PlanasR , LlachJ , GinèsP , PanésJ , VargasV , SalmeronJM , et al. Albumin versus dextran‐70 in cirrhotics with tense ascites treated with total paracentesis. Final results of a multicenter randomized comparative study. Journal of Hepatology1990;11(Suppl 2):S49. ">Planas 1990</a>; <a href="./references#CD004039-bbs2-0025" title="SmartHL , TrigerDR . A randomised prospective trial comparing daily paracentesis and intravenous albumin with recirculation in diuretic refractory ascites. Journal of Hepatology1990;10(2):191‐7. [PUBMED: 2185298] ">Smart 1990</a>; <a href="./references#CD004039-bbs2-0005" title="BertránX , Fernández‐BañaresF , PlanasF , CabréE , MorillasR , DeLeónR , et al. Effect on the nutritional status of total paracentesis plus albumin or dextran‐70 i.v. infusion for the treatment of tense ascites in liver cirrhosis [Repercusión sobre el estado nutricional energético‐proteico de la paracentesis total asociada a la infusión de albúmina o dextano‐70 en el tratamiento de la ascitis a tensión en la cirrhosis hepática]. Revista Espanola de Enfermedades Digestivas1991;79(5):320‐4. ">Bertrán 1991</a>; <a href="./references#CD004039-bbs2-0023" title="SalernoF , BadalamentiS , LorenzanoE , MoserP , IncertiP . Randomized comparative study of hemaccel vs albumin infusion after total paracentesis in cirrhotic patients with refractory ascites. Hepatology1991;13(4):707‐13. [PUBMED: 1826281] ">Salerno 1991</a>; <a href="./references#CD004039-bbs2-0024" title="RinaldiF , SimonettiRG , MaisanoS , DinoO , MilazzoG , LucaA , et al. Refractory ascites in cirrhosis: treatment with total paracentesis and reinfusion of filtrated and concentrated ascitic fluid. Italian Journal of Gastroenterology1990;22(4):261. SimonettiRG , RinaldiF , MilazzoG , DinoO , MaisanoS , LucaA , et al. Treatment of refractory ascites: a randomized prospective trial of total paracentesis with concentrated ascitic fluid reinfusion vs repeated paracentesis and albumin infusion. Italian Journal of Gastroenterology1991;23(7):473. ">Simonetti 1991</a>; <a href="./references#CD004039-bbs2-0006" title="BrunoS , BorzioM , RomagnoniM , BattezzatiPM , RossiS , ChiesaA , et al. Comparison of spontaneous ascites filtration and reinfusion with total paracentesis with intravenous albumin infusion in cirrhotic patients with tense ascites. BMJ1992;304:1655‐8. [PUBMED: 1633517] BrunoS , BorzioM , RomagnoniM , ChiesaA , RossiS , PavesiS , et al. Spontaneous ascites filtration and reinfusion (SAFR) vs total paracentesis (TP) with i.v. albumin infusion in cirrhotic patients with tense ascites. Hepatology1990;12:855. ">Bruno 1992</a>; <a href="./references#CD004039-bbs2-0009" title="FassioE , TergR , LandeiraG , AbecasisR , SalemneM , PodestaA , et al. Paracentesis with dextran 70 vs paracentesis with albumin in cirrhosis with tense ascites. Results of a randomized study. Journal of Hepatology1992;14(2‐3):310‐6. [PUBMED: 1380024] ">Fassio 1992</a>; <a href="./references#CD004039-bbs2-0010" title="García‐CompeánD , VillarealJZ , CuevasHB , CantúDAG , EstrellaM , TamezEG , et al. Total therapeutic paracentesis (TTP) with and without intravenous albumin in the treatment of cirrhotic tense ascites: a randomized controlled trial. Liver1993;13(5):233‐8. [PUBMED: 8259034] ">García‐Compeán 1993</a>; <a href="./references#CD004039-bbs2-0015" title="Hernández PérezRE , Aguilar RamírezJR , Hernández LopezJM , Gómez Maganday Silva T . Total paracentesis and infusion of dextran 70 vs albumin in cirrhotic patients with tense ascites [Paracentesis masiva con reposición de dextran 70 vs albúmina en pacientes cirróticos con ascitis a tensión]. Revista de Gastroenterologia de Mexico1995;60(1):22‐6. [PUBMED: 7543691] ">Hernández Pérez 1995</a>; <a href="./references#CD004039-bbs2-0018" title="LucaA , García‐PagánJ , BoschJ , FeuF , JiménezW , GinésA , et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology1995;22(3):753‐8. [PUBMED: 7657279] ">Luca 1995</a>; <a href="./references#CD004039-bbs2-0013" title="GinèsA , Fernández‐EsparrachG , MonescilloA , VilaC , DomènechE , AbecasisR , et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology1996;111(4):1002‐10. [PUBMED: 8831595] International Group for the Study of Ascites in Cirrhosis. Comparison of albumin, dextran‐70 and hemaccel in the prevention of effective hypovolemia in cirrhotic patients with ascites treated with total paracentesis. A randomized multicenter study. Hepatology1995;22(4 Suppl):220A. ">Ginès 1996</a>; <a href="./references#CD004039-bbs2-0014" title="GraziottoA , RossaroL , InturriP , SalvagniniM . Reinfusion of concentrated ascitic fluid versus total paracentesis. A randomized prospective trial. Digestive Diseases and Sciences1997;42(8):1708‐14. [PUBMED: 9286238] ">Graziotto 1997</a>; <a href="./references#CD004039-bbs2-0003" title="AltmanC , BernardB , RoulotD , VitteR‐L , InkO . Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis. European Journal of Gastroenterology &amp; Hepatology1998;10:5‐10. [PUBMED: 9512946] ">Altman 1998</a>; <a href="./references#CD004039-bbs2-0019" title="MehtaNN , AbrahamP , AsharVJ , ShikareSS , SavantSS , KarnadDR , et al. Ascitic fluid filtration and intravenous infusion versus total‐volume paracentesis with infusion of plasma expander in cirrhosis with tense or intractable ascites. Indian Journal of Gastroenterology1998;17(3):93‐6. ">Mehta 1998</a>; <a href="./references#CD004039-bbs2-0027" title="ZhaoJ , YuanC , WangD , LIX . Mannitolum infusion on cirrhotic patients with tense ascites treated by paracentesis. Chinese Medical Journal2000;113(1):27‐30. [PUBMED: 11775204] ">Zhao 2000</a>; <a href="./references#CD004039-bbs2-0026" title="Sola‐VeraJ , MinanaJ , SorianoG , GonzalezB , PlanellaM , Lopez‐BalaguerJM , et al. Expansion with saline vs albumin in cirrhotic patients with tense ascites treated with total paracentesis. Result of a prospective randomized study. Gastroenterologia y Hepatologia2001;24(2):90 A6. Sola‐VeraJ , MiñanaJ , RicartE , PlanellaM , GonzálezB , TorrasX , et al. Randomized trial comparing albumin and saline in the prevention of paracentesis‐induced circultory dysfunction in cirrhotic patients with ascites. Hepatology2003;37(5):1147‐53. [PUBMED: 12717396] ">Sola‐Vera 2003</a>; <a href="./references#CD004039-bbs2-0001" title="Abdel‐KhalekEE , ArifS . Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients With liver cirrhosis and tense ascites after large‐volume paracentesis. Journal of Hepatology2010;52:S327. Abdel‐KhalekEE , ArifSE . Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients with liver cirrhosis and tense ascites following large volume paracentesis. Arab Journal of Gastroenterology2010;11:24‐9. ">Abdel‐Khalek 2010</a>). We judged the remaining eight trials as having unclear risk because they were published as abstracts (<a href="./references#CD004039-bbs2-0020" title="MéndezC , SorianoG , GuarnerC , TomásA , MoyanoD , ToroH , et al. Total paracentesis in cirrhotics with refractory ascites: albumin vs HES as plasmatic expanders. Journal of Hepatology1991;13(Suppl 2):S145. ">Méndez 1991</a>; <a href="./references#CD004039-bbs2-0002" title="Al SebaeyA , Abdel‐RazekW , BassuniA , RewishaEA , KhalilM , WakedI , et al. Alternatives to albumin for prevention of paracentesis induced circulatory dysfunction (PICD) in cirrhosis. Hepatology2012;56(S1):915A. ">Al Sebaey 2012</a>), or the information was not enough (<a href="./references#CD004039-bbs2-0016" title="KangKE , KimBH , DongSH , KimHJ , ChangYW , LeeJII , et al. The efficacy of hydroxyethyl starch as plasma expander in cirrhotic patients with tense ascites treated with large volume paracentesis. Korean Journal of Gastroenterology1998;31:651‐60. ">Kang 1998</a>; <a href="./references#CD004039-bbs2-0004" title="BaikSK , KimHS , LeeDK , KimIH , KwonSO . Hemodynamic changes after single large volume paracentesis (SLVP) in cirrhosis with tense ascites ‐ focusing on the effect of albumin as plasma expander. Korean Journal of Medicine2000;58:276‐82. ">Baik 2000</a>; <a href="./references#CD004039-bbs2-0021" title="MoreauR , VallaD‐C , Durand‐ZaleskiI , BronowickiJ‐P , DurandF , ChaputJ‐C , et al. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trial. Liver International2006;26(1):46‐54. [PUBMED: 16420509] ">Moreau 2006</a>; <a href="./references#CD004039-bbs2-0017" title="KhanMU , RahimIU , LatifM . Hemaccel as a cheaper alternative to human albumin for plasma expansion during paracentesis in cirrhotic patients. Pakistan Journal of Medical and Health Sciences2015;9(3):948‐51. ">Khan 2015</a>), or because of the characteristics of the design and analysis (<a href="./references#CD004039-bbs2-0011" title="García‐CompeánD , BlancP , LarreyD , DauresJ‐P , HirtzJ , MendozaE , et al. Treatment of cirrhotic tense ascites with dextran‐40 versus albumin associated with large volume paracentesis. A randomized controlled trial. Annals of Hepatology2002;1(1):29‐35. [PUBMED: 15114293] ">García‐Compeán 2002</a>; <a href="./references#CD004039-bbs2-0007" title="DegoricijaV , Zjacic‐RotkvicV , MaroutJ , SeferS , TroskotB . Clinical and neurohumoral response to posture, physical exercise, and ascites treatment in Child‐Pugh C liver cirrhosis: randomized prospective trial. Croatian Medical Journal2003;44(2):178‐86. [PUBMED: 12698509] DegoricijaV , Zjacic‐RotkvicV , TroskotB , ŠeferS . Postparacentesis neurohumoral changes and impairment of renal water excretion in Child‐Pugh C cirrhosis with and without volume replacement. Journal of Hepatology2001;34:51. ">Degoricija 2003</a>). </p> <section id="CD004039-sec-0083"> <h5 class="title">Overall risk of bias</h5> <p>We judged all trials to be at high risk of bias because they were assessed as having an uncertain risk of bias or a high risk of bias in one or more of the bias risk domains. </p> </section> </section> </section> <section id="CD004039-sec-0084"> <h3 class="title" id="CD004039-sec-0084">Effects of interventions</h3> <p>See: <a href="./full#CD004039-tbl-0001"><b>Summary of findings for the main comparison</b> Plasma expanders versus no plasma expanders for people with cirrhosis and large ascites treated with abdominal paracentesis</a>; <a href="./full#CD004039-tbl-0002"><b>Summary of findings 2</b> Other plasma expanders versus albumin for people with cirrhosis and large ascites treated with abdominal paracentesis</a> </p> <section id="CD004039-sec-0085"> <h4 class="title">Plasma expanders versus no plasma expander</h4> </section> <section id="CD004039-sec-0086"> <h4 class="title">Primary outcomes</h4> <section id="CD004039-sec-0087"> <h5 class="title">All‐cause mortality</h5> <p>Four trials provided data on mortality with a mean follow‐up of 64 days. Three trials had a follow‐up less than one month. No mortality occurred in two of the trials (<a href="./references#CD004039-bbs2-0010" title="García‐CompeánD , VillarealJZ , CuevasHB , CantúDAG , EstrellaM , TamezEG , et al. Total therapeutic paracentesis (TTP) with and without intravenous albumin in the treatment of cirrhotic tense ascites: a randomized controlled trial. Liver1993;13(5):233‐8. [PUBMED: 8259034] ">García‐Compeán 1993</a>; <a href="./references#CD004039-bbs2-0018" title="LucaA , García‐PagánJ , BoschJ , FeuF , JiménezW , GinésA , et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology1995;22(3):753‐8. [PUBMED: 7657279] ">Luca 1995</a>). The effect of plasma expanders (albumin and ascites infusion) compared with no plasma expander in terms of reduction in all‐cause mortality was very uncertain (RR 0.52, 95% CI 0.06 to 4.83; 248 participants; 4 trials; I<sup>2</sup> = 76%; <a href="./references#CD004039-fig-0013" title="">Analysis 1.1</a>; <a href="./references#CD004039-bbs2-0008" title="DescosL , GauthierA , LevyVG , MichelH , QuintonA , RueffB , et al. Comparison of six treatments of ascites in patients with liver cirrhosis. A clinical trial. Hepato‐gastroenterology1983;30:15‐20. [PUBMED: 6339343] ">Descos 1983</a>; <a href="./references#CD004039-bbs2-0012" title="GinèsP , TitóL , ArroyoV , PlanasR , PanésJ , ViverJ , et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology1988;94(6):1493‐1502. [PUBMED: 3360270] ">Ginès 1988</a>; <a href="./references#CD004039-bbs2-0010" title="García‐CompeánD , VillarealJZ , CuevasHB , CantúDAG , EstrellaM , TamezEG , et al. Total therapeutic paracentesis (TTP) with and without intravenous albumin in the treatment of cirrhotic tense ascites: a randomized controlled trial. Liver1993;13(5):233‐8. [PUBMED: 8259034] ">García‐Compeán 1993</a>; <a href="./references#CD004039-bbs2-0018" title="LucaA , García‐PagánJ , BoschJ , FeuF , JiménezW , GinésA , et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology1995;22(3):753‐8. [PUBMED: 7657279] ">Luca 1995</a>). </p> <p>We assessed the certainty of the evidence with GRADE as very low. We downgraded the evidence by four levels because all trials were at high risk of bias; there was high heterogeneity; and the required information size was not reached (<a href="./full#CD004039-tbl-0001">summary of findings Table for the main comparison</a>; <a href="#CD004039-tbl-0003">Table 1</a>). </p> <div class="table" id="CD004039-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Comparison of imprecision by GRADE and Trial Sequential Analysis for the evaluation of primary and secondary outcomes in the comparison of plasma expanders versus no plasma expander</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Comparison of imprecision evaluation with GRADE based on the GRADE Handbook, with GRADE based on authors' choice of plausible relative risk reduction and multiplicity correction, and according to our Trial Sequential Analysis with a similar choice of plausible relative risk reduction and multiplicity correction, in addition to considering the choice of meta‐analytic model and diversity</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion in control group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relative risk reduction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Alpha</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Beta</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Diversity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Required information size (OIS or DARIS)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Downgrading of evidence for imprecision based on required information size</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality ‐‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2056</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality ‐‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16,634</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality ‐‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143,664</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events ‐‐ GRADE Handbook</p> <p><b>(1)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="3" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events ‐‐ GRADE plausible RRR</p> <p><b>(1)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events ‐‐ TSA</p> <p><b>(1)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life ‐‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>No data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life ‐‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>No data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life ‐‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>No data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Refractory ascites ‐‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>No data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Refractory ascites ‐‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>No data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Refractory ascites ‐‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>No data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Renal impairment ‐‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Renal impairment ‐‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.00%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35,290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Renal impairment ‐‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.00%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35,293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other liver‐related complications ‐‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4498</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other liver‐related complications ‐‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.00%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38,750</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other liver‐related complications ‐‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.00%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38,752</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐serious adverse events ‐‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6670</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐serious adverse events ‐‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.00%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56,464</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐serious adverse events ‐‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.00%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56,467</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>(1)</b> Serious adverse events: 0/68 in plasma expander group and 0/40 in no plasma expander group, RR 1.00 (95% CI 0.00 to 217…) </p> <p>OIS: optimal information size; DARIS: diversity‐adjusted required information size; RRR: relative risk reduction; TSA: Trial Sequential Analysis </p> </div> </div> <p>Including the two trials with zero deaths in the Trial Sequential Analysis produced a comparable result (RR 0.64; 95% CI 0.14 to 2.93; P = 0.56; D<sup>2</sup>= 88%). </p> <p>The Trial Sequential Analysis of this comparison was based on a mortality of 18% in the control group, a relative risk reduction of 10% with albumin or other plasma expanders, a type I error of 2.5%, a type II error of 20% (80% power), and 88% diversity. The DARIS was 143,664 participants. Due to the fact that only 248 participants were recruited (which is 0.17% of the DARIS of 143,664 participants), the Trial Sequential Analysis program could not construct an interpretable figure and could not calculate Trial Sequential Analysis‐adjusted CIs. </p> <section id="CD004039-sec-0088"> <h6 class="title">Subgroup analysis</h6> <p>We could not perform subgroup analysis of trials according to their risk of bias because all the trials were assessed at high risk of bias; and according to participants with and participants without refractory ascites because all the trials included participants without refractory ascites. </p> <section id="CD004039-sec-0089"> <p><b>Type of plasma expanders</b></p> <p>The test for subgroup differences comparing the effects of each type of plasma expander (albumin and ascites infusion) suggested a difference between the plasma expanders used (P = 0.04, I² = 75.3%; <a href="./references#CD004039-fig-0013" title="">Analysis 1.1</a>). In trials comparing albumin versus no plasma expander, RR was 1.27, 95% CI 0.75 to 2.17; 158 participants; 3 trials; I<sup>2</sup> not calculated because 2/3 of the trials had 0 events, <a href="./references#CD004039-fig-0013" title="">Analysis 1.1</a>.1; <a href="./references#CD004039-bbs2-0012" title="GinèsP , TitóL , ArroyoV , PlanasR , PanésJ , ViverJ , et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology1988;94(6):1493‐1502. [PUBMED: 3360270] ">Ginès 1988</a>; <a href="./references#CD004039-bbs2-0010" title="García‐CompeánD , VillarealJZ , CuevasHB , CantúDAG , EstrellaM , TamezEG , et al. Total therapeutic paracentesis (TTP) with and without intravenous albumin in the treatment of cirrhotic tense ascites: a randomized controlled trial. Liver1993;13(5):233‐8. [PUBMED: 8259034] ">García‐Compeán 1993</a>; <a href="./references#CD004039-bbs2-0018" title="LucaA , García‐PagánJ , BoschJ , FeuF , JiménezW , GinésA , et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology1995;22(3):753‐8. [PUBMED: 7657279] ">Luca 1995</a>) whereas in trials comparing intravenous ascitic fluid infusion versus no plasma expander RR was 0.13, 95% CI 0.02 to 1.13; 90 participants; 1 trial (<a href="./references#CD004039-fig-0013" title="">Analysis 1.1</a>.2; <a href="./references#CD004039-bbs2-0008" title="DescosL , GauthierA , LevyVG , MichelH , QuintonA , RueffB , et al. Comparison of six treatments of ascites in patients with liver cirrhosis. A clinical trial. Hepato‐gastroenterology1983;30:15‐20. [PUBMED: 6339343] ">Descos 1983</a>). </p> </section> <section id="CD004039-sec-0090"> <p><b>Modality of paracentesis</b></p> <p>The test for subgroup differences comparing the effects of plasma expander versus no plasma expander in people treated by partial or total paracentesis suggested a difference between the two subgroups (P = 0.04, I² = 75.3%; <a href="./references#CD004039-fig-0020" title="">Analysis 2.1</a>). In trials in which partial paracentesis were used, RR was 1.27, 95% CI 0.75 to 2.17; 105 participants; 1 trial (<a href="./references#CD004039-fig-0020" title="">Analysis 2.1</a>.1; <a href="./references#CD004039-bbs2-0012" title="GinèsP , TitóL , ArroyoV , PlanasR , PanésJ , ViverJ , et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology1988;94(6):1493‐1502. [PUBMED: 3360270] ">Ginès 1988</a>) whereas the subgroup of trials in which total paracentesis were used, RR was 0.13, 95% CI 0.02 to 1.13; 143 participants; 3 trials; I<sup>2</sup> not calculated because 2/3 of the trials had 0 events (<a href="./references#CD004039-fig-0020" title="">Analysis 2.1</a>.2; <a href="./references#CD004039-bbs2-0008" title="DescosL , GauthierA , LevyVG , MichelH , QuintonA , RueffB , et al. Comparison of six treatments of ascites in patients with liver cirrhosis. A clinical trial. Hepato‐gastroenterology1983;30:15‐20. [PUBMED: 6339343] ">Descos 1983</a>; <a href="./references#CD004039-bbs2-0010" title="García‐CompeánD , VillarealJZ , CuevasHB , CantúDAG , EstrellaM , TamezEG , et al. Total therapeutic paracentesis (TTP) with and without intravenous albumin in the treatment of cirrhotic tense ascites: a randomized controlled trial. Liver1993;13(5):233‐8. [PUBMED: 8259034] ">García‐Compeán 1993</a>; <a href="./references#CD004039-bbs2-0018" title="LucaA , García‐PagánJ , BoschJ , FeuF , JiménezW , GinésA , et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology1995;22(3):753‐8. [PUBMED: 7657279] ">Luca 1995</a>). </p> </section> <section id="CD004039-sec-0091"> <p><b>Length of follow‐up</b></p> <p>The test for subgroup differences comparing the effects of plasma expander versus no plasma expander in trials with a short follow‐up (up to one month) to trials with a long follow‐up (more than one month) suggested a difference (P = 0.04, I² = 75.3%; <a href="./references#CD004039-fig-0025" title="">Analysis 3.1</a>). In trials with a short follow‐up, RR was 0.13, 95% CI 0.02 to 1.13; 143 participants; 3 trials; I<sup>2</sup> not calculated because 2/3 of the trials had 0 events (<a href="./references#CD004039-fig-0025" title="">Analysis 3.1</a>.1; <a href="./references#CD004039-bbs2-0008" title="DescosL , GauthierA , LevyVG , MichelH , QuintonA , RueffB , et al. Comparison of six treatments of ascites in patients with liver cirrhosis. A clinical trial. Hepato‐gastroenterology1983;30:15‐20. [PUBMED: 6339343] ">Descos 1983</a>; <a href="./references#CD004039-bbs2-0010" title="García‐CompeánD , VillarealJZ , CuevasHB , CantúDAG , EstrellaM , TamezEG , et al. Total therapeutic paracentesis (TTP) with and without intravenous albumin in the treatment of cirrhotic tense ascites: a randomized controlled trial. Liver1993;13(5):233‐8. [PUBMED: 8259034] ">García‐Compeán 1993</a>; <a href="./references#CD004039-bbs2-0018" title="LucaA , García‐PagánJ , BoschJ , FeuF , JiménezW , GinésA , et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology1995;22(3):753‐8. [PUBMED: 7657279] ">Luca 1995</a>) whereas in the trial with a long follow‐up RR was 1.27, 95% CI 0.75 to 2.17; 105 participants; 1 trial; I<sup>2</sup> not applicable (<a href="./references#CD004039-fig-0025" title="">Analysis 3.1</a>.2; <a href="./references#CD004039-bbs2-0012" title="GinèsP , TitóL , ArroyoV , PlanasR , PanésJ , ViverJ , et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology1988;94(6):1493‐1502. [PUBMED: 3360270] ">Ginès 1988</a>). </p> </section> <section id="CD004039-sec-0092"> <p><b>For‐profit support</b></p> <p>In the subgroup of trials without for‐profit funding, RR was 0.52, 95% CI 0.06 to 4.83; 213 participants; 3 trials; I<sup>2</sup> = 76% (<a href="./references#CD004039-fig-0030" title="">Analysis 4.1</a>.1). In the only trial without information on for‐profit funding, no deaths were reported (<a href="./references#CD004039-bbs2-0010" title="García‐CompeánD , VillarealJZ , CuevasHB , CantúDAG , EstrellaM , TamezEG , et al. Total therapeutic paracentesis (TTP) with and without intravenous albumin in the treatment of cirrhotic tense ascites: a randomized controlled trial. Liver1993;13(5):233‐8. [PUBMED: 8259034] ">García‐Compeán 1993</a>). </p> </section> </section> <section id="CD004039-sec-0093"> <h6 class="title">Sensitivity analysis</h6> <p>The best‐worst (RR 0.49, 95% CI 0.06 to 3.76; 248 participants; 4 trials; I<sup>2</sup> = 73%; <a href="./references#CD004039-fig-0035" title="">Analysis 5.1</a>) and the worst‐best scenario analyses (RR 0.87, 95% CI 0.28 to 2.76; 248 participants; 4 trials; I<sup>2</sup> = 60%; <a href="./references#CD004039-fig-0036" title="">Analysis 6.1</a>) both suggested neutral results. </p> </section> </section> <section id="CD004039-sec-0094"> <h5 class="title">Serious adverse events</h5> <p>Out of the five trials assessing plasma volume expansion versus no plasma volume expansion, two trials reported that there were no serious adverse events (<a href="./references#CD004039-bbs2-0008" title="DescosL , GauthierA , LevyVG , MichelH , QuintonA , RueffB , et al. Comparison of six treatments of ascites in patients with liver cirrhosis. A clinical trial. Hepato‐gastroenterology1983;30:15‐20. [PUBMED: 6339343] ">Descos 1983</a>; <a href="./references#CD004039-bbs2-0018" title="LucaA , García‐PagánJ , BoschJ , FeuF , JiménezW , GinésA , et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology1995;22(3):753‐8. [PUBMED: 7657279] ">Luca 1995</a>). The remaining three trials did not mention if serious adverse events occurred (<a href="./references#CD004039-bbs2-0012" title="GinèsP , TitóL , ArroyoV , PlanasR , PanésJ , ViverJ , et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology1988;94(6):1493‐1502. [PUBMED: 3360270] ">Ginès 1988</a>; <a href="./references#CD004039-bbs2-0010" title="García‐CompeánD , VillarealJZ , CuevasHB , CantúDAG , EstrellaM , TamezEG , et al. Total therapeutic paracentesis (TTP) with and without intravenous albumin in the treatment of cirrhotic tense ascites: a randomized controlled trial. Liver1993;13(5):233‐8. [PUBMED: 8259034] ">García‐Compeán 1993</a>; <a href="./references#CD004039-bbs2-0004" title="BaikSK , KimHS , LeeDK , KimIH , KwonSO . Hemodynamic changes after single large volume paracentesis (SLVP) in cirrhosis with tense ascites ‐ focusing on the effect of albumin as plasma expander. Korean Journal of Medicine2000;58:276‐82. ">Baik 2000</a>) (<a href="./references#CD004039-fig-0014" title="">Analysis 1.2</a>). </p> <p>We assessed the certainty of the evidence with GRADE as very low. We downgraded the evidence by four levels because all trials were at high risk of bias; there was substantial imprecision due to the lack of events (<a href="./full#CD004039-tbl-0001">summary of findings Table for the main comparison</a>). The required information size was not reached (<a href="#CD004039-tbl-0003">Table 1</a>). </p> <section id="CD004039-sec-0095"> <h6 class="title">Subgroup analysis</h6> <p>We could not perform subgroup analysis of trials according to their risk of bias because the two trials were assessed at high risk of bias; according to participants with and participants without refractory ascites because the two trials included participants without refractory ascites; according to modality of paracentesis because the two trials performed total paracentesis; according to length of follow‐up because the two trials had short follow‐up; and according to for‐profit funding because the two trials were without for‐profit funding (<a href="#CD004039-sec-0060">Subgroup analysis and investigation of heterogeneity</a>). </p> </section> </section> <section id="CD004039-sec-0096"> <h5 class="title">Health‐related quality of life</h5> <p>None of the included trials reported health‐related quality of life.</p> </section> </section> <section id="CD004039-sec-0097"> <h4 class="title">Secondary outcomes</h4> <section id="CD004039-sec-0098"> <h5 class="title">Refractory ascites</h5> <p>None of the included trials provided information on refractory ascites.</p> </section> <section id="CD004039-sec-0099"> <h5 class="title">Renal impairment</h5> <p>Four trials reported data on renal impairment (<a href="./references#CD004039-bbs2-0012" title="GinèsP , TitóL , ArroyoV , PlanasR , PanésJ , ViverJ , et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology1988;94(6):1493‐1502. [PUBMED: 3360270] ">Ginès 1988</a>; <a href="./references#CD004039-bbs2-0010" title="García‐CompeánD , VillarealJZ , CuevasHB , CantúDAG , EstrellaM , TamezEG , et al. Total therapeutic paracentesis (TTP) with and without intravenous albumin in the treatment of cirrhotic tense ascites: a randomized controlled trial. Liver1993;13(5):233‐8. [PUBMED: 8259034] ">García‐Compeán 1993</a>; <a href="./references#CD004039-bbs2-0018" title="LucaA , García‐PagánJ , BoschJ , FeuF , JiménezW , GinésA , et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology1995;22(3):753‐8. [PUBMED: 7657279] ">Luca 1995</a>; <a href="./references#CD004039-bbs2-0004" title="BaikSK , KimHS , LeeDK , KimIH , KwonSO . Hemodynamic changes after single large volume paracentesis (SLVP) in cirrhosis with tense ascites ‐ focusing on the effect of albumin as plasma expander. Korean Journal of Medicine2000;58:276‐82. ">Baik 2000</a>). All four trials used albumin as a plasma expander. In two of the trials, renal impairment did not occur (<a href="./references#CD004039-bbs2-0018" title="LucaA , García‐PagánJ , BoschJ , FeuF , JiménezW , GinésA , et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology1995;22(3):753‐8. [PUBMED: 7657279] ">Luca 1995</a>; <a href="./references#CD004039-bbs2-0004" title="BaikSK , KimHS , LeeDK , KimIH , KwonSO . Hemodynamic changes after single large volume paracentesis (SLVP) in cirrhosis with tense ascites ‐ focusing on the effect of albumin as plasma expander. Korean Journal of Medicine2000;58:276‐82. ">Baik 2000</a>). The effect of albumin versus no plasma expander on renal impairment was uncertain (RR 0.32, 95% CI 0.02 to 5.88; 181 participants; 4 trials; I<sup>2</sup> = 67%; <a href="./references#CD004039-fig-0015" title="">Analysis 1.3</a>). </p> <p>We assessed the certainty of the evidence with GRADE as very low. We downgraded the evidence by five levels because all trials were at high risk of bias; there was high heterogeneity; there were few events and the CI included appreciable benefit and harm (<a href="./full#CD004039-tbl-0001">summary of findings Table for the main comparison</a>). The required information size was not reached (<a href="#CD004039-tbl-0003">Table 1</a>). </p> <p>Including the two trials with zero events in Trial Sequetial Analysis produced a comparable result (RR 1.02, 95% CI 0.16 to 6.43; P = 0.98). </p> <p>The Trial Sequential Analysis of the four trials assessing plasma expander versus no plasma expander was constructed based on the renal impairment proportion of 9.8% in the control group, a relative risk reduction of 10.0% with plasma expander, a type I error of 2.00%, and a type II error of 20% (80% power). There was no diversity (D<sup>2</sup> = 0%). The DARIS was 35,293 participants. Due to the fact that only 181 participants were recruited (0.51% of the DARIS of 35,293 participants), the Trial Sequential Analysis program could not construct an interpretable figure and could not calculate Trial Sequential Analysis‐adjusted CIs. </p> <section id="CD004039-sec-0100"> <h6 class="title">Subgroup analysis</h6> <p>None of the first three planned subgroup analyses could be performed because the risk of bias in the four trials providing data on renal impairment was high, all the four trials included participants without refractory ascites, and all the four trials used albumin. </p> <section id="CD004039-sec-0101"> <p><b>Modality of paracentesis</b></p> <p>The test for subgroup differences comparing the effects of plasma expander versus no plasma expander on renal impairment in participants treated by partial paracentesis and by total paracentesis showed no difference (P = 0.11, I² = 60.5%; <a href="./references#CD004039-fig-0021" title="">Analysis 2.2</a>). There was no evidence of a difference in renal impairment after partial paracentesis (RR 0.07, 95% CI 0.00 to 1.16; 105 participants; 1 trial; <a href="./references#CD004039-fig-0021" title="">Analysis 2.2</a>.1; <a href="./references#CD004039-bbs2-0012" title="GinèsP , TitóL , ArroyoV , PlanasR , PanésJ , ViverJ , et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology1988;94(6):1493‐1502. [PUBMED: 3360270] ">Ginès 1988</a>) and after total paracentesis (RR 1.06, 95% CI 0.17 to 6.70; 76 participants; 3 trials; I<sup>2</sup> not applicable because 2/3 of the trials had 0 events; <a href="./references#CD004039-fig-0021" title="">Analysis 2.2</a>.2; <a href="./references#CD004039-bbs2-0010" title="García‐CompeánD , VillarealJZ , CuevasHB , CantúDAG , EstrellaM , TamezEG , et al. Total therapeutic paracentesis (TTP) with and without intravenous albumin in the treatment of cirrhotic tense ascites: a randomized controlled trial. Liver1993;13(5):233‐8. [PUBMED: 8259034] ">García‐Compeán 1993</a>; <a href="./references#CD004039-bbs2-0018" title="LucaA , García‐PagánJ , BoschJ , FeuF , JiménezW , GinésA , et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology1995;22(3):753‐8. [PUBMED: 7657279] ">Luca 1995</a>; <a href="./references#CD004039-bbs2-0004" title="BaikSK , KimHS , LeeDK , KimIH , KwonSO . Hemodynamic changes after single large volume paracentesis (SLVP) in cirrhosis with tense ascites ‐ focusing on the effect of albumin as plasma expander. Korean Journal of Medicine2000;58:276‐82. ">Baik 2000</a>). </p> </section> <section id="CD004039-sec-0102"> <p><b>Length of follow‐up</b></p> <p>The test for subgroup differences comparing the effects of plasma expander versus no plasma expander in trials with a short follow‐up (up to one month) compared to trials with a long follow‐up (more than one month) showed no difference (P = 0.11, I² = 60.5; <a href="./references#CD004039-fig-0026" title="">Analysis 3.2</a>). We found no evidence of a difference in the effect of albumin‐treated participants and the untreated participants in trials with up to one month follow‐up in renal impairment (RR 1.06, 95% CI 0.17 to 6.70; 53 participants; 2 trials; I<sup>2</sup> not applicable because 1/2 of the trials had 0 events; <a href="./references#CD004039-fig-0026" title="">Analysis 3.2</a>.1; <a href="./references#CD004039-bbs2-0010" title="García‐CompeánD , VillarealJZ , CuevasHB , CantúDAG , EstrellaM , TamezEG , et al. Total therapeutic paracentesis (TTP) with and without intravenous albumin in the treatment of cirrhotic tense ascites: a randomized controlled trial. Liver1993;13(5):233‐8. [PUBMED: 8259034] ">García‐Compeán 1993</a>; <a href="./references#CD004039-bbs2-0018" title="LucaA , García‐PagánJ , BoschJ , FeuF , JiménezW , GinésA , et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology1995;22(3):753‐8. [PUBMED: 7657279] ">Luca 1995</a>), and the same was observed between the albumin‐treated participants and the untreated participants in trials with a follow‐up of more than one month (RR 0.07, 95% CI 0.00 to 1.16; 105 participants; 1 trial; <a href="./references#CD004039-fig-0026" title="">Analysis 3.2</a>.2). </p> </section> <section id="CD004039-sec-0103"> <p><b>For‐profit support</b></p> <p>The test for subgroup differences comparing for‐profit support showed no differences between the two subgroups (P = 0.11, I<sup>2</sup> = 60.5%; <a href="./references#CD004039-fig-0031" title="">Analysis 4.2</a>). We found no difference in renal impairment either in the subgroup of trials without for‐profit funding (RR 0.07, 95% CI 0.00 to 1.16; 123 participants; 2 trials; I<sup>2</sup> not applicable because 1/2 trial had 0 events; <a href="./references#CD004039-fig-0031" title="">Analysis 4.2</a>.1) or in the subgroup of trials without information on for‐profit funding (RR 1.06, 95% CI 0.17 to 6.70; 58 participants; 2 trials; I<sup>2</sup> not applicable because 1/2 trial had 0 events; <a href="./references#CD004039-fig-0031" title="">Analysis 4.2</a>.2). </p> </section> </section> </section> <section id="CD004039-sec-0104"> <h5 class="title">Other liver‐related complications</h5> <p>Four trials reported data on other liver‐related complications such as gastrointestinal bleeding, hepatic encephalopathy, or infections (<a href="./references#CD004039-bbs2-0008" title="DescosL , GauthierA , LevyVG , MichelH , QuintonA , RueffB , et al. Comparison of six treatments of ascites in patients with liver cirrhosis. A clinical trial. Hepato‐gastroenterology1983;30:15‐20. [PUBMED: 6339343] ">Descos 1983</a>; <a href="./references#CD004039-bbs2-0012" title="GinèsP , TitóL , ArroyoV , PlanasR , PanésJ , ViverJ , et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology1988;94(6):1493‐1502. [PUBMED: 3360270] ">Ginès 1988</a>; <a href="./references#CD004039-bbs2-0010" title="García‐CompeánD , VillarealJZ , CuevasHB , CantúDAG , EstrellaM , TamezEG , et al. Total therapeutic paracentesis (TTP) with and without intravenous albumin in the treatment of cirrhotic tense ascites: a randomized controlled trial. Liver1993;13(5):233‐8. [PUBMED: 8259034] ">García‐Compeán 1993</a>; <a href="./references#CD004039-bbs2-0018" title="LucaA , García‐PagánJ , BoschJ , FeuF , JiménezW , GinésA , et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology1995;22(3):753‐8. [PUBMED: 7657279] ">Luca 1995</a>). The meta‐analysed results of these four trials showed no evidence of a difference in the effect of plasma expander (albumin and infusion of ascitic fluid) versus no plasma expander on other liver‐related complications (RR 1.61, 95% CI 0.79 to 3.27; 248 participants; 4 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0016" title="">Analysis 1.4</a>). </p> <p>Including the trial with zero events in Trial Sequential Analysis produced a comparable result (RR 1.61, 95% CI 0.79 to 3.27; P = 0.19). </p> <p>We assessed the certainty of the evidence with GRADE as very low. We downgraded the evidence by three levels because all trials were at high risk of bias; and there was imprecision: the required information size was not reached (<a href="./full#CD004039-tbl-0001">summary of findings Table for the main comparison</a>; <a href="#CD004039-tbl-0003">Table 1</a>). </p> <p>Trial Sequential Analysis was constructed based on risk of other liver‐related complications of 9% in the control group, a relative risk reduction of 10% with plasma expander, a type I error of 2.00%, and a type II error of 20% (80% power). There was low diversity (D<sup>2</sup> = 0%). The DARIS was 38,752 participants. Due to the fact that only 248 participants were recruited (0.64% of the DARIS of 38,752 participants), the Trial Sequential Analysis program could not construct an interpretable figure and could not calculate Trial Sequential Analysis‐adjusted CIs. </p> <section id="CD004039-sec-0105"> <h6 class="title">Subgroup analysis</h6> <p>We could not perform two of the subgroup analyses because the risk of bias in the five trials was high, and because all trials included participants without refractory ascites (<a href="#CD004039-sec-0060">Subgroup analysis and investigation of heterogeneity</a>). </p> <section id="CD004039-sec-0106"> <p><b>Type of plasma expanders</b></p> <p>The test for subgroup differences comparing the effects of each type of plasma expander showed no difference between the plasma expanders used (P = 0.99, I² = 0%) regarding other liver‐related complications: albumin versus the no plasma expander (RR 1.61, 95% CI 0.76 to 3.41; 158 participants; 3 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0016" title="">Analysis 1.4</a>.1; <a href="./references#CD004039-bbs2-0012" title="GinèsP , TitóL , ArroyoV , PlanasR , PanésJ , ViverJ , et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology1988;94(6):1493‐1502. [PUBMED: 3360270] ">Ginès 1988</a>; <a href="./references#CD004039-bbs2-0010" title="García‐CompeánD , VillarealJZ , CuevasHB , CantúDAG , EstrellaM , TamezEG , et al. Total therapeutic paracentesis (TTP) with and without intravenous albumin in the treatment of cirrhotic tense ascites: a randomized controlled trial. Liver1993;13(5):233‐8. [PUBMED: 8259034] ">García‐Compeán 1993</a>; <a href="./references#CD004039-bbs2-0018" title="LucaA , García‐PagánJ , BoschJ , FeuF , JiménezW , GinésA , et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology1995;22(3):753‐8. [PUBMED: 7657279] ">Luca 1995</a>) and intravenous infusion of ascitic fluid versus the no plasma expander (RR 1.58, 95% CI 0.17 to 14.53; 90 participants; 1 trial; <a href="./references#CD004039-fig-0016" title="">Analysis 1.4</a>.2; <a href="./references#CD004039-bbs2-0008" title="DescosL , GauthierA , LevyVG , MichelH , QuintonA , RueffB , et al. Comparison of six treatments of ascites in patients with liver cirrhosis. A clinical trial. Hepato‐gastroenterology1983;30:15‐20. [PUBMED: 6339343] ">Descos 1983</a>). </p> </section> <section id="CD004039-sec-0107"> <p><b>Modality of paracentesis</b></p> <p>The test for subgroup differences comparing the effects of the modality of paracentesis showed no difference (P = 0.97, I² = 0%; <a href="./references#CD004039-fig-0022" title="">Analysis 2.3</a>) regarding other liver‐related complications: participants with partial paracentesis (RR 1.63, 95% CI 0.57 to 4.66; 105 participants; 1 trial; <a href="./references#CD004039-fig-0022" title="">Analysis 2.3</a>.1; <a href="./references#CD004039-bbs2-0012" title="GinèsP , TitóL , ArroyoV , PlanasR , PanésJ , ViverJ , et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology1988;94(6):1493‐1502. [PUBMED: 3360270] ">Ginès 1988</a>) and participants with total paracentesis (RR 1.59, 95% CI 0.60 to 4.18; 143 participants; 3 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0022" title="">Analysis 2.3</a>.2; <a href="./references#CD004039-bbs2-0008" title="DescosL , GauthierA , LevyVG , MichelH , QuintonA , RueffB , et al. Comparison of six treatments of ascites in patients with liver cirrhosis. A clinical trial. Hepato‐gastroenterology1983;30:15‐20. [PUBMED: 6339343] ">Descos 1983</a>; <a href="./references#CD004039-bbs2-0010" title="García‐CompeánD , VillarealJZ , CuevasHB , CantúDAG , EstrellaM , TamezEG , et al. Total therapeutic paracentesis (TTP) with and without intravenous albumin in the treatment of cirrhotic tense ascites: a randomized controlled trial. Liver1993;13(5):233‐8. [PUBMED: 8259034] ">García‐Compeán 1993</a>; <a href="./references#CD004039-bbs2-0018" title="LucaA , García‐PagánJ , BoschJ , FeuF , JiménezW , GinésA , et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology1995;22(3):753‐8. [PUBMED: 7657279] ">Luca 1995</a>). </p> </section> <section id="CD004039-sec-0108"> <p><b>Length of follow‐up</b></p> <p>The test for subgroup differences comparing the effects of duration of follow‐up showed no difference between the trials with a short follow‐up and the trials with a long follow‐up (P = 0.97; I² = 0%; <a href="./references#CD004039-fig-0027" title="">Analysis 3.3</a>) regarding other liver‐related complications: in trials with a follow‐up up to one month (RR 1.59, 95% CI 0.60 to 4.18; 143 participants; 3 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0027" title="">Analysis 3.3</a>.1; <a href="./references#CD004039-bbs2-0008" title="DescosL , GauthierA , LevyVG , MichelH , QuintonA , RueffB , et al. Comparison of six treatments of ascites in patients with liver cirrhosis. A clinical trial. Hepato‐gastroenterology1983;30:15‐20. [PUBMED: 6339343] ">Descos 1983</a>; <a href="./references#CD004039-bbs2-0010" title="García‐CompeánD , VillarealJZ , CuevasHB , CantúDAG , EstrellaM , TamezEG , et al. Total therapeutic paracentesis (TTP) with and without intravenous albumin in the treatment of cirrhotic tense ascites: a randomized controlled trial. Liver1993;13(5):233‐8. [PUBMED: 8259034] ">García‐Compeán 1993</a>; <a href="./references#CD004039-bbs2-0018" title="LucaA , García‐PagánJ , BoschJ , FeuF , JiménezW , GinésA , et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology1995;22(3):753‐8. [PUBMED: 7657279] ">Luca 1995</a>) and in the single trial with more than one month follow‐up (RR 1.63, 95% CI 0.57 to 4.66; 105 participants; <a href="./references#CD004039-fig-0027" title="">Analysis 3.3</a>.2; <a href="./references#CD004039-bbs2-0012" title="GinèsP , TitóL , ArroyoV , PlanasR , PanésJ , ViverJ , et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology1988;94(6):1493‐1502. [PUBMED: 3360270] ">Ginès 1988</a>). </p> </section> <section id="CD004039-sec-0109"> <p><b>For‐profit support</b></p> <p>The test for subgroup differences comparing for‐profit support showed no difference between the two subgroups (P = 0.98, I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0032" title="">Analysis 4.3</a>). We found no evidence of a difference in other liver‐related complications either in the subgroup of trials without for‐profit funding (RR 1.62, 95% CI 0.63 to 4.19; 213 participants; 3 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0032" title="">Analysis 4.3</a>.1) or in the subgroup with the only trial without information on for‐profit funding (RR 1.59, 95% CI 0.54 to 4.67; 35 participants; 1 trial; <a href="./references#CD004039-fig-0032" title="">Analysis 4.3</a>.2). </p> </section> </section> </section> <section id="CD004039-sec-0110"> <h5 class="title">Non‐serious adverse events</h5> <p>Non‐serious adverse events were reported in three trials; they included local hematoma, fistula, transient fever, hyperkalaemia, leakage, or oedema of the abdominal wall (<a href="./references#CD004039-bbs2-0012" title="GinèsP , TitóL , ArroyoV , PlanasR , PanésJ , ViverJ , et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology1988;94(6):1493‐1502. [PUBMED: 3360270] ">Ginès 1988</a>; <a href="./references#CD004039-bbs2-0010" title="García‐CompeánD , VillarealJZ , CuevasHB , CantúDAG , EstrellaM , TamezEG , et al. Total therapeutic paracentesis (TTP) with and without intravenous albumin in the treatment of cirrhotic tense ascites: a randomized controlled trial. Liver1993;13(5):233‐8. [PUBMED: 8259034] ">García‐Compeán 1993</a>; <a href="./references#CD004039-bbs2-0018" title="LucaA , García‐PagánJ , BoschJ , FeuF , JiménezW , GinésA , et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology1995;22(3):753‐8. [PUBMED: 7657279] ">Luca 1995</a>). The analysis result of these three trials showed no evidence of a difference between plasma expander and no plasma expander (RR 1.04, 95% CI 0.32 to 3.40; 158 participants; I² = 0%; <a href="./references#CD004039-fig-0017" title="">Analysis 1.5</a>). Including the trial with zero deaths in the Trial Sequential Analysis produced a comparable result (RR 1.04; 95% CI 0.32 to 3.40; P = 0.95). </p> <p>We assessed the certainty of the evidence with GRADE as very low. We downgraded the evidence by four levels because all trials were at high risk of bias; and there was imprecision: there were few events and the CI included appreciable benefit and harm (<a href="./full#CD004039-tbl-0001">summary of findings Table for the main comparison</a>). The required information size was not reached (<a href="#CD004039-tbl-0003">Table 1</a>). </p> <p>Trial Sequential Analysis was constructed based on the risk in the control group of 6.25%, a relative risk reduction of 10% with plasma expansion, a type I error of 2.00%, and a type II error of 20% (80% power). There was no diversity (D<sup>2</sup> = 0%). The DARIS was 56,467 participants. Due to the fact that only 158 participants were recruited (which is 0.27% of the DARIS of 56,467 participants), the Trial Sequential Analysis program could not construct an interpretable figure and could not calculate Trial Sequential Analysis‐adjusted CIs. </p> <section id="CD004039-sec-0111"> <h6 class="title">Subgroup analysis</h6> <p>We could not perform three of the subgroup analyses because the risk of bias in the three trials was high, all the three trials included participants without refractory ascites, and non‐serious adverse events were reported only in the trial that used albumin. </p> <section id="CD004039-sec-0112"> <p><b>Modality of paracentesis</b></p> <p>The test for subgroup differences comparing the effects of modality of paracentesis showed no difference between the two subgroups (P = 0.98; I² = 0%; <a href="./references#CD004039-fig-0023" title="">Analysis 2.4</a>): plasma expanders versus no plasma expander in trials with partial paracentesis (RR 1.02, 95% CI 0.22 to 4.82; 105 participants; 1 trial; <a href="./references#CD004039-fig-0023" title="">Analysis 2.4</a>.1) and in trials with total paracentesis (RR 1.06, 95% CI 0.17 to 6.70; 53 participants; 2 trials; I² not applicable because 1/2 trials had 0 events; <a href="./references#CD004039-fig-0023" title="">Analysis 2.4</a>.2). </p> </section> <section id="CD004039-sec-0113"> <p><b>Length of follow‐up</b></p> <p>The test for subgroup differences comparing the effects of duration of follow‐up showed no difference between the trials with a short follow‐up and the trials with more than one month follow‐up (P = 0.98, I² = 0%; <a href="./references#CD004039-fig-0028" title="">Analysis 3.4</a>): trials with a short follow‐up (RR 1.06, 95% CI 0.17 to 6.70; 53 participants; 2 trials; I<sup>2</sup> not applicable; <a href="./references#CD004039-fig-0028" title="">Analysis 3.4</a>.1; <a href="./references#CD004039-bbs2-0010" title="García‐CompeánD , VillarealJZ , CuevasHB , CantúDAG , EstrellaM , TamezEG , et al. Total therapeutic paracentesis (TTP) with and without intravenous albumin in the treatment of cirrhotic tense ascites: a randomized controlled trial. Liver1993;13(5):233‐8. [PUBMED: 8259034] ">García‐Compeán 1993</a>; <a href="./references#CD004039-bbs2-0018" title="LucaA , García‐PagánJ , BoschJ , FeuF , JiménezW , GinésA , et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology1995;22(3):753‐8. [PUBMED: 7657279] ">Luca 1995</a>) and trials with a long follow‐up (RR 1.02, 95% CI 0.22 to 4.82; 105 participants; 1 trial; I<sup>2</sup> not applicable; <a href="./references#CD004039-fig-0028" title="">Analysis 3.4</a>.2; <a href="./references#CD004039-bbs2-0012" title="GinèsP , TitóL , ArroyoV , PlanasR , PanésJ , ViverJ , et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology1988;94(6):1493‐1502. [PUBMED: 3360270] ">Ginès 1988</a>). </p> </section> <section id="CD004039-sec-0114"> <p><b>For‐profit support</b></p> <p>The test for subgroup differences comparing for‐profit support showed no difference between the two subgroups (P = 0.98, I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0033" title="">Analysis 4.4</a>). We found no evidence of difference in non‐serious adverse events either in the subgroup of trials without for‐profit funding (RR 1.02, 95% CI 0.22 to 4.82; 123 participants; 2 trials; I<sup>2</sup> not applicable because 1/2 trial had 0 events; <a href="./references#CD004039-fig-0033" title="">Analysis 4.4</a>.1) or in the subgroup with the only trial without information on for‐profit funding (RR 1.06, 95% CI 0.17 to 6.70; 35 participants; <a href="./references#CD004039-fig-0033" title="">Analysis 4.4</a>.2). </p> </section> </section> </section> </section> <section id="CD004039-sec-0115"> <h4 class="title">Exploratory outcomes</h4> <section id="CD004039-sec-0116"> <h5 class="title">Recurrence of ascites</h5> <p>Plasma expanders showed no evidence of a difference in effect on the recurrence of ascites (RR 1.30, 95% CI 0.49 to 3.42; 195 participants; 2 trials; I<sup>2</sup> = 37%; <a href="./references#CD004039-fig-0018" title="">Analysis 1.6</a>). </p> <p>We assessed the certainty of the evidence with GRADE as very low. We downgraded the evidence by three levels because the two trials were at high risk of bias; and there was imprecision: the required information size was not reached (<a href="#CD004039-tbl-0004">Table 2</a>; <a href="#CD004039-tbl-0005">Table 3</a>). </p> <div class="table" id="CD004039-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Plasma expanders versus no plasma expander for people with cirrhosis and large ascites treated with abdominal paracentesis: exploratory outcomes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Plasma expanders versus no plasma expander for people with cirrhosis and large ascites treated with abdominal paracentesis: exploratory outcomes</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> cirrhotic participants with large ascites treated by paracentesis </p> <p><b>Settings:</b> specialised units in an intensive or semi‐intensive setting </p> <p><b>Intervention:</b> plasma expander </p> <p><b>Comparison:</b> no plasma expander </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No plasma expander</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Plasma expander</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrence of ascites</b> </p> <p>mean follow‐up 126 days (30‐222)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.30</b> (0.49 to 3.42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>195<br/> (2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>155 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>201 per 1000</b><br/> (76 to 529) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hypotension</b> </p> <p>follow‐up 2 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>See comment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>See comment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There was a single trial with 0 events in each group.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Hyponatraemia</b> </p> <p>mean follow‐up 57 days (1‐222)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.53</b> (0.05 to 5.65) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>181<br/> (4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>130 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>69 per 1000</b><br/> (7 to 734) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>* <b>Assumed risk</b> is the risk in comparison group. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup> Downgraded 3 levels because of within study risk of bias: all trials were at high risk of bias (‐2 levels); imprecision: the required information size as calculated by GRADE not reached (‐1 levels)<br/> <sup>2</sup> Downgraded 4 levels because of within study risk of bias: all trials were at high risk of bias (‐2 levels); high heterogeneity (67%) (‐1 level); imprecision: the required information size as calculated by GRADE was not reached (‐1 level) </p> </div> </div> <div class="table" id="CD004039-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Comparison of imprecision by GRADE and Trial Sequential Analysis for the evaluation of exploratory outcomes in the comparison of plasma expanders versus no plasma expander</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Comparison of imprecision evaluation with GRADE based on the GRADE Handbook, with GRADE based on authors' choice of plausible relative risk reduction and multiplicity correction, and according to our Trial Sequential Analysis with a similar choice of plausible relative risk reduction and multiplicity correction, in addition to considering the choice of meta‐analytic model and diversity</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion in control group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relative risk reduction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Alpha</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Beta</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Diversity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Required information size (OIS or DARIS)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Downgrading of evidence for imprecision based on required information size</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recurrence of ascites ‐‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2444</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recurrence of ascites ‐‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20,980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recurrence of ascites ‐‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43,013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension ‐‐ GRADE Handbook <sup>(1)</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="3" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension ‐‐ GRADE plausible RRR <sup>(1)</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension ‐‐ TSA <sup>(1)</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyponatraemia ‐‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyponatraemia ‐‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25,712</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyponatraemia ‐‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28,526</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>(1)</sup> There was a single trial with 0 events in each group </p> <p>OIS: optimal information size; DARIS: diversity‐adjusted required information size; RRR: relative risk reduction; TSA: Trial Sequential Analysis </p> </div> </div> <p>Trial Sequential Analysis was constructed based on the risk of 15.5% in the control group, a relative risk reduction of 10% in the plasma expander group, a type I error of 2.00%, and a type II error of 20% (80% power). Diversity was present (D<sup>2</sup> = 51%). The DARIS was 43,013 participants. Due to the fact that only 195 participants were recruited (which is 0.45% of the DARIS of 43,013 participants), the Trial Sequential Analysis program could not construct an interpretable figure and could not calculate Trial Sequential Analysis‐adjusted CIs. </p> <section id="CD004039-sec-0117"> <h6 class="title">Subgroup analysis</h6> <p>We did not conduct subgroup analysis because there were only two trials.</p> </section> </section> <section id="CD004039-sec-0118"> <h5 class="title">Hypotension</h5> <p>Only one of the trials reported that there was no occurrence of hypotension (<a href="./references#CD004039-bbs2-0004" title="BaikSK , KimHS , LeeDK , KimIH , KwonSO . Hemodynamic changes after single large volume paracentesis (SLVP) in cirrhosis with tense ascites ‐ focusing on the effect of albumin as plasma expander. Korean Journal of Medicine2000;58:276‐82. ">Baik 2000</a>) (<a href="#CD004039-tbl-0004">Table 2</a>; <a href="#CD004039-tbl-0005">Table 3</a>). </p> </section> <section id="CD004039-sec-0119"> <h5 class="title">Hyponatraemia</h5> <p>Plasma expansion versus no plasma expansion showed no evidence of a difference in effect on the incidence of hyponatraemia (RR 0.53, 95% CI 0.05 to 5.65; 181 participants; 4 trials; I<sup>2</sup> = 67%; <a href="./references#CD004039-fig-0019" title="">Analysis 1.7</a>). Including the trials with zero events in Trial Sequential Analysis produced a comparable result (RR 0.38, 95% CI 0.11 to 1.38; P = 0.15). </p> <p>We assessed the certainty of the evidence with GRADE as very low. We downgraded the evidence by four levels because all trials were at high risk of bias; there was high heterogeneity; and there was imprecision: the required information size was not reached (<a href="#CD004039-tbl-0004">Table 2</a>; <a href="#CD004039-tbl-0005">Table 3</a>). </p> <p>Trial Sequential Analysis was based on risk of 13% in the control group, a relative risk reduction of 10% with plasma expansion, a type I error of 2.00%, and a type II error of 20% (80% power). Diversity (D<sup>2</sup>) was 10%. The DARIS was 28,526 participants. Due to the fact that only 181 participants were recruited (which is 0.63% of the DARIS of 28,526 participants), the Trial Sequential Analysis program could not construct an interpretable figure and could not calculate Trial Sequential Analysis‐adjusted CIs. </p> <section id="CD004039-sec-0120"> <h6 class="title">Subgroup analyses</h6> <p>We could not perform three of the subgroup analysis because all the four trials were assessed at high risk of bias, included participants without refractory ascites, and used albumin. </p> <section id="CD004039-sec-0121"> <p><b>Modality of paracentesis</b></p> <p>The test for subgroup differences comparing the effects of modality of paracentesis showed a difference between the two subgroups (P = 0.08, I² = 67.3%; <a href="./references#CD004039-fig-0024" title="">Analysis 2.5</a>): trials using partial paracentesis (RR 0.19, 95% CI 0.04 to 0.80; 105 participants; 1 trial; <a href="./references#CD004039-fig-0024" title="">Analysis 2.5</a>.1; <a href="./references#CD004039-bbs2-0012" title="GinèsP , TitóL , ArroyoV , PlanasR , PanésJ , ViverJ , et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology1988;94(6):1493‐1502. [PUBMED: 3360270] ">Ginès 1988</a>) and trials using total paracentesis (RR 2.12, 95% CI 0.21 to 21.27; 76 participants; 3 trials; I<sup>2</sup> not applicable because 2/3 trials had 0 events <a href="./references#CD004039-fig-0024" title="">Analysis 2.5</a>.2; <a href="./references#CD004039-bbs2-0010" title="García‐CompeánD , VillarealJZ , CuevasHB , CantúDAG , EstrellaM , TamezEG , et al. Total therapeutic paracentesis (TTP) with and without intravenous albumin in the treatment of cirrhotic tense ascites: a randomized controlled trial. Liver1993;13(5):233‐8. [PUBMED: 8259034] ">García‐Compeán 1993</a>; <a href="./references#CD004039-bbs2-0018" title="LucaA , García‐PagánJ , BoschJ , FeuF , JiménezW , GinésA , et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology1995;22(3):753‐8. [PUBMED: 7657279] ">Luca 1995</a>; <a href="./references#CD004039-bbs2-0004" title="BaikSK , KimHS , LeeDK , KimIH , KwonSO . Hemodynamic changes after single large volume paracentesis (SLVP) in cirrhosis with tense ascites ‐ focusing on the effect of albumin as plasma expander. Korean Journal of Medicine2000;58:276‐82. ">Baik 2000</a>). </p> </section> <section id="CD004039-sec-0122"> <p><b>Length of follow‐up</b></p> <p>The test for subgroup differences comparing the effects of duration of follow‐up showed a difference between the two subgroups (P = 0.08, I² = 67.3% <a href="./references#CD004039-fig-0029" title="">Analysis 3.5</a>): trials with a short follow‐up (RR 2.12, 95% CI 0.21 to 21.27; 76 participants; 3 trials; I<sup>2</sup> not applicable because 2/3 trials had 0 events; <a href="./references#CD004039-fig-0029" title="">Analysis 3.5</a>.1; <a href="./references#CD004039-bbs2-0010" title="García‐CompeánD , VillarealJZ , CuevasHB , CantúDAG , EstrellaM , TamezEG , et al. Total therapeutic paracentesis (TTP) with and without intravenous albumin in the treatment of cirrhotic tense ascites: a randomized controlled trial. Liver1993;13(5):233‐8. [PUBMED: 8259034] ">García‐Compeán 1993</a>; <a href="./references#CD004039-bbs2-0018" title="LucaA , García‐PagánJ , BoschJ , FeuF , JiménezW , GinésA , et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology1995;22(3):753‐8. [PUBMED: 7657279] ">Luca 1995</a>; <a href="./references#CD004039-bbs2-0004" title="BaikSK , KimHS , LeeDK , KimIH , KwonSO . Hemodynamic changes after single large volume paracentesis (SLVP) in cirrhosis with tense ascites ‐ focusing on the effect of albumin as plasma expander. Korean Journal of Medicine2000;58:276‐82. ">Baik 2000</a>) and trials with a long follow‐up (RR 0.19, 95% CI 0.04 to 0.80; 105 participants; <a href="./references#CD004039-fig-0029" title="">Analysis 3.5</a>.2; <a href="./references#CD004039-bbs2-0012" title="GinèsP , TitóL , ArroyoV , PlanasR , PanésJ , ViverJ , et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology1988;94(6):1493‐1502. [PUBMED: 3360270] ">Ginès 1988</a>). </p> </section> <section id="CD004039-sec-0123"> <p><b>For‐profit support</b></p> <p>The test for subgroup differences comparing for‐profit support showed a difference between the two subgroups (P = 0.08, I<sup>2</sup> = 67.3%; <a href="./references#CD004039-fig-0034" title="">Analysis 4.5</a>). Albumin versus no plasma expansion reduced hyponatraemia in the subgroup of trials without for‐profit funding (RR 0.19, 95% CI 0.04 to 0.80; 123 participants; 2 trials; I<sup>2</sup> not applicable because 1/2 trial had 0 events; <a href="./references#CD004039-fig-0034" title="">Analysis 4.5</a>.1). No evidence of a difference was found in the subgroup of trials without information on for‐profit funding (RR 2.12, 95% CI 0.21 to 21.27; 58 participants; 2 trials; I<sup>2</sup> not applicable because 1/2 trial had 0 events; <a href="./references#CD004039-fig-0034" title="">Analysis 4.5</a>.2). </p> </section> </section> </section> <section id="CD004039-sec-0124"> <h5 class="title">Post‐paracentesis circulatory dysfunction</h5> <p>None of the included trials reported data on post‐paracentesis circulatory dysfunction.</p> </section> </section> <section id="CD004039-sec-0125"> <h4 class="title">Plasma expanders versus other plasma expanders</h4> <p>The trials compared different plasma expanders. Therefore, to achieve maximal homogeneity, we first analysed all the trials in which albumin was used as a control intervention, and then we analysed the trials in which both intervention groups used plasma expanders different from albumin. </p> </section> <section id="CD004039-sec-0126"> <h4 class="title">Experimental plasma expanders versus albumin</h4> <p>Twenty‐one trials compared non‐albumin plasma expanders versus albumin (<a href="./references#CD004039-bbs2-0022" title="PlanasR , GinèsP , ArroyoV , LlachJ , PanésJ , VargasV , et al. Dextran‐70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study. Gastroenterology1990;99(6):1736‐44. [PUBMED: 1699835] PlanasR , LlachJ , GinèsP , PanésJ , VargasV , SalmeronJM , et al. Albumin versus dextran‐70 in cirrhotics with tense ascites treated with total paracentesis. Final results of a multicenter randomized comparative study. Journal of Hepatology1990;11(Suppl 2):S49. ">Planas 1990</a>; <a href="./references#CD004039-bbs2-0025" title="SmartHL , TrigerDR . A randomised prospective trial comparing daily paracentesis and intravenous albumin with recirculation in diuretic refractory ascites. Journal of Hepatology1990;10(2):191‐7. [PUBMED: 2185298] ">Smart 1990</a>; <a href="./references#CD004039-bbs2-0005" title="BertránX , Fernández‐BañaresF , PlanasF , CabréE , MorillasR , DeLeónR , et al. Effect on the nutritional status of total paracentesis plus albumin or dextran‐70 i.v. infusion for the treatment of tense ascites in liver cirrhosis [Repercusión sobre el estado nutricional energético‐proteico de la paracentesis total asociada a la infusión de albúmina o dextano‐70 en el tratamiento de la ascitis a tensión en la cirrhosis hepática]. Revista Espanola de Enfermedades Digestivas1991;79(5):320‐4. ">Bertrán 1991</a>; <a href="./references#CD004039-bbs2-0020" title="MéndezC , SorianoG , GuarnerC , TomásA , MoyanoD , ToroH , et al. Total paracentesis in cirrhotics with refractory ascites: albumin vs HES as plasmatic expanders. Journal of Hepatology1991;13(Suppl 2):S145. ">Méndez 1991</a>; <a href="./references#CD004039-bbs2-0023" title="SalernoF , BadalamentiS , LorenzanoE , MoserP , IncertiP . Randomized comparative study of hemaccel vs albumin infusion after total paracentesis in cirrhotic patients with refractory ascites. Hepatology1991;13(4):707‐13. [PUBMED: 1826281] ">Salerno 1991</a>; <a href="./references#CD004039-bbs2-0024" title="RinaldiF , SimonettiRG , MaisanoS , DinoO , MilazzoG , LucaA , et al. Refractory ascites in cirrhosis: treatment with total paracentesis and reinfusion of filtrated and concentrated ascitic fluid. Italian Journal of Gastroenterology1990;22(4):261. SimonettiRG , RinaldiF , MilazzoG , DinoO , MaisanoS , LucaA , et al. Treatment of refractory ascites: a randomized prospective trial of total paracentesis with concentrated ascitic fluid reinfusion vs repeated paracentesis and albumin infusion. Italian Journal of Gastroenterology1991;23(7):473. ">Simonetti 1991</a>; <a href="./references#CD004039-bbs2-0006" title="BrunoS , BorzioM , RomagnoniM , BattezzatiPM , RossiS , ChiesaA , et al. Comparison of spontaneous ascites filtration and reinfusion with total paracentesis with intravenous albumin infusion in cirrhotic patients with tense ascites. BMJ1992;304:1655‐8. [PUBMED: 1633517] BrunoS , BorzioM , RomagnoniM , ChiesaA , RossiS , PavesiS , et al. Spontaneous ascites filtration and reinfusion (SAFR) vs total paracentesis (TP) with i.v. albumin infusion in cirrhotic patients with tense ascites. Hepatology1990;12:855. ">Bruno 1992</a>; <a href="./references#CD004039-bbs2-0009" title="FassioE , TergR , LandeiraG , AbecasisR , SalemneM , PodestaA , et al. Paracentesis with dextran 70 vs paracentesis with albumin in cirrhosis with tense ascites. Results of a randomized study. Journal of Hepatology1992;14(2‐3):310‐6. [PUBMED: 1380024] ">Fassio 1992</a>; <a href="./references#CD004039-bbs2-0015" title="Hernández PérezRE , Aguilar RamírezJR , Hernández LopezJM , Gómez Maganday Silva T . Total paracentesis and infusion of dextran 70 vs albumin in cirrhotic patients with tense ascites [Paracentesis masiva con reposición de dextran 70 vs albúmina en pacientes cirróticos con ascitis a tensión]. Revista de Gastroenterologia de Mexico1995;60(1):22‐6. [PUBMED: 7543691] ">Hernández Pérez 1995</a>; <a href="./references#CD004039-bbs2-0013" title="GinèsA , Fernández‐EsparrachG , MonescilloA , VilaC , DomènechE , AbecasisR , et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology1996;111(4):1002‐10. [PUBMED: 8831595] International Group for the Study of Ascites in Cirrhosis. Comparison of albumin, dextran‐70 and hemaccel in the prevention of effective hypovolemia in cirrhotic patients with ascites treated with total paracentesis. A randomized multicenter study. Hepatology1995;22(4 Suppl):220A. ">Ginès 1996</a>; <a href="./references#CD004039-bbs2-0014" title="GraziottoA , RossaroL , InturriP , SalvagniniM . Reinfusion of concentrated ascitic fluid versus total paracentesis. A randomized prospective trial. Digestive Diseases and Sciences1997;42(8):1708‐14. [PUBMED: 9286238] ">Graziotto 1997</a>; <a href="./references#CD004039-bbs2-0003" title="AltmanC , BernardB , RoulotD , VitteR‐L , InkO . Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis. European Journal of Gastroenterology &amp; Hepatology1998;10:5‐10. [PUBMED: 9512946] ">Altman 1998</a>; <a href="./references#CD004039-bbs2-0016" title="KangKE , KimBH , DongSH , KimHJ , ChangYW , LeeJII , et al. The efficacy of hydroxyethyl starch as plasma expander in cirrhotic patients with tense ascites treated with large volume paracentesis. Korean Journal of Gastroenterology1998;31:651‐60. ">Kang 1998</a>; <a href="./references#CD004039-bbs2-0027" title="ZhaoJ , YuanC , WangD , LIX . Mannitolum infusion on cirrhotic patients with tense ascites treated by paracentesis. Chinese Medical Journal2000;113(1):27‐30. [PUBMED: 11775204] ">Zhao 2000</a>; <a href="./references#CD004039-bbs2-0011" title="García‐CompeánD , BlancP , LarreyD , DauresJ‐P , HirtzJ , MendozaE , et al. Treatment of cirrhotic tense ascites with dextran‐40 versus albumin associated with large volume paracentesis. A randomized controlled trial. Annals of Hepatology2002;1(1):29‐35. [PUBMED: 15114293] ">García‐Compeán 2002</a>; <a href="./references#CD004039-bbs2-0007" title="DegoricijaV , Zjacic‐RotkvicV , MaroutJ , SeferS , TroskotB . Clinical and neurohumoral response to posture, physical exercise, and ascites treatment in Child‐Pugh C liver cirrhosis: randomized prospective trial. Croatian Medical Journal2003;44(2):178‐86. [PUBMED: 12698509] DegoricijaV , Zjacic‐RotkvicV , TroskotB , ŠeferS . Postparacentesis neurohumoral changes and impairment of renal water excretion in Child‐Pugh C cirrhosis with and without volume replacement. Journal of Hepatology2001;34:51. ">Degoricija 2003</a>; <a href="./references#CD004039-bbs2-0026" title="Sola‐VeraJ , MinanaJ , SorianoG , GonzalezB , PlanellaM , Lopez‐BalaguerJM , et al. Expansion with saline vs albumin in cirrhotic patients with tense ascites treated with total paracentesis. Result of a prospective randomized study. Gastroenterologia y Hepatologia2001;24(2):90 A6. Sola‐VeraJ , MiñanaJ , RicartE , PlanellaM , GonzálezB , TorrasX , et al. Randomized trial comparing albumin and saline in the prevention of paracentesis‐induced circultory dysfunction in cirrhotic patients with ascites. Hepatology2003;37(5):1147‐53. [PUBMED: 12717396] ">Sola‐Vera 2003</a>; <a href="./references#CD004039-bbs2-0021" title="MoreauR , VallaD‐C , Durand‐ZaleskiI , BronowickiJ‐P , DurandF , ChaputJ‐C , et al. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trial. Liver International2006;26(1):46‐54. [PUBMED: 16420509] ">Moreau 2006</a>; <a href="./references#CD004039-bbs2-0001" title="Abdel‐KhalekEE , ArifS . Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients With liver cirrhosis and tense ascites after large‐volume paracentesis. Journal of Hepatology2010;52:S327. Abdel‐KhalekEE , ArifSE . Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients with liver cirrhosis and tense ascites following large volume paracentesis. Arab Journal of Gastroenterology2010;11:24‐9. ">Abdel‐Khalek 2010</a>; <a href="./references#CD004039-bbs2-0002" title="Al SebaeyA , Abdel‐RazekW , BassuniA , RewishaEA , KhalilM , WakedI , et al. Alternatives to albumin for prevention of paracentesis induced circulatory dysfunction (PICD) in cirrhosis. Hepatology2012;56(S1):915A. ">Al Sebaey 2012</a>; <a href="./references#CD004039-bbs2-0017" title="KhanMU , RahimIU , LatifM . Hemaccel as a cheaper alternative to human albumin for plasma expansion during paracentesis in cirrhotic patients. Pakistan Journal of Medical and Health Sciences2015;9(3):948‐51. ">Khan 2015</a>). </p> <p>As one of these twenty‐one trials had three intervention groups, we performed the analysis splitting the trial as if there were two trials performed; i.e. polygeline versus albumin and dextran 70 versus albumin, using half of the participants in the albumin group for each of the comparisons (<a href="./references#CD004039-bbs2-0013" title="GinèsA , Fernández‐EsparrachG , MonescilloA , VilaC , DomènechE , AbecasisR , et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology1996;111(4):1002‐10. [PUBMED: 8831595] International Group for the Study of Ascites in Cirrhosis. Comparison of albumin, dextran‐70 and hemaccel in the prevention of effective hypovolemia in cirrhotic patients with ascites treated with total paracentesis. A randomized multicenter study. Hepatology1995;22(4 Suppl):220A. ">Ginès 1996</a>). The trial by <a href="./references#CD004039-bbs2-0011" title="García‐CompeánD , BlancP , LarreyD , DauresJ‐P , HirtzJ , MendozaE , et al. Treatment of cirrhotic tense ascites with dextran‐40 versus albumin associated with large volume paracentesis. A randomized controlled trial. Annals of Hepatology2002;1(1):29‐35. [PUBMED: 15114293] ">García‐Compeán 2002</a> did not report the number of participants allocated to the treatment groups, and, hence, we could not use their data for quantitative analysis. The trial by <a href="./references#CD004039-bbs2-0007" title="DegoricijaV , Zjacic‐RotkvicV , MaroutJ , SeferS , TroskotB . Clinical and neurohumoral response to posture, physical exercise, and ascites treatment in Child‐Pugh C liver cirrhosis: randomized prospective trial. Croatian Medical Journal2003;44(2):178‐86. [PUBMED: 12698509] DegoricijaV , Zjacic‐RotkvicV , TroskotB , ŠeferS . Postparacentesis neurohumoral changes and impairment of renal water excretion in Child‐Pugh C cirrhosis with and without volume replacement. Journal of Hepatology2001;34:51. ">Degoricija 2003</a> did not report the number of events per intervention group, and, hence, we could not use it for quantitative analysis. </p> </section> <section id="CD004039-sec-0127"> <h4 class="title">Primary outcomes</h4> <section id="CD004039-sec-0128"> <h5 class="title">All‐cause mortality</h5> <p>Data on in‐hospital mortality were reported by five trials with albumin as the control intervention (<a href="./references#CD004039-bbs2-0006" title="BrunoS , BorzioM , RomagnoniM , BattezzatiPM , RossiS , ChiesaA , et al. Comparison of spontaneous ascites filtration and reinfusion with total paracentesis with intravenous albumin infusion in cirrhotic patients with tense ascites. BMJ1992;304:1655‐8. [PUBMED: 1633517] BrunoS , BorzioM , RomagnoniM , ChiesaA , RossiS , PavesiS , et al. Spontaneous ascites filtration and reinfusion (SAFR) vs total paracentesis (TP) with i.v. albumin infusion in cirrhotic patients with tense ascites. Hepatology1990;12:855. ">Bruno 1992</a>; <a href="./references#CD004039-bbs2-0013" title="GinèsA , Fernández‐EsparrachG , MonescilloA , VilaC , DomènechE , AbecasisR , et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology1996;111(4):1002‐10. [PUBMED: 8831595] International Group for the Study of Ascites in Cirrhosis. Comparison of albumin, dextran‐70 and hemaccel in the prevention of effective hypovolemia in cirrhotic patients with ascites treated with total paracentesis. A randomized multicenter study. Hepatology1995;22(4 Suppl):220A. ">Ginès 1996</a>; <a href="./references#CD004039-bbs2-0016" title="KangKE , KimBH , DongSH , KimHJ , ChangYW , LeeJII , et al. The efficacy of hydroxyethyl starch as plasma expander in cirrhotic patients with tense ascites treated with large volume paracentesis. Korean Journal of Gastroenterology1998;31:651‐60. ">Kang 1998</a>; <a href="./references#CD004039-bbs2-0026" title="Sola‐VeraJ , MinanaJ , SorianoG , GonzalezB , PlanellaM , Lopez‐BalaguerJM , et al. Expansion with saline vs albumin in cirrhotic patients with tense ascites treated with total paracentesis. Result of a prospective randomized study. Gastroenterologia y Hepatologia2001;24(2):90 A6. Sola‐VeraJ , MiñanaJ , RicartE , PlanellaM , GonzálezB , TorrasX , et al. Randomized trial comparing albumin and saline in the prevention of paracentesis‐induced circultory dysfunction in cirrhotic patients with ascites. Hepatology2003;37(5):1147‐53. [PUBMED: 12717396] ">Sola‐Vera 2003</a>; <a href="./references#CD004039-bbs2-0017" title="KhanMU , RahimIU , LatifM . Hemaccel as a cheaper alternative to human albumin for plasma expansion during paracentesis in cirrhotic patients. Pakistan Journal of Medical and Health Sciences2015;9(3):948‐51. ">Khan 2015</a>). In another five trials with a short follow‐up, mortality was not reported (<a href="./references#CD004039-bbs2-0005" title="BertránX , Fernández‐BañaresF , PlanasF , CabréE , MorillasR , DeLeónR , et al. Effect on the nutritional status of total paracentesis plus albumin or dextran‐70 i.v. infusion for the treatment of tense ascites in liver cirrhosis [Repercusión sobre el estado nutricional energético‐proteico de la paracentesis total asociada a la infusión de albúmina o dextano‐70 en el tratamiento de la ascitis a tensión en la cirrhosis hepática]. Revista Espanola de Enfermedades Digestivas1991;79(5):320‐4. ">Bertrán 1991</a>; <a href="./references#CD004039-bbs2-0020" title="MéndezC , SorianoG , GuarnerC , TomásA , MoyanoD , ToroH , et al. Total paracentesis in cirrhotics with refractory ascites: albumin vs HES as plasmatic expanders. Journal of Hepatology1991;13(Suppl 2):S145. ">Méndez 1991</a>; <a href="./references#CD004039-bbs2-0015" title="Hernández PérezRE , Aguilar RamírezJR , Hernández LopezJM , Gómez Maganday Silva T . Total paracentesis and infusion of dextran 70 vs albumin in cirrhotic patients with tense ascites [Paracentesis masiva con reposición de dextran 70 vs albúmina en pacientes cirróticos con ascitis a tensión]. Revista de Gastroenterologia de Mexico1995;60(1):22‐6. [PUBMED: 7543691] ">Hernández Pérez 1995</a>; <a href="./references#CD004039-bbs2-0003" title="AltmanC , BernardB , RoulotD , VitteR‐L , InkO . Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis. European Journal of Gastroenterology &amp; Hepatology1998;10:5‐10. [PUBMED: 9512946] ">Altman 1998</a>; <a href="./references#CD004039-bbs2-0002" title="Al SebaeyA , Abdel‐RazekW , BassuniA , RewishaEA , KhalilM , WakedI , et al. Alternatives to albumin for prevention of paracentesis induced circulatory dysfunction (PICD) in cirrhosis. Hepatology2012;56(S1):915A. ">Al Sebaey 2012</a>). </p> <p>Another nine trials provided mortality after discharge from hospital (<a href="./references#CD004039-bbs2-0022" title="PlanasR , GinèsP , ArroyoV , LlachJ , PanésJ , VargasV , et al. Dextran‐70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study. Gastroenterology1990;99(6):1736‐44. [PUBMED: 1699835] PlanasR , LlachJ , GinèsP , PanésJ , VargasV , SalmeronJM , et al. Albumin versus dextran‐70 in cirrhotics with tense ascites treated with total paracentesis. Final results of a multicenter randomized comparative study. Journal of Hepatology1990;11(Suppl 2):S49. ">Planas 1990</a>; <a href="./references#CD004039-bbs2-0025" title="SmartHL , TrigerDR . A randomised prospective trial comparing daily paracentesis and intravenous albumin with recirculation in diuretic refractory ascites. Journal of Hepatology1990;10(2):191‐7. [PUBMED: 2185298] ">Smart 1990</a>; <a href="./references#CD004039-bbs2-0023" title="SalernoF , BadalamentiS , LorenzanoE , MoserP , IncertiP . Randomized comparative study of hemaccel vs albumin infusion after total paracentesis in cirrhotic patients with refractory ascites. Hepatology1991;13(4):707‐13. [PUBMED: 1826281] ">Salerno 1991</a>; <a href="./references#CD004039-bbs2-0024" title="RinaldiF , SimonettiRG , MaisanoS , DinoO , MilazzoG , LucaA , et al. Refractory ascites in cirrhosis: treatment with total paracentesis and reinfusion of filtrated and concentrated ascitic fluid. Italian Journal of Gastroenterology1990;22(4):261. SimonettiRG , RinaldiF , MilazzoG , DinoO , MaisanoS , LucaA , et al. Treatment of refractory ascites: a randomized prospective trial of total paracentesis with concentrated ascitic fluid reinfusion vs repeated paracentesis and albumin infusion. Italian Journal of Gastroenterology1991;23(7):473. ">Simonetti 1991</a>; <a href="./references#CD004039-bbs2-0009" title="FassioE , TergR , LandeiraG , AbecasisR , SalemneM , PodestaA , et al. Paracentesis with dextran 70 vs paracentesis with albumin in cirrhosis with tense ascites. Results of a randomized study. Journal of Hepatology1992;14(2‐3):310‐6. [PUBMED: 1380024] ">Fassio 1992</a>; <a href="./references#CD004039-bbs2-0014" title="GraziottoA , RossaroL , InturriP , SalvagniniM . Reinfusion of concentrated ascitic fluid versus total paracentesis. A randomized prospective trial. Digestive Diseases and Sciences1997;42(8):1708‐14. [PUBMED: 9286238] ">Graziotto 1997</a>; <a href="./references#CD004039-bbs2-0027" title="ZhaoJ , YuanC , WangD , LIX . Mannitolum infusion on cirrhotic patients with tense ascites treated by paracentesis. Chinese Medical Journal2000;113(1):27‐30. [PUBMED: 11775204] ">Zhao 2000</a>; <a href="./references#CD004039-bbs2-0021" title="MoreauR , VallaD‐C , Durand‐ZaleskiI , BronowickiJ‐P , DurandF , ChaputJ‐C , et al. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trial. Liver International2006;26(1):46‐54. [PUBMED: 16420509] ">Moreau 2006</a>; <a href="./references#CD004039-bbs2-0001" title="Abdel‐KhalekEE , ArifS . Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients With liver cirrhosis and tense ascites after large‐volume paracentesis. Journal of Hepatology2010;52:S327. Abdel‐KhalekEE , ArifSE . Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients with liver cirrhosis and tense ascites following large volume paracentesis. Arab Journal of Gastroenterology2010;11:24‐9. ">Abdel‐Khalek 2010</a>). Ginès and colleagues wrote that there was no difference in mortality between the two groups at follow‐up after discharge, but the trial did not report the number of events, and we received no reply from the trial authors to our data request (<a href="./references#CD004039-bbs2-0013" title="GinèsA , Fernández‐EsparrachG , MonescilloA , VilaC , DomènechE , AbecasisR , et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology1996;111(4):1002‐10. [PUBMED: 8831595] International Group for the Study of Ascites in Cirrhosis. Comparison of albumin, dextran‐70 and hemaccel in the prevention of effective hypovolemia in cirrhotic patients with ascites treated with total paracentesis. A randomized multicenter study. Hepatology1995;22(4 Suppl):220A. ">Ginès 1996</a>). </p> <p>There was no evidence of a difference in all‐cause mortality between the experimental plasma expanders group and the albumin group (RR 1.03, 95% CI 0.82 to 1.30; 1014 participants; 14 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0037" title="">Analysis 7.1</a>; <a href="#CD004039-fig-0004">Figure 4</a>). The intervention effect on all‐cause mortality did not change after inclusion of the two trials with zero deaths (RR 1.04; 95% CI 0.82 to 1.31; P = 0.75; D<sup>2</sup> = 0%). </p> <div class="figure" id="CD004039-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 6 Experimental plasma expanders versus albumin, outcome: 6.1 All‐cause mortality." data-id="CD004039-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 6 Experimental plasma expanders versus albumin, outcome: 6.1 All‐cause mortality. </p> </div> </div> </div> <p>We assessed the certainty of the evidence with GRADE as very low. We downgraded the evidence by four levels because all trials were at high risk of bias; there was imprecision: the required information size was not reached; there was evidence of publication bias (<a href="./full#CD004039-tbl-0002">summary of findings Table 2</a>; <a href="#CD004039-tbl-0006">Table 4</a>; <a href="#CD004039-fig-0004">Figure 4</a>). </p> <div class="table" id="CD004039-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Comparison of imprecision by GRADE and Trial Sequential Analysis for the evaluation of primary and secondary outcomes in the comparison of plasma expanders versus albumin</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Comparison of imprecision evaluation with GRADE based on the GRADE Handbook, with GRADE based on authors' choice of plausible relative risk reduction and multiplicity correction, and according to our Trial Sequential Analysis with a similar choice of plausible relative risk reduction and multiplicity correction, in addition to considering the choice of meta‐analytic model and diversity</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion in control group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relative risk reduction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Alpha</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Beta</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Diversity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Required information size (OIS or DARIS)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Downgrading of evidence for imprecision based on required information size</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality ‐‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2030</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality ‐‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16,415</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality ‐‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16,415</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events ‐‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24,032</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events ‐‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>809,313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events ‐‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>809,313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life ‐‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>No data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life ‐‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>No data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life ‐‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>No data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Refractory ascites ‐‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>No data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Refractory ascites ‐‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>No data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Refractory ascites ‐‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>No data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Renal impairment ‐‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8404</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Renal impairment ‐‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.00%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72,650</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Renal impairment ‐‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.00%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72,651</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other liver‐related complications ‐‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other liver‐related complications ‐‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.00%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16,990</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other liver‐related complications ‐‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.00%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16,992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐serious adverse events ‐‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16,904</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐serious adverse events ‐‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.00%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148,922</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐serious adverse events ‐‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.00%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148,925</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>OIS: optimal information size; DARIS: diversity‐adjusted required information size; RRR: relative risk reduction; TSA: Trial Sequential Analysis </p> </div> </div> <p>Trial Sequential Analysis of this comparison was constructed on an all‐cause mortality of 18.2% in the albumin group, a relative risk reduction of 10% with the experimental plasma expanders, a type I error of 2.5%, and a type II error of 20% (80% power). There was no diversity (D<sup>2</sup> = 0%). The DARIS was 16,415 participants. In Trial Sequential Analysis, the information fraction was too small to produce an inner wedge futility area. The cumulative Z curve (blue line) did not approach the monitoring boundaries (red lines) for benefit or harm or futility (<a href="#CD004039-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD004039-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Experimental plasma expanders versus albumin ‐ 6.1 All‐cause mortality.The diversity‐adjusted required information size of 16,415 participants was calculated based on a proportion of participants of 18.2% of participants dying in the control group; a relative risk reduction (RRR) of 10% in the plasma expander group; an alpha of 2.5%; a power of 80%; and a diversity of 0%.The cumulative Z score did not cross borders for benefit, harm, or futility." data-id="CD004039-fig-0005" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Experimental plasma expanders versus albumin ‐ 6.1 All‐cause mortality.</p> <p>The diversity‐adjusted required information size of 16,415 participants was calculated based on a proportion of participants of 18.2% of participants dying in the control group; a relative risk reduction (RRR) of 10% in the plasma expander group; an alpha of 2.5%; a power of 80%; and a diversity of 0%. </p> <p>The cumulative Z score did not cross borders for benefit, harm, or futility.</p> </div> </div> </div> <section id="CD004039-sec-0129"> <h6 class="title">Subgroup analyses</h6> <p>We could not perform subgroup analysis of trials in terms of all‐cause mortality according to their risk of bias because all the trials were assessed at high risk. </p> <section id="CD004039-sec-0130"> <p><b>Type of plasma expanders</b></p> <p>The test for subgroup differences comparing the effects of distinct plasma expanders showed no difference between the six subgroups (P = 0.89, I² = 0%; <a href="./references#CD004039-fig-0037" title="">Analysis 7.1</a>). </p> <p>The type of plasma expander compared with albumin showed no evidence of difference in effect on all‐cause mortality: dextran (RR 1.28, 95% CI 0.79 to 2.06; 271 participants; 3 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0037" title="">Analysis 7.1</a>.1; <a href="./references#CD004039-bbs2-0022" title="PlanasR , GinèsP , ArroyoV , LlachJ , PanésJ , VargasV , et al. Dextran‐70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study. Gastroenterology1990;99(6):1736‐44. [PUBMED: 1699835] PlanasR , LlachJ , GinèsP , PanésJ , VargasV , SalmeronJM , et al. Albumin versus dextran‐70 in cirrhotics with tense ascites treated with total paracentesis. Final results of a multicenter randomized comparative study. Journal of Hepatology1990;11(Suppl 2):S49. ">Planas 1990</a>; <a href="./references#CD004039-bbs2-0009" title="FassioE , TergR , LandeiraG , AbecasisR , SalemneM , PodestaA , et al. Paracentesis with dextran 70 vs paracentesis with albumin in cirrhosis with tense ascites. Results of a randomized study. Journal of Hepatology1992;14(2‐3):310‐6. [PUBMED: 1380024] ">Fassio 1992</a>; <a href="./references#CD004039-bbs2-0013" title="GinèsA , Fernández‐EsparrachG , MonescilloA , VilaC , DomènechE , AbecasisR , et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology1996;111(4):1002‐10. [PUBMED: 8831595] International Group for the Study of Ascites in Cirrhosis. Comparison of albumin, dextran‐70 and hemaccel in the prevention of effective hypovolemia in cirrhotic patients with ascites treated with total paracentesis. A randomized multicenter study. Hepatology1995;22(4 Suppl):220A. ">Ginès 1996</a>); hydroxyethyl starch (RR 1.16, 95% CI 0.45 to 3.02; 147 participants; 2 trials; I<sup>2</sup> not applicable because 1 out of 2 trials had 0 events; <a href="./references#CD004039-fig-0037" title="">Analysis 7.1</a>.2; <a href="./references#CD004039-bbs2-0016" title="KangKE , KimBH , DongSH , KimHJ , ChangYW , LeeJII , et al. The efficacy of hydroxyethyl starch as plasma expander in cirrhotic patients with tense ascites treated with large volume paracentesis. Korean Journal of Gastroenterology1998;31:651‐60. ">Kang 1998</a>; <a href="./references#CD004039-bbs2-0001" title="Abdel‐KhalekEE , ArifS . Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients With liver cirrhosis and tense ascites after large‐volume paracentesis. Journal of Hepatology2010;52:S327. Abdel‐KhalekEE , ArifSE . Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients with liver cirrhosis and tense ascites following large volume paracentesis. Arab Journal of Gastroenterology2010;11:24‐9. ">Abdel‐Khalek 2010</a>); polygeline (RR 1.12, 95% CI 0.67 to 1.89; 319 participants; 4 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0037" title="">Analysis 7.1</a>.3; <a href="./references#CD004039-bbs2-0023" title="SalernoF , BadalamentiS , LorenzanoE , MoserP , IncertiP . Randomized comparative study of hemaccel vs albumin infusion after total paracentesis in cirrhotic patients with refractory ascites. Hepatology1991;13(4):707‐13. [PUBMED: 1826281] ">Salerno 1991</a>; <a href="./references#CD004039-bbs2-0013" title="GinèsA , Fernández‐EsparrachG , MonescilloA , VilaC , DomènechE , AbecasisR , et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology1996;111(4):1002‐10. [PUBMED: 8831595] International Group for the Study of Ascites in Cirrhosis. Comparison of albumin, dextran‐70 and hemaccel in the prevention of effective hypovolemia in cirrhotic patients with ascites treated with total paracentesis. A randomized multicenter study. Hepatology1995;22(4 Suppl):220A. ">Ginès 1996</a>; <a href="./references#CD004039-bbs2-0021" title="MoreauR , VallaD‐C , Durand‐ZaleskiI , BronowickiJ‐P , DurandF , ChaputJ‐C , et al. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trial. Liver International2006;26(1):46‐54. [PUBMED: 16420509] ">Moreau 2006</a>; <a href="./references#CD004039-bbs2-0017" title="KhanMU , RahimIU , LatifM . Hemaccel as a cheaper alternative to human albumin for plasma expansion during paracentesis in cirrhotic patients. Pakistan Journal of Medical and Health Sciences2015;9(3):948‐51. ">Khan 2015</a>); intravenous infusion of ascites (RR 0.89, 95% CI 0.61 to 1.31; 137 participants; 4 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0037" title="">Analysis 7.1</a>.4; <a href="./references#CD004039-bbs2-0025" title="SmartHL , TrigerDR . A randomised prospective trial comparing daily paracentesis and intravenous albumin with recirculation in diuretic refractory ascites. Journal of Hepatology1990;10(2):191‐7. [PUBMED: 2185298] ">Smart 1990</a>; <a href="./references#CD004039-bbs2-0024" title="RinaldiF , SimonettiRG , MaisanoS , DinoO , MilazzoG , LucaA , et al. Refractory ascites in cirrhosis: treatment with total paracentesis and reinfusion of filtrated and concentrated ascitic fluid. Italian Journal of Gastroenterology1990;22(4):261. SimonettiRG , RinaldiF , MilazzoG , DinoO , MaisanoS , LucaA , et al. Treatment of refractory ascites: a randomized prospective trial of total paracentesis with concentrated ascitic fluid reinfusion vs repeated paracentesis and albumin infusion. Italian Journal of Gastroenterology1991;23(7):473. ">Simonetti 1991</a>; <a href="./references#CD004039-bbs2-0006" title="BrunoS , BorzioM , RomagnoniM , BattezzatiPM , RossiS , ChiesaA , et al. Comparison of spontaneous ascites filtration and reinfusion with total paracentesis with intravenous albumin infusion in cirrhotic patients with tense ascites. BMJ1992;304:1655‐8. [PUBMED: 1633517] BrunoS , BorzioM , RomagnoniM , ChiesaA , RossiS , PavesiS , et al. Spontaneous ascites filtration and reinfusion (SAFR) vs total paracentesis (TP) with i.v. albumin infusion in cirrhotic patients with tense ascites. Hepatology1990;12:855. ">Bruno 1992</a>; <a href="./references#CD004039-bbs2-0014" title="GraziottoA , RossaroL , InturriP , SalvagniniM . Reinfusion of concentrated ascitic fluid versus total paracentesis. A randomized prospective trial. Digestive Diseases and Sciences1997;42(8):1708‐14. [PUBMED: 9286238] ">Graziotto 1997</a>); mannitol (RR 0.88, 95% CI 0.47 to 1.66; <a href="./references#CD004039-fig-0037" title="">Analysis 7.1</a>.5; <a href="./references#CD004039-bbs2-0027" title="ZhaoJ , YuanC , WangD , LIX . Mannitolum infusion on cirrhotic patients with tense ascites treated by paracentesis. Chinese Medical Journal2000;113(1):27‐30. [PUBMED: 11775204] ">Zhao 2000</a>); and crystalloids (RR 1.06, 95% CI 0.07 to 16.26; <a href="./references#CD004039-fig-0037" title="">Analysis 7.1</a>.6; <a href="./references#CD004039-bbs2-0026" title="Sola‐VeraJ , MinanaJ , SorianoG , GonzalezB , PlanellaM , Lopez‐BalaguerJM , et al. Expansion with saline vs albumin in cirrhotic patients with tense ascites treated with total paracentesis. Result of a prospective randomized study. Gastroenterologia y Hepatologia2001;24(2):90 A6. Sola‐VeraJ , MiñanaJ , RicartE , PlanellaM , GonzálezB , TorrasX , et al. Randomized trial comparing albumin and saline in the prevention of paracentesis‐induced circultory dysfunction in cirrhotic patients with ascites. Hepatology2003;37(5):1147‐53. [PUBMED: 12717396] ">Sola‐Vera 2003</a>). </p> </section> <section id="CD004039-sec-0131"> <p><b>Refractory ascites</b></p> <p>The test for subgroup differences comparing the effects of refractory ascites showed no difference between the two subgroups (P = 0.59, I² = 0%; <a href="./references#CD004039-fig-0045" title="">Analysis 8.1</a>): trials including participants without refractory ascites (RR 1.15, 95% CI 0.80 to 1.66; 723 participants; 9 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0045" title="">Analysis 8.1</a>.1) and trials including participants with refractory ascites (RR 1.01, 95% CI 0.75 to 1.37; 291 participants; 5 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0045" title="">Analysis 8.1</a>.2). </p> </section> <section id="CD004039-sec-0132"> <p><b>Modality of paracentesis</b></p> <p>The test for subgroup differences comparing the effects of modality of paracentesis showed no difference between the two subgroups (P = 0.73, I² = 0%; <a href="./references#CD004039-fig-0051" title="">Analysis 9.1</a>). We found no evidence of a difference in all‐cause mortality either in the partial paracentesis subgroup (RR 0.98, 95% CI 0.59 to 1.65; 109 participants; 2 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0051" title="">Analysis 9.1</a>.1) or in the total paracentesis subgroup (RR 1.09, 95% CI 0.84 to 1.41; 905 participants; 12 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0051" title="">Analysis 9.1</a>.2). </p> </section> <section id="CD004039-sec-0133"> <p><b>Length of follow‐up</b></p> <p>The test for subgroup differences comparing the effect of length of follow‐up showed no difference between the two subgroups (P = 0.48, I² = 0%; <a href="./references#CD004039-fig-0057" title="">Analysis 10.1</a>). In the trials with a short follow‐up, we found a RR 1.59, 95% CI 0.47 to 5.33; 458 participants; 5 trials; I<sup>2</sup> = 0% (<a href="./references#CD004039-fig-0057" title="">Analysis 10.1</a>.1); and in the trials with a long follow‐up, we found a RR 1.02, 95% CI 0.80 to 1.29; 556 participants; 9 trials; I<sup>2</sup> = 0% (<a href="./references#CD004039-fig-0057" title="">Analysis 10.1</a>.2). </p> </section> <section id="CD004039-sec-0134"> <p><b>For‐profit support</b></p> <p>The test for subgroup differences comparing for‐profit support showed no difference (P = 0.41, I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0064" title="">Analysis 11.1</a>). We found no evidence of a difference in all‐cause mortality either in the trials without for‐profit funding (RR 1.19, 95% CI 0.79 to 1.81; 357 participants; 6 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0064" title="">Analysis 11.1</a>.1) or in the trials with or unknown for‐profit funding (RR 0.97, 95% CI 0.73 to 1.28; 657 participants; 8 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0064" title="">Analysis 11.1</a>.2). </p> </section> </section> <section id="CD004039-sec-0135"> <h6 class="title">Sensitivity analysis</h6> <p>Hypothesising the best‐worst scenario, mortality was increased by the other plasma expanders in comparison with albumin (RR 1.29, 95% CI 1.04 to 1.60; 1016 participants; 14 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0071" title="">Analysis 12.1</a>). The worst‐best scenario analysis showed no evidence of a difference between other plasma expanders versus albumin (RR 0.99, 95% CI 0.96 to 1.03; 1016 participants; 14 trials; I<sup>2</sup> = 8%; <a href="./references#CD004039-fig-0072" title="">Analysis 13.1</a>). </p> </section> </section> <section id="CD004039-sec-0136"> <h5 class="title">Serious adverse events</h5> <p>Two trials reported data on serious adverse events. There was no evidence of a difference between other plasma expanders versus albumin in serious adverse events (<a href="./references#CD004039-bbs2-0021" title="MoreauR , VallaD‐C , Durand‐ZaleskiI , BronowickiJ‐P , DurandF , ChaputJ‐C , et al. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trial. Liver International2006;26(1):46‐54. [PUBMED: 16420509] ">Moreau 2006</a>; <a href="./references#CD004039-bbs2-0017" title="KhanMU , RahimIU , LatifM . Hemaccel as a cheaper alternative to human albumin for plasma expansion during paracentesis in cirrhotic patients. Pakistan Journal of Medical and Health Sciences2015;9(3):948‐51. ">Khan 2015</a>) (RR 0.89, 95% CI 0.10 to 8.30; 118 participants; 2 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0038" title="">Analysis 7.2</a>). </p> <p>We assessed the certainty of the evidence with GRADE as very low. We downgraded the evidence by four levels because: all trials were at high risk of bias; and there was imprecision: there were few events and the CI included appreciable benefit and harm (<a href="./full#CD004039-tbl-0002">summary of findings Table 2</a>). The optimal information size as calculated by GRADE was not reached (<a href="#CD004039-tbl-0006">Table 4</a>). </p> <p>The Trial Sequential Analysis of this comparison was based on a risk of 1.8% in the control group, a relative risk reduction of 5% with experimental plasma expanders, a type I error of 2.5%, and a type II error of 20% (80% power). There was no diversity (D<sup>2</sup> = 0%). The DARIS was 809,313 participants. Due to the fact that only 118 participants were recruited (which is 0.01% of the DARIS of 809,313 participants), the Trial Sequential Analysis program could not construct an interpretable figure and could not calculate Trial Sequential Analysis‐adjusted CIs. </p> <section id="CD004039-sec-0137"> <h6 class="title">Subgroup analyses</h6> <p>We could not perform subgroup analysis of trials according to their risk of bias, presence of refractory ascites, type of plasma expanders, modality of paracentesis, or for‐profit funding because both trials included participants with and without refractory ascites, used polygeline, performed total paracentesis, and were without for‐profit funding. </p> <section id="CD004039-sec-0138"> <p><b>Length of follow‐up</b></p> <p>The subgroup analysis comparing the effects of length of follow‐up showed no differences (P = 0.39, I² = 0%; <a href="./references#CD004039-fig-0058" title="">Analysis 10.2</a>): in the single trial with a short follow‐up (<a href="./references#CD004039-bbs2-0017" title="KhanMU , RahimIU , LatifM . Hemaccel as a cheaper alternative to human albumin for plasma expansion during paracentesis in cirrhotic patients. Pakistan Journal of Medical and Health Sciences2015;9(3):948‐51. ">Khan 2015</a>) (RR 0.33, 95% CI 0.01 to 7.81; 50 participants; <a href="./references#CD004039-fig-0058" title="">Analysis 10.2</a>.1) and in the single trial with a long follow‐up (<a href="./references#CD004039-bbs2-0021" title="MoreauR , VallaD‐C , Durand‐ZaleskiI , BronowickiJ‐P , DurandF , ChaputJ‐C , et al. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trial. Liver International2006;26(1):46‐54. [PUBMED: 16420509] ">Moreau 2006</a>) (RR 2.38, 95% CI 0.10 to 56.53; 68 participants; <a href="./references#CD004039-fig-0058" title="">Analysis 10.2</a>.2). </p> </section> </section> </section> <section id="CD004039-sec-0139"> <h5 class="title">Health‐related quality of life</h5> <p>None of the included trials assessed the health‐related quality of life.</p> </section> </section> <section id="CD004039-sec-0140"> <h4 class="title">Secondary outcomes</h4> <section id="CD004039-sec-0141"> <h5 class="title">Refractory ascites</h5> <p>None of the included trials comparing a plasma expander versus albumin reported data on refractory ascites. </p> </section> <section id="CD004039-sec-0142"> <h5 class="title">Renal impairment</h5> <p>Seventeen trials reported data on renal impairment (<a href="./references#CD004039-bbs2-0022" title="PlanasR , GinèsP , ArroyoV , LlachJ , PanésJ , VargasV , et al. Dextran‐70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study. Gastroenterology1990;99(6):1736‐44. [PUBMED: 1699835] PlanasR , LlachJ , GinèsP , PanésJ , VargasV , SalmeronJM , et al. Albumin versus dextran‐70 in cirrhotics with tense ascites treated with total paracentesis. Final results of a multicenter randomized comparative study. Journal of Hepatology1990;11(Suppl 2):S49. ">Planas 1990</a>; <a href="./references#CD004039-bbs2-0025" title="SmartHL , TrigerDR . A randomised prospective trial comparing daily paracentesis and intravenous albumin with recirculation in diuretic refractory ascites. Journal of Hepatology1990;10(2):191‐7. [PUBMED: 2185298] ">Smart 1990</a>; <a href="./references#CD004039-bbs2-0005" title="BertránX , Fernández‐BañaresF , PlanasF , CabréE , MorillasR , DeLeónR , et al. Effect on the nutritional status of total paracentesis plus albumin or dextran‐70 i.v. infusion for the treatment of tense ascites in liver cirrhosis [Repercusión sobre el estado nutricional energético‐proteico de la paracentesis total asociada a la infusión de albúmina o dextano‐70 en el tratamiento de la ascitis a tensión en la cirrhosis hepática]. Revista Espanola de Enfermedades Digestivas1991;79(5):320‐4. ">Bertrán 1991</a>; <a href="./references#CD004039-bbs2-0023" title="SalernoF , BadalamentiS , LorenzanoE , MoserP , IncertiP . Randomized comparative study of hemaccel vs albumin infusion after total paracentesis in cirrhotic patients with refractory ascites. Hepatology1991;13(4):707‐13. [PUBMED: 1826281] ">Salerno 1991</a>; <a href="./references#CD004039-bbs2-0024" title="RinaldiF , SimonettiRG , MaisanoS , DinoO , MilazzoG , LucaA , et al. Refractory ascites in cirrhosis: treatment with total paracentesis and reinfusion of filtrated and concentrated ascitic fluid. Italian Journal of Gastroenterology1990;22(4):261. SimonettiRG , RinaldiF , MilazzoG , DinoO , MaisanoS , LucaA , et al. Treatment of refractory ascites: a randomized prospective trial of total paracentesis with concentrated ascitic fluid reinfusion vs repeated paracentesis and albumin infusion. Italian Journal of Gastroenterology1991;23(7):473. ">Simonetti 1991</a>; <a href="./references#CD004039-bbs2-0006" title="BrunoS , BorzioM , RomagnoniM , BattezzatiPM , RossiS , ChiesaA , et al. Comparison of spontaneous ascites filtration and reinfusion with total paracentesis with intravenous albumin infusion in cirrhotic patients with tense ascites. BMJ1992;304:1655‐8. [PUBMED: 1633517] BrunoS , BorzioM , RomagnoniM , ChiesaA , RossiS , PavesiS , et al. Spontaneous ascites filtration and reinfusion (SAFR) vs total paracentesis (TP) with i.v. albumin infusion in cirrhotic patients with tense ascites. Hepatology1990;12:855. ">Bruno 1992</a>; <a href="./references#CD004039-bbs2-0009" title="FassioE , TergR , LandeiraG , AbecasisR , SalemneM , PodestaA , et al. Paracentesis with dextran 70 vs paracentesis with albumin in cirrhosis with tense ascites. Results of a randomized study. Journal of Hepatology1992;14(2‐3):310‐6. [PUBMED: 1380024] ">Fassio 1992</a>; <a href="./references#CD004039-bbs2-0015" title="Hernández PérezRE , Aguilar RamírezJR , Hernández LopezJM , Gómez Maganday Silva T . Total paracentesis and infusion of dextran 70 vs albumin in cirrhotic patients with tense ascites [Paracentesis masiva con reposición de dextran 70 vs albúmina en pacientes cirróticos con ascitis a tensión]. Revista de Gastroenterologia de Mexico1995;60(1):22‐6. [PUBMED: 7543691] ">Hernández Pérez 1995</a>; <a href="./references#CD004039-bbs2-0013" title="GinèsA , Fernández‐EsparrachG , MonescilloA , VilaC , DomènechE , AbecasisR , et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology1996;111(4):1002‐10. [PUBMED: 8831595] International Group for the Study of Ascites in Cirrhosis. Comparison of albumin, dextran‐70 and hemaccel in the prevention of effective hypovolemia in cirrhotic patients with ascites treated with total paracentesis. A randomized multicenter study. Hepatology1995;22(4 Suppl):220A. ">Ginès 1996</a>; <a href="./references#CD004039-bbs2-0014" title="GraziottoA , RossaroL , InturriP , SalvagniniM . Reinfusion of concentrated ascitic fluid versus total paracentesis. A randomized prospective trial. Digestive Diseases and Sciences1997;42(8):1708‐14. [PUBMED: 9286238] ">Graziotto 1997</a>; <a href="./references#CD004039-bbs2-0003" title="AltmanC , BernardB , RoulotD , VitteR‐L , InkO . Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis. European Journal of Gastroenterology &amp; Hepatology1998;10:5‐10. [PUBMED: 9512946] ">Altman 1998</a>; <a href="./references#CD004039-bbs2-0016" title="KangKE , KimBH , DongSH , KimHJ , ChangYW , LeeJII , et al. The efficacy of hydroxyethyl starch as plasma expander in cirrhotic patients with tense ascites treated with large volume paracentesis. Korean Journal of Gastroenterology1998;31:651‐60. ">Kang 1998</a>; <a href="./references#CD004039-bbs2-0027" title="ZhaoJ , YuanC , WangD , LIX . Mannitolum infusion on cirrhotic patients with tense ascites treated by paracentesis. Chinese Medical Journal2000;113(1):27‐30. [PUBMED: 11775204] ">Zhao 2000</a>; <a href="./references#CD004039-bbs2-0026" title="Sola‐VeraJ , MinanaJ , SorianoG , GonzalezB , PlanellaM , Lopez‐BalaguerJM , et al. Expansion with saline vs albumin in cirrhotic patients with tense ascites treated with total paracentesis. Result of a prospective randomized study. Gastroenterologia y Hepatologia2001;24(2):90 A6. Sola‐VeraJ , MiñanaJ , RicartE , PlanellaM , GonzálezB , TorrasX , et al. Randomized trial comparing albumin and saline in the prevention of paracentesis‐induced circultory dysfunction in cirrhotic patients with ascites. Hepatology2003;37(5):1147‐53. [PUBMED: 12717396] ">Sola‐Vera 2003</a>; <a href="./references#CD004039-bbs2-0021" title="MoreauR , VallaD‐C , Durand‐ZaleskiI , BronowickiJ‐P , DurandF , ChaputJ‐C , et al. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trial. Liver International2006;26(1):46‐54. [PUBMED: 16420509] ">Moreau 2006</a>; <a href="./references#CD004039-bbs2-0001" title="Abdel‐KhalekEE , ArifS . Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients With liver cirrhosis and tense ascites after large‐volume paracentesis. Journal of Hepatology2010;52:S327. Abdel‐KhalekEE , ArifSE . Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients with liver cirrhosis and tense ascites following large volume paracentesis. Arab Journal of Gastroenterology2010;11:24‐9. ">Abdel‐Khalek 2010</a>; <a href="./references#CD004039-bbs2-0017" title="KhanMU , RahimIU , LatifM . Hemaccel as a cheaper alternative to human albumin for plasma expansion during paracentesis in cirrhotic patients. Pakistan Journal of Medical and Health Sciences2015;9(3):948‐51. ">Khan 2015</a>). There was no evidence of a difference between experimental plasma expanders versus albumin in renal impairment (RR 1.17, 95% CI 0.71 to 1.91; 1107 participants; 17 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0039" title="">Analysis 7.3</a>; <a href="#CD004039-fig-0006">Figure 6</a>). Including the six trials with 0 events in Trial Sequential Analysis, renal impairment did not change significantly (RR 1.25, 95% CI 0.65 to 2.07; P = 0.39, D<sup>2</sup> = 0%) (<a href="./references#CD004039-bbs2-0006" title="BrunoS , BorzioM , RomagnoniM , BattezzatiPM , RossiS , ChiesaA , et al. Comparison of spontaneous ascites filtration and reinfusion with total paracentesis with intravenous albumin infusion in cirrhotic patients with tense ascites. BMJ1992;304:1655‐8. [PUBMED: 1633517] BrunoS , BorzioM , RomagnoniM , ChiesaA , RossiS , PavesiS , et al. Spontaneous ascites filtration and reinfusion (SAFR) vs total paracentesis (TP) with i.v. albumin infusion in cirrhotic patients with tense ascites. Hepatology1990;12:855. ">Bruno 1992</a>; <a href="./references#CD004039-bbs2-0014" title="GraziottoA , RossaroL , InturriP , SalvagniniM . Reinfusion of concentrated ascitic fluid versus total paracentesis. A randomized prospective trial. Digestive Diseases and Sciences1997;42(8):1708‐14. [PUBMED: 9286238] ">Graziotto 1997</a>; <a href="./references#CD004039-bbs2-0003" title="AltmanC , BernardB , RoulotD , VitteR‐L , InkO . Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis. European Journal of Gastroenterology &amp; Hepatology1998;10:5‐10. [PUBMED: 9512946] ">Altman 1998</a>; <a href="./references#CD004039-bbs2-0016" title="KangKE , KimBH , DongSH , KimHJ , ChangYW , LeeJII , et al. The efficacy of hydroxyethyl starch as plasma expander in cirrhotic patients with tense ascites treated with large volume paracentesis. Korean Journal of Gastroenterology1998;31:651‐60. ">Kang 1998</a>; <a href="./references#CD004039-bbs2-0027" title="ZhaoJ , YuanC , WangD , LIX . Mannitolum infusion on cirrhotic patients with tense ascites treated by paracentesis. Chinese Medical Journal2000;113(1):27‐30. [PUBMED: 11775204] ">Zhao 2000</a>; <a href="./references#CD004039-bbs2-0017" title="KhanMU , RahimIU , LatifM . Hemaccel as a cheaper alternative to human albumin for plasma expansion during paracentesis in cirrhotic patients. Pakistan Journal of Medical and Health Sciences2015;9(3):948‐51. ">Khan 2015</a>). </p> <div class="figure" id="CD004039-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 6 Experimental plasma expanders versus albumin, outcome: 6.3 Renal impairment." data-id="CD004039-fig-0006" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 6 Experimental plasma expanders versus albumin, outcome: 6.3 Renal impairment. </p> </div> </div> </div> <p>We assessed the certainty of the evidence with GRADE as very low. We downgraded the evidence by four levels because all trials were at high risk of bias; the required information size was not reached; and the funnel plot suggested publication bias (<a href="./full#CD004039-tbl-0002">summary of findings Table 2</a>; <a href="#CD004039-tbl-0006">Table 4</a>; <a href="#CD004039-fig-0006">Figure 6</a>). </p> <p>Trial Sequential Analysis of this comparison was based on a renal impairment proportion of 5% in the albumin group, a relative risk reduction of 10% with experimental plasma expanders, a type I error of 2.00%, and a type II error of 20% (80% power). There was no diversity (D<sup>2</sup> = 0%). The DARIS was 72,651 participants. The Trial Sequential Analysis program could not construct an interpretable figure due to too little information (1.52%) (figure not shown) and Trial Sequential Analysis‐adjusted CIs could not be calculated. </p> <section id="CD004039-sec-0143"> <h6 class="title">Subgroup analysis</h6> <p>We could not perform subgroup analysis of trials in terms of renal impairment according to their risk of bias because all the trials were at high risk. </p> <section id="CD004039-sec-0144"> <p><b>Type of plasma expanders</b></p> <p>The test for subgroup differences comparing the effects of different plasma expanders showed no difference (P = 0.88, I² = 0%; <a href="./references#CD004039-fig-0039" title="">Analysis 7.3</a>): trials assessing versus albumin: dextran (RR 0.85, 95% CI 0.34 to 2.08; 304 participants; 5 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0039" title="">Analysis 7.3</a>.1), hydroxyethyl starch (RR 1.01, 95% CI 0.06 to 15.90; 207 participants; 3 trials; I<sup>2</sup> not applicable because 2/3 trials had 0 events; <a href="./references#CD004039-fig-0039" title="">Analysis 7.3</a>.2), polygeline (RR 1.53, 95% CI 0.70 to 3.38; 319 participants; 4 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0039" title="">Analysis 7.3</a>.3), intravenous infusion of ascites (RR 0.90, 95% CI 0.22 to 3.62; 137 participants; 4 trials; I<sup>2</sup> = 24%; <a href="./references#CD004039-fig-0039" title="">Analysis 7.3</a>.4), and crystalloids (RR 1.59, 95% CI 0.28 to 8.93; 72 participants; 1 trial; <a href="./references#CD004039-fig-0039" title="">Analysis 7.3</a>.6). No events were observed in the only trial in which mannitol was assessed (<a href="./references#CD004039-bbs2-0027" title="ZhaoJ , YuanC , WangD , LIX . Mannitolum infusion on cirrhotic patients with tense ascites treated by paracentesis. Chinese Medical Journal2000;113(1):27‐30. [PUBMED: 11775204] ">Zhao 2000</a>) (<a href="./references#CD004039-fig-0039" title="">Analysis 7.3</a>.5). </p> </section> <section id="CD004039-sec-0145"> <p><b>Refractory ascites</b></p> <p>The test for subgroup differences comparing the trials including participants without refractory ascites to the trials with participants with refractory ascites showed no difference (P = 0.69, I² = 0%; <a href="./references#CD004039-fig-0046" title="">Analysis 8.2</a>): trials including participants without refractory ascites (RR 1.24, 95% CI 0.70 to 2.20; 816 participants; 12 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0046" title="">Analysis 8.2</a>.1) and trials including participants with refractory ascites (RR 0.98, 95% CI 0.37 to 2.65; 291 participants; 5 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0046" title="">Analysis 8.2</a>.2). </p> </section> <section id="CD004039-sec-0146"> <p><b>Modality of paracentesis</b></p> <p>The test for subgroup differences comparing different modality of paracentesis showed no difference (P = 0.99, I² = 0%; <a href="./references#CD004039-fig-0052" title="">Analysis 9.2</a>): trials in which partial paracentesis was used (RR 1.05, 95% CI 0.07 to 15.68; 169 participants; 3 trials; I<sup>2</sup> not applicable because 2/3 trials had 0 events; <a href="./references#CD004039-fig-0052" title="">Analysis 9.2</a>.1) and trials in which total paracentesis was used (RR 1.04, 95% CI 0.59 to 1.84; 870 participants; 13 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0052" title="">Analysis 9.2</a>.2). </p> </section> <section id="CD004039-sec-0147"> <p><b>Length of follow‐up</b></p> <p>The test for subgroup differences comparing different lengths of follow‐up showed no difference between subgroups (P = 0.98, I² = 0%; <a href="./references#CD004039-fig-0059" title="">Analysis 10.3</a>): trials with a follow‐up up to one month (RR 1.13, 95% CI 0.56 to 2.25; 551 participants; 8 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0059" title="">Analysis 10.3</a>.1) and trials with more than one month follow‐up (RR 1.14, 95% CI 0.58 to 2.22; 556 participants; 9 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0059" title="">Analysis 10.3</a>.2). </p> </section> <section id="CD004039-sec-0148"> <p><b>For‐profit support</b></p> <p>The test for subgroup differences comparing for‐profit support showed no difference between the two subgroups (P = 0.40, I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0065" title="">Analysis 11.2</a>). We found no evidence of a difference in renal impairment either in the subgroup of trials without for‐profit funding (RR 1.46, 95% CI 0.72 to 2.97; 357 participants; 6 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0065" title="">Analysis 11.2</a>.1) or in the subgroup of trials with or unknown for‐profit funding (RR 0.95, 95% CI 0.48 to 1.90; 750 participants; 11 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0065" title="">Analysis 11.2</a>.2). </p> </section> </section> </section> <section id="CD004039-sec-0149"> <h5 class="title">Other liver‐related complications</h5> <p>Other liver‐related complications were reported In 16 trials (<a href="./references#CD004039-bbs2-0022" title="PlanasR , GinèsP , ArroyoV , LlachJ , PanésJ , VargasV , et al. Dextran‐70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study. Gastroenterology1990;99(6):1736‐44. [PUBMED: 1699835] PlanasR , LlachJ , GinèsP , PanésJ , VargasV , SalmeronJM , et al. Albumin versus dextran‐70 in cirrhotics with tense ascites treated with total paracentesis. Final results of a multicenter randomized comparative study. Journal of Hepatology1990;11(Suppl 2):S49. ">Planas 1990</a>; <a href="./references#CD004039-bbs2-0025" title="SmartHL , TrigerDR . A randomised prospective trial comparing daily paracentesis and intravenous albumin with recirculation in diuretic refractory ascites. Journal of Hepatology1990;10(2):191‐7. [PUBMED: 2185298] ">Smart 1990</a>; <a href="./references#CD004039-bbs2-0005" title="BertránX , Fernández‐BañaresF , PlanasF , CabréE , MorillasR , DeLeónR , et al. Effect on the nutritional status of total paracentesis plus albumin or dextran‐70 i.v. infusion for the treatment of tense ascites in liver cirrhosis [Repercusión sobre el estado nutricional energético‐proteico de la paracentesis total asociada a la infusión de albúmina o dextano‐70 en el tratamiento de la ascitis a tensión en la cirrhosis hepática]. Revista Espanola de Enfermedades Digestivas1991;79(5):320‐4. ">Bertrán 1991</a>; <a href="./references#CD004039-bbs2-0023" title="SalernoF , BadalamentiS , LorenzanoE , MoserP , IncertiP . Randomized comparative study of hemaccel vs albumin infusion after total paracentesis in cirrhotic patients with refractory ascites. Hepatology1991;13(4):707‐13. [PUBMED: 1826281] ">Salerno 1991</a>; <a href="./references#CD004039-bbs2-0024" title="RinaldiF , SimonettiRG , MaisanoS , DinoO , MilazzoG , LucaA , et al. Refractory ascites in cirrhosis: treatment with total paracentesis and reinfusion of filtrated and concentrated ascitic fluid. Italian Journal of Gastroenterology1990;22(4):261. SimonettiRG , RinaldiF , MilazzoG , DinoO , MaisanoS , LucaA , et al. Treatment of refractory ascites: a randomized prospective trial of total paracentesis with concentrated ascitic fluid reinfusion vs repeated paracentesis and albumin infusion. Italian Journal of Gastroenterology1991;23(7):473. ">Simonetti 1991</a>; <a href="./references#CD004039-bbs2-0006" title="BrunoS , BorzioM , RomagnoniM , BattezzatiPM , RossiS , ChiesaA , et al. Comparison of spontaneous ascites filtration and reinfusion with total paracentesis with intravenous albumin infusion in cirrhotic patients with tense ascites. BMJ1992;304:1655‐8. [PUBMED: 1633517] BrunoS , BorzioM , RomagnoniM , ChiesaA , RossiS , PavesiS , et al. Spontaneous ascites filtration and reinfusion (SAFR) vs total paracentesis (TP) with i.v. albumin infusion in cirrhotic patients with tense ascites. Hepatology1990;12:855. ">Bruno 1992</a>; <a href="./references#CD004039-bbs2-0009" title="FassioE , TergR , LandeiraG , AbecasisR , SalemneM , PodestaA , et al. Paracentesis with dextran 70 vs paracentesis with albumin in cirrhosis with tense ascites. Results of a randomized study. Journal of Hepatology1992;14(2‐3):310‐6. [PUBMED: 1380024] ">Fassio 1992</a>; <a href="./references#CD004039-bbs2-0015" title="Hernández PérezRE , Aguilar RamírezJR , Hernández LopezJM , Gómez Maganday Silva T . Total paracentesis and infusion of dextran 70 vs albumin in cirrhotic patients with tense ascites [Paracentesis masiva con reposición de dextran 70 vs albúmina en pacientes cirróticos con ascitis a tensión]. Revista de Gastroenterologia de Mexico1995;60(1):22‐6. [PUBMED: 7543691] ">Hernández Pérez 1995</a>; <a href="./references#CD004039-bbs2-0013" title="GinèsA , Fernández‐EsparrachG , MonescilloA , VilaC , DomènechE , AbecasisR , et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology1996;111(4):1002‐10. [PUBMED: 8831595] International Group for the Study of Ascites in Cirrhosis. Comparison of albumin, dextran‐70 and hemaccel in the prevention of effective hypovolemia in cirrhotic patients with ascites treated with total paracentesis. A randomized multicenter study. Hepatology1995;22(4 Suppl):220A. ">Ginès 1996</a>; <a href="./references#CD004039-bbs2-0003" title="AltmanC , BernardB , RoulotD , VitteR‐L , InkO . Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis. European Journal of Gastroenterology &amp; Hepatology1998;10:5‐10. [PUBMED: 9512946] ">Altman 1998</a>; <a href="./references#CD004039-bbs2-0016" title="KangKE , KimBH , DongSH , KimHJ , ChangYW , LeeJII , et al. The efficacy of hydroxyethyl starch as plasma expander in cirrhotic patients with tense ascites treated with large volume paracentesis. Korean Journal of Gastroenterology1998;31:651‐60. ">Kang 1998</a>; <a href="./references#CD004039-bbs2-0027" title="ZhaoJ , YuanC , WangD , LIX . Mannitolum infusion on cirrhotic patients with tense ascites treated by paracentesis. Chinese Medical Journal2000;113(1):27‐30. [PUBMED: 11775204] ">Zhao 2000</a>; <a href="./references#CD004039-bbs2-0026" title="Sola‐VeraJ , MinanaJ , SorianoG , GonzalezB , PlanellaM , Lopez‐BalaguerJM , et al. Expansion with saline vs albumin in cirrhotic patients with tense ascites treated with total paracentesis. Result of a prospective randomized study. Gastroenterologia y Hepatologia2001;24(2):90 A6. Sola‐VeraJ , MiñanaJ , RicartE , PlanellaM , GonzálezB , TorrasX , et al. Randomized trial comparing albumin and saline in the prevention of paracentesis‐induced circultory dysfunction in cirrhotic patients with ascites. Hepatology2003;37(5):1147‐53. [PUBMED: 12717396] ">Sola‐Vera 2003</a>; <a href="./references#CD004039-bbs2-0021" title="MoreauR , VallaD‐C , Durand‐ZaleskiI , BronowickiJ‐P , DurandF , ChaputJ‐C , et al. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trial. Liver International2006;26(1):46‐54. [PUBMED: 16420509] ">Moreau 2006</a>; <a href="./references#CD004039-bbs2-0001" title="Abdel‐KhalekEE , ArifS . Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients With liver cirrhosis and tense ascites after large‐volume paracentesis. Journal of Hepatology2010;52:S327. Abdel‐KhalekEE , ArifSE . Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients with liver cirrhosis and tense ascites following large volume paracentesis. Arab Journal of Gastroenterology2010;11:24‐9. ">Abdel‐Khalek 2010</a>; <a href="./references#CD004039-bbs2-0017" title="KhanMU , RahimIU , LatifM . Hemaccel as a cheaper alternative to human albumin for plasma expansion during paracentesis in cirrhotic patients. Pakistan Journal of Medical and Health Sciences2015;9(3):948‐51. ">Khan 2015</a>). There was no evidence of a difference between experimental plasma expanders versus albumin in other liver‐related complications (RR 1.10, 95% CI 0.82 to 1.48; 1083 participants; 16 trials; I<sup>2</sup> = 19%; <a href="./references#CD004039-fig-0040" title="">Analysis 7.4</a>; <a href="#CD004039-fig-0007">Figure 7</a>). The effect of the interventions on the occurrence of other liver‐related complications did not change by including the four trials with zero events (<a href="./references#CD004039-bbs2-0006" title="BrunoS , BorzioM , RomagnoniM , BattezzatiPM , RossiS , ChiesaA , et al. Comparison of spontaneous ascites filtration and reinfusion with total paracentesis with intravenous albumin infusion in cirrhotic patients with tense ascites. BMJ1992;304:1655‐8. [PUBMED: 1633517] BrunoS , BorzioM , RomagnoniM , ChiesaA , RossiS , PavesiS , et al. Spontaneous ascites filtration and reinfusion (SAFR) vs total paracentesis (TP) with i.v. albumin infusion in cirrhotic patients with tense ascites. Hepatology1990;12:855. ">Bruno 1992</a>; <a href="./references#CD004039-bbs2-0015" title="Hernández PérezRE , Aguilar RamírezJR , Hernández LopezJM , Gómez Maganday Silva T . Total paracentesis and infusion of dextran 70 vs albumin in cirrhotic patients with tense ascites [Paracentesis masiva con reposición de dextran 70 vs albúmina en pacientes cirróticos con ascitis a tensión]. Revista de Gastroenterologia de Mexico1995;60(1):22‐6. [PUBMED: 7543691] ">Hernández Pérez 1995</a>; <a href="./references#CD004039-bbs2-0016" title="KangKE , KimBH , DongSH , KimHJ , ChangYW , LeeJII , et al. The efficacy of hydroxyethyl starch as plasma expander in cirrhotic patients with tense ascites treated with large volume paracentesis. Korean Journal of Gastroenterology1998;31:651‐60. ">Kang 1998</a>; <a href="./references#CD004039-bbs2-0017" title="KhanMU , RahimIU , LatifM . Hemaccel as a cheaper alternative to human albumin for plasma expansion during paracentesis in cirrhotic patients. Pakistan Journal of Medical and Health Sciences2015;9(3):948‐51. ">Khan 2015</a>) (RR 1.17, 95% CI 0.92 to 1.48; P = 0.20; D<sup>2</sup> = 0%). </p> <div class="figure" id="CD004039-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 6 Experimental plasma expanders versus albumin, outcome: 6.4 Other liver‐related complications." data-id="CD004039-fig-0007" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 6 Experimental plasma expanders versus albumin, outcome: 6.4 Other liver‐related complications. </p> </div> </div> </div> <p>We assessed the certainty of the evidence for this outcome as very low. We downgraded the evidence by four levels because all trials were at high risk of bias; there was imprecision: the required information size was not reached; and the funnel plot suggested publication bias (<a href="./full#CD004039-tbl-0002">summary of findings Table 2</a>; <a href="#CD004039-tbl-0006">Table 4</a>; <a href="#CD004039-fig-0007">Figure 7</a>). </p> <p>Trial Sequential Analysis of this comparison was based on an incidence of other liver‐related complications of 18.5% in the albumin group, a relative risk reduction of 10% with experimental plasma expanders, a type I error of 2.00%, and a type II error of 20% (80% power). There was no diversity (D<sup>2</sup> = 0%). The diversity‐adjusted required information size was 16,992 participants. In Trial Sequential Analysis, the accrued information fraction was too small to produce the inner wedge futility area. The cumulative Z curve (blue line) did not reach the monitoring boundary (red line) suggesting that the results were not stable to adjustments for sparse data and multiple testing (<a href="#CD004039-fig-0008">Figure 8</a>). </p> <div class="figure" id="CD004039-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Experimental plasma expander versus albumin ‐ 6.4 Other liver‐related complications.The diversity‐adjusted required information size of 16,992 participants was calculated based on a proportion of participants of 18.5% with other liver‐related complications in the control group; a relative risk reduction (RRR) of 10% in the plasma expander group; an alpha of 2.00%; a power of 80%; and a diversity of 0%.The cumulative Z score did not cross borders for benefit, harm, or futility." data-id="CD004039-fig-0008" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Experimental plasma expander versus albumin ‐ 6.4 Other liver‐related complications.</p> <p>The diversity‐adjusted required information size of 16,992 participants was calculated based on a proportion of participants of 18.5% with other liver‐related complications in the control group; a relative risk reduction (RRR) of 10% in the plasma expander group; an alpha of 2.00%; a power of 80%; and a diversity of 0%. </p> <p>The cumulative Z score did not cross borders for benefit, harm, or futility.</p> </div> </div> </div> <section id="CD004039-sec-0150"> <h6 class="title">Subgroup analysis</h6> <p>We could not perform subgroup analysis of trials according to the risk of bias because all the trials were assessed at high risk. </p> <section id="CD004039-sec-0151"> <p><b>Type of plasma expanders</b></p> <p>The test for subgroup differences comparing the effects of different plasma expanders versus albumin showed a difference (P = 0.09, I² = 47.9%; <a href="./references#CD004039-fig-0040" title="">Analysis 7.4</a>): dextran (RR 1.49, 95% CI 0.98 to 2.28; 304 participants; 5 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0040" title="">Analysis 7.4</a>.1); hydroxyethyl starch (RR 1.13, 95% CI 0.69 to 1.85; 207 participants; 3 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0040" title="">Analysis 7.4</a>.2); polygeline (RR 0.91, 95% CI 0.43 to 1.93; 319 participants; 4 trials; I<sup>2</sup> = 46%; <a href="./references#CD004039-fig-0040" title="">Analysis 7.4</a>.3); mannitol (RR 1.45, 95% CI 0.61 to 3.44; 68 participants; 1 trial; <a href="./references#CD004039-fig-0040" title="">Analysis 7.4</a>.5); and crystalloids (RR 1.06, 95% CI 0.16 to 7.10; 72 participants; 1 trial; <a href="./references#CD004039-fig-0040" title="">Analysis 7.4</a>.6)). Intravenous infusion of ascites reduced significantly other liver‐related complications in comparison with albumin (RR 0.23, 95% CI 0.07 to 0.73; 113 participants; 3 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0040" title="">Analysis 7.4</a>.4). </p> </section> <section id="CD004039-sec-0152"> <p><b>Refractory ascites</b></p> <p>The test for subgroup differences comparing separately the trials including participants without refractory ascites to trials including participants with refractory ascites showed a difference (P = 0.005, I² = 87%; <a href="./references#CD004039-fig-0047" title="">Analysis 8.3</a>): trials including participants without refractory ascites (RR 1.36, 95% CI 1.03 to 1.80; 766 participants; 12 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0047" title="">Analysis 8.3</a>.1) and in trials including participants with refractory ascites (RR 0.64, 95% CI 0.41 to 1.00; 267 participants; 4 trials; I<sup>2</sup> = 61%; <a href="./references#CD004039-fig-0047" title="">Analysis 8.3</a>.2). </p> </section> <section id="CD004039-sec-0153"> <p><b>Modality of paracentesis</b></p> <p>The test for subgroup differences comparing the effects of the experimental plasma expanders versus albumin in people treated by total compared to partial paracentesis showed no difference (P = 0.26, I² = 20.9%; <a href="./references#CD004039-fig-0053" title="">Analysis 9.3</a>): trials with partial paracentesis (RR 1.54, 95% CI 0.76 to 3.11; 169 participants; 3 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0053" title="">Analysis 9.3</a>.1) and trials with total paracentesis (RR 0.98, 95% CI 0.67 to 1.42; 864 participants; 13 trials; I<sup>2</sup> = 37%); <a href="./references#CD004039-fig-0053" title="">Analysis 9.3</a>.2)). </p> </section> <section id="CD004039-sec-0154"> <p><b>Length of follow‐up</b></p> <p>The test for subgroup differences comparing separately the trials with a short follow‐up to the trials with a long follow‐up showed no difference (P = 0.66, I² = 0%; <a href="./references#CD004039-fig-0060" title="">Analysis 10.4</a>): trials with up to one month follow‐up (RR 1.17, 95% CI 0.64 to 2.16; 501 participants; 7 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0060" title="">Analysis 10.4</a>.1) and trials with more than one month follow‐up (RR 0.99, 95% CI 0.65 to 1.53; 532 participants; 8 trials; I<sup>2</sup> = 50%; <a href="./references#CD004039-fig-0060" title="">Analysis 10.4</a>.2). </p> </section> <section id="CD004039-sec-0155"> <p><b>For‐profit support</b></p> <p>The test for subgroup differences comparing for‐profit support showed no difference between the two subgroups (P = 0.20, I<sup>2</sup> = 40.3%; <a href="./references#CD004039-fig-0066" title="">Analysis 11.3</a>). Experimental plasma expanders versus albumin led to more participants with other liver‐related complications in the subgroup of trials without for‐profit funding (RR 1.42, 95% CI 1.03 to 1.97; 357 participants; 6 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0066" title="">Analysis 11.3</a>.1). We found no evidence of a difference in the subgroup of trials with or unknown for‐profit funding (RR 1.02, 95% CI 0.69 to 1.50; 726 participants; 10 trials; I<sup>2</sup> = 7%; <a href="./references#CD004039-fig-0066" title="">Analysis 11.3</a>.2). </p> </section> </section> </section> <section id="CD004039-sec-0156"> <h5 class="title">Non‐serious adverse events</h5> <p>Non‐serious adverse events were reported in 14 trials (<a href="./references#CD004039-bbs2-0022" title="PlanasR , GinèsP , ArroyoV , LlachJ , PanésJ , VargasV , et al. Dextran‐70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study. Gastroenterology1990;99(6):1736‐44. [PUBMED: 1699835] PlanasR , LlachJ , GinèsP , PanésJ , VargasV , SalmeronJM , et al. Albumin versus dextran‐70 in cirrhotics with tense ascites treated with total paracentesis. Final results of a multicenter randomized comparative study. Journal of Hepatology1990;11(Suppl 2):S49. ">Planas 1990</a>; <a href="./references#CD004039-bbs2-0025" title="SmartHL , TrigerDR . A randomised prospective trial comparing daily paracentesis and intravenous albumin with recirculation in diuretic refractory ascites. Journal of Hepatology1990;10(2):191‐7. [PUBMED: 2185298] ">Smart 1990</a>; <a href="./references#CD004039-bbs2-0023" title="SalernoF , BadalamentiS , LorenzanoE , MoserP , IncertiP . Randomized comparative study of hemaccel vs albumin infusion after total paracentesis in cirrhotic patients with refractory ascites. Hepatology1991;13(4):707‐13. [PUBMED: 1826281] ">Salerno 1991</a>; <a href="./references#CD004039-bbs2-0024" title="RinaldiF , SimonettiRG , MaisanoS , DinoO , MilazzoG , LucaA , et al. Refractory ascites in cirrhosis: treatment with total paracentesis and reinfusion of filtrated and concentrated ascitic fluid. Italian Journal of Gastroenterology1990;22(4):261. SimonettiRG , RinaldiF , MilazzoG , DinoO , MaisanoS , LucaA , et al. Treatment of refractory ascites: a randomized prospective trial of total paracentesis with concentrated ascitic fluid reinfusion vs repeated paracentesis and albumin infusion. Italian Journal of Gastroenterology1991;23(7):473. ">Simonetti 1991</a>; <a href="./references#CD004039-bbs2-0006" title="BrunoS , BorzioM , RomagnoniM , BattezzatiPM , RossiS , ChiesaA , et al. Comparison of spontaneous ascites filtration and reinfusion with total paracentesis with intravenous albumin infusion in cirrhotic patients with tense ascites. BMJ1992;304:1655‐8. [PUBMED: 1633517] BrunoS , BorzioM , RomagnoniM , ChiesaA , RossiS , PavesiS , et al. Spontaneous ascites filtration and reinfusion (SAFR) vs total paracentesis (TP) with i.v. albumin infusion in cirrhotic patients with tense ascites. Hepatology1990;12:855. ">Bruno 1992</a>; <a href="./references#CD004039-bbs2-0015" title="Hernández PérezRE , Aguilar RamírezJR , Hernández LopezJM , Gómez Maganday Silva T . Total paracentesis and infusion of dextran 70 vs albumin in cirrhotic patients with tense ascites [Paracentesis masiva con reposición de dextran 70 vs albúmina en pacientes cirróticos con ascitis a tensión]. Revista de Gastroenterologia de Mexico1995;60(1):22‐6. [PUBMED: 7543691] ">Hernández Pérez 1995</a>; <a href="./references#CD004039-bbs2-0013" title="GinèsA , Fernández‐EsparrachG , MonescilloA , VilaC , DomènechE , AbecasisR , et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology1996;111(4):1002‐10. [PUBMED: 8831595] International Group for the Study of Ascites in Cirrhosis. Comparison of albumin, dextran‐70 and hemaccel in the prevention of effective hypovolemia in cirrhotic patients with ascites treated with total paracentesis. A randomized multicenter study. Hepatology1995;22(4 Suppl):220A. ">Ginès 1996</a>; <a href="./references#CD004039-bbs2-0014" title="GraziottoA , RossaroL , InturriP , SalvagniniM . Reinfusion of concentrated ascitic fluid versus total paracentesis. A randomized prospective trial. Digestive Diseases and Sciences1997;42(8):1708‐14. [PUBMED: 9286238] ">Graziotto 1997</a>; <a href="./references#CD004039-bbs2-0003" title="AltmanC , BernardB , RoulotD , VitteR‐L , InkO . Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis. European Journal of Gastroenterology &amp; Hepatology1998;10:5‐10. [PUBMED: 9512946] ">Altman 1998</a>; <a href="./references#CD004039-bbs2-0016" title="KangKE , KimBH , DongSH , KimHJ , ChangYW , LeeJII , et al. The efficacy of hydroxyethyl starch as plasma expander in cirrhotic patients with tense ascites treated with large volume paracentesis. Korean Journal of Gastroenterology1998;31:651‐60. ">Kang 1998</a>; <a href="./references#CD004039-bbs2-0027" title="ZhaoJ , YuanC , WangD , LIX . Mannitolum infusion on cirrhotic patients with tense ascites treated by paracentesis. Chinese Medical Journal2000;113(1):27‐30. [PUBMED: 11775204] ">Zhao 2000</a>; <a href="./references#CD004039-bbs2-0026" title="Sola‐VeraJ , MinanaJ , SorianoG , GonzalezB , PlanellaM , Lopez‐BalaguerJM , et al. Expansion with saline vs albumin in cirrhotic patients with tense ascites treated with total paracentesis. Result of a prospective randomized study. Gastroenterologia y Hepatologia2001;24(2):90 A6. Sola‐VeraJ , MiñanaJ , RicartE , PlanellaM , GonzálezB , TorrasX , et al. Randomized trial comparing albumin and saline in the prevention of paracentesis‐induced circultory dysfunction in cirrhotic patients with ascites. Hepatology2003;37(5):1147‐53. [PUBMED: 12717396] ">Sola‐Vera 2003</a>; <a href="./references#CD004039-bbs2-0021" title="MoreauR , VallaD‐C , Durand‐ZaleskiI , BronowickiJ‐P , DurandF , ChaputJ‐C , et al. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trial. Liver International2006;26(1):46‐54. [PUBMED: 16420509] ">Moreau 2006</a>; <a href="./references#CD004039-bbs2-0001" title="Abdel‐KhalekEE , ArifS . Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients With liver cirrhosis and tense ascites after large‐volume paracentesis. Journal of Hepatology2010;52:S327. Abdel‐KhalekEE , ArifSE . Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients with liver cirrhosis and tense ascites following large volume paracentesis. Arab Journal of Gastroenterology2010;11:24‐9. ">Abdel‐Khalek 2010</a>). There was no evidence of a difference between the experimental plasma expanders group versus the albumin group in other liver‐related complications (RR 1.37, 95% CI 0.66 to 2.85; 977 participants; 14 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0041" title="">Analysis 7.5</a>; <a href="#CD004039-fig-0009">Figure 9</a>). </p> <div class="figure" id="CD004039-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 6 Experimental plasma expanders versus albumin, outcome: 6.5 Non‐serious adverse events." data-id="CD004039-fig-0009" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-AFig-FIG09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 6 Experimental plasma expanders versus albumin, outcome: 6.5 Non‐serious adverse events. </p> </div> </div> </div> <p>Including the four trials with zero events produced a similar result (RR 0.92, 95% CI 0.36 to 2.35; P = 0.85; D<sup>2</sup> = 0%) (<a href="./references#CD004039-bbs2-0015" title="Hernández PérezRE , Aguilar RamírezJR , Hernández LopezJM , Gómez Maganday Silva T . Total paracentesis and infusion of dextran 70 vs albumin in cirrhotic patients with tense ascites [Paracentesis masiva con reposición de dextran 70 vs albúmina en pacientes cirróticos con ascitis a tensión]. Revista de Gastroenterologia de Mexico1995;60(1):22‐6. [PUBMED: 7543691] ">Hernández Pérez 1995</a>; <a href="./references#CD004039-bbs2-0013" title="GinèsA , Fernández‐EsparrachG , MonescilloA , VilaC , DomènechE , AbecasisR , et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology1996;111(4):1002‐10. [PUBMED: 8831595] International Group for the Study of Ascites in Cirrhosis. Comparison of albumin, dextran‐70 and hemaccel in the prevention of effective hypovolemia in cirrhotic patients with ascites treated with total paracentesis. A randomized multicenter study. Hepatology1995;22(4 Suppl):220A. ">Ginès 1996</a>; <a href="./references#CD004039-bbs2-0027" title="ZhaoJ , YuanC , WangD , LIX . Mannitolum infusion on cirrhotic patients with tense ascites treated by paracentesis. Chinese Medical Journal2000;113(1):27‐30. [PUBMED: 11775204] ">Zhao 2000</a>; <a href="./references#CD004039-bbs2-0026" title="Sola‐VeraJ , MinanaJ , SorianoG , GonzalezB , PlanellaM , Lopez‐BalaguerJM , et al. Expansion with saline vs albumin in cirrhotic patients with tense ascites treated with total paracentesis. Result of a prospective randomized study. Gastroenterologia y Hepatologia2001;24(2):90 A6. Sola‐VeraJ , MiñanaJ , RicartE , PlanellaM , GonzálezB , TorrasX , et al. Randomized trial comparing albumin and saline in the prevention of paracentesis‐induced circultory dysfunction in cirrhotic patients with ascites. Hepatology2003;37(5):1147‐53. [PUBMED: 12717396] ">Sola‐Vera 2003</a>). </p> <p>We assessed the level of certainty of the evidence for this outcome as very low. We downgraded the evidence by three levels because all trials were at high risk of bias; and there was imprecision: the required information size was not reached (<a href="./full#CD004039-tbl-0002">summary of findings Table 2</a>; <a href="#CD004039-tbl-0006">Table 4</a>). There was no publication bias (<a href="#CD004039-fig-0009">Figure 9</a>). </p> <p>Trial Sequential Analysis of this comparison was based on a non‐serious adverse event proportion of 2.5% in the albumin group, a relative risk reduction of 10% with experimental plasma expanders, a type I error of 2.00%, and a type II error of 20% (80% power). There was no diversity (D<sup>2</sup> = 0%). The diversity‐adjusted required information size was 148,925 participants. Due to the fact that only 977 participants were recruited (which is 0.65% of the diversity‐adjusted required information size of 148,925 participants), the Trial Sequential Analysis program could not construct an interpretable figure and could not calculate the Trial Sequential Analysis‐adjusted confidence intervals. </p> <section id="CD004039-sec-0157"> <h6 class="title">Subgroup analysis</h6> <p>We could not perform subgroup analysis of trials according to the risk of bias because all the trials were at high risk. </p> <section id="CD004039-sec-0158"> <p><b>Type of plasma expanders</b></p> <p>The test for subgroup differences comparing the effects of different plasma expanders versus albumin showed no difference (P = 0.66, I² = 0%; <a href="./references#CD004039-fig-0041" title="">Analysis 7.5</a>): trials assessing dextran (RR 0.48, 95% CI 0.04 to 5.08; 246 participants; 3 trials; I<sup>2</sup> not applicable because 2/3 trials had 0 events; <a href="./references#CD004039-fig-0041" title="">Analysis 7.5</a>.1); hydroxyethyl starch (RR 2.26, 95% CI 0.66 to 7.71; 207 participants; 3 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0041" title="">Analysis 7.5</a>.2); polygeline (RR 0.91, 95% CI 0.15 to 5.47; 277 participants; 3 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0041" title="">Analysis 7.5</a>.3); intravenous infusion of ascites (RR 1.54, 95% CI 0.41 to 5.71; 137 participants; 4 trials; I<sup>2</sup> = 14%; <a href="./references#CD004039-fig-0041" title="">Analysis 7.5</a>.4). No events were observed in the mannitol and in the crystalloids subgroups. </p> </section> <section id="CD004039-sec-0159"> <p><b>Refractory ascites</b></p> <p>The test for subgroup differences comparing separately the trials including participants without refractory ascites to trials including participants with refractory ascites showed no difference (P = 0.88, I² = 0%; <a href="./references#CD004039-fig-0048" title="">Analysis 8.4</a>): trials with participants without refractory ascites (RR 1.47, 95% CI 0.49 to 4.36; 686 participants; 10 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0048" title="">Analysis 8.4</a>.1) and trials with participants with refractory ascites (RR 1.30, 95% CI 0.49 to 3.47; 291 participants; 5 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0048" title="">Analysis 8.4</a>.2). </p> </section> <section id="CD004039-sec-0160"> <p><b>Modality of paracentesis</b></p> <p>The test for subgroup differences comparing the effects of experimental plasma expanders versus albumin in participants treated by partial or total paracentesis showed no difference (P = 0.21, I<sup>2</sup> = 37.3%; <a href="./references#CD004039-fig-0054" title="">Analysis 9.4</a>): trials in which partial paracentesis was performed (RR 8.50, 95% CI 0.46 to 157.71; 98 participants; 2 trials; I<sup>2</sup> not applicable because 1/2 trials had 0 events; <a href="./references#CD004039-fig-0054" title="">Analysis 9.4</a>.1) and trials in which total paracentesis was performed (RR 1.22, 95% CI 0.57 to 2.58; 879 participants; 13 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0054" title="">Analysis 9.4</a>.2). </p> </section> <section id="CD004039-sec-0161"> <p><b>Length of follow‐up</b></p> <p>The test for subgroup differences comparing the effects of experimental plasma expanders versus albumin in participants with a short (up to one month) follow‐up compared to a long follow‐up showed no difference (P = 0.26, I² = 22.6%; <a href="./references#CD004039-fig-0061" title="">Analysis 10.5</a>): trials with a short follow‐up (RR 2.20, 95% CI 0.73 to 6.59; participants 484; 6 trials; I<sup>2</sup> = 0; <a href="./references#CD004039-fig-0061" title="">Analysis 10.5</a>.1) and trials with a long follow‐up (RR 0.97, 95% CI 0.41 to 2.32; 493 participants; 8 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0061" title="">Analysis 10.5</a>.2). </p> </section> <section id="CD004039-sec-0162"> <p><b>For‐profit support</b></p> <p>The test for subgroup differences comparing for‐profit support showed no difference between the two subgroups (P = 0.27, I<sup>2</sup> = 18.2%; <a href="./references#CD004039-fig-0067" title="">Analysis 11.4</a>). We found no evidence of a difference in non‐serious adverse events either in the subgroup of trials without for‐profit funding (RR 0.62, 95% CI 0.12 to 3.05; 274 participants; 4 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0067" title="">Analysis 11.4</a>.1) or in the subgroup of trials with or unknown for‐profit funding (RR 1.70, 95% CI 0.75 to 3.85; 703 participants; 10 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0067" title="">Analysis 11.4</a>.2). </p> </section> </section> </section> </section> <section id="CD004039-sec-0163"> <h4 class="title">Exploratory outcomes</h4> <section id="CD004039-sec-0164"> <h5 class="title">Recurrence of ascites</h5> <p>Recurrence of ascites was reported in 12 trials (<a href="./references#CD004039-bbs2-0022" title="PlanasR , GinèsP , ArroyoV , LlachJ , PanésJ , VargasV , et al. Dextran‐70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study. Gastroenterology1990;99(6):1736‐44. [PUBMED: 1699835] PlanasR , LlachJ , GinèsP , PanésJ , VargasV , SalmeronJM , et al. Albumin versus dextran‐70 in cirrhotics with tense ascites treated with total paracentesis. Final results of a multicenter randomized comparative study. Journal of Hepatology1990;11(Suppl 2):S49. ">Planas 1990</a>; <a href="./references#CD004039-bbs2-0025" title="SmartHL , TrigerDR . A randomised prospective trial comparing daily paracentesis and intravenous albumin with recirculation in diuretic refractory ascites. Journal of Hepatology1990;10(2):191‐7. [PUBMED: 2185298] ">Smart 1990</a>; <a href="./references#CD004039-bbs2-0023" title="SalernoF , BadalamentiS , LorenzanoE , MoserP , IncertiP . Randomized comparative study of hemaccel vs albumin infusion after total paracentesis in cirrhotic patients with refractory ascites. Hepatology1991;13(4):707‐13. [PUBMED: 1826281] ">Salerno 1991</a>; <a href="./references#CD004039-bbs2-0024" title="RinaldiF , SimonettiRG , MaisanoS , DinoO , MilazzoG , LucaA , et al. Refractory ascites in cirrhosis: treatment with total paracentesis and reinfusion of filtrated and concentrated ascitic fluid. Italian Journal of Gastroenterology1990;22(4):261. SimonettiRG , RinaldiF , MilazzoG , DinoO , MaisanoS , LucaA , et al. Treatment of refractory ascites: a randomized prospective trial of total paracentesis with concentrated ascitic fluid reinfusion vs repeated paracentesis and albumin infusion. Italian Journal of Gastroenterology1991;23(7):473. ">Simonetti 1991</a>; <a href="./references#CD004039-bbs2-0009" title="FassioE , TergR , LandeiraG , AbecasisR , SalemneM , PodestaA , et al. Paracentesis with dextran 70 vs paracentesis with albumin in cirrhosis with tense ascites. Results of a randomized study. Journal of Hepatology1992;14(2‐3):310‐6. [PUBMED: 1380024] ">Fassio 1992</a>; <a href="./references#CD004039-bbs2-0020" title="MéndezC , SorianoG , GuarnerC , TomásA , MoyanoD , ToroH , et al. Total paracentesis in cirrhotics with refractory ascites: albumin vs HES as plasmatic expanders. Journal of Hepatology1991;13(Suppl 2):S145. ">Méndez 1991</a>; <a href="./references#CD004039-bbs2-0015" title="Hernández PérezRE , Aguilar RamírezJR , Hernández LopezJM , Gómez Maganday Silva T . Total paracentesis and infusion of dextran 70 vs albumin in cirrhotic patients with tense ascites [Paracentesis masiva con reposición de dextran 70 vs albúmina en pacientes cirróticos con ascitis a tensión]. Revista de Gastroenterologia de Mexico1995;60(1):22‐6. [PUBMED: 7543691] ">Hernández Pérez 1995</a>; <a href="./references#CD004039-bbs2-0003" title="AltmanC , BernardB , RoulotD , VitteR‐L , InkO . Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis. European Journal of Gastroenterology &amp; Hepatology1998;10:5‐10. [PUBMED: 9512946] ">Altman 1998</a>; <a href="./references#CD004039-bbs2-0027" title="ZhaoJ , YuanC , WangD , LIX . Mannitolum infusion on cirrhotic patients with tense ascites treated by paracentesis. Chinese Medical Journal2000;113(1):27‐30. [PUBMED: 11775204] ">Zhao 2000</a>; <a href="./references#CD004039-bbs2-0026" title="Sola‐VeraJ , MinanaJ , SorianoG , GonzalezB , PlanellaM , Lopez‐BalaguerJM , et al. Expansion with saline vs albumin in cirrhotic patients with tense ascites treated with total paracentesis. Result of a prospective randomized study. Gastroenterologia y Hepatologia2001;24(2):90 A6. Sola‐VeraJ , MiñanaJ , RicartE , PlanellaM , GonzálezB , TorrasX , et al. Randomized trial comparing albumin and saline in the prevention of paracentesis‐induced circultory dysfunction in cirrhotic patients with ascites. Hepatology2003;37(5):1147‐53. [PUBMED: 12717396] ">Sola‐Vera 2003</a>; <a href="./references#CD004039-bbs2-0021" title="MoreauR , VallaD‐C , Durand‐ZaleskiI , BronowickiJ‐P , DurandF , ChaputJ‐C , et al. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trial. Liver International2006;26(1):46‐54. [PUBMED: 16420509] ">Moreau 2006</a>; <a href="./references#CD004039-bbs2-0001" title="Abdel‐KhalekEE , ArifS . Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients With liver cirrhosis and tense ascites after large‐volume paracentesis. Journal of Hepatology2010;52:S327. Abdel‐KhalekEE , ArifSE . Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients with liver cirrhosis and tense ascites following large volume paracentesis. Arab Journal of Gastroenterology2010;11:24‐9. ">Abdel‐Khalek 2010</a>). Experimental plasma expanders had no effect in the recurrence of ascites in comparison with albumin (RR 1.14, 95% CI 0.96 to 1.36; 700 participants; 12 trials; I<sup>2</sup> = 8%; <a href="./references#CD004039-fig-0042" title="">Analysis 7.6</a>; <a href="#CD004039-fig-0010">Figure 10</a>). </p> <div class="figure" id="CD004039-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 6 Experimental plasma expanders versus albumin, outcome: 6.6 Recurrence of ascites." data-id="CD004039-fig-0010" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-AFig-FIG10.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 6 Experimental plasma expanders versus albumin, outcome: 6.6 Recurrence of ascites. </p> </div> </div> </div> <p>We assessed the level of certainty of the evidence with GRADE as very low. We downgraded the evidence by three levels because all trials were at high risk of bias; and there was imprecision: the required information size was not reached (<a href="#CD004039-tbl-0007">Table 5</a>; <a href="#CD004039-tbl-0008">Table 6</a>). There was no evidence of publication bias (<a href="#CD004039-fig-0010">Figure 10</a>). </p> <div class="table" id="CD004039-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Plasma expanders versus albumin for people with cirrhosis and large ascites treated with abdominal paracentesis: exploratory outcomes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Plasma expanders versus albumin for people with cirrhosis and large ascites treated with abdominal paracentesis: exploratory outcomes</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> cirrhotic participants with large ascites treated by paracentesis </p> <p><b>Settings:</b> specialised units in an intensive or semi‐intensive setting </p> <p><b>Intervention:</b> all plasma expanders except albumin </p> <p><b>Comparison:</b> albumin </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Albumin</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Experimental plasma expanders</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrence of ascites</b> </p> <p>mean follow‐up 169 days (5‐638)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.14</b> (0.96 to 1.36) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>700<br/> (12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>363 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>412 per 1000</b><br/> (348 to 493) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hypotension</b> </p> <p>follow‐up 6 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>88 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>239 per 1000</b><br/> (100 to 573) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.71</b> (1.13 to 6.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty of the evidence not assessed<br/> <sup><b>2</b> </sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Hyponatraemia</b> </p> <p>mean follow‐up 174 days (3‐638)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 1.49</b> (1.03 to 2.14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1107<br/> (17) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>73 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>108 per 1000</b><br/> (75 to 155) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Post‐paracentesis circulatory dysfunction</b> </p> <p>mean follow‐up 100 days (6‐288)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.98</b> (1.31 to 2.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>432<br/> (3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>148 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>294 per 1000</b><br/> (194 to 443) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>* <b>Assumed risk</b> is the risk in comparison group. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup> Downgraded 3 levels because of within study risk of bias: all trials were at high risk of bias (‐2 levels); imprecision: required information size as calculated by GRADE not reached (‐1 level)<br/> <sup>2</sup> Not evaluated because there was only one trial<br/> <sup>3</sup> Downgraded 4 levels because of within study risk of bias: all trials were at high risk of bias (‐2 levels); imprecision: the required information size as calculated by GRADE was not reached (‐1 level); publication bias(‐1 level)<br/> <sup>4</sup> Downgraded 3 levels because of within study risk of bias: all trials were at high risk of bias (‐2 levels); imprecision: the required information size as calculated by GRADE was not reached (‐1 level) </p> </div> </div> <div class="table" id="CD004039-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Comparison of imprecision by GRADE and Trial Sequential Analysis for the evaluation of exploratory outcomes in the comparison of plasma expanders versus albumin</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Comparison of imprecision evaluation with GRADE based on the GRADE Handbook, with GRADE based on authors' choice of plausible relative risk reduction and multiplicity correction, and according to our Trial Sequential Analysis with a similar choice of plausible relative risk reduction and multiplicity correction, in addition to considering the choice of meta‐analytic model and diversity</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion in control group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relative risk reduction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Alpha</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Beta</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Diversity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Required information size (OIS or DARIS)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Downgrading of evidence for imprecision based on required information size</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recurrence of ascites ‐‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>824</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recurrence of ascites ‐‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6882</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recurrence of ascites ‐‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension ‐‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4608</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension ‐‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39,712</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension ‐‐ TSA <sup>(1)</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyponatraemia ‐‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5602</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyponatraemia ‐‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48,618</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyponatraemia ‐‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48,620</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Post‐paracentesis circulatory dysfunction ‐‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2584</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Post‐paracentesis circulatory dysfunction ‐‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22,144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Post‐paracentesis circulatory dysfunction ‐‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22,146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One level</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>(1)</sup> TSA non calculated because there was only one trial </p> <p>OIS: optimal information size; DARIS: diversity‐adjusted required information size; RRR: relative risk reduction; TSA: Trial Sequential Analysis </p> </div> </div> <p>Trial Sequential Analysis of this comparison was based on a recurrence of ascites proportion of 36.3% in the albumin group, a relative risk reduction of 10% with experimental plasma expanders, a type I error of 2.00%, and a type II error of 20% (80% power). The diversity (D<sup>2</sup>) was 3%. The diversity‐adjusted required information size was 7104 participants. In Trial Sequential Analysis, the accrued information fraction was too small to produce an inner wedge futility area. The cumulative Z curve (blue line) did not approach the monitoring boundaries (red lines) for benefit or harm, demonstrating too few data (<a href="#CD004039-fig-0011">Figure 11</a>). </p> <div class="figure" id="CD004039-fig-0011"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 11</div> </div> <hr class="top"/><img alt="Experimental plasma expanders versus albumin ‐ 6.6 Recurrence of ascites.The diversity‐adjusted required information size of 7104 participants was calculated based on a proportion of participants of 36.3% of participants suffering recurrence of ascites in the control group; a relative risk reduction (RRR) of 10% in the plasma expander group; an alpha of 2%; a power of 80%; and a diversity of 3%.The cumulative Z score did not cross borders for benefit, harm, or futility." data-id="CD004039-fig-0011" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-AFig-FIG11.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Experimental plasma expanders versus albumin ‐ 6.6 Recurrence of ascites.</p> <p>The diversity‐adjusted required information size of 7104 participants was calculated based on a proportion of participants of 36.3% of participants suffering recurrence of ascites in the control group; a relative risk reduction (RRR) of 10% in the plasma expander group; an alpha of 2%; a power of 80%; and a diversity of 3%. </p> <p>The cumulative Z score did not cross borders for benefit, harm, or futility.</p> </div> </div> </div> <section id="CD004039-sec-0165"> <h6 class="title">Subgroup analysis</h6> <p>We could not perform subgroup analysis of trials according to the risk of bias because all the trials were at high risk of bias. </p> <section id="CD004039-sec-0166"> <p><b>Type of plasma expanders</b></p> <p>The test for subgroup differences comparing the effects of different plasma expanders versus albumin showed no differences between subgroups (P = 0.56, I² = 0%; <a href="./references#CD004039-fig-0042" title="">Analysis 7.6</a>): trials assessing dextran (RR 0.85, 95% CI 0.53 to 1.37; 145 participants; 3 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0042" title="">Analysis 7.6</a>.1); polygeline (RR 1.03, 95% CI 0.69 to 1.54; 122 participants; 2 trials; I<sup>2</sup> = 38%; <a href="./references#CD004039-fig-0042" title="">Analysis 7.6</a>.3); intravenous infusion of ascites (RR 1.03, 95% CI 0.46 to 2.34; 78 participants; 2 trials; I<sup>2</sup> = 79%; <a href="./references#CD004039-fig-0042" title="">Analysis 7.6</a>.4); mannitol (RR 0.90, 95% CI 0.26 to 3.07; 68 participants; <a href="./references#CD004039-fig-0042" title="">Analysis 7.6</a>.5); and crystalloids (RR 1.16, 95% CI 0.57 to 2.39; 72 participants; <a href="./references#CD004039-fig-0042" title="">Analysis 7.6</a>.6). Hydroxyethyl starch increased the risk of recurrence of ascites in comparison with albumin (RR 1.49, 95% CI 1.03 to 2.15; 215 participants; 3 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0042" title="">Analysis 7.6</a>.2). </p> </section> <section id="CD004039-sec-0167"> <p><b>Refractory ascites</b></p> <p>The test for subgroup differences comparing the trials including participants without refractory ascites to trials including participants with refractory ascites did not show differences (P = 0.70, I² = 0%; <a href="./references#CD004039-fig-0049" title="">Analysis 8.5</a>): participants without refractory ascites (RR 1.10, 95% CI 0.90 to 1.35; 487 participants; 9 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0049" title="">Analysis 8.5</a>.1) and participants with refractory ascites (RR 1.19, 95% CI 0.86 to 1.66; 235 participants; 4 trials; I<sup>2</sup> = 30%; <a href="./references#CD004039-fig-0049" title="">Analysis 8.5</a>.2). </p> </section> <section id="CD004039-sec-0168"> <p><b>Modality of paracentesis</b></p> <p>The test for subgroup difference comparing the effects of experimental plasma expanders versus albumin in people treated by partial or total paracentesis showed no differences (P = 0.60, I² = 0%; <a href="./references#CD004039-fig-0055" title="">Analysis 9.5</a>): participants treated by partial paracentesis (RR 1.28, 95% CI 0.72 to 2.26; 169 participants; 3 trials; I<sup>2</sup> = 0%, <a href="./references#CD004039-fig-0055" title="">Analysis 9.5</a>.1) and participants treated by total paracentesis (RR 1.09, 95% CI 0.91 to 1.30; 533 participants; 9 trials; I<sup>2</sup> = 8%; <a href="./references#CD004039-fig-0055" title="">Analysis 9.5</a>.2). </p> </section> <section id="CD004039-sec-0169"> <p><b>Length of follow‐up</b></p> <p>The test for subgroup differences comparing the effects of experimental plasma expanders versus albumin in participants with a short (up to one month) follow‐up compared to a long (more than one month) follow‐up showed a difference between the subgroups (P = 0.03, I² = 77.9%; <a href="./references#CD004039-fig-0062" title="">Analysis 10.6</a>): trials with a short follow‐up (RR 2.07, 95% CI 1.12 to 3.83; 96 participants; 3 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0062" title="">Analysis 10.6</a>.1) and trials with a follow‐up longer than one month (RR 1.03, 95% CI 0.86 to 1.24; 606 participants; 9 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0062" title="">Analysis 10.6</a>.2). </p> </section> <section id="CD004039-sec-0170"> <p><b>For‐profit support</b></p> <p>The test for subgroup differences comparing for‐profit support showed no difference between the two subgroups (P = 0.87, I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0068" title="">Analysis 11.5</a>). We found no evidence of difference in recurrence of ascites either in the subgroup of trials without for‐profit funding (RR 1.16, 95% CI 0.96 to 1.42; 307 participants; 5 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0068" title="">Analysis 11.5</a>.1) or in the subgroup of trials with or unknown for‐profit funding (RR 1.13, 95% CI 0.79 to 1.60; 393 participants; 7 trials; I<sup>2</sup> = 28%; <a href="./references#CD004039-fig-0068" title="">Analysis 11.5</a>.2). </p> </section> </section> </section> <section id="CD004039-sec-0171"> <h5 class="title">Hypotension</h5> <p>One trial mentioned clinical hypotension that was more frequent in the hydroxyethyl starch group (16/67 participants, 24%) than in the albumin group (6/68 participants, 8%) (P = 0.02) (<a href="./references#CD004039-bbs2-0001" title="Abdel‐KhalekEE , ArifS . Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients With liver cirrhosis and tense ascites after large‐volume paracentesis. Journal of Hepatology2010;52:S327. Abdel‐KhalekEE , ArifSE . Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients with liver cirrhosis and tense ascites following large volume paracentesis. Arab Journal of Gastroenterology2010;11:24‐9. ">Abdel‐Khalek 2010</a>) (<a href="#CD004039-tbl-0007">Table 5</a>; <a href="#CD004039-tbl-0008">Table 6</a>). </p> </section> <section id="CD004039-sec-0172"> <h5 class="title">Hyponatraemia</h5> <p>Hyponatraemia was reported in seventeen trials (<a href="./references#CD004039-bbs2-0022" title="PlanasR , GinèsP , ArroyoV , LlachJ , PanésJ , VargasV , et al. Dextran‐70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study. Gastroenterology1990;99(6):1736‐44. [PUBMED: 1699835] PlanasR , LlachJ , GinèsP , PanésJ , VargasV , SalmeronJM , et al. Albumin versus dextran‐70 in cirrhotics with tense ascites treated with total paracentesis. Final results of a multicenter randomized comparative study. Journal of Hepatology1990;11(Suppl 2):S49. ">Planas 1990</a>; <a href="./references#CD004039-bbs2-0025" title="SmartHL , TrigerDR . A randomised prospective trial comparing daily paracentesis and intravenous albumin with recirculation in diuretic refractory ascites. Journal of Hepatology1990;10(2):191‐7. [PUBMED: 2185298] ">Smart 1990</a>; <a href="./references#CD004039-bbs2-0005" title="BertránX , Fernández‐BañaresF , PlanasF , CabréE , MorillasR , DeLeónR , et al. Effect on the nutritional status of total paracentesis plus albumin or dextran‐70 i.v. infusion for the treatment of tense ascites in liver cirrhosis [Repercusión sobre el estado nutricional energético‐proteico de la paracentesis total asociada a la infusión de albúmina o dextano‐70 en el tratamiento de la ascitis a tensión en la cirrhosis hepática]. Revista Espanola de Enfermedades Digestivas1991;79(5):320‐4. ">Bertrán 1991</a>; <a href="./references#CD004039-bbs2-0023" title="SalernoF , BadalamentiS , LorenzanoE , MoserP , IncertiP . Randomized comparative study of hemaccel vs albumin infusion after total paracentesis in cirrhotic patients with refractory ascites. Hepatology1991;13(4):707‐13. [PUBMED: 1826281] ">Salerno 1991</a>; <a href="./references#CD004039-bbs2-0024" title="RinaldiF , SimonettiRG , MaisanoS , DinoO , MilazzoG , LucaA , et al. Refractory ascites in cirrhosis: treatment with total paracentesis and reinfusion of filtrated and concentrated ascitic fluid. Italian Journal of Gastroenterology1990;22(4):261. SimonettiRG , RinaldiF , MilazzoG , DinoO , MaisanoS , LucaA , et al. Treatment of refractory ascites: a randomized prospective trial of total paracentesis with concentrated ascitic fluid reinfusion vs repeated paracentesis and albumin infusion. Italian Journal of Gastroenterology1991;23(7):473. ">Simonetti 1991</a>; <a href="./references#CD004039-bbs2-0006" title="BrunoS , BorzioM , RomagnoniM , BattezzatiPM , RossiS , ChiesaA , et al. Comparison of spontaneous ascites filtration and reinfusion with total paracentesis with intravenous albumin infusion in cirrhotic patients with tense ascites. BMJ1992;304:1655‐8. [PUBMED: 1633517] BrunoS , BorzioM , RomagnoniM , ChiesaA , RossiS , PavesiS , et al. Spontaneous ascites filtration and reinfusion (SAFR) vs total paracentesis (TP) with i.v. albumin infusion in cirrhotic patients with tense ascites. Hepatology1990;12:855. ">Bruno 1992</a>; <a href="./references#CD004039-bbs2-0009" title="FassioE , TergR , LandeiraG , AbecasisR , SalemneM , PodestaA , et al. Paracentesis with dextran 70 vs paracentesis with albumin in cirrhosis with tense ascites. Results of a randomized study. Journal of Hepatology1992;14(2‐3):310‐6. [PUBMED: 1380024] ">Fassio 1992</a>; <a href="./references#CD004039-bbs2-0015" title="Hernández PérezRE , Aguilar RamírezJR , Hernández LopezJM , Gómez Maganday Silva T . Total paracentesis and infusion of dextran 70 vs albumin in cirrhotic patients with tense ascites [Paracentesis masiva con reposición de dextran 70 vs albúmina en pacientes cirróticos con ascitis a tensión]. Revista de Gastroenterologia de Mexico1995;60(1):22‐6. [PUBMED: 7543691] ">Hernández Pérez 1995</a>; <a href="./references#CD004039-bbs2-0013" title="GinèsA , Fernández‐EsparrachG , MonescilloA , VilaC , DomènechE , AbecasisR , et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology1996;111(4):1002‐10. [PUBMED: 8831595] International Group for the Study of Ascites in Cirrhosis. Comparison of albumin, dextran‐70 and hemaccel in the prevention of effective hypovolemia in cirrhotic patients with ascites treated with total paracentesis. A randomized multicenter study. Hepatology1995;22(4 Suppl):220A. ">Ginès 1996</a>; <a href="./references#CD004039-bbs2-0014" title="GraziottoA , RossaroL , InturriP , SalvagniniM . Reinfusion of concentrated ascitic fluid versus total paracentesis. A randomized prospective trial. Digestive Diseases and Sciences1997;42(8):1708‐14. [PUBMED: 9286238] ">Graziotto 1997</a>; <a href="./references#CD004039-bbs2-0003" title="AltmanC , BernardB , RoulotD , VitteR‐L , InkO . Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis. European Journal of Gastroenterology &amp; Hepatology1998;10:5‐10. [PUBMED: 9512946] ">Altman 1998</a>; <a href="./references#CD004039-bbs2-0016" title="KangKE , KimBH , DongSH , KimHJ , ChangYW , LeeJII , et al. The efficacy of hydroxyethyl starch as plasma expander in cirrhotic patients with tense ascites treated with large volume paracentesis. Korean Journal of Gastroenterology1998;31:651‐60. ">Kang 1998</a>; <a href="./references#CD004039-bbs2-0027" title="ZhaoJ , YuanC , WangD , LIX . Mannitolum infusion on cirrhotic patients with tense ascites treated by paracentesis. Chinese Medical Journal2000;113(1):27‐30. [PUBMED: 11775204] ">Zhao 2000</a>; <a href="./references#CD004039-bbs2-0026" title="Sola‐VeraJ , MinanaJ , SorianoG , GonzalezB , PlanellaM , Lopez‐BalaguerJM , et al. Expansion with saline vs albumin in cirrhotic patients with tense ascites treated with total paracentesis. Result of a prospective randomized study. Gastroenterologia y Hepatologia2001;24(2):90 A6. Sola‐VeraJ , MiñanaJ , RicartE , PlanellaM , GonzálezB , TorrasX , et al. Randomized trial comparing albumin and saline in the prevention of paracentesis‐induced circultory dysfunction in cirrhotic patients with ascites. Hepatology2003;37(5):1147‐53. [PUBMED: 12717396] ">Sola‐Vera 2003</a>; <a href="./references#CD004039-bbs2-0021" title="MoreauR , VallaD‐C , Durand‐ZaleskiI , BronowickiJ‐P , DurandF , ChaputJ‐C , et al. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trial. Liver International2006;26(1):46‐54. [PUBMED: 16420509] ">Moreau 2006</a>; <a href="./references#CD004039-bbs2-0001" title="Abdel‐KhalekEE , ArifS . Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients With liver cirrhosis and tense ascites after large‐volume paracentesis. Journal of Hepatology2010;52:S327. Abdel‐KhalekEE , ArifSE . Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients with liver cirrhosis and tense ascites following large volume paracentesis. Arab Journal of Gastroenterology2010;11:24‐9. ">Abdel‐Khalek 2010</a>; <a href="./references#CD004039-bbs2-0017" title="KhanMU , RahimIU , LatifM . Hemaccel as a cheaper alternative to human albumin for plasma expansion during paracentesis in cirrhotic patients. Pakistan Journal of Medical and Health Sciences2015;9(3):948‐51. ">Khan 2015</a>). Hyponatraemia was more frequent in the experimental plasma expander group than in the albumin group (RR 1.49, 95% CI 1.03 to 2.14; 1107 participants; 17 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0043" title="">Analysis 7.7</a>; <a href="#CD004039-fig-0012">Figure 12</a>). </p> <div class="figure" id="CD004039-fig-0012"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 12</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 6 Experimental plasma expanders versus albumin, outcome: 6.7 Hyponatraemia." data-id="CD004039-fig-0012" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-AFig-FIG12.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 6 Experimental plasma expanders versus albumin, outcome: 6.7 Hyponatraemia. </p> </div> </div> </div> <p>Including the five trials with zero events (<a href="./references#CD004039-bbs2-0024" title="RinaldiF , SimonettiRG , MaisanoS , DinoO , MilazzoG , LucaA , et al. Refractory ascites in cirrhosis: treatment with total paracentesis and reinfusion of filtrated and concentrated ascitic fluid. Italian Journal of Gastroenterology1990;22(4):261. SimonettiRG , RinaldiF , MilazzoG , DinoO , MaisanoS , LucaA , et al. Treatment of refractory ascites: a randomized prospective trial of total paracentesis with concentrated ascitic fluid reinfusion vs repeated paracentesis and albumin infusion. Italian Journal of Gastroenterology1991;23(7):473. ">Simonetti 1991</a>; <a href="./references#CD004039-bbs2-0014" title="GraziottoA , RossaroL , InturriP , SalvagniniM . Reinfusion of concentrated ascitic fluid versus total paracentesis. A randomized prospective trial. Digestive Diseases and Sciences1997;42(8):1708‐14. [PUBMED: 9286238] ">Graziotto 1997</a>; <a href="./references#CD004039-bbs2-0016" title="KangKE , KimBH , DongSH , KimHJ , ChangYW , LeeJII , et al. The efficacy of hydroxyethyl starch as plasma expander in cirrhotic patients with tense ascites treated with large volume paracentesis. Korean Journal of Gastroenterology1998;31:651‐60. ">Kang 1998</a>; <a href="./references#CD004039-bbs2-0027" title="ZhaoJ , YuanC , WangD , LIX . Mannitolum infusion on cirrhotic patients with tense ascites treated by paracentesis. Chinese Medical Journal2000;113(1):27‐30. [PUBMED: 11775204] ">Zhao 2000</a>; <a href="./references#CD004039-bbs2-0017" title="KhanMU , RahimIU , LatifM . Hemaccel as a cheaper alternative to human albumin for plasma expansion during paracentesis in cirrhotic patients. Pakistan Journal of Medical and Health Sciences2015;9(3):948‐51. ">Khan 2015</a>), the result was similar (RR 1.45, 95% CI 1.00 to 2.09, P = 0.05). </p> <p>We assessed the certainty of the evidence for this outcome as very low. We downgraded the evidence by four levels because all trials were at high risk of bias; there was imprecision: the required information size was not reached; and there was publication bias (<a href="#CD004039-tbl-0007">Table 5</a>; <a href="#CD004039-tbl-0008">Table 6</a>; <a href="#CD004039-fig-0012">Figure 12</a>). </p> <p>Trial Sequential Analysis of this comparison was based on a hyponatraemia proportion of 7.3% in the albumin group, a relative risk reduction of 10% with experimental plasma expanders, a type I error of 2.00%, and a type II error of 20% (80% power). There was no diversity (D<sup>2</sup> = 0%). The diversity‐adjusted required information size was 48,620 participants. The Trial Sequential Monitoring boundary could not be constructed due to too little information (2.28%) (figure not shown). </p> <section id="CD004039-sec-0173"> <h6 class="title">Subgroup analysis</h6> <p>We could not perform subgroup analysis of trials according to the risk of bias because all the trials were at high risk of bias. </p> <section id="CD004039-sec-0174"> <p><b>Type of plasma expanders</b></p> <p>The test for subgroup differences comparing the effects of different plasma expanders showed no difference between the subgroups (P = 0.94, I² = 0%; <a href="./references#CD004039-fig-0043" title="">Analysis 7.7</a>). No evidence of a difference in hyponatraemia was reported in the trials assessing dextran (RR 1.44, 95% CI 0.81 to 2.58; 304 participants; 5 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0043" title="">Analysis 7.7</a>.1), hydroxyethyl starch (RR 1.87, 95% CI 0.40 to 8.69; 207 participants; 3 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0043" title="">Analysis 7.7</a>.2), polygeline (RR 1.43, 95% CI 0.83 to 2.46; 319 participants; 4 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0043" title="">Analysis 7.7</a>.3), intravenous infusion of ascites (RR 1.03, 95% CI 0.15 to 6.93; 137 participants; 4 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0043" title="">Analysis 7.7</a>.4), and crystalloids (RR 2.64, 95% CI 0.55 to 12.75; 72 participants; <a href="./references#CD004039-fig-0043" title="">Analysis 7.7</a>.6) versus albumin. No events occurred in the mannitol trial (<a href="./references#CD004039-bbs2-0027" title="ZhaoJ , YuanC , WangD , LIX . Mannitolum infusion on cirrhotic patients with tense ascites treated by paracentesis. Chinese Medical Journal2000;113(1):27‐30. [PUBMED: 11775204] ">Zhao 2000</a>) (<a href="./references#CD004039-fig-0043" title="">Analysis 7.7</a>.5). </p> </section> <section id="CD004039-sec-0175"> <p><b>Refractory ascites</b></p> <p>The test for subgroup differences comparing the trials including participants without refractory ascites to the trials including participants with refractory ascites did not show a difference between the subgroups (P = 0.74, I² = 0%; <a href="./references#CD004039-fig-0050" title="">Analysis 8.6</a>). In the trials including participants without refractory ascites, the experimental plasma expanders increased the risk of hyponatraemia in comparison with albumin (RR 1.53, 95% CI 1.03 to 2.27; P = 0.04; 816 participants; 13 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0050" title="">Analysis 8.6</a>.1). In the trials including participants with refractory ascites, no differences between the experimental plasma expanders and albumin were shown (RR 1.29, 95% CI 0.51 to 3.26; I<sup>2</sup> = 0%; 291 participants; 5 trials; <a href="./references#CD004039-fig-0050" title="">Analysis 8.6</a>.2). </p> </section> <section id="CD004039-sec-0176"> <p><b>Modality of paracentesis</b></p> <p>The test for subgroup differences comparing the effects of experimental plasma expanders versus albumin in participants treated by total compared to partial paracentesis showed no difference (P = 0.52, I² = 0%; <a href="./references#CD004039-fig-0056" title="">Analysis 9.6</a>). </p> <p>Experimental plasma expanders did not affect hyponatraemia in comparison with albumin in the trials in which partial paracentesis was used (RR 1.00, 95% CI 0.29 to 3.51; 169 participants; 3 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0056" title="">Analysis 9.6</a>.1). Experimental plasma expanders increased the risk of hyponatraemia in comparison with albumin in the trials in which total paracentesis was used (RR 1.54, 95% CI 1.05 to 2.26; 938 participants; 14 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0056" title="">Analysis 9.6</a>.2). </p> </section> <section id="CD004039-sec-0177"> <p><b>Length of follow‐up</b></p> <p>The test for subgroup differences comparing the effects of experimental plasma expanders versus albumin in people with a short (up to one month) follow‐up compared to a long follow‐up showed no difference (P = 0.56, I² = 0%; <a href="./references#CD004039-fig-0063" title="">Analysis 10.7</a>). Experimental plasma expanders versus albumin resulted in more participants with hyponatraemia in the trials with a short follow‐up (RR 1.64, 95% CI 1.01 to 2.68; 551 participants; 8 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0063" title="">Analysis 10.7</a>.1). No difference was found in the trials with more than one month of follow‐up (RR 1.31, 95% CI 0.76 to 2.28; 556 participants; 9 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0063" title="">Analysis 10.7</a>.2). </p> </section> <section id="CD004039-sec-0178"> <p><b>For‐profit support</b></p> <p>The test for subgroup differences comparing funding support showed no difference between the two subgroups (P = 0.99, I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0069" title="">Analysis 11.6</a>). We found no evidence of a difference in hyponatraemia either in the subgroup of trials without for‐profit funding (RR 1.48, 95% CI 0.79 to 2.77; 357 participants; 6 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0069" title="">Analysis 11.6</a>.1) or in the subgroup of trials with or unknown for‐profit funding (RR 1.49, 95% CI 0.95 to 2.34; 750 participants; 11 trials; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0069" title="">Analysis 11.6</a>.2). </p> </section> </section> </section> <section id="CD004039-sec-0179"> <h5 class="title">Post‐paracentesis circulatory dysfunction</h5> <p>Post‐paracentesis circulatory dysfunction was assessed in three trials including 432 participants (<a href="./references#CD004039-bbs2-0013" title="GinèsA , Fernández‐EsparrachG , MonescilloA , VilaC , DomènechE , AbecasisR , et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology1996;111(4):1002‐10. [PUBMED: 8831595] International Group for the Study of Ascites in Cirrhosis. Comparison of albumin, dextran‐70 and hemaccel in the prevention of effective hypovolemia in cirrhotic patients with ascites treated with total paracentesis. A randomized multicenter study. Hepatology1995;22(4 Suppl):220A. ">Ginès 1996</a>; <a href="./references#CD004039-bbs2-0026" title="Sola‐VeraJ , MinanaJ , SorianoG , GonzalezB , PlanellaM , Lopez‐BalaguerJM , et al. Expansion with saline vs albumin in cirrhotic patients with tense ascites treated with total paracentesis. Result of a prospective randomized study. Gastroenterologia y Hepatologia2001;24(2):90 A6. Sola‐VeraJ , MiñanaJ , RicartE , PlanellaM , GonzálezB , TorrasX , et al. Randomized trial comparing albumin and saline in the prevention of paracentesis‐induced circultory dysfunction in cirrhotic patients with ascites. Hepatology2003;37(5):1147‐53. [PUBMED: 12717396] ">Sola‐Vera 2003</a>; <a href="./references#CD004039-bbs2-0002" title="Al SebaeyA , Abdel‐RazekW , BassuniA , RewishaEA , KhalilM , WakedI , et al. Alternatives to albumin for prevention of paracentesis induced circulatory dysfunction (PICD) in cirrhosis. Hepatology2012;56(S1):915A. ">Al Sebaey 2012</a>). Post‐paracentesis circulatory dysfunction was more frequent in participants treated by experimental plasma expanders in comparison with albumin (RR 1.98, 95% CI 1.31 to 2.99; P = 0.001; I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0044" title="">Analysis 7.8</a>). </p> <p>We assessed the level of certainty of the evidence for this outcome as very low. We downgraded the evidence by three levels because all trials were at high risk of bias; and imprecision: the required information size was not reached (<a href="#CD004039-tbl-0007">Table 5</a>; <a href="#CD004039-tbl-0008">Table 6</a>). Trial Sequential Analysis of this comparison was based on a post‐paracentesis circulatory dysfunction proportion of 14.8% in the albumin group, a relative risk reduction of 10% with experimental plasma expanders, a type I error of 2.00%, and a type II error of 20% (80% power). There was no diversity (D<sup>2</sup> = 0%). The diversity‐adjusted required information size was 22,146 participants. The trial sequential monitoring boundary could not be constructed due to too little information (1.95%). </p> <section id="CD004039-sec-0180"> <h6 class="title">Subgroup analysis</h6> <p>We could not perform subgroup analysis of trials according to the risk of bias because all the trials were at high risk. In all three trials, the included participants were without refractory ascites and total paracentesis was used. So we could not perform subgroup analysis according to the presence of refractory ascites and to modality of paracentesis. Post‐paracentesis circulatory dysfunction by definition was assessed at six days after paracentesis. So we could not perform subgroup analysis according to length of follow‐up. </p> <section id="CD004039-sec-0181"> <p><b>Type of plasma expanders</b></p> <p>The test for subgroup differences comparing the effects of different plasma expanders showed no difference between the subgroups (P = 0.48; I² = 0%; <a href="./references#CD004039-fig-0044" title="">Analysis 7.8</a>). No evidence of a difference in post‐paracentesis circulatory dysfunction was reported in comparison with albumin in the trial assessing hydroxyethyl starch (RR 0.67, 95% CI 0.14 to 3.07; 75 participants; <a href="./references#CD004039-fig-0044" title="">Analysis 7.8</a>.2; <a href="./references#CD004039-bbs2-0002" title="Al SebaeyA , Abdel‐RazekW , BassuniA , RewishaEA , KhalilM , WakedI , et al. Alternatives to albumin for prevention of paracentesis induced circulatory dysfunction (PICD) in cirrhosis. Hepatology2012;56(S1):915A. ">Al Sebaey 2012</a>). In comparison with albumin, there was an increased risk for post‐paracentesis circulatory dysfunction in the trials evaluating dextran (RR 1.99, 95% CI 1.04 to 3.81; 142 participants; <a href="./references#CD004039-fig-0044" title="">Analysis 7.8</a>.1; <a href="./references#CD004039-bbs2-0013" title="GinèsA , Fernández‐EsparrachG , MonescilloA , VilaC , DomènechE , AbecasisR , et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology1996;111(4):1002‐10. [PUBMED: 8831595] International Group for the Study of Ascites in Cirrhosis. Comparison of albumin, dextran‐70 and hemaccel in the prevention of effective hypovolemia in cirrhotic patients with ascites treated with total paracentesis. A randomized multicenter study. Hepatology1995;22(4 Suppl):220A. ">Ginès 1996</a>), polygeline (RR 2.06, 95% CI 1.03 to 4.10; 147 participants; <a href="./references#CD004039-fig-0044" title="">Analysis 7.8</a>.3; <a href="./references#CD004039-bbs2-0013" title="GinèsA , Fernández‐EsparrachG , MonescilloA , VilaC , DomènechE , AbecasisR , et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology1996;111(4):1002‐10. [PUBMED: 8831595] International Group for the Study of Ascites in Cirrhosis. Comparison of albumin, dextran‐70 and hemaccel in the prevention of effective hypovolemia in cirrhotic patients with ascites treated with total paracentesis. A randomized multicenter study. Hepatology1995;22(4 Suppl):220A. ">Ginès 1996</a>), and crystalloids (RR 2.92, 95% CI 1.03 to 8.26; 68 participants; <a href="./references#CD004039-fig-0044" title="">Analysis 7.8</a>.4; <a href="./references#CD004039-bbs2-0026" title="Sola‐VeraJ , MinanaJ , SorianoG , GonzalezB , PlanellaM , Lopez‐BalaguerJM , et al. Expansion with saline vs albumin in cirrhotic patients with tense ascites treated with total paracentesis. Result of a prospective randomized study. Gastroenterologia y Hepatologia2001;24(2):90 A6. Sola‐VeraJ , MiñanaJ , RicartE , PlanellaM , GonzálezB , TorrasX , et al. Randomized trial comparing albumin and saline in the prevention of paracentesis‐induced circultory dysfunction in cirrhotic patients with ascites. Hepatology2003;37(5):1147‐53. [PUBMED: 12717396] ">Sola‐Vera 2003</a>). </p> </section> <section id="CD004039-sec-0182"> <p><b>For‐profit support</b></p> <p>The test for subgroup differences comparing funding support showed no difference between the two subgroups (P = 0.73, I<sup>2</sup> = 0%; <a href="./references#CD004039-fig-0070" title="">Analysis 11.7</a>). We found no evidence of a difference in post‐paracentesis circulatory dysfunction in the subgroup of trials without for‐profit funding (RR 1.56, 95% CI 0.37 to 6.51; 143 participants; 2 trials; I<sup>2</sup> = 59%; <a href="./references#CD004039-fig-0070" title="">Analysis 11.7</a>.1). Experimental plasma expander versus albumin resulted in more participants with post‐paracentesis circulatory dysfunction in the single trial with for‐profit funding (RR 2.02, 95% CI 1.26 to 3.24; 289 participants; <a href="./references#CD004039-fig-0070" title="">Analysis 11.7</a>.2). </p> </section> </section> </section> </section> <section id="CD004039-sec-0183"> <h4 class="title">Reinfusion of ascitic fluid versus polygeline</h4> <p>One trial including 10 participants per comparison group assessed intravenous infusion of ascitic fluid versus polygeline (<a href="./references#CD004039-bbs2-0019" title="MehtaNN , AbrahamP , AsharVJ , ShikareSS , SavantSS , KarnadDR , et al. Ascitic fluid filtration and intravenous infusion versus total‐volume paracentesis with infusion of plasma expander in cirrhosis with tense or intractable ascites. Indian Journal of Gastroenterology1998;17(3):93‐6. ">Mehta 1998</a>). No procedure‐related mortality was reported in the trial, but all‐cause mortality was not reported. The trial did not report data on serious adverse events, health‐related quality of life, renal impairment, hypotension, hyponatraemia, and post‐paracentesis circulatory dysfunction. There was one liver‐related complication (spontaneous bacterial peritonitis) in the intravenous infusion of ascitic fluid group, and no events occurred in the polygeline group (P = 1.00) (<a href="./references#CD004039-fig-0073" title="">Analysis 14.1</a>). Non‐serious adverse events were more frequent in the intravenous infusion of ascitic fluid group than in the polygeline group (7 and 0, respectively, P = 0.003) (<a href="./references#CD004039-fig-0074" title="">Analysis 14.2</a>). Recurrence of ascites was similar in both treatment groups (9 and 10, respectively, P = 1.00) (<a href="./references#CD004039-fig-0075" title="">Analysis 14.3</a>). </p> </section> <section id="CD004039-sec-0184"> <h4 class="title">Dextran versus polygeline</h4> <p><a href="./references#CD004039-bbs2-0013" title="GinèsA , Fernández‐EsparrachG , MonescilloA , VilaC , DomènechE , AbecasisR , et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology1996;111(4):1002‐10. [PUBMED: 8831595] International Group for the Study of Ascites in Cirrhosis. Comparison of albumin, dextran‐70 and hemaccel in the prevention of effective hypovolemia in cirrhotic patients with ascites treated with total paracentesis. A randomized multicenter study. Hepatology1995;22(4 Suppl):220A. ">Ginès 1996</a> assessed dextran (93 participants) versus polygeline (99 participants). There were no differences between the two treatments in mortality (4/93 (4%) versus 6/99 (6%) (P = 0.74)); renal impairment (8/93 (9%) versus 10/99 (10%) (P = 0.80)); other liver‐related complications (12/93 (13%) versus 9/99 (9%) (P = 0.48)); non‐serious adverse events (0/93 versus 1/99 (1%) (P = 1.00)); hyponatraemia (23/93 (25%) versus 19/99 (19%) (P = 0.38)); and post‐paracentesis circulatory dysfunction (34/93 (36%) versus 34/99 (34%) (P = 0.76). </p> </section> <section id="CD004039-sec-0185"> <h4 class="title">Comparison of imprecision with GRADE and with Trial Sequential Analysis</h4> <p>The optimal information size (OIS) obtained with GRADE based on the GRADE Handbook, and with GRADE based on authors' choice of plausible relative risk reduction (RRR), and the diversity‐adjusted required information size (DARIS) obtained by Trial Sequential Analysis (TSA) were not reached in any primary, secondary, and exploratory outcomes. The agreement in the evaluation of imprecision, obtained by the TSA and GRADE methods, was substantial. We reported the comparison of imprecision evaluation for the primary, secondary and exploratory outcomes in <a href="#CD004039-tbl-0003">Table 1</a>; <a href="#CD004039-tbl-0005">Table 3</a>; <a href="#CD004039-tbl-0006">Table 4</a>; <a href="#CD004039-tbl-0008">Table 6</a>. </p> </section> <section id="CD004039-sec-0186"> <h4 class="title">Number needed to treat for a beneficial outcome</h4> <p>Number needed to treat for a beneficial outcome (NNTB) was not calculated for each outcome because we judged it was useless to attempt to give an absolute measure of the effect based on a very low level of certainty. </p> </section> <section id="CD004039-sec-0187"> <h4 class="title">Data from the two trials not included in the meta‐analysis</h4> <p>In the <a href="./references#CD004039-bbs2-0011" title="García‐CompeánD , BlancP , LarreyD , DauresJ‐P , HirtzJ , MendozaE , et al. Treatment of cirrhotic tense ascites with dextran‐40 versus albumin associated with large volume paracentesis. A randomized controlled trial. Annals of Hepatology2002;1(1):29‐35. [PUBMED: 15114293] ">García‐Compeán 2002</a> trial, the authors reported outcomes referring to the number of paracentesis procedures (48 in dextran group and 48 in albumin group) and not to the number of included participants for each group. There were no deaths during the first hospitalisation, and 18 and 11, respectively during the follow‐up in the two groups. Recurrence was observed in 34 and 30 participants in each group. There were no differences between Dextran 40 and albumin in the number and type of complications: renal impairment; hyponatraemia; hyperkalaemia; and local haematoma. </p> <p>In the <a href="./references#CD004039-bbs2-0007" title="DegoricijaV , Zjacic‐RotkvicV , MaroutJ , SeferS , TroskotB . Clinical and neurohumoral response to posture, physical exercise, and ascites treatment in Child‐Pugh C liver cirrhosis: randomized prospective trial. Croatian Medical Journal2003;44(2):178‐86. [PUBMED: 12698509] DegoricijaV , Zjacic‐RotkvicV , TroskotB , ŠeferS . Postparacentesis neurohumoral changes and impairment of renal water excretion in Child‐Pugh C cirrhosis with and without volume replacement. Journal of Hepatology2001;34:51. ">Degoricija 2003</a> trial, it was not possible to extract numerical data on the outcomes of interest for the meta‐analysis. The authors reported that the different plasma expanders (albumin, fresh frozen plasma, or polygeline) after a single paracentesis of 6 L, associated with 24‐h bed rest before and after the procedure, did not induce significant changes in clinical measurements and laboratory parameters of hepatic and renal function, and plasma renin activity. No local complications related to the procedures were observed. </p> <p>We judged both the two trials to be at high risk of bias (<a href="#CD004039-fig-0002">Figure 2</a>). No data on benefit or harm were available. Thus, it was not possible to assess the certainty of the evidence. </p> </section> <section id="CD004039-sec-0188"> <h4 class="title">Adverse events reported in non‐randomised studies retrieved with the searches for this review </h4> <p>In the <a href="./references#CD004039-bbs2-0031" title="ZaakD , PaquetKJ , KuhnR . Prospective study comparing human albumin vs reinfusion of ultrafiltated‐ascitic fluid after total paracentesis in cirrhotic patients with tense ascites. Zeitschrift fur Gastroenterologie2001;39(1):5‐10. [PUBMED: 11215366] ">Zaak 2001</a> study, intravenous infusion of ascitic fluid was compared to albumin. Among the 14 participants treated by intravenous infusion of ascitic fluid, there were 11 deaths (78%), 8 complications (57%), 4 cases of hyponatraemia (28%), 1 case of renal impairment (7%), and 3 cases of hepatic encephalopathy (21%). Among the 21 participants treated with albumin, there were 16 deaths (76%), 3 cases of hyponatraemia (14%), 2 cases of renal impairment (9%), and 2 cases of hepatic encephalopathy (9%). </p> <p>In the <a href="./references#CD004039-bbs2-0030" title="NasrG , HassanA , AhmedS , SerwahA . Predictors of large volume paracentesis induced circulatory dysfunction in patients with massive hepatic ascites. Journal of Cardiovascular Disease Research2010;1(3):136‐44. [PUBMED: 21187868] ">Nasr 2010</a> study, Dextran 70 was compared to albumin. None of the study participants developed serious complications in the form of spontaneous bacterial peritonitis, sepsis, bleeding, or increase in the grade of hepatic encephalopathy until discharge after one week at least. </p> <section id="CD004039-sec-0189"> <h5 class="title">Adverse events reported in other studies with insufficient information on design, conduct, and results, retrieved with the searches for this review </h5> <p>Antillon and colleagues referred to a randomised trial comparing albumin infusion versus no plasma expander after large volume paracentesis in people with cirrhosis and refractory ascites in three publications (<a href="./references#CD004039-bbs2-0028" title="AntillonMR , RunyonBA , SteindelH , MontanoAA . Is albumin infusion needed after large volume paracentesis in patients with refractory ascites?. Gastroenterology1990;98:A565. ">Antillon 1990</a> ‐ abstract; <a href="./references#CD004039-bbs2-0029" title="AntillonMR , RunyonBA . Postparacentesis plasma expansion prevents asymptomatic laboratory abnormalities, but does it have any impact on morbidity or mortality?. Gastroenterology1991;101(5):1455‐7. [PUBMED: 1936822] ">Antillon 1991</a> ‐ letter of comment to the <a href="./references#CD004039-bbs2-0022" title="PlanasR , GinèsP , ArroyoV , LlachJ , PanésJ , VargasV , et al. Dextran‐70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study. Gastroenterology1990;99(6):1736‐44. [PUBMED: 1699835] PlanasR , LlachJ , GinèsP , PanésJ , VargasV , SalmeronJM , et al. Albumin versus dextran‐70 in cirrhotics with tense ascites treated with total paracentesis. Final results of a multicenter randomized comparative study. Journal of Hepatology1990;11(Suppl 2):S49. ">Planas 1990</a> trial; <a href="./references#CD004039-bbs2-0041" title="AntillonMR , RunyonBA . Extracorporeal ultrafiltration and intravenous reinfusion of ascitic fluid vs. large‐volume paracentesis: a randomised controlled trial. Hepatology1993;17(3):520‐2. [PUBMED: 8444427] ">Antillon 1993</a> ‐ comment to the <a href="./references#CD004039-bbs2-0006" title="BrunoS , BorzioM , RomagnoniM , BattezzatiPM , RossiS , ChiesaA , et al. Comparison of spontaneous ascites filtration and reinfusion with total paracentesis with intravenous albumin infusion in cirrhotic patients with tense ascites. BMJ1992;304:1655‐8. [PUBMED: 1633517] BrunoS , BorzioM , RomagnoniM , ChiesaA , RossiS , PavesiS , et al. Spontaneous ascites filtration and reinfusion (SAFR) vs total paracentesis (TP) with i.v. albumin infusion in cirrhotic patients with tense ascites. Hepatology1990;12:855. ">Bruno 1992</a> trial). In the abstract, they reported three deaths out of seven participants (43%) in the albumin group and two deaths out of seven participants (29%) in the no plasma expander group (<a href="./references#CD004039-bbs2-0028" title="AntillonMR , RunyonBA , SteindelH , MontanoAA . Is albumin infusion needed after large volume paracentesis in patients with refractory ascites?. Gastroenterology1990;98:A565. ">Antillon 1990</a>). In the letter of comment to <a href="./references#CD004039-bbs2-0022" title="PlanasR , GinèsP , ArroyoV , LlachJ , PanésJ , VargasV , et al. Dextran‐70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study. Gastroenterology1990;99(6):1736‐44. [PUBMED: 1699835] PlanasR , LlachJ , GinèsP , PanésJ , VargasV , SalmeronJM , et al. Albumin versus dextran‐70 in cirrhotics with tense ascites treated with total paracentesis. Final results of a multicenter randomized comparative study. Journal of Hepatology1990;11(Suppl 2):S49. ">Planas 1990</a>, Antillon reported that, in their "ongoing trial" including 28 participants, the one‐year survival was 45.0% in the albumin group and 41.6% in the no plasma expander group, and that the incidence of hepatorenal syndrome was 50% and 33% in the two groups, respectively (<a href="./references#CD004039-bbs2-0029" title="AntillonMR , RunyonBA . Postparacentesis plasma expansion prevents asymptomatic laboratory abnormalities, but does it have any impact on morbidity or mortality?. Gastroenterology1991;101(5):1455‐7. [PUBMED: 1936822] ">Antillon 1991</a>). However, they did not report the number of participants in each group. In the comment to the <a href="./references#CD004039-bbs2-0006" title="BrunoS , BorzioM , RomagnoniM , BattezzatiPM , RossiS , ChiesaA , et al. Comparison of spontaneous ascites filtration and reinfusion with total paracentesis with intravenous albumin infusion in cirrhotic patients with tense ascites. BMJ1992;304:1655‐8. [PUBMED: 1633517] BrunoS , BorzioM , RomagnoniM , ChiesaA , RossiS , PavesiS , et al. Spontaneous ascites filtration and reinfusion (SAFR) vs total paracentesis (TP) with i.v. albumin infusion in cirrhotic patients with tense ascites. Hepatology1990;12:855. ">Bruno 1992</a> trial, they referred to the trial again as "ongoing" without new results (<a href="./references#CD004039-bbs2-0041" title="AntillonMR , RunyonBA . Extracorporeal ultrafiltration and intravenous reinfusion of ascitic fluid vs. large‐volume paracentesis: a randomised controlled trial. Hepatology1993;17(3):520‐2. [PUBMED: 8444427] ">Antillon 1993</a>). No further information, requested by email and letter, was obtained from the authors. </p> </section> </section> <section id="CD004039-sec-0190"> <h4 class="title">Analyses not planned in the protocol</h4> <section id="CD004039-sec-0191"> <h5 class="title">Trials comparing different amounts of albumin</h5> <p>We assessed the effect of two different doses of albumin in a separate analysis: 4 g/L versus 8 g/L of removed ascites (<a href="./references#CD004039-bbs2-0040" title="AlessandriaC , EliaC , MazzabottaL , RissoA , AndrealliA , SpandraM , et al. Prevention of paracentesis‐induced circulatory dysfunction in cirrhosis: standard vs half albumin doses. A prospective, randomized, unblinded pilot study. Digestive and Liver Disease2011;43(11):881‐6. [PUBMED: 21741331] ">Alessandria 2011</a>) and 2 g/L versus 6 g/L of removed ascites (<a href="./references#CD004039-bbs2-0038" title="Al SebaeyA , RazekWA , BassuniA , KhalilM , RewishaE , WakedI . Low‐dose albumin is equally effective as standard dose albumin in preventing PICD following large volume paracentesis (LVP). Hepatology International2013;7 (Suppl 1):S451. ">Al Sebaey 2013</a>). </p> <p>The trial by <a href="./references#CD004039-bbs2-0040" title="AlessandriaC , EliaC , MazzabottaL , RissoA , AndrealliA , SpandraM , et al. Prevention of paracentesis‐induced circulatory dysfunction in cirrhosis: standard vs half albumin doses. A prospective, randomized, unblinded pilot study. Digestive and Liver Disease2011;43(11):881‐6. [PUBMED: 21741331] ">Alessandria 2011</a> assessed low versus high dose of albumin in 35 participants in each group. There were no differences in the doses administered to the two groups in terms of mortality (3 events in each group, P = 1.00); renal impairment (0 events in each group); other complications (4 and 5 events, respectively, P = 1.00); and hyponatraemia (3 and 2 respectively, P = 1.00). </p> <p>Post‐paracentesis circulatory dysfunction, assessed in the <a href="./references#CD004039-bbs2-0038" title="Al SebaeyA , RazekWA , BassuniA , KhalilM , RewishaE , WakedI . Low‐dose albumin is equally effective as standard dose albumin in preventing PICD following large volume paracentesis (LVP). Hepatology International2013;7 (Suppl 1):S451. ">Al Sebaey 2013</a> and <a href="./references#CD004039-bbs2-0040" title="AlessandriaC , EliaC , MazzabottaL , RissoA , AndrealliA , SpandraM , et al. Prevention of paracentesis‐induced circulatory dysfunction in cirrhosis: standard vs half albumin doses. A prospective, randomized, unblinded pilot study. Digestive and Liver Disease2011;43(11):881‐6. [PUBMED: 21741331] ">Alessandria 2011</a> trials, was similar between the two groups: 8/60 events in the low dose albumin group and 10/60 in high dose albumin group (RR 1.00, 95% CI 0.22 to 4.49; 120 participants; I<sup>2</sup> = 0) (forest‐plot not shown). </p> </section> <section id="CD004039-sec-0192"> <h5 class="title">Trials including participants with acute‐on‐chronic liver failure</h5> <p>One randomised clinical trial, published as abstracts (<a href="./references#CD004039-bbs2-0042" title="AroraV , MaiwallR , ThomasSS , RajanV , AliR , KumarG , et al. Albumin decreases the incidence of paracentesis induced circulatory dysfunction with less than 5 litres of ascitic tap in acute on chronic liver failure (ACLF) patients: randomized controlled trial (NCT02467348). Journal of Hepatology2018;68(S1):S42‐S43. ">Arora 2018a</a>; <a href="./references#CD004039-bbs2-0043" title="AroraV , MaiwallR , AliR , KumarG , ThomasSS , JainP , et al. Paracentesis induced circulatory dysfunction with modest paracentesis is reduced by albumin in acute‐on‐chronic liver failure: a randomized controlled trial (NCT02467348). Indian Journal of Gastroenterology2018;37(S1):A17. ">Arora 2018b</a>), compared albumin with no plasma expander after a single &lt; 5 L paracentesis in participants with acute‐on‐chronic liver failure (ACLF). </p> <p>Forty participants received albumin (8 g/L of ascitic fluid) and forty received no plasma expander. </p> <p>Albumin versus no plasma expansion reduced acute kidney injury (12/40 versus 25/40, P = 0.0067), hyponatraemia (9/40 versus 27/40, P = 0.0001), post‐paracentesis circulatory dysfunction (12/40 versus 28/40, P = 0.0007), but not hepatic encephalopathy (11/40 versus 20/40, P = 0.07). People without post‐paracentesis circulatory dysfunction (PPCD) had a higher mortality than people with PPCD (10/40 compared to 26/40, P = 0.0006). </p> <p>Acute‐on‐chronic liver failure has peculiar pathophysiological, clinical, and prognostic features (<a href="./references#CD004039-bbs2-0045" title="ArroyoV , MoreauR , KamathPS , JalanR , GinèsP , NevensF , et al. Acute‐on‐chronic liver failure in cirrhosis. Nature Reviews. Disease Primers2016;2:16041. [PUBMED: 27277335] ">Arroyo 2016</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD004039-sec-0193" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004039-sec-0193">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004039-sec-0250">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD004039-sec-0193"></div> <section id="CD004039-sec-0194"> <h3 class="title" id="CD004039-sec-0194">Summary of main results</h3> <p>The present systematic review with meta‐analyses assessed the role of plasma expanders after therapeutic paracentesis for large ascites in people with cirrhosis. The review aimed at answering two questions: whether plasma expanders are needed and whether there are differences between plasma expanders. </p> <p>Five trials, including 271 participants, compared plasma expanders versus no plasma expander. Albumin was used in four trials (<a href="./references#CD004039-bbs2-0012" title="GinèsP , TitóL , ArroyoV , PlanasR , PanésJ , ViverJ , et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology1988;94(6):1493‐1502. [PUBMED: 3360270] ">Ginès 1988</a>; <a href="./references#CD004039-bbs2-0010" title="García‐CompeánD , VillarealJZ , CuevasHB , CantúDAG , EstrellaM , TamezEG , et al. Total therapeutic paracentesis (TTP) with and without intravenous albumin in the treatment of cirrhotic tense ascites: a randomized controlled trial. Liver1993;13(5):233‐8. [PUBMED: 8259034] ">García‐Compeán 1993</a>; <a href="./references#CD004039-bbs2-0018" title="LucaA , García‐PagánJ , BoschJ , FeuF , JiménezW , GinésA , et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology1995;22(3):753‐8. [PUBMED: 7657279] ">Luca 1995</a>; <a href="./references#CD004039-bbs2-0004" title="BaikSK , KimHS , LeeDK , KimIH , KwonSO . Hemodynamic changes after single large volume paracentesis (SLVP) in cirrhosis with tense ascites ‐ focusing on the effect of albumin as plasma expander. Korean Journal of Medicine2000;58:276‐82. ">Baik 2000</a>). Intravenous infusion of concentrated or unmodified ascitic fluid was used in one trial (<a href="./references#CD004039-bbs2-0008" title="DescosL , GauthierA , LevyVG , MichelH , QuintonA , RueffB , et al. Comparison of six treatments of ascites in patients with liver cirrhosis. A clinical trial. Hepato‐gastroenterology1983;30:15‐20. [PUBMED: 6339343] ">Descos 1983</a>). Most of the trials were only designed to assess outcomes during hospitalisation. Two trials assessed immediate, within 1 to 2 days, haemodynamic changes after paracentesis (<a href="./references#CD004039-bbs2-0018" title="LucaA , García‐PagánJ , BoschJ , FeuF , JiménezW , GinésA , et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology1995;22(3):753‐8. [PUBMED: 7657279] ">Luca 1995</a>; <a href="./references#CD004039-bbs2-0004" title="BaikSK , KimHS , LeeDK , KimIH , KwonSO . Hemodynamic changes after single large volume paracentesis (SLVP) in cirrhosis with tense ascites ‐ focusing on the effect of albumin as plasma expander. Korean Journal of Medicine2000;58:276‐82. ">Baik 2000</a>). Only one trial reported follow‐up after discharge (<a href="./references#CD004039-bbs2-0012" title="GinèsP , TitóL , ArroyoV , PlanasR , PanésJ , ViverJ , et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology1988;94(6):1493‐1502. [PUBMED: 3360270] ">Ginès 1988</a>). </p> <p>We found very low‐certainty evidence that plasma expanders may make little or no difference to mortality. We found very low‐certainty evidence that plasma expanders may make little or no difference to serious adverse events, renal impairment, other liver‐related complications, non‐serious adverse events, recurrence of ascites, and hyponatraemia. We found very low‐certainty evidence that albumin decreases the risk of hyponatraemia in the subgroup of trials in which partial paracentesis was used, with a follow‐up more than one month, and without for‐profit funding. No evidence of a difference was detected for each of the other outcomes in subgroup analyses regarding the type of plasma expander, modality of paracentesis, or duration of follow‐up. No trials assessed health‐related quality of life, incidence of refractory ascites, or post‐paracentesis circulatory dysfunction. </p> <p>Twenty‐one trials, including 1291 participants, assessed different plasma expanders versus albumin (<a href="./references#CD004039-bbs2-0022" title="PlanasR , GinèsP , ArroyoV , LlachJ , PanésJ , VargasV , et al. Dextran‐70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study. Gastroenterology1990;99(6):1736‐44. [PUBMED: 1699835] PlanasR , LlachJ , GinèsP , PanésJ , VargasV , SalmeronJM , et al. Albumin versus dextran‐70 in cirrhotics with tense ascites treated with total paracentesis. Final results of a multicenter randomized comparative study. Journal of Hepatology1990;11(Suppl 2):S49. ">Planas 1990</a>; <a href="./references#CD004039-bbs2-0025" title="SmartHL , TrigerDR . A randomised prospective trial comparing daily paracentesis and intravenous albumin with recirculation in diuretic refractory ascites. Journal of Hepatology1990;10(2):191‐7. [PUBMED: 2185298] ">Smart 1990</a>; <a href="./references#CD004039-bbs2-0005" title="BertránX , Fernández‐BañaresF , PlanasF , CabréE , MorillasR , DeLeónR , et al. Effect on the nutritional status of total paracentesis plus albumin or dextran‐70 i.v. infusion for the treatment of tense ascites in liver cirrhosis [Repercusión sobre el estado nutricional energético‐proteico de la paracentesis total asociada a la infusión de albúmina o dextano‐70 en el tratamiento de la ascitis a tensión en la cirrhosis hepática]. Revista Espanola de Enfermedades Digestivas1991;79(5):320‐4. ">Bertrán 1991</a>; <a href="./references#CD004039-bbs2-0023" title="SalernoF , BadalamentiS , LorenzanoE , MoserP , IncertiP . Randomized comparative study of hemaccel vs albumin infusion after total paracentesis in cirrhotic patients with refractory ascites. Hepatology1991;13(4):707‐13. [PUBMED: 1826281] ">Salerno 1991</a>; <a href="./references#CD004039-bbs2-0024" title="RinaldiF , SimonettiRG , MaisanoS , DinoO , MilazzoG , LucaA , et al. Refractory ascites in cirrhosis: treatment with total paracentesis and reinfusion of filtrated and concentrated ascitic fluid. Italian Journal of Gastroenterology1990;22(4):261. SimonettiRG , RinaldiF , MilazzoG , DinoO , MaisanoS , LucaA , et al. Treatment of refractory ascites: a randomized prospective trial of total paracentesis with concentrated ascitic fluid reinfusion vs repeated paracentesis and albumin infusion. Italian Journal of Gastroenterology1991;23(7):473. ">Simonetti 1991</a>; <a href="./references#CD004039-bbs2-0006" title="BrunoS , BorzioM , RomagnoniM , BattezzatiPM , RossiS , ChiesaA , et al. Comparison of spontaneous ascites filtration and reinfusion with total paracentesis with intravenous albumin infusion in cirrhotic patients with tense ascites. BMJ1992;304:1655‐8. [PUBMED: 1633517] BrunoS , BorzioM , RomagnoniM , ChiesaA , RossiS , PavesiS , et al. Spontaneous ascites filtration and reinfusion (SAFR) vs total paracentesis (TP) with i.v. albumin infusion in cirrhotic patients with tense ascites. Hepatology1990;12:855. ">Bruno 1992</a>; <a href="./references#CD004039-bbs2-0009" title="FassioE , TergR , LandeiraG , AbecasisR , SalemneM , PodestaA , et al. Paracentesis with dextran 70 vs paracentesis with albumin in cirrhosis with tense ascites. Results of a randomized study. Journal of Hepatology1992;14(2‐3):310‐6. [PUBMED: 1380024] ">Fassio 1992</a>; <a href="./references#CD004039-bbs2-0020" title="MéndezC , SorianoG , GuarnerC , TomásA , MoyanoD , ToroH , et al. Total paracentesis in cirrhotics with refractory ascites: albumin vs HES as plasmatic expanders. Journal of Hepatology1991;13(Suppl 2):S145. ">Méndez 1991</a>; <a href="./references#CD004039-bbs2-0015" title="Hernández PérezRE , Aguilar RamírezJR , Hernández LopezJM , Gómez Maganday Silva T . Total paracentesis and infusion of dextran 70 vs albumin in cirrhotic patients with tense ascites [Paracentesis masiva con reposición de dextran 70 vs albúmina en pacientes cirróticos con ascitis a tensión]. Revista de Gastroenterologia de Mexico1995;60(1):22‐6. [PUBMED: 7543691] ">Hernández Pérez 1995</a>; <a href="./references#CD004039-bbs2-0013" title="GinèsA , Fernández‐EsparrachG , MonescilloA , VilaC , DomènechE , AbecasisR , et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology1996;111(4):1002‐10. [PUBMED: 8831595] International Group for the Study of Ascites in Cirrhosis. Comparison of albumin, dextran‐70 and hemaccel in the prevention of effective hypovolemia in cirrhotic patients with ascites treated with total paracentesis. A randomized multicenter study. Hepatology1995;22(4 Suppl):220A. ">Ginès 1996</a>; <a href="./references#CD004039-bbs2-0014" title="GraziottoA , RossaroL , InturriP , SalvagniniM . Reinfusion of concentrated ascitic fluid versus total paracentesis. A randomized prospective trial. Digestive Diseases and Sciences1997;42(8):1708‐14. [PUBMED: 9286238] ">Graziotto 1997</a>; <a href="./references#CD004039-bbs2-0003" title="AltmanC , BernardB , RoulotD , VitteR‐L , InkO . Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis. European Journal of Gastroenterology &amp; Hepatology1998;10:5‐10. [PUBMED: 9512946] ">Altman 1998</a>; <a href="./references#CD004039-bbs2-0016" title="KangKE , KimBH , DongSH , KimHJ , ChangYW , LeeJII , et al. The efficacy of hydroxyethyl starch as plasma expander in cirrhotic patients with tense ascites treated with large volume paracentesis. Korean Journal of Gastroenterology1998;31:651‐60. ">Kang 1998</a>; <a href="./references#CD004039-bbs2-0027" title="ZhaoJ , YuanC , WangD , LIX . Mannitolum infusion on cirrhotic patients with tense ascites treated by paracentesis. Chinese Medical Journal2000;113(1):27‐30. [PUBMED: 11775204] ">Zhao 2000</a>; <a href="./references#CD004039-bbs2-0011" title="García‐CompeánD , BlancP , LarreyD , DauresJ‐P , HirtzJ , MendozaE , et al. Treatment of cirrhotic tense ascites with dextran‐40 versus albumin associated with large volume paracentesis. A randomized controlled trial. Annals of Hepatology2002;1(1):29‐35. [PUBMED: 15114293] ">García‐Compeán 2002</a>; <a href="./references#CD004039-bbs2-0026" title="Sola‐VeraJ , MinanaJ , SorianoG , GonzalezB , PlanellaM , Lopez‐BalaguerJM , et al. Expansion with saline vs albumin in cirrhotic patients with tense ascites treated with total paracentesis. Result of a prospective randomized study. Gastroenterologia y Hepatologia2001;24(2):90 A6. Sola‐VeraJ , MiñanaJ , RicartE , PlanellaM , GonzálezB , TorrasX , et al. Randomized trial comparing albumin and saline in the prevention of paracentesis‐induced circultory dysfunction in cirrhotic patients with ascites. Hepatology2003;37(5):1147‐53. [PUBMED: 12717396] ">Sola‐Vera 2003</a>; <a href="./references#CD004039-bbs2-0021" title="MoreauR , VallaD‐C , Durand‐ZaleskiI , BronowickiJ‐P , DurandF , ChaputJ‐C , et al. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trial. Liver International2006;26(1):46‐54. [PUBMED: 16420509] ">Moreau 2006</a>; <a href="./references#CD004039-bbs2-0001" title="Abdel‐KhalekEE , ArifS . Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients With liver cirrhosis and tense ascites after large‐volume paracentesis. Journal of Hepatology2010;52:S327. Abdel‐KhalekEE , ArifSE . Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients with liver cirrhosis and tense ascites following large volume paracentesis. Arab Journal of Gastroenterology2010;11:24‐9. ">Abdel‐Khalek 2010</a>; <a href="./references#CD004039-bbs2-0002" title="Al SebaeyA , Abdel‐RazekW , BassuniA , RewishaEA , KhalilM , WakedI , et al. Alternatives to albumin for prevention of paracentesis induced circulatory dysfunction (PICD) in cirrhosis. Hepatology2012;56(S1):915A. ">Al Sebaey 2012</a>; <a href="./references#CD004039-bbs2-0017" title="KhanMU , RahimIU , LatifM . Hemaccel as a cheaper alternative to human albumin for plasma expansion during paracentesis in cirrhotic patients. Pakistan Journal of Medical and Health Sciences2015;9(3):948‐51. ">Khan 2015</a>) or versus another plasma expander (<a href="./references#CD004039-bbs2-0019" title="MehtaNN , AbrahamP , AsharVJ , ShikareSS , SavantSS , KarnadDR , et al. Ascitic fluid filtration and intravenous infusion versus total‐volume paracentesis with infusion of plasma expander in cirrhosis with tense or intractable ascites. Indian Journal of Gastroenterology1998;17(3):93‐6. ">Mehta 1998</a>). </p> <p>We found very low‐certainty evidence that experimental plasma expanders may make little or no difference to mortality. No evidence of a difference in mortality was found by analysing each experimental plasma expander (dextran, hydroxyethyl starch, polygeline, intravenous infusion of ascites, mannitol, saline solution) versus albumin. No evidence of a difference in mortality was found in the subgroups of trials including participants with refractory ascites or without refractory ascites, treated by different modality of paracentesis (total one session or partial repeated paracentesis), with different length of follow‐up (up to one month or more than one month), and type of funding. No trials assessed health‐related quality of life or incidence of refractory ascites. We found very low‐certainty evidence that experimental plasma expanders versus albumin may make little or no difference to serious adverse events, renal impairment, other liver related complications, non‐serious adverse events, and recurrence of ascites. </p> <p>We found very low‐certainty evidence that experimental plasma expanders versus albumin increased incidence of hyponatraemia. </p> <p>Hyponatraemia is associated with a significantly higher risk of death in cirrhosis (<a href="./references#CD004039-bbs2-0080" title="GinésP , GuevaraM . Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management. Hepatology2008;48(3):1002‐10. [PUBMED: 18671303] ">Ginés 2008</a>; <a href="./references#CD004039-bbs2-0128" title="MohantyA , Garcia‐TsaoG . Hyponatremia and hepatorenal syndrome. Gastroenterology and Hepatology2015;11(4):220‐9. [PUBMED: 27099594] ">Mohanty 2015</a>). Kim and colleagues demonstrated that serum sodium in patients on the waiting list for liver transplantation is an important predictor of mortality, independent of the model for end‐stage liver disease (MELD) score (<a href="./references#CD004039-bbs2-0116" title="KimWR , BigginsSW , KremersWK , WiesnerRH , KamathPS , BensonJT , et al. Hyponatremia and mortality among patients on the liver‐transplant waiting list. New England Journal of Medicine2008;359(10):1018‐26. [PUBMED: 18768945] ">Kim 2008</a>). Whether this association is attributable to hyponatraemia itself or reflects the fact that patients with hyponatraemia tend to be ill in general, remains to be determined. The MELD‐Na, including serum Na, has been shown to predict survival more accurately than MELD alone (<a href="./references#CD004039-bbs2-0055" title="BigginsSW , KimWR , TerraultNA , SaabS , BalanV , SchianoT , et al. Evidence‐based incorporation of serum sodium concentration into MELD. Gastroenterology2006;130(6):1652‐60. [PUBMED: 16697729] ">Biggins 2006</a>) and it was proposed as a prognostic score in identifying patients for inclusion in the waiting list for liver transplantation. In addition, hyponatraemia is related to a higher risk of hepatic encephalopathy (<a href="./references#CD004039-bbs2-0085" title="GuevaraM , BaccaroME , TorreA , Gómez‐AnsónB , RíosJ , TorresF , et al. Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time‐dependent analysis. American Journal of Gastroenterology2009;104(6):1382‐9. [PUBMED: 19455124] ">Guevara 2009</a>; <a href="./references#CD004039-bbs2-0086" title="GuevaraM , BaccaroME , RíosJ , Martín‐LlahíM , UrizJ , Ruiz del ArbolL , et al. Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentration. Liver International2010;30(8):1137‐42. [PUBMED: 20602681] ">Guevara 2010</a>) and to an impaired health‐related quality of life (HRQOL) (<a href="./references#CD004039-bbs2-0159" title="SolàE , WatsonH , GrauperaI , TurónF , BarretoR , RodríguezE , et al. Factors related to quality of life in patients with cirrhosis and ascites: relevance of serum sodium concentration and leg edema. Journal of Hepatology2012;57(6):1199‐206. [PUBMED: 22824819] ">Sola 2012</a>). In this systematic review, there was an increased risk of hyponatraemia, but not of mortality, with experimental plasma expanders other than albumin, so the prognostic meaning of the increased risk of hyponatraemia is not clear. </p> <p>Three trials provided very low certainty of evidence that experimental plasma expanders versus albumin increased the occurrence of post‐paracentesis circulatory dysfunction, addressed according to the formal definition proposed by <a href="./references#CD004039-bbs2-0013" title="GinèsA , Fernández‐EsparrachG , MonescilloA , VilaC , DomènechE , AbecasisR , et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology1996;111(4):1002‐10. [PUBMED: 8831595] International Group for the Study of Ascites in Cirrhosis. Comparison of albumin, dextran‐70 and hemaccel in the prevention of effective hypovolemia in cirrhotic patients with ascites treated with total paracentesis. A randomized multicenter study. Hepatology1995;22(4 Suppl):220A. ">Ginès 1996</a> and colleagues (<a href="./references#CD004039-bbs2-0013" title="GinèsA , Fernández‐EsparrachG , MonescilloA , VilaC , DomènechE , AbecasisR , et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology1996;111(4):1002‐10. [PUBMED: 8831595] International Group for the Study of Ascites in Cirrhosis. Comparison of albumin, dextran‐70 and hemaccel in the prevention of effective hypovolemia in cirrhotic patients with ascites treated with total paracentesis. A randomized multicenter study. Hepatology1995;22(4 Suppl):220A. ">Ginès 1996</a>; <a href="./references#CD004039-bbs2-0026" title="Sola‐VeraJ , MinanaJ , SorianoG , GonzalezB , PlanellaM , Lopez‐BalaguerJM , et al. Expansion with saline vs albumin in cirrhotic patients with tense ascites treated with total paracentesis. Result of a prospective randomized study. Gastroenterologia y Hepatologia2001;24(2):90 A6. Sola‐VeraJ , MiñanaJ , RicartE , PlanellaM , GonzálezB , TorrasX , et al. Randomized trial comparing albumin and saline in the prevention of paracentesis‐induced circultory dysfunction in cirrhotic patients with ascites. Hepatology2003;37(5):1147‐53. [PUBMED: 12717396] ">Sola‐Vera 2003</a>; <a href="./references#CD004039-bbs2-0002" title="Al SebaeyA , Abdel‐RazekW , BassuniA , RewishaEA , KhalilM , WakedI , et al. Alternatives to albumin for prevention of paracentesis induced circulatory dysfunction (PICD) in cirrhosis. Hepatology2012;56(S1):915A. ">Al Sebaey 2012</a>). Post‐paracentesis circulatory dysfunction is defined as an increase in the plasma renin activity of more than 50% of the pretreatment value to a level of more than 4 ng/mL/h on the sixth day after paracentesis (<a href="./references#CD004039-bbs2-0013" title="GinèsA , Fernández‐EsparrachG , MonescilloA , VilaC , DomènechE , AbecasisR , et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology1996;111(4):1002‐10. [PUBMED: 8831595] International Group for the Study of Ascites in Cirrhosis. Comparison of albumin, dextran‐70 and hemaccel in the prevention of effective hypovolemia in cirrhotic patients with ascites treated with total paracentesis. A randomized multicenter study. Hepatology1995;22(4 Suppl):220A. ">Ginès 1996</a>, <a href="./references#CD004039-bbs2-0148" title="Ruiz‐del–ArbolL , MonescilloA , JimenénW , Garcia‐PlazaA , ArroyoV , RodésJ . Paracentesis‐induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology1997;113(2):579‐86. [PUBMED: 9247479] ">Ruiz‐del‐Arbol 1997</a>). Increase of renin activity suggests an activation of neurohumoral mechanism to maintain the correct homeostasis when reduction of effective plasma volume is induced by paracentesis (<a href="./references#CD004039-bbs2-0148" title="Ruiz‐del–ArbolL , MonescilloA , JimenénW , Garcia‐PlazaA , ArroyoV , RodésJ . Paracentesis‐induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology1997;113(2):579‐86. [PUBMED: 9247479] ">Ruiz‐del‐Arbol 1997</a>), which interferes with the extremely sensible, precarious balance of the homeostatic mechanism in ascitic cirrhotic patients. However, the relationship of post‐paracentesis circulatory dysfunction with the prognosis is not definitely documented, as it is an unvalidated surrogate outcome for clinical effects (<a href="./references#CD004039-bbs2-0081" title="GluudC , BrokJ , GongY , KoretzRL . Hepatology may have problems with putative surrogate outcome measures. Journal of Hepatology2007;46(4):734‐42. [PUBMED: 17316871] ">Gluud 2007</a>; <a href="./references#CD004039-bbs2-0112" title="JakobsenJC , NielsenEE , FeinbergJ , KatakamKK , FobianK , HauserG , et al. Direct‐acting antivirals for chronic hepatitis C. Cochrane Database of Systematic Reviews2017, Issue 9. [DOI: 10.1002/14651858.CD012143.pub3; PUBMED: 28922704] ">Jakobsen 2017</a>; <a href="./references#CD004039-bbs2-0113" title="JakobsenJC , NielsenEE , KoretzRL , GluudC . Do direct acting antivirals cure chronic hepatitis C?. BMJ2018;361:K1382. [PUBMED: 29748173] ">Jakobsen 2018</a>). Moreover, in many trials, since renin activity is tested at different time points and by using different cut‐off values, the relationship with prognosis is totally lacking. </p> <p>In the subgroup analysis, we found very low‐certainty evidence that experimental plasma expanders versus albumin increased incidence of other liver‐related complications in trials including people without refractory ascites and in trials without for‐profit funding, recurrence of ascites in trials with a short follow‐up, hyponatraemia in trials including people without refractory ascites, in trials in which total paracentesis was used and in those trials with a short follow‐up. Regarding the type of plasma expanders, we found very low‐certainty evidence that hydroxyethyl starch increased the risk of recurrence; polygeline, dextran, and crystalloids increased the risk of post‐paracentesis circulatory dysfunction; and intravenous infusion of ascitic fluid reduced the risk of other liver‐related complications. Experimental plasma expanders increased the risk of post‐paracentesis circulatory dysfunction in trials with for‐profit funding. No differences in the remaining subgroups were observed. </p> <p>Overall, data to perform the subgroup analyses were lacking.</p> <p>The differences between experimental plasma expanders versus albumin in some secondary and exploratory outcomes and in some subgroup analyses cannot be taken as proof of any intervention effect, considering the very low certainty of the evidence, the uncertain clinical meaning of the exploratory outcomes, and the number of comparisons that could generate false positive results. However, such differences can act as a stimulus to conduct more randomised clinical trials. </p> </section> <section id="CD004039-sec-0195"> <h3 class="title" id="CD004039-sec-0195">Overall completeness and applicability of evidence</h3> <p>The included trial participants had a wide range of characteristics, but their stage of cirrhosis was not very advanced, as exclusion criteria in some of the trials were presence of hepatocellular carcinoma, recent gastrointestinal bleeding, hepatic encephalopathy, and recent infection. In the majority of these trials, the participants were without renal failure and hyponatraemia. Some trials did not describe clearly if the trial participants had refractory ascites. So, based on our summary of the evidence, we conclude that the results are applicable to only people with intermediate to advanced stage of cirrhosis, usually treated by paracentesis in the clinics. </p> <p>The present systematic review with meta‐analyses indicates insufficient evidence whether plasma expanders are better than no plasma expanders. This comparison should show that plasma expanders are superior to no plasma expanders before the comparison of different plasma expanders becomes of interest. Without such information, it becomes hard to interpret the comparison between the experimental plasma expanders versus albumin or versus other plasma expanders. </p> </section> <section id="CD004039-sec-0196"> <h3 class="title" id="CD004039-sec-0196">Quality of the evidence</h3> <p>Our current review has identified a number of methodological concerns. All trials were at high risk of bias. Moreover, there were high risks of random errors. The a priori required number of participants for a meta‐analysis to be conclusive was not reached, so this meta‐analysis has not enough information to reject or to accept the hypotheses. </p> <p>Our assessments of risk of bias, and hence the certainty of the evidence, reflects lack of description or poor description of the trial design and performance, as well as incomplete reporting of results. We often failed in our attempts to obtain missing information from authors of the trial reports. Morever, there is a risk of chance effects due to multiple testing. </p> <p>We used GRADE to consider the effect of study limitations on our outcomes. The conclusion is that the certainty of information is very low. When we assessed, in a sensitivity analysis, imprecision with Trial Sequential Analysis, then our assessment of the certainty of the evidence was also very low ‐ observations in accordance with previous studies (<a href="./references#CD004039-bbs2-0060" title="CastelliniG , BruschettiniM , GianolaS , GluudC , MojaL . Assessing imprecision in Cochrane systematic reviews: a comparison of GRADE and Trial Sequential Analysis. Systematic Reviews2018;7(1):110. [PUBMED: 30055658] ">Castellini 2018</a>; <a href="./references#CD004039-bbs2-0077" title="GartlehnerG , Nussbaumer‐StreitB , WagnerG , PatelS , Swinson‐EvansT , DobrescuA , et al. Increased risks for random errors are common in outcomes graded as high certainty of evidence. Journal of Clinical Epidemiology2018;106:50‐9. [DOI: 10.1016/j.jclinepi.2018.10.009; PUBMED: 30342970] ">Gartlehner 2018</a>). </p> </section> <section id="CD004039-sec-0197"> <h3 class="title" id="CD004039-sec-0197">Potential biases in the review process</h3> <p>We performed a comprehensive literature search for published and unpublished studies, and we combined electronic data searches with manual searches of the reference lists of the identified studies and also conference proceedings and abstract books from relevant national and international society meetings. We included trials regardless of their language of publication and whether they reported data on the outcomes we needed. We contacted relevant authors for additional information. </p> <p>We consider it unlikely that we have failed to identify any published and unpublished trials. Two review authors independently assessed study eligibility, extracted data, and assessed risk of bias in included studies, and we believe that this has reduced potential biases in the review process. We included only quasi‐randomised trials and not observational studies for the assessment of adverse events. This may have biased our review towards assessment of benefits and might have overlooked late or rare harms. We did not seek translation of the full study reports for two studies that were reported in Korean (<a href="./references#CD004039-bbs2-0016" title="KangKE , KimBH , DongSH , KimHJ , ChangYW , LeeJII , et al. The efficacy of hydroxyethyl starch as plasma expander in cirrhotic patients with tense ascites treated with large volume paracentesis. Korean Journal of Gastroenterology1998;31:651‐60. ">Kang 1998</a>; <a href="./references#CD004039-bbs2-0004" title="BaikSK , KimHS , LeeDK , KimIH , KwonSO . Hemodynamic changes after single large volume paracentesis (SLVP) in cirrhosis with tense ascites ‐ focusing on the effect of albumin as plasma expander. Korean Journal of Medicine2000;58:276‐82. ">Baik 2000</a>); our judgements and data were limited to information available in the abstract or the tables. </p> </section> <section id="CD004039-sec-0198"> <h3 class="title" id="CD004039-sec-0198">Agreements and disagreements with other studies or reviews</h3> <p>Several meta‐analyses have been published on the use of albumin and other plasma expanders in cirrhotic patients with ascites undergoing paracentesis (<a href="./references#CD004039-bbs2-0177" title="WongCL , Holroyd‐LeducJ , ThorpeKE , StrausSE . Does this patient have bacterial peritonitis or portal hypertension? How do I perform a paracentesis and analyze the results?. JAMA2008;299(10):1166‐78. [PUBMED: 18334692] ">Wong 2008</a>; <a href="./references#CD004039-bbs2-0051" title="BernardiM , CaraceniP , NavickisRJ , WilkesMM . Albumin infusion in patients undergoing large‐volume paracentesis: a meta‐analysis of randomized trials. Hepatology2012;55(4):1172‐81. [PUBMED: 22095893] ">Bernardi 2012</a>; <a href="./references#CD004039-bbs2-0171" title="WangY‐C , FengM‐l . A meta‐analysis of albumin infusion in patients undergoing large‐volume paracentesis [大量放腹水后输注人体白蛋白疗效的 Meta分析]. Chinese Hepatology2015;20(5):381‐5. [DOI: 10.14000/j.cnki.issn.1008‐1704.2015.05.010] ">Wang 2015</a>; <a href="./references#CD004039-bbs2-0119" title="KüttingF , SchubertJ , FranklinJ , BoweA , HoffmannV , DemirM , et al. Insufficient evidence of benefit regarding mortality due to albumin substitution in HCC‐free cirrhotic patients undergoing large volume paracentesis. Journal of Gastroenterology and Hepatology2017;32(2):327–38. [PUBMED: 27149296] ">Kütting 2017</a>). </p> <p>The <a href="./references#CD004039-bbs2-0177" title="WongCL , Holroyd‐LeducJ , ThorpeKE , StrausSE . Does this patient have bacterial peritonitis or portal hypertension? How do I perform a paracentesis and analyze the results?. JAMA2008;299(10):1166‐78. [PUBMED: 18334692] ">Wong 2008</a> meta‐analysis with nine trials found no difference in mortality and morbidity (renal impairment, hepatic encephalopathy, hyponatraemia) between plasma expansion versus no plasma expansion and between other plasma expanders versus albumin. The <a href="./references#CD004039-bbs2-0051" title="BernardiM , CaraceniP , NavickisRJ , WilkesMM . Albumin infusion in patients undergoing large‐volume paracentesis: a meta‐analysis of randomized trials. Hepatology2012;55(4):1172‐81. [PUBMED: 22095893] ">Bernardi 2012</a> meta‐analysis with 17 trials found that albumin in comparison with other plasma expanders and vasoconstrictors such as terlipressin, norepinephrine and midodrine, reduced mortality, hyponatraemia, and post‐paracentesis circulatory dysfunction and that albumin in comparison with no treatment reduced hyponatraemia and post‐paracentesis circulatory dysfunction. However, <a href="./references#CD004039-bbs2-0062" title="ChenRP , ChenC , YuJY , HuangXL , ZhouMT , HuangZM . Trial sequence meta‐analysis can reject false‐positive result calculated from conventional meta‐analysis. Hepatology2014;60(4):1442‐3. [PUBMED: 24585570] ">Chen 2014</a> and colleagues published a letter in which they presented the Trial Sequential Analysis of the data from the Bernardi's meta‐analysis which did not confirm their results and conclusions. On the other hand, Bernardi's reply confirmed the conclusions of the <a href="./references#CD004039-bbs2-0051" title="BernardiM , CaraceniP , NavickisRJ , WilkesMM . Albumin infusion in patients undergoing large‐volume paracentesis: a meta‐analysis of randomized trials. Hepatology2012;55(4):1172‐81. [PUBMED: 22095893] ">Bernardi 2012</a> meta‐analysis (<a href="./references#CD004039-bbs2-0052" title="BernardiM , CaraceniP , NavickisRJ , WilkesMM . Reply to PMID 22095893. Hepatology2014;60(4):1443‐5. [PUBMED: 24585539] ">Bernardi 2014</a>). The <a href="./references#CD004039-bbs2-0171" title="WangY‐C , FengM‐l . A meta‐analysis of albumin infusion in patients undergoing large‐volume paracentesis [大量放腹水后输注人体白蛋白疗效的 Meta分析]. Chinese Hepatology2015;20(5):381‐5. [DOI: 10.14000/j.cnki.issn.1008‐1704.2015.05.010] ">Wang 2015</a> meta‐analysis with 13 trials found that albumin infusion had an advantage over alternative treatments in reducing hospital mortality, hyponatraemia, and post‐paracentesis circulatory dysfunction. Kütting and colleagues (<a href="./references#CD004039-bbs2-0119" title="KüttingF , SchubertJ , FranklinJ , BoweA , HoffmannV , DemirM , et al. Insufficient evidence of benefit regarding mortality due to albumin substitution in HCC‐free cirrhotic patients undergoing large volume paracentesis. Journal of Gastroenterology and Hepatology2017;32(2):327–38. [PUBMED: 27149296] ">Kütting 2017</a>) instead, in their meta‐analysis of 21 trials, assessing albumin versus no plasma expanders, other plasma expanders, and vasoconstrictors, found insufficient evidence of benefit in mortality due to albumin substitution in hepatocellular carcinoma‐free cirrhotic patients undergoing large volume paracentesis. </p> <p>We can explain the discrepant conclusions in the afore‐mentioned analyses and in our review by the differences in systematic review methodology, tested treatments, and selection of outcomes. Our review is the only one based on a pre‐published protocol, which was updated in conformity with the updated Cochrane methodology during the time of the review preparation. We used Trial Sequential Analysis to control the risks of random errors to which the conventional meta‐analysis is exposed (<a href="./references#CD004039-bbs2-0173" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [PUBMED: 18083463] ">Wetterslev 2008</a>; <a href="./references#CD004039-bbs2-0165" title="ThorlundK , AnemaA , MillsE . Interpreting meta‐analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV‐infected individuals. Clinical Epidemiology2010;2:57‐66. [PUBMED: 20865104] ">Thorlund 2010</a>; <a href="./references#CD004039-bbs2-0111" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14:120. [PUBMED: 25416419] ">Jakobsen 2014</a>; <a href="./references#CD004039-bbs2-0082" title="GluudC , NikolovaD , KlingenbergSL , Cochrane Hepato‐Biliary Group. About Cochrane (Cochrane Review Groups (CRGs)). CHBG Module. hbg.cochrane.org (accessed prior to 16 June 2019). ">Gluud 2015</a>). </p> <p>Our search for randomised clinical trials is current up to January 2019, which resulted in the inclusion of more trials than those included in the mentioned meta‐analyses. </p> <p>We addressed, in two separate comparisons, the role of one plasma expander versus no plasma expander, and the role of different plasma expanders, similar to Wong (<a href="./references#CD004039-bbs2-0177" title="WongCL , Holroyd‐LeducJ , ThorpeKE , StrausSE . Does this patient have bacterial peritonitis or portal hypertension? How do I perform a paracentesis and analyze the results?. JAMA2008;299(10):1166‐78. [PUBMED: 18334692] ">Wong 2008</a>) and Bernardi (<a href="./references#CD004039-bbs2-0051" title="BernardiM , CaraceniP , NavickisRJ , WilkesMM . Albumin infusion in patients undergoing large‐volume paracentesis: a meta‐analysis of randomized trials. Hepatology2012;55(4):1172‐81. [PUBMED: 22095893] ">Bernardi 2012</a>). Kutting and colleagues analysed together trials in which plasma expanders were tested against no treatment and against other plasma expanders (<a href="./references#CD004039-bbs2-0119" title="KüttingF , SchubertJ , FranklinJ , BoweA , HoffmannV , DemirM , et al. Insufficient evidence of benefit regarding mortality due to albumin substitution in HCC‐free cirrhotic patients undergoing large volume paracentesis. Journal of Gastroenterology and Hepatology2017;32(2):327–38. [PUBMED: 27149296] ">Kütting 2017</a>). Wang did not include trials comparing plasma expanders versus no treatment (<a href="./references#CD004039-bbs2-0171" title="WangY‐C , FengM‐l . A meta‐analysis of albumin infusion in patients undergoing large‐volume paracentesis [大量放腹水后输注人体白蛋白疗效的 Meta分析]. Chinese Hepatology2015;20(5):381‐5. [DOI: 10.14000/j.cnki.issn.1008‐1704.2015.05.010] ">Wang 2015</a>). </p> <p>In this systematic review, in order to have a higher homogeneity of tested treatments, we chose to evaluate only substances aimed at maintaining a correct balance after paracentesis, by increasing intravascular volume (fluids and/or colloids). We excluded treatments which act by increasing peripheral resistance, such as the vasoconstrictors terlipressin, norepinephrine, and midodrine included in Bernardi's, Wang's and Kutting's meta‐analyses (<a href="./references#CD004039-bbs2-0051" title="BernardiM , CaraceniP , NavickisRJ , WilkesMM . Albumin infusion in patients undergoing large‐volume paracentesis: a meta‐analysis of randomized trials. Hepatology2012;55(4):1172‐81. [PUBMED: 22095893] ">Bernardi 2012</a>, <a href="./references#CD004039-bbs2-0171" title="WangY‐C , FengM‐l . A meta‐analysis of albumin infusion in patients undergoing large‐volume paracentesis [大量放腹水后输注人体白蛋白疗效的 Meta分析]. Chinese Hepatology2015;20(5):381‐5. [DOI: 10.14000/j.cnki.issn.1008‐1704.2015.05.010] ">Wang 2015</a>; <a href="./references#CD004039-bbs2-0119" title="KüttingF , SchubertJ , FranklinJ , BoweA , HoffmannV , DemirM , et al. Insufficient evidence of benefit regarding mortality due to albumin substitution in HCC‐free cirrhotic patients undergoing large volume paracentesis. Journal of Gastroenterology and Hepatology2017;32(2):327–38. [PUBMED: 27149296] ">Kütting 2017</a>). </p> <p>We included all the trials assessing every intravenous infusion of fluids which can act as plasma expanders and which have been tested in connection with paracentesis, including intravenous infusion of ascitic fluid after filtration, and in some cases, concentration, excluded in the other meta‐analyses. The rationale of its use is not different from that of other plasma expanders, such as colloids or saline solution. </p> <p>After the publication of the trial by <a href="./references#CD004039-bbs2-0012" title="GinèsP , TitóL , ArroyoV , PlanasR , PanésJ , ViverJ , et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology1988;94(6):1493‐1502. [PUBMED: 3360270] ">Ginès 1988</a>, albumin was judged beneficial in connection with paracentesis, but expensive. Many trials were performed testing cheaper plasma expanders, or a modified system of intravenous infusion of ascitic fluid versus albumin. In our systematic review, we decided to test 'other than albumin plasma expanders' as the experimental treatment versus albumin as control treatment, in order to be more adherent to the real structure of the performed trials, whereas in the other meta‐analyses, albumin was tested as experimental treatment. </p> <p>An important difference between this review and the meta‐analyses performed by others was the choice of outcomes, which we classified as primary, secondary, and exploratory according to their clinical importance. In particular, hyponatraemia and post‐paracentesis circulatory dysfunction were chosen as exploratory outcomes in the present review, whereas in <a href="./references#CD004039-bbs2-0051" title="BernardiM , CaraceniP , NavickisRJ , WilkesMM . Albumin infusion in patients undergoing large‐volume paracentesis: a meta‐analysis of randomized trials. Hepatology2012;55(4):1172‐81. [PUBMED: 22095893] ">Bernardi 2012</a> they were chosen as primary outcomes in addition to mortality, and in <a href="./references#CD004039-bbs2-0119" title="KüttingF , SchubertJ , FranklinJ , BoweA , HoffmannV , DemirM , et al. Insufficient evidence of benefit regarding mortality due to albumin substitution in HCC‐free cirrhotic patients undergoing large volume paracentesis. Journal of Gastroenterology and Hepatology2017;32(2):327–38. [PUBMED: 27149296] ">Kütting 2017</a> as secondary outcomes. Our choice is due to the putative surrogate character of hyponatraemia and of post‐paracentesis circulatory dysfunction (see above). </p> <p>Morever, regarding post‐paracentesis circulatory dysfunction, we followed the Gines' definition (<a href="./references#CD004039-bbs2-0013" title="GinèsA , Fernández‐EsparrachG , MonescilloA , VilaC , DomènechE , AbecasisR , et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology1996;111(4):1002‐10. [PUBMED: 8831595] International Group for the Study of Ascites in Cirrhosis. Comparison of albumin, dextran‐70 and hemaccel in the prevention of effective hypovolemia in cirrhotic patients with ascites treated with total paracentesis. A randomized multicenter study. Hepatology1995;22(4 Suppl):220A. ">Ginès 1996</a>), which is what the scientific community usually refers to. We included the <a href="./references#CD004039-bbs2-0002" title="Al SebaeyA , Abdel‐RazekW , BassuniA , RewishaEA , KhalilM , WakedI , et al. Alternatives to albumin for prevention of paracentesis induced circulatory dysfunction (PICD) in cirrhosis. Hepatology2012;56(S1):915A. ">Al Sebaey 2012</a> trial because the definition of post‐paracentesis circulatory dysfunction was only very slightly different from <a href="./references#CD004039-bbs2-0013" title="GinèsA , Fernández‐EsparrachG , MonescilloA , VilaC , DomènechE , AbecasisR , et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology1996;111(4):1002‐10. [PUBMED: 8831595] International Group for the Study of Ascites in Cirrhosis. Comparison of albumin, dextran‐70 and hemaccel in the prevention of effective hypovolemia in cirrhotic patients with ascites treated with total paracentesis. A randomized multicenter study. Hepatology1995;22(4 Suppl):220A. ">Ginès 1996</a>. On the contrary, <a href="./references#CD004039-bbs2-0051" title="BernardiM , CaraceniP , NavickisRJ , WilkesMM . Albumin infusion in patients undergoing large‐volume paracentesis: a meta‐analysis of randomized trials. Hepatology2012;55(4):1172‐81. [PUBMED: 22095893] ">Bernardi 2012</a> and <a href="./references#CD004039-bbs2-0119" title="KüttingF , SchubertJ , FranklinJ , BoweA , HoffmannV , DemirM , et al. Insufficient evidence of benefit regarding mortality due to albumin substitution in HCC‐free cirrhotic patients undergoing large volume paracentesis. Journal of Gastroenterology and Hepatology2017;32(2):327–38. [PUBMED: 27149296] ">Kütting 2017</a> defined post‐paracentesis circulatory dysfunction in the methods section as an increase of plasma renin activity ≥ 50% (irrespective of observation time), but then in the results section they reported under the label of post‐paracentesis circulatory dysfunction any change of renin activity, irrespective of the rate of increase and timing of the assessment, and any change of aldosterone levels too. The relationship of these humoral changes and differences between treatments with robust clinical and prognostic outcomes has been not analysed and validated. </p> <p>In a recent trial (<a href="./references#CD004039-bbs2-0059" title="CaraceniP , RiggioO , AngeliP , AlessandriaC , NeriS , FoschiFG , et al. Long‐term albumin administration in decompensated cirrhosis (ANSWER): an open‐label randomised trial. Lancet2018;391(10138):2417‐29. [PUBMED: 29861076] ">Caraceni 2018</a>), long‐term albumin administration in participants with cirrhosis and uncomplicated ascites treated by diuretics increased survival and reduced incidence of complications. This trial did not evaluate the role of albumin after therapeutic paracentesis. Albumin was administered in a weekly fixed schedule associated with the standard medical treatment for up to 18 months. In addition, the great majority of participants had moderate (grade 2) ascites, without refractory ascites. On the contrary, the trials of the present systematic review evaluated the benefits and harms of any plasma volume expanders versus no plasma volume expanders or versus another plasma volume expander after paracentesis, included mostly participants with large ascites, and some trials included participants with refractory ascites. So, Caraceni’s trial did not match the question of our systematic review, and its results cannot be applied to patients treated by paracentesis. However, they can raise stimulating issues on the role of albumin as a promising disease‐modifying treatment (<a href="./references#CD004039-bbs2-0053" title="BernardiM , CaraceniP . Novel perspectives in the management of decompensated cirrhosis. Nature Reviews. Gastroenterology and Hepatology2018;15(12):753‐64. [PUBMED: 30026556] ">Bernardi 2018</a>). </p> <p>.</p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD004039-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD004039-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/full#CD004039-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD004039-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/full#CD004039-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD004039-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/full#CD004039-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 6 Experimental plasma expanders versus albumin, outcome: 6.1 All‐cause mortality." data-id="CD004039-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 6 Experimental plasma expanders versus albumin, outcome: 6.1 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/full#CD004039-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Experimental plasma expanders versus albumin ‐ 6.1 All‐cause mortality.The diversity‐adjusted required information size of 16,415 participants was calculated based on a proportion of participants of 18.2% of participants dying in the control group; a relative risk reduction (RRR) of 10% in the plasma expander group; an alpha of 2.5%; a power of 80%; and a diversity of 0%.The cumulative Z score did not cross borders for benefit, harm, or futility." data-id="CD004039-fig-0005" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Experimental plasma expanders versus albumin ‐ 6.1 All‐cause mortality.</p> <p>The diversity‐adjusted required information size of 16,415 participants was calculated based on a proportion of participants of 18.2% of participants dying in the control group; a relative risk reduction (RRR) of 10% in the plasma expander group; an alpha of 2.5%; a power of 80%; and a diversity of 0%. </p> <p>The cumulative Z score did not cross borders for benefit, harm, or futility.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/full#CD004039-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 6 Experimental plasma expanders versus albumin, outcome: 6.3 Renal impairment." data-id="CD004039-fig-0006" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Funnel plot of comparison: 6 Experimental plasma expanders versus albumin, outcome: 6.3 Renal impairment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/full#CD004039-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 6 Experimental plasma expanders versus albumin, outcome: 6.4 Other liver‐related complications." data-id="CD004039-fig-0007" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Funnel plot of comparison: 6 Experimental plasma expanders versus albumin, outcome: 6.4 Other liver‐related complications. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/full#CD004039-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Experimental plasma expander versus albumin ‐ 6.4 Other liver‐related complications.The diversity‐adjusted required information size of 16,992 participants was calculated based on a proportion of participants of 18.5% with other liver‐related complications in the control group; a relative risk reduction (RRR) of 10% in the plasma expander group; an alpha of 2.00%; a power of 80%; and a diversity of 0%.The cumulative Z score did not cross borders for benefit, harm, or futility." data-id="CD004039-fig-0008" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Experimental plasma expander versus albumin ‐ 6.4 Other liver‐related complications.</p> <p>The diversity‐adjusted required information size of 16,992 participants was calculated based on a proportion of participants of 18.5% with other liver‐related complications in the control group; a relative risk reduction (RRR) of 10% in the plasma expander group; an alpha of 2.00%; a power of 80%; and a diversity of 0%. </p> <p>The cumulative Z score did not cross borders for benefit, harm, or futility.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/full#CD004039-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-AFig-FIG09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-AFig-FIG09.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 6 Experimental plasma expanders versus albumin, outcome: 6.5 Non‐serious adverse events." data-id="CD004039-fig-0009" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-AFig-FIG09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Funnel plot of comparison: 6 Experimental plasma expanders versus albumin, outcome: 6.5 Non‐serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/full#CD004039-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-AFig-FIG09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-AFig-FIG10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-AFig-FIG10.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 6 Experimental plasma expanders versus albumin, outcome: 6.6 Recurrence of ascites." data-id="CD004039-fig-0010" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-AFig-FIG10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>Funnel plot of comparison: 6 Experimental plasma expanders versus albumin, outcome: 6.6 Recurrence of ascites. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/full#CD004039-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-AFig-FIG10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-AFig-FIG11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-AFig-FIG11.png" target="_blank"><b></b></a></p> </div><img alt="Experimental plasma expanders versus albumin ‐ 6.6 Recurrence of ascites.The diversity‐adjusted required information size of 7104 participants was calculated based on a proportion of participants of 36.3% of participants suffering recurrence of ascites in the control group; a relative risk reduction (RRR) of 10% in the plasma expander group; an alpha of 2%; a power of 80%; and a diversity of 3%.The cumulative Z score did not cross borders for benefit, harm, or futility." data-id="CD004039-fig-0011" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-AFig-FIG11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 11</div> <div class="figure-caption"> <p>Experimental plasma expanders versus albumin ‐ 6.6 Recurrence of ascites.</p> <p>The diversity‐adjusted required information size of 7104 participants was calculated based on a proportion of participants of 36.3% of participants suffering recurrence of ascites in the control group; a relative risk reduction (RRR) of 10% in the plasma expander group; an alpha of 2%; a power of 80%; and a diversity of 3%. </p> <p>The cumulative Z score did not cross borders for benefit, harm, or futility.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/full#CD004039-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-AFig-FIG11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-AFig-FIG12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-AFig-FIG12.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 6 Experimental plasma expanders versus albumin, outcome: 6.7 Hyponatraemia." data-id="CD004039-fig-0012" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-AFig-FIG12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 12</div> <div class="figure-caption"> <p>Funnel plot of comparison: 6 Experimental plasma expanders versus albumin, outcome: 6.7 Hyponatraemia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/full#CD004039-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-AFig-FIG12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Plasma expanders versus no plasma expander, Outcome 1 All‐cause mortality." data-id="CD004039-fig-0013" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Plasma expanders versus no plasma expander, Outcome 1 All‐cause mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Plasma expanders versus no plasma expander, Outcome 2 Serious adverse events." data-id="CD004039-fig-0014" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Plasma expanders versus no plasma expander, Outcome 2 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Plasma expanders versus no plasma expander, Outcome 3 Renal impairment." data-id="CD004039-fig-0015" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Plasma expanders versus no plasma expander, Outcome 3 Renal impairment.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Plasma expanders versus no plasma expander, Outcome 4 Other liver‐related complications." data-id="CD004039-fig-0016" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Plasma expanders versus no plasma expander, Outcome 4 Other liver‐related complications. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Plasma expanders versus no plasma expander, Outcome 5 Non‐serious adverse events." data-id="CD004039-fig-0017" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Plasma expanders versus no plasma expander, Outcome 5 Non‐serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Plasma expanders versus no plasma expander, Outcome 6 Recurrence of ascites." data-id="CD004039-fig-0018" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Plasma expanders versus no plasma expander, Outcome 6 Recurrence of ascites.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Plasma expanders versus no plasma expander, Outcome 7 Hyponatraemia." data-id="CD004039-fig-0019" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Plasma expanders versus no plasma expander, Outcome 7 Hyponatraemia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis of plasma expanders versus no plasma expander regarding modality of paracentesis, Outcome 1 All‐cause mortality." data-id="CD004039-fig-0020" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis of plasma expanders versus no plasma expander regarding modality of paracentesis, Outcome 1 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis of plasma expanders versus no plasma expander regarding modality of paracentesis, Outcome 2 Renal impairment." data-id="CD004039-fig-0021" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis of plasma expanders versus no plasma expander regarding modality of paracentesis, Outcome 2 Renal impairment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis of plasma expanders versus no plasma expander regarding modality of paracentesis, Outcome 3 Other liver‐related complications." data-id="CD004039-fig-0022" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis of plasma expanders versus no plasma expander regarding modality of paracentesis, Outcome 3 Other liver‐related complications. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis of plasma expanders versus no plasma expander regarding modality of paracentesis, Outcome 4 Non‐serious adverse events." data-id="CD004039-fig-0023" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis of plasma expanders versus no plasma expander regarding modality of paracentesis, Outcome 4 Non‐serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis of plasma expanders versus no plasma expander regarding modality of paracentesis, Outcome 5 Hyponatraemia." data-id="CD004039-fig-0024" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis of plasma expanders versus no plasma expander regarding modality of paracentesis, Outcome 5 Hyponatraemia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Subgroup analysis of plasma expanders versus no plasma expander regarding duration of follow‐up, Outcome 1 All‐cause mortality." data-id="CD004039-fig-0025" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Subgroup analysis of plasma expanders versus no plasma expander regarding duration of follow‐up, Outcome 1 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Subgroup analysis of plasma expanders versus no plasma expander regarding duration of follow‐up, Outcome 2 Renal impairment." data-id="CD004039-fig-0026" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Subgroup analysis of plasma expanders versus no plasma expander regarding duration of follow‐up, Outcome 2 Renal impairment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Subgroup analysis of plasma expanders versus no plasma expander regarding duration of follow‐up, Outcome 3 Other liver‐related complications." data-id="CD004039-fig-0027" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Subgroup analysis of plasma expanders versus no plasma expander regarding duration of follow‐up, Outcome 3 Other liver‐related complications. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Subgroup analysis of plasma expanders versus no plasma expander regarding duration of follow‐up, Outcome 4 Non‐serious adverse events." data-id="CD004039-fig-0028" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Subgroup analysis of plasma expanders versus no plasma expander regarding duration of follow‐up, Outcome 4 Non‐serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Subgroup analysis of plasma expanders versus no plasma expander regarding duration of follow‐up, Outcome 5 Hyponatraemia." data-id="CD004039-fig-0029" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Subgroup analysis of plasma expanders versus no plasma expander regarding duration of follow‐up, Outcome 5 Hyponatraemia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Subgroup analysis of plasma expanders versus no plasma expander regarding funding, Outcome 1 All‐cause mortality." data-id="CD004039-fig-0030" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Subgroup analysis of plasma expanders versus no plasma expander regarding funding, Outcome 1 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Subgroup analysis of plasma expanders versus no plasma expander regarding funding, Outcome 2 Renal impairment." data-id="CD004039-fig-0031" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Subgroup analysis of plasma expanders versus no plasma expander regarding funding, Outcome 2 Renal impairment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Subgroup analysis of plasma expanders versus no plasma expander regarding funding, Outcome 3 Other liver‐related complications." data-id="CD004039-fig-0032" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Subgroup analysis of plasma expanders versus no plasma expander regarding funding, Outcome 3 Other liver‐related complications. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Subgroup analysis of plasma expanders versus no plasma expander regarding funding, Outcome 4 Non‐serious adverse events." data-id="CD004039-fig-0033" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Subgroup analysis of plasma expanders versus no plasma expander regarding funding, Outcome 4 Non‐serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Subgroup analysis of plasma expanders versus no plasma expander regarding funding, Outcome 5 Hyponatraemia." data-id="CD004039-fig-0034" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Subgroup analysis of plasma expanders versus no plasma expander regarding funding, Outcome 5 Hyponatraemia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Plasma expanders versus no plasma expander: best‐worst case scenario analysis, Outcome 1 All‐cause mortality." data-id="CD004039-fig-0035" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Plasma expanders versus no plasma expander: best‐worst case scenario analysis, Outcome 1 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Plasma expanders versus no plasma expander: worst‐best case scenario analysis, Outcome 1 All‐cause mortality." data-id="CD004039-fig-0036" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Plasma expanders versus no plasma expander: worst‐best case scenario analysis, Outcome 1 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-007-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Experimental plasma expanders versus albumin, Outcome 1 All‐cause mortality." data-id="CD004039-fig-0037" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Experimental plasma expanders versus albumin, Outcome 1 All‐cause mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Experimental plasma expanders versus albumin, Outcome 2 Serious adverse events." data-id="CD004039-fig-0038" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Experimental plasma expanders versus albumin, Outcome 2 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-007-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-007-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Experimental plasma expanders versus albumin, Outcome 3 Renal impairment." data-id="CD004039-fig-0039" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-007-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 Experimental plasma expanders versus albumin, Outcome 3 Renal impairment.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-007-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-007-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-007-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Experimental plasma expanders versus albumin, Outcome 4 Other liver‐related complications." data-id="CD004039-fig-0040" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-007-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7 Experimental plasma expanders versus albumin, Outcome 4 Other liver‐related complications. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-007-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-007-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-007-05.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Experimental plasma expanders versus albumin, Outcome 5 Non‐serious adverse events." data-id="CD004039-fig-0041" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-007-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7 Experimental plasma expanders versus albumin, Outcome 5 Non‐serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-007-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-007-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-007-06.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Experimental plasma expanders versus albumin, Outcome 6 Recurrence of ascites." data-id="CD004039-fig-0042" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-007-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.6</div> <div class="figure-caption"> <p>Comparison 7 Experimental plasma expanders versus albumin, Outcome 6 Recurrence of ascites. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-007-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-007-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-007-07.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Experimental plasma expanders versus albumin, Outcome 7 Hyponatraemia." data-id="CD004039-fig-0043" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-007-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.7</div> <div class="figure-caption"> <p>Comparison 7 Experimental plasma expanders versus albumin, Outcome 7 Hyponatraemia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-007-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-007-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-007-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Experimental plasma expanders versus albumin, Outcome 8 Post‐paracentesis circulatory dysfunction." data-id="CD004039-fig-0044" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-007-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.8</div> <div class="figure-caption"> <p>Comparison 7 Experimental plasma expanders versus albumin, Outcome 8 Post‐paracentesis circulatory dysfunction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-007-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Subgroup analysis of experimental plasma expanders versus albumin regarding presence or absence of refractory ascites, Outcome 1 All‐cause mortality." data-id="CD004039-fig-0045" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Subgroup analysis of experimental plasma expanders versus albumin regarding presence or absence of refractory ascites, Outcome 1 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Subgroup analysis of experimental plasma expanders versus albumin regarding presence or absence of refractory ascites, Outcome 2 Renal impairment." data-id="CD004039-fig-0046" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 Subgroup analysis of experimental plasma expanders versus albumin regarding presence or absence of refractory ascites, Outcome 2 Renal impairment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-008-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-008-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Subgroup analysis of experimental plasma expanders versus albumin regarding presence or absence of refractory ascites, Outcome 3 Other liver‐related complications." data-id="CD004039-fig-0047" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-008-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8 Subgroup analysis of experimental plasma expanders versus albumin regarding presence or absence of refractory ascites, Outcome 3 Other liver‐related complications. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-008-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-008-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-008-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Subgroup analysis of experimental plasma expanders versus albumin regarding presence or absence of refractory ascites, Outcome 4 Non‐serious adverse events." data-id="CD004039-fig-0048" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-008-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8 Subgroup analysis of experimental plasma expanders versus albumin regarding presence or absence of refractory ascites, Outcome 4 Non‐serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-008-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-008-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-008-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Subgroup analysis of experimental plasma expanders versus albumin regarding presence or absence of refractory ascites, Outcome 5 Recurrence of ascites." data-id="CD004039-fig-0049" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-008-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8 Subgroup analysis of experimental plasma expanders versus albumin regarding presence or absence of refractory ascites, Outcome 5 Recurrence of ascites. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-008-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-008-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-008-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Subgroup analysis of experimental plasma expanders versus albumin regarding presence or absence of refractory ascites, Outcome 6 Hyponatraemia." data-id="CD004039-fig-0050" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-008-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.6</div> <div class="figure-caption"> <p>Comparison 8 Subgroup analysis of experimental plasma expanders versus albumin regarding presence or absence of refractory ascites, Outcome 6 Hyponatraemia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-008-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Subgroup analysis of experimental plasma expanders versus albumin regarding modality of paracentesis, Outcome 1 All‐cause mortality." data-id="CD004039-fig-0051" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 Subgroup analysis of experimental plasma expanders versus albumin regarding modality of paracentesis, Outcome 1 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-009-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-009-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Subgroup analysis of experimental plasma expanders versus albumin regarding modality of paracentesis, Outcome 2 Renal impairment." data-id="CD004039-fig-0052" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-009-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9 Subgroup analysis of experimental plasma expanders versus albumin regarding modality of paracentesis, Outcome 2 Renal impairment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-009-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-009-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-009-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Subgroup analysis of experimental plasma expanders versus albumin regarding modality of paracentesis, Outcome 3 Other liver‐related complications." data-id="CD004039-fig-0053" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-009-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9 Subgroup analysis of experimental plasma expanders versus albumin regarding modality of paracentesis, Outcome 3 Other liver‐related complications. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-009-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-009-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-009-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Subgroup analysis of experimental plasma expanders versus albumin regarding modality of paracentesis, Outcome 4 Non‐serious adverse events." data-id="CD004039-fig-0054" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-009-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9 Subgroup analysis of experimental plasma expanders versus albumin regarding modality of paracentesis, Outcome 4 Non‐serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-009-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-009-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-009-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Subgroup analysis of experimental plasma expanders versus albumin regarding modality of paracentesis, Outcome 5 Recurrences of ascites." data-id="CD004039-fig-0055" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-009-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.5</div> <div class="figure-caption"> <p>Comparison 9 Subgroup analysis of experimental plasma expanders versus albumin regarding modality of paracentesis, Outcome 5 Recurrences of ascites. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-009-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-009-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-009-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Subgroup analysis of experimental plasma expanders versus albumin regarding modality of paracentesis, Outcome 6 Hyponatraemia." data-id="CD004039-fig-0056" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-009-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.6</div> <div class="figure-caption"> <p>Comparison 9 Subgroup analysis of experimental plasma expanders versus albumin regarding modality of paracentesis, Outcome 6 Hyponatraemia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-009-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-010-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-010-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Subgroup analysis of experimental plasma expanders versus albumin regarding duration of follow‐up, Outcome 1 All‐cause mortality." data-id="CD004039-fig-0057" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-010-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 Subgroup analysis of experimental plasma expanders versus albumin regarding duration of follow‐up, Outcome 1 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-010-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-010-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-010-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Subgroup analysis of experimental plasma expanders versus albumin regarding duration of follow‐up, Outcome 2 Serious adverse events." data-id="CD004039-fig-0058" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-010-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10 Subgroup analysis of experimental plasma expanders versus albumin regarding duration of follow‐up, Outcome 2 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-010-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-010-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-010-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Subgroup analysis of experimental plasma expanders versus albumin regarding duration of follow‐up, Outcome 3 Renal impairment." data-id="CD004039-fig-0059" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-010-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10 Subgroup analysis of experimental plasma expanders versus albumin regarding duration of follow‐up, Outcome 3 Renal impairment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-010-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-010-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-010-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Subgroup analysis of experimental plasma expanders versus albumin regarding duration of follow‐up, Outcome 4 Other liver‐related complications." data-id="CD004039-fig-0060" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-010-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.4</div> <div class="figure-caption"> <p>Comparison 10 Subgroup analysis of experimental plasma expanders versus albumin regarding duration of follow‐up, Outcome 4 Other liver‐related complications. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-010-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-010-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-010-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Subgroup analysis of experimental plasma expanders versus albumin regarding duration of follow‐up, Outcome 5 Non‐serious adverse events." data-id="CD004039-fig-0061" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-010-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.5</div> <div class="figure-caption"> <p>Comparison 10 Subgroup analysis of experimental plasma expanders versus albumin regarding duration of follow‐up, Outcome 5 Non‐serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-010-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-010-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-010-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Subgroup analysis of experimental plasma expanders versus albumin regarding duration of follow‐up, Outcome 6 Recurrence of ascites." data-id="CD004039-fig-0062" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-010-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.6</div> <div class="figure-caption"> <p>Comparison 10 Subgroup analysis of experimental plasma expanders versus albumin regarding duration of follow‐up, Outcome 6 Recurrence of ascites. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-010-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-010-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-010-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Subgroup analysis of experimental plasma expanders versus albumin regarding duration of follow‐up, Outcome 7 Hyponatraemia." data-id="CD004039-fig-0063" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-010-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.7</div> <div class="figure-caption"> <p>Comparison 10 Subgroup analysis of experimental plasma expanders versus albumin regarding duration of follow‐up, Outcome 7 Hyponatraemia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-010-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-011-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-011-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Subgroup analysis of experimental plasma expanders versus albumin regarding funding, Outcome 1 All‐cause mortality." data-id="CD004039-fig-0064" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-011-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11 Subgroup analysis of experimental plasma expanders versus albumin regarding funding, Outcome 1 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-011-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-011-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-011-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Subgroup analysis of experimental plasma expanders versus albumin regarding funding, Outcome 2 Renal impairment." data-id="CD004039-fig-0065" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-011-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11 Subgroup analysis of experimental plasma expanders versus albumin regarding funding, Outcome 2 Renal impairment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-011-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-011-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-011-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Subgroup analysis of experimental plasma expanders versus albumin regarding funding, Outcome 3 Other liver‐related complications." data-id="CD004039-fig-0066" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-011-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.3</div> <div class="figure-caption"> <p>Comparison 11 Subgroup analysis of experimental plasma expanders versus albumin regarding funding, Outcome 3 Other liver‐related complications. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-011-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-011-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-011-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Subgroup analysis of experimental plasma expanders versus albumin regarding funding, Outcome 4 Non‐serious adverse events." data-id="CD004039-fig-0067" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-011-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.4</div> <div class="figure-caption"> <p>Comparison 11 Subgroup analysis of experimental plasma expanders versus albumin regarding funding, Outcome 4 Non‐serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-011-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-011-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-011-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Subgroup analysis of experimental plasma expanders versus albumin regarding funding, Outcome 5 Recurrence of ascites." data-id="CD004039-fig-0068" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-011-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.5</div> <div class="figure-caption"> <p>Comparison 11 Subgroup analysis of experimental plasma expanders versus albumin regarding funding, Outcome 5 Recurrence of ascites. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-011-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-011-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-011-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Subgroup analysis of experimental plasma expanders versus albumin regarding funding, Outcome 6 Hyponatraemia." data-id="CD004039-fig-0069" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-011-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.6</div> <div class="figure-caption"> <p>Comparison 11 Subgroup analysis of experimental plasma expanders versus albumin regarding funding, Outcome 6 Hyponatraemia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-011-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-011-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-011-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Subgroup analysis of experimental plasma expanders versus albumin regarding funding, Outcome 7 Post‐paracentesis circulatory dysfunction." data-id="CD004039-fig-0070" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-011-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.7</div> <div class="figure-caption"> <p>Comparison 11 Subgroup analysis of experimental plasma expanders versus albumin regarding funding, Outcome 7 Post‐paracentesis circulatory dysfunction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-011-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-012-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-012-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Experimental plasma expanders versus albumin ‐ best‐worst case scenario, Outcome 1 All‐cause mortality." data-id="CD004039-fig-0071" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-012-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12 Experimental plasma expanders versus albumin ‐ best‐worst case scenario, Outcome 1 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-012-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-013-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-013-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Experimental plasma expanders versus albumin ‐ worst‐best case scenario, Outcome 1 All‐cause mortality." data-id="CD004039-fig-0072" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-013-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13 Experimental plasma expanders versus albumin ‐ worst‐best case scenario, Outcome 1 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-013-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-014-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-014-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Intravenous infusion of ascites versus polygeline, Outcome 1 Other liver‐related complications." data-id="CD004039-fig-0073" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-014-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14 Intravenous infusion of ascites versus polygeline, Outcome 1 Other liver‐related complications. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-014-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-014-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-014-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Intravenous infusion of ascites versus polygeline, Outcome 2 Non‐serious adverse events." data-id="CD004039-fig-0074" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-014-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.2</div> <div class="figure-caption"> <p>Comparison 14 Intravenous infusion of ascites versus polygeline, Outcome 2 Non‐serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-014-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004039-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/urn:x-wiley:14651858:media:CD004039:CD004039-CMP-014-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_t/tCD004039-CMP-014-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Intravenous infusion of ascites versus polygeline, Outcome 3 Recurrence of ascites." data-id="CD004039-fig-0075" src="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-014-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.3</div> <div class="figure-caption"> <p>Comparison 14 Intravenous infusion of ascites versus polygeline, Outcome 3 Recurrence of ascites. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/media/CDSR/CD004039/image_n/nCD004039-CMP-014-03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD004039-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Plasma expanders versus no plasma expanders for people with cirrhosis and large ascites treated with abdominal paracentesis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Plasma expanders versus no plasma expanders for people with cirrhosis and large ascites treated with abdominal paracentesis: primary and secondary outcomes</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> cirrhotic participants with large ascites treated by paracentesis </p> <p><b>Settings:</b> specialised units in an intensive or semi‐intensive setting </p> <p><b>Intervention:</b> plasma expander </p> <p><b>Comparison:</b> no plasma expander </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No plasma expander</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Plasma expander</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality</b> </p> <p>mean follow‐up 64 days (1‐222)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR</b> 0.52 (0.06 to 4.83) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>248<br/> (4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> very low<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>180 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>94 per 1000</b><br/> (11 to 869) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>mean follow‐up 15 days (1‐30)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>See comment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>See comment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>See comment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108<br/> (2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> very low<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two trials reported that no serious adverse events occurred</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data provided in any of the six trials</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Refractory ascites</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data provided in any of the six trials</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Other liver‐related complications</b> </p> <p>mean follow‐up 64 days (1‐222)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.61</b> </p> <p>(0.79 to 3.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>248<br/> (4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> very low<sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>90 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>145 per 1000</b><br/> (71 to 294) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Non‐serious adverse events</b> </p> <p>mean follow‐up 91 days (1‐222)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.04</b> </p> <p>(0.32 to 3.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>158<br/> (3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> very low<sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>62 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>64 per 1000</b><br/> (20 to 210) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>* <b>Assumed risk</b> is the risk in comparison group. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded 4 levels because of within study risk of bias: all trials were at high risk of bias (‐2 levels); heterogeneity: high heterogeneity (76%) (‐1 level); imprecision: the required information size as calculated by GRADE was not reached (‐1 level)<br/> <sup>2</sup> Downgraded 4 levels because of within study risk of bias: all trials were at high risk of bias (‐2 levels); imprecision: there were no events (‐2 levels)<br/> <sup>3</sup> Downgraded 5 levels because of within study risk of bias: all trials were at high risk of bias (‐2 levels); high heterogeneity (67%) (‐1 level); imprecision: there were few events and the CI included appreciable benefit and harm (‐2 levels)<br/> <sup>4</sup> Downgraded 3 levels because of within study risk of bias: all trials were at high risk of bias (‐2 levels); imprecision: the required information size as calculated by GRADE was not met (‐1 level)<br/> <sup>5</sup> Downgraded 4 levels because of within study risk of bias: all trials were at high risk of bias (‐2 levels); imprecision: there were few events and the CI included appreciable benefit and harm (‐2 levels) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Plasma expanders versus no plasma expanders for people with cirrhosis and large ascites treated with abdominal paracentesis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/full#CD004039-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004039-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Other plasma expanders versus albumin for people with cirrhosis and large ascites treated with abdominal paracentesis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Other plasma expanders versus albumin for people with cirrhosis and large ascites treated with abdominal paracentesis: primary and secondary outcomes</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> cirrhotic participants with large ascites treated by paracentesis </p> <p><b>Settings:</b> specialised units in an intensive or semi‐intensive setting </p> <p><b>Intervention:</b> all plasma expanders except albumin </p> <p><b>Comparison:</b> albumin </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Albumin</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Experimental plasma expanders</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality</b> </p> <p>mean follow‐up 208 days</p> <p>(3‐638)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.03</p> <p>(0.82 to 1.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1014<br/> (14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝</p> <p>very low <sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>183 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>188 per 1000</b><br/> (150 to 238) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events</b> </p> <p>mean follow‐up 93 days</p> <p>(6‐180)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.89 (0.10 to 8.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>118<br/> (2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝</p> <p>very low <sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>16 per 1000</b><br/> (1.8 to 149) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data provided in any of the 20 trials</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Refractory ascites</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data provided in any of the 20 trials</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Renal impairment</b> </p> <p>mean follow‐up 174 days</p> <p>(3‐628)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.17</p> <p>(0.71 to 1.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1107<br/> (17) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> very low <sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>49 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>57 per 1000</b><br/> (35 to 94) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Other liver‐related complications</b> </p> <p>mean follow‐up 147 days</p> <p>(3‐638)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.10</p> <p>(0.82 to 1.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1083<br/> (16) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> very low <sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>185 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>203 per 1000</b><br/> (152 to 274) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Non‐serious adverse events</b> </p> <p>mean follow‐up 194 days</p> <p>(3‐638)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.37</p> <p>(0.66 to 2.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>977</p> <p>(14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> very low <sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b><br/> (16 to 71) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>* <b>Assumed risk</b> is the risk in comparison group. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded 4 levels because of within study risk of bias: all trials were at high risk of bias (‐2 levels); imprecision: the required information size as calculated by GRADE was not reached (‐1 level); publication bias (‐1 level)<br/> <sup>2</sup> Downgraded 4 levels because of within study risk of bias: all trials were at high risk of bias (‐2 levels); imprecision: there were few events and the CI included appreciable benefit and harm (‐2 levels)<br/> <sup>3</sup> Downgraded 4 levels because of within study risk of bias: all trials were at high risk of bias (‐2 levels); imprecision: the required information size as calculated by GRADE was not reached (‐1 level); publication bias (‐ 1 level)<br/> <sup>4</sup> Downgraded 4 levels because of within study risk of bias: all trials were at high risk of bias (‐2 levels); imprecision: the required information size as calculated by GRADE was not reached (‐1 level); publication bias (‐ 1 level)<br/> <sup>5</sup> Downgraded 3 levels because of within study risk of bias: all trials were at high risk of bias (‐2 levels); imprecision: the required information size as calculated by GRADE was not reached (‐1 level). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Other plasma expanders versus albumin for people with cirrhosis and large ascites treated with abdominal paracentesis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/full#CD004039-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004039-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Comparison of imprecision by GRADE and Trial Sequential Analysis for the evaluation of primary and secondary outcomes in the comparison of plasma expanders versus no plasma expander</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Comparison of imprecision evaluation with GRADE based on the GRADE Handbook, with GRADE based on authors' choice of plausible relative risk reduction and multiplicity correction, and according to our Trial Sequential Analysis with a similar choice of plausible relative risk reduction and multiplicity correction, in addition to considering the choice of meta‐analytic model and diversity</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion in control group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relative risk reduction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Alpha</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Beta</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Diversity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Required information size (OIS or DARIS)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Downgrading of evidence for imprecision based on required information size</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality ‐‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2056</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality ‐‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16,634</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality ‐‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143,664</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events ‐‐ GRADE Handbook</p> <p><b>(1)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="3" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events ‐‐ GRADE plausible RRR</p> <p><b>(1)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events ‐‐ TSA</p> <p><b>(1)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life ‐‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>No data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life ‐‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>No data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life ‐‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>No data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Refractory ascites ‐‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>No data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Refractory ascites ‐‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>No data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Refractory ascites ‐‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>No data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Renal impairment ‐‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Renal impairment ‐‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.00%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35,290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Renal impairment ‐‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.00%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35,293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other liver‐related complications ‐‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4498</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other liver‐related complications ‐‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.00%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38,750</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other liver‐related complications ‐‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.00%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38,752</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐serious adverse events ‐‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6670</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐serious adverse events ‐‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.00%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56,464</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐serious adverse events ‐‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.00%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56,467</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><b>(1)</b> Serious adverse events: 0/68 in plasma expander group and 0/40 in no plasma expander group, RR 1.00 (95% CI 0.00 to 217…) </p> <p>OIS: optimal information size; DARIS: diversity‐adjusted required information size; RRR: relative risk reduction; TSA: Trial Sequential Analysis </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Comparison of imprecision by GRADE and Trial Sequential Analysis for the evaluation of primary and secondary outcomes in the comparison of plasma expanders versus no plasma expander</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/full#CD004039-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004039-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Plasma expanders versus no plasma expander for people with cirrhosis and large ascites treated with abdominal paracentesis: exploratory outcomes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Plasma expanders versus no plasma expander for people with cirrhosis and large ascites treated with abdominal paracentesis: exploratory outcomes</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> cirrhotic participants with large ascites treated by paracentesis </p> <p><b>Settings:</b> specialised units in an intensive or semi‐intensive setting </p> <p><b>Intervention:</b> plasma expander </p> <p><b>Comparison:</b> no plasma expander </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No plasma expander</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Plasma expander</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrence of ascites</b> </p> <p>mean follow‐up 126 days (30‐222)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.30</b> (0.49 to 3.42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>195<br/> (2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>155 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>201 per 1000</b><br/> (76 to 529) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hypotension</b> </p> <p>follow‐up 2 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>See comment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>See comment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There was a single trial with 0 events in each group.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Hyponatraemia</b> </p> <p>mean follow‐up 57 days (1‐222)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.53</b> (0.05 to 5.65) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>181<br/> (4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>130 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>69 per 1000</b><br/> (7 to 734) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>* <b>Assumed risk</b> is the risk in comparison group. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded 3 levels because of within study risk of bias: all trials were at high risk of bias (‐2 levels); imprecision: the required information size as calculated by GRADE not reached (‐1 levels)<br/> <sup>2</sup> Downgraded 4 levels because of within study risk of bias: all trials were at high risk of bias (‐2 levels); high heterogeneity (67%) (‐1 level); imprecision: the required information size as calculated by GRADE was not reached (‐1 level) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Plasma expanders versus no plasma expander for people with cirrhosis and large ascites treated with abdominal paracentesis: exploratory outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/full#CD004039-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004039-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Comparison of imprecision by GRADE and Trial Sequential Analysis for the evaluation of exploratory outcomes in the comparison of plasma expanders versus no plasma expander</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Comparison of imprecision evaluation with GRADE based on the GRADE Handbook, with GRADE based on authors' choice of plausible relative risk reduction and multiplicity correction, and according to our Trial Sequential Analysis with a similar choice of plausible relative risk reduction and multiplicity correction, in addition to considering the choice of meta‐analytic model and diversity</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion in control group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relative risk reduction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Alpha</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Beta</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Diversity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Required information size (OIS or DARIS)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Downgrading of evidence for imprecision based on required information size</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recurrence of ascites ‐‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2444</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recurrence of ascites ‐‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20,980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recurrence of ascites ‐‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43,013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension ‐‐ GRADE Handbook <sup>(1)</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="3" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension ‐‐ GRADE plausible RRR <sup>(1)</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension ‐‐ TSA <sup>(1)</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyponatraemia ‐‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyponatraemia ‐‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25,712</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyponatraemia ‐‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28,526</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>(1)</sup> There was a single trial with 0 events in each group </p> <p>OIS: optimal information size; DARIS: diversity‐adjusted required information size; RRR: relative risk reduction; TSA: Trial Sequential Analysis </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Comparison of imprecision by GRADE and Trial Sequential Analysis for the evaluation of exploratory outcomes in the comparison of plasma expanders versus no plasma expander</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/full#CD004039-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004039-tbl-0006"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Comparison of imprecision by GRADE and Trial Sequential Analysis for the evaluation of primary and secondary outcomes in the comparison of plasma expanders versus albumin</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Comparison of imprecision evaluation with GRADE based on the GRADE Handbook, with GRADE based on authors' choice of plausible relative risk reduction and multiplicity correction, and according to our Trial Sequential Analysis with a similar choice of plausible relative risk reduction and multiplicity correction, in addition to considering the choice of meta‐analytic model and diversity</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion in control group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relative risk reduction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Alpha</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Beta</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Diversity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Required information size (OIS or DARIS)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Downgrading of evidence for imprecision based on required information size</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality ‐‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2030</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality ‐‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16,415</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality ‐‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16,415</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events ‐‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24,032</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events ‐‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>809,313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events ‐‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>809,313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life ‐‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>No data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life ‐‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>No data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life ‐‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>No data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Refractory ascites ‐‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>No data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Refractory ascites ‐‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>No data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Refractory ascites ‐‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>No data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Renal impairment ‐‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8404</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Renal impairment ‐‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.00%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72,650</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Renal impairment ‐‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.00%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72,651</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other liver‐related complications ‐‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other liver‐related complications ‐‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.00%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16,990</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other liver‐related complications ‐‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.00%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16,992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐serious adverse events ‐‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16,904</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐serious adverse events ‐‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.00%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148,922</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐serious adverse events ‐‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.00%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148,925</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>OIS: optimal information size; DARIS: diversity‐adjusted required information size; RRR: relative risk reduction; TSA: Trial Sequential Analysis </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Comparison of imprecision by GRADE and Trial Sequential Analysis for the evaluation of primary and secondary outcomes in the comparison of plasma expanders versus albumin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/full#CD004039-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004039-tbl-0007"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Plasma expanders versus albumin for people with cirrhosis and large ascites treated with abdominal paracentesis: exploratory outcomes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Plasma expanders versus albumin for people with cirrhosis and large ascites treated with abdominal paracentesis: exploratory outcomes</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> cirrhotic participants with large ascites treated by paracentesis </p> <p><b>Settings:</b> specialised units in an intensive or semi‐intensive setting </p> <p><b>Intervention:</b> all plasma expanders except albumin </p> <p><b>Comparison:</b> albumin </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Albumin</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Experimental plasma expanders</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrence of ascites</b> </p> <p>mean follow‐up 169 days (5‐638)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.14</b> (0.96 to 1.36) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>700<br/> (12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>363 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>412 per 1000</b><br/> (348 to 493) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hypotension</b> </p> <p>follow‐up 6 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>88 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>239 per 1000</b><br/> (100 to 573) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.71</b> (1.13 to 6.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty of the evidence not assessed<br/> <sup><b>2</b> </sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Hyponatraemia</b> </p> <p>mean follow‐up 174 days (3‐638)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 1.49</b> (1.03 to 2.14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1107<br/> (17) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>73 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>108 per 1000</b><br/> (75 to 155) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Post‐paracentesis circulatory dysfunction</b> </p> <p>mean follow‐up 100 days (6‐288)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.98</b> (1.31 to 2.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>432<br/> (3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>148 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>294 per 1000</b><br/> (194 to 443) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>* <b>Assumed risk</b> is the risk in comparison group. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded 3 levels because of within study risk of bias: all trials were at high risk of bias (‐2 levels); imprecision: required information size as calculated by GRADE not reached (‐1 level)<br/> <sup>2</sup> Not evaluated because there was only one trial<br/> <sup>3</sup> Downgraded 4 levels because of within study risk of bias: all trials were at high risk of bias (‐2 levels); imprecision: the required information size as calculated by GRADE was not reached (‐1 level); publication bias(‐1 level)<br/> <sup>4</sup> Downgraded 3 levels because of within study risk of bias: all trials were at high risk of bias (‐2 levels); imprecision: the required information size as calculated by GRADE was not reached (‐1 level) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Plasma expanders versus albumin for people with cirrhosis and large ascites treated with abdominal paracentesis: exploratory outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/full#CD004039-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004039-tbl-0008"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Comparison of imprecision by GRADE and Trial Sequential Analysis for the evaluation of exploratory outcomes in the comparison of plasma expanders versus albumin</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Comparison of imprecision evaluation with GRADE based on the GRADE Handbook, with GRADE based on authors' choice of plausible relative risk reduction and multiplicity correction, and according to our Trial Sequential Analysis with a similar choice of plausible relative risk reduction and multiplicity correction, in addition to considering the choice of meta‐analytic model and diversity</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion in control group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relative risk reduction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Alpha</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Beta</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Diversity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Required information size (OIS or DARIS)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Downgrading of evidence for imprecision based on required information size</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recurrence of ascites ‐‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>824</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recurrence of ascites ‐‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6882</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recurrence of ascites ‐‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension ‐‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4608</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension ‐‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39,712</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension ‐‐ TSA <sup>(1)</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyponatraemia ‐‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5602</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyponatraemia ‐‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48,618</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyponatraemia ‐‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48,620</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Post‐paracentesis circulatory dysfunction ‐‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2584</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Post‐paracentesis circulatory dysfunction ‐‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22,144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Post‐paracentesis circulatory dysfunction ‐‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22,146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One level</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>(1)</sup> TSA non calculated because there was only one trial </p> <p>OIS: optimal information size; DARIS: diversity‐adjusted required information size; RRR: relative risk reduction; TSA: Trial Sequential Analysis </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Comparison of imprecision by GRADE and Trial Sequential Analysis for the evaluation of exploratory outcomes in the comparison of plasma expanders versus albumin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/full#CD004039-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004039-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Plasma expanders versus no plasma expander</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.06, 4.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Albumin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.75, 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Ascites infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.02, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Albumin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Infusion of ascites</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Renal impairment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.02, 5.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Other liver‐related complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [0.79, 3.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Albumin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [0.76, 3.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Infusion of ascitic fluid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.58 [0.17, 14.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Non‐serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.32, 3.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Albumin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.32, 3.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Recurrence of ascites <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.49, 3.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Albumin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.43, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Ascites infusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.63 [0.61, 11.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Hyponatraemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.05, 5.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Plasma expanders versus no plasma expander</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004039-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup analysis of plasma expanders versus no plasma expander regarding modality of paracentesis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Participants with partial paracentesis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.75, 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Participants with total paracentesis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.02, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Renal impairment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Participants with partial paracentesis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.00, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Participants with total paracentesis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.17, 6.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Other liver‐related complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Participants with partial paracentesis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [0.57, 4.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Participants with total paracentesis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [0.60, 4.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Non‐serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Participants with partial paracentesis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.22, 4.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Participants with total paracentesis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.17, 6.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Hyponatraemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Participants with partial paracentesis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.04, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Participants with total paracentesis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.12 [0.21, 21.27]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup analysis of plasma expanders versus no plasma expander regarding modality of paracentesis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004039-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Subgroup analysis of plasma expanders versus no plasma expander regarding duration of follow‐up</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Up to 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.02, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 More than 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.75, 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Renal impairment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.02, 5.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Up to 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.17, 6.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 More than 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.00, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Other liver‐related complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [0.79, 3.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Up to 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [0.60, 4.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 More than 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [0.57, 4.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Non‐serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.32, 3.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Up to 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.17, 6.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 More than 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.22, 4.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Hyponatraemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.05, 5.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Up to 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.12 [0.21, 21.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 More than 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.04, 0.80]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Subgroup analysis of plasma expanders versus no plasma expander regarding duration of follow‐up</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004039-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Subgroup analysis of plasma expanders versus no plasma expander regarding funding</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.06, 4.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Trials without for‐profit funding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.06, 4.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Trials with for‐profit funding or unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Renal impairment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.02, 5.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Trials without for‐profit funding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.00, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Trials with for‐profit funding or unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.17, 6.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Other liver‐related complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [0.79, 3.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Trials without for‐profit funding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [0.63, 4.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Trials with for‐profit funding or unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [0.54, 4.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Non‐serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.32, 3.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Trials without for‐profit funding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.22, 4.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Trials with for‐profit funding or unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.17, 6.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Hyponatraemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.05, 5.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Trials without for‐profit funding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.04, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Trials with for‐profit funding or unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.12 [0.21, 21.27]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Subgroup analysis of plasma expanders versus no plasma expander regarding funding</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004039-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Plasma expanders versus no plasma expander: best‐worst case scenario analysis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.06, 3.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Plasma expanders versus no plasma expander: best‐worst case scenario analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004039-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Plasma expanders versus no plasma expander: worst‐best case scenario analysis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.28, 2.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Plasma expanders versus no plasma expander: worst‐best case scenario analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004039-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Experimental plasma expanders versus albumin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.82, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Dextran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.79, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Hydroxyethyl starch</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.45, 3.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Polygeline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>319</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.67, 1.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Infusion of ascites</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.61, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Mannitolum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.47, 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 Crystalloids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.07, 16.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.10, 8.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Renal impairment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.71, 1.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Dextran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.35, 2.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Hydroxylethylstarch</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.06, 15.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Polygeline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>319</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.70, 3.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Infusion of ascites</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.22, 3.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Mannitolum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 Crystalloids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [0.28, 8.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Other liver‐related complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1083</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.82, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Dextran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [0.98, 2.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Hydroxyethyl starch</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.69, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Polygeline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>319</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.43, 1.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Infusion of ascites</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.07, 0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Mannitolum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.61, 3.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 Crystalloids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.16, 7.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Non‐serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>977</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.66, 2.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Dextran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.04, 5.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Hydroxyethyl starch</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.26 [0.66, 7.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Polygeline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.15, 5.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Infusion of ascites</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [0.41, 5.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 Mannitolum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6 Crystalloids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Recurrence of ascites <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>700</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.96, 1.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Dextran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.53, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Hydroxyethyl starch</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [1.03, 2.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Polygeline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.69, 1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Infusion of ascites</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.46, 2.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 Mannitolum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.9 [0.26, 3.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6 Crystalloids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.57, 2.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Hyponatraemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [1.03, 2.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Dextran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [0.81, 2.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Hydroxyethil starch</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.87 [0.40, 8.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Polygeline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>319</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.83, 2.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Infusion of ascites</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.15, 6.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5 Mannitolum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6 Crystalloids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.64 [0.55, 12.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Post‐paracentesis circulatory dysfunction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [1.31, 2.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Dextran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.99 [1.04, 3.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Hydroxylethyl starch</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.14, 3.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Polygeline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.06 [1.03, 4.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 Crystalloids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.92 [1.03, 8.26]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Experimental plasma expanders versus albumin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004039-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Subgroup analysis of experimental plasma expanders versus albumin regarding presence or absence of refractory ascites</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.85, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Trials with participants without refractory ascites</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>723</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.80, 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Trials with participants with refractory ascites</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>291</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.75, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Renal impairment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.71, 1.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Trials with participants without refractory ascites</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>816</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.70, 2.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Trials with participants with refractory ascites</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>291</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.37, 2.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Other liver‐related complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1033</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.82, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Trials with participants without refractory ascites</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>766</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [1.03, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Trials with participants with refractory ascites</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.16, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Non‐serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>977</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.66, 2.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Trials with participants without refractory ascites</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>686</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.49, 4.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Trials with participants with refractory ascites</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>291</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.49, 3.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Recurrence of ascites <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>722</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.97, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Trials with participants without refractory ascites</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>487</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.90, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Trials with participants with refractory ascites</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>235</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.86, 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Hyponatraemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [1.03, 2.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Trials with participants without refractory ascites</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>816</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [1.03, 2.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Trials with participants with refractory ascites</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>291</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.51, 3.26]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Subgroup analysis of experimental plasma expanders versus albumin regarding presence or absence of refractory ascites</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004039-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Subgroup analysis of experimental plasma expanders versus albumin regarding modality of paracentesis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.85, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Participants with partial paracentesis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.59, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Participants with total paracentesis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>905</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.84, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Renal impairment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1039</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.60, 1.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Participants with partial paracentesis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>169</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.07, 15.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Participants with total paracentesis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>870</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.59, 1.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Other liver‐related complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1033</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.82, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Participants with partial paracentesis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>169</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [0.76, 3.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Participants with total paracentesis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>864</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.67, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Non‐serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>977</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.66, 2.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Participants with partial paracentesis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.5 [0.46, 157.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Participants with total paracentesis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>879</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.57, 2.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Recurrences of ascites <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.93, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Participants with partial paracentesis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>169</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.72, 2.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Participants with total paracentesis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>533</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.91, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Hyponatraemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [1.03, 2.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Participants with partial paracentesis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>169</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.29, 3.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Participants with total paracentesis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>938</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [1.05, 2.26]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Subgroup analysis of experimental plasma expanders versus albumin regarding modality of paracentesis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004039-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Subgroup analysis of experimental plasma expanders versus albumin regarding duration of follow‐up</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.82, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Up to 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [0.47, 5.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 More than 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>556</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.80, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.12, 6.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Up to 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 More than 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.38 [0.10, 56.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Renal impairment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.70, 1.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Up to 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>551</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.56, 2.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 More than 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>556</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.58, 2.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Other liver‐related complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1033</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.79, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Up to 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>501</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.64, 2.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 More than 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>532</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.65, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Non‐serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>977</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.67, 2.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Up to 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>484</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.20 [0.73, 6.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 More than 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>493</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.41, 2.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Recurrence of ascites <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.93, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Up to 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.07 [1.12, 3.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 More than 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.86, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Hyponatraemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [1.03, 2.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Up to 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>551</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.64 [1.01, 2.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 More than 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>556</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.76, 2.28]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Subgroup analysis of experimental plasma expanders versus albumin regarding duration of follow‐up</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004039-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Subgroup analysis of experimental plasma expanders versus albumin regarding funding</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Trials without for‐profit funding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.79, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Trials with for‐profit funding or unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>657</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.73, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Renal impairment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.71, 1.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Trials without for‐profit funding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.72, 2.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Trials with for‐profit funding or unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>750</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.48, 1.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Other liver‐related complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1083</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.97, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Trials without for‐profit funding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [1.03, 1.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Trials with for‐profit funding or unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>726</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.69, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Non‐serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>977</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.66, 2.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Trials without for‐profit funding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.12, 3.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Trials with for‐profit funding or unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>703</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [0.75, 3.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Recurrence of ascites <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>700</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.96, 1.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Trials without for‐profit funding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>307</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.96, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Trials with for‐profit funding or unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>393</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.79, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Hyponatraemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [1.03, 2.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Trials without for‐profit funding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.79, 2.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Trials with for‐profit funding or unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>750</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [0.95, 2.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Post‐paracentesis circulatory dysfunction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.93 [1.12, 3.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Trials without for‐profit funding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [0.37, 6.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Trials with for‐profit funding or unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.02 [1.26, 3.24]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Subgroup analysis of experimental plasma expanders versus albumin regarding funding</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004039-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Experimental plasma expanders versus albumin ‐ best‐worst case scenario</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [1.04, 1.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Experimental plasma expanders versus albumin ‐ best‐worst case scenario</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004039-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Experimental plasma expanders versus albumin ‐ worst‐best case scenario</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.96, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Experimental plasma expanders versus albumin ‐ worst‐best case scenario</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004039-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Intravenous infusion of ascites versus polygeline</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Other liver‐related complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.14, 65.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Non‐serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.0 [0.97, 231.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Recurrence of ascites <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.69, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Intravenous infusion of ascites versus polygeline</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004039.pub2/references#CD004039-tbl-0022">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD004039.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD004039-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD004039-note-0017">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD004039-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD004039-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD004039-note-0001">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD004039-note-0002">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004039\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004039\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004039\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004039\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004039\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004039\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004039\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004039\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004039\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004039\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004039\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004039\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004039\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004039\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004039\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004039\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004039\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004039\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Nio3SV1W&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004039.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004039.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD004039.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD004039.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004039.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729214620"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004039.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729214624"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004039.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ed76d8c90f55b',t:'MTc0MDcyOTIxNi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 